# Patent

## Title
Complement component C5 iRNA compositions and methods of use thereof

## Abstract

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.

## Background
RELATED APPLICATIONS
This application is a 35 U.S.C. 111(a) continuation application, which claims the benefit of priority to PCT/US2014/025882, filed on Mar. 13, 2014; U.S. Provisional Patent Application No. 61/782,531, filed on Mar. 14, 2013; U.S. Provisional Patent Application No. 61/837,399, filed on Jun. 20, 2013; U.S. Provisional Patent Application No. 61/904,579, filed on Nov. 15, 2013; U.S. Provisional Patent Application No. 61/912,777, filed on Dec. 6, 2013; and U.S. Provisional Patent Application No. 61/942,367, filed on Feb. 20, 2014. The entire contents of each of the foregoing patent applications are hereby incorporated herein by reference.


SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Apr. 28, 2015, is named 121301-00506_SL.txt and is 734,881 bytes in size.
BACKGROUND OF THE INVENTION
Complement was first discovered in the 1890s when it was found to aid or “complement” the killing of bacteria by heat-stable antibodies present in normal serum (Walport, M. J. (2001) N Engl J Med. 344:1058). The complement system consists of more than 30 proteins that are either present as soluble proteins in the blood or are present as membrane-associated proteins. Activation of complement leads to a sequential cascade of enzymatic reactions, known as complement activation pathways, resulting in the formation of the potent anaphylatoxins C3a and C5a that elicit a plethora of physiological responses that range from chemoattraction to apoptosis. Initially, complement was thought to play a major role in innate immunity where a robust and rapid response is mounted against invading pathogens. However, recently it is becoming increasingly evident that complement also plays an important role in adaptive immunity involving T and B cells that help in elimination of pathogens (Dunkelberger J R and Song W C. (2010) Cell Res. 20:34; Molina H, et al. (1996) Proc Natl Acad Sci USA. 93:3357), in maintaining immunologic memory preventing pathogenic re-invasion, and is involved in numerous human pathological states (Qu, H, et al. (2009) Mol Immunol. 47:185; Wagner, E. and Frank M M. (2010) Nat Rev Drug Discov. 9:43).
Complement activation is known to occur through three different pathways: alternate, classical, and lectin (FIG. 1), involving proteins that mostly exist as inactive zymogens that are then sequentially cleaved and activated. All pathways of complement activation lead to cleavage of the C5 molecule generating the anaphylatoxin C5a and, C5b that subsequently forms the terminal complement complex (C5b-9). C5a exerts a predominant pro-inflammatory activity through interactions with the classical G-protein coupled receptor C5aR (CD88) as well as with the non-G protein coupled receptor C5L2 (GPR77), expressed on various immune and non-immune cells. C5b-9 causes cytolysis through the formation of the membrane attack complex (MAC), and sub-lytic MAC and soluble C5b-9 also possess a multitude of non-cytolytic immune functions. These two complement effectors, C5a and C5b-9, generated from C5 cleavage, are key components of the complement system responsible for propagating and/or initiating pathology in different diseases, including paroxysmal nocturnal hemoglobinuria, rheumatoid arthritis, ischemia-reperfusion injuries and neurodegenerative diseases.
To date, only one therapeutic that targets the C5-C5a axis is available for the treatment of complement component C5-associated diseases, the anti-C5 antibody, eculizumab (Soliris®). Although eculizumab has been shown to be effective for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) and is currently being evaluated in clinical trials for additional complement component C5-associated diseases, eculizumab therapy requires weekly high dose infusions followed by biweekly maintenance infusions at a yearly cost of about $400,000. Accordingly, there is a need in the art for alternative therapies and combination therapies for subjects having a complement component C5-associated disease.
SUMMARY OF THE INVENTION
The present invention provides iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a C5 gene. The C5 gene may be within a cell, e.g., a cell within a subject, such as a human. The present invention also provides methods and combination therapies for treating a subject having a disorder that would benefit from inhibiting or reducing the expression of a C5 gene, e.g., a complement component C5-associated disease, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) using iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a C5 gene for inhibiting the expression of a C5 gene.
Accordingly, in one aspect, the present invention provides a double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5, wherein the dsRNA comprises a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5.
In another aspect, the present invention provides a double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5, wherein the dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense sequences listed in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23.
In one embodiment, the sense and antisense strands comprise sequences selected from the group consisting of A-118320, A-118321, A-118316, A-118317, A-118332, A-118333, A-118396, A-118397, A-118386, A-118387, A-118312, A-118313, A-118324, A-118325, A-119324, A-119325, A-119332, A-119333, A-119328, A-119329, A-119322, A-119323, A-119324, A-119325, A-119334, A-119335, A-119330, A-119331, A-119326, A-119327, A-125167, A-125173, A-125647, A-125157, A-125173, and A-125127. In another embodiment, the sense and antisense strands comprise sequences selected from the group consisting of any of the sequences in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23. In one embodiment, the dsRNA agent comprises at least one modified nucleotide.
In one aspect, the present invention provides a double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence AAGCAAGAUAUUUUUAUAAUA (SEQ ID NO:62) and wherein the antisense strand comprises the nucleotide sequence UAUUAUAAAAAUAUCUUGCUUUU (SEQ ID NO:113). In one embodiment, the dsRNA agent comprises at least one modified nucleotide, as described below.
In one aspect, the present invention provides a double stranded RNAi agent for inhibiting expression of complement component C5 wherein the double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5, wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides, and wherein the sense strand is conjugated to a ligand attached at the 3′-terminus.
In one embodiment, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.
In one embodiment, substantially all of the nucleotides of the sense strand are modified nucleotides selected from the group consisting of a 2′-O-methyl modification, a 2′-fluoro modification and a 3′-terminal deoxy-thymine (dT) nucleotide. In another embodiment, substantially all of the nucleotides of the antisense strand are modified nucleotides selected from the group consisting of a 2′-O-methyl modification, a 2′-fluoro modification and a 3′-terminal deoxy-thymine (dT) nucleotide. In another embodiment, the modified nucleotides are a short sequence of deoxy-thymine (dT) nucleotides. In another embodiment, the sense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus. In one embodiment, the antisense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus and two phosphorothioate internucleotide linkages at the 3′-terminus. In yet another embodiment, the sense strand is conjugated to one or more GalNAc derivatives attached through a branched bivalent or trivalent linker at the 3′-terminus.
In one embodiment, at least one of the modified nucleotides is selected from the group consisting of a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or a dodecanoic acid bisdecylamide group.
In another embodiment, the modified nucleotides comprise a short sequence of 3′-terminal deoxy-thymine (dT) nucleotides.
In one embodiment, the region of complementarity is at least 17 nucleotides in length. In another embodiment, the region of complementarity is between 19 and 21 nucleotides in length.
In one embodiment, the region of complementarity is 19 nucleotides in length.
In one embodiment, each strand is no more than 30 nucleotides in length.
In one embodiment, at least one strand comprises a 3′ overhang of at least 1 nucleotide. In another embodiment, at least one strand comprises a 3′ overhang of at least 2 nucleotides.
In one embodiment, the dsRNA agent further comprises a ligand.
In one embodiment, the ligand is conjugated to the 3′ end of the sense strand of the dsRNA agent.
In one embodiment, the ligand is an N-acetylgalactosamine (GalNAc) derivative.
In one embodiment, the ligand is




In one embodiment, the dsRNA agent is conjugated to the ligand as shown in the following schematic




and, wherein X is O or S.

In one embodiment, the X is O.
In one embodiment, the region of complementarity consists of one of the antisense sequences of any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23.
In one embodiment, the dsRNA agent is selected from the group consisting of AD-58123, AD-58111, AD-58121, AD-58116, AD-58133, AD-58099, AD-58088, AD-58642, AD-58644, AD-58641, AD-58647, AD-58645, AD-58643, AD-58646, AD-62510, AD-62643, AD-62645, AD-62646, AD-62650, and AD-62651.
In another aspect, the present invention provides a double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence AAGCAAGAUAUUUUUAUAAUA (SEQ ID NO:62) and wherein the antisense strand comprises the nucleotide sequence








UAUUAUAAAAAUAUCUUGCUUUUdTdT.
(SEQ ID NO: 2899)






In another aspect, the present invention provides a double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises the nucleotide sequence asasGfcAfaGfaUfAfUfuUfuuAfuAfauaL96 (SEQ ID NO:2876) and wherein the antisense strand comprises the nucleotide sequence usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT (SEQ ID NO:2889).
In one aspect, the present invention provides a double stranded RNAi agent capable of inhibiting the expression of complement component C5 in a cell, wherein the double stranded RNAi agent comprises a sense strand complementary to an antisense strand, wherein the antisense strand comprises a region complementary to part of an mRNA encoding C5, wherein each strand is about 14 to about 30 nucleotides in length, wherein the double stranded RNAi agent is represented by formula (III):








sense:
(III)


5′ np-Na-(X X X)i-Nb-Y Y Y-Nb-(Z Z Z)j-Na-nq 3′



antisense:



3′ np′-Na′-(X′X′X′)k-Nb′-Y′Y′Y′-Nb′-(Z′Z′Z′)l-Na′-



nq′ 5′ 







wherein:
i, j, k, and l are each independently 0 or 1;
p, p′, q, and q′ are each independently 0-6;
each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;

    
    
        each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
    
    


each np, np′, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;

    
    
        XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides;
        modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′; and
        wherein the sense strand is conjugated to at least one ligand.
    
    


In one embodiment, i is 0; j is 0; i is 1; j is 1; both i and j are 0; or both i and j are 1.
In one embodiment, k is 0; l is 0; k is 1; l is 1; both k and l are 0; or both k and l are 1.
In one embodiment, XXX is complementary to X′X′X′, YYY is complementary to Y′Y′Y′, and ZZZ is complementary to Z′Z′Z′.
In one embodiment, the YYY motif occurs at or near the cleavage site of the sense strand.
In one embodiment, the Y′Y′Y′ motif occurs at the 11, 12 and 13 positions of the antisense strand from the 5′-end.
In one embodiment, the Y′ is 2′-O-methyl.
In one embodiment, formula (III) is represented by formula (IIIa):











sense:
5′ np-Na-Y Y Y-Na-nq 3′
(IIIa)



 



antisense:
3′ np′-Na′-Y′Y′Y′-Na,-nq′ 5′.







In another embodiment, formula (III) is represented by formula (IIIb):










sense:
(IIIb)



5′ np-Na-Y Y Y-Nb-Z Z Z-Na-nq 3′




antisense:




3′ np′-Na′-Y′Y′Y′-Nb′-Z′Z′Z′-Na′-nq′ 5′







wherein each Nb and Nb′ independently represents an oligonucleotide sequence comprising 1-5 modified nucleotides.
In yet another embodiment, formula (III) is represented by formula (IIIc):










sense:
(IIIc)



5′ np-Na-X X X-Nb-Y Y Y-Na-nq 3′




antisense:




3′ np′-Na′-X′X′X′-Nb′-Y′Y′Y′-Na′-nq′ 5′ 







wherein each Nb and Nb′ independently represents an oligonucleotide sequence comprising 1-5 modified nucleotides.
In another embodiment, formula (III) is represented by formula (IIId):








sense:
(IIId)


5′ np-Na-X X X-Nb-Y Y Y-Nb-Z Z Z-Na-nq 3′



antisense:



3′ np′-Na′-X′X′X′-Nb′-Y′Y′Y′-Nb′-Z′Z′Z′-Na′-nq′ 5′







wherein each Nb and Nb′ independently represents an oligonucleotide sequence comprising 1-5 modified nucleotides and each Na and Na′ independently represents an oligonucleotide sequence comprising 2-10 modified nucleotides.
In one embodiment, the double-stranded region is 15-30 nucleotide pairs in length.
In one embodiment, the double-stranded region is 17-23 nucleotide pairs in length. In another embodiment, the double-stranded region is 17-25 nucleotide pairs in length. In another embodiment, the double-stranded region is 23-27 nucleotide pairs in length. In yet another embodiment, the double-stranded region is 19-21 nucleotide pairs in length. In another embodiment, the double-stranded region is 21-23 nucleotide pairs in length.
In one embodiment, each strand has 15-30 nucleotides.
In one embodiment, the modifications on the nucleotides are selected from the group consisting of LNA, HNA, CeNA, 2′-methoxyethyl, 2′-O-alkyl, 2′-O-allyl, 2′-C-allyl, 2′-fluoro, 2′-deoxy, 2′-hydroxyl, and combinations thereof.
In one embodiment, the modifications on the nucleotides are 2′-O-methyl or 2′-fluoro modifications.
In one embodiment, the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.
In one embodiment, the ligand is




In one embodiment, the ligand is attached to the 3′ end of the sense strand.
In one embodiment, the RNAi agent is conjugated to the ligand as shown in the following schematic




In one embodiment, the agent further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.
In one embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the 3′-terminus of one strand.
In one embodiment, the strand is the antisense strand. In another embodiment, the strand is the sense strand.
In one embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the 5′-terminus of one strand.
In one embodiment, the strand is the antisense strand. In another embodiment, the strand is the sense strand.
In one embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the both the 5′- and 3′-terminus of one strand.
In one embodiment, the strand is the antisense strand.
In one embodiment, the base pair at the 1 position of the 5′-end of the antisense strand of the duplex is an AU base pair.
In one embodiment, the Y nucleotides contain a 2′-fluoro modification.
In one embodiment, the Y′ nucleotides contain a 2′-O-methyl modification.
In one embodiment, p′>0.
In one embodiment, p′=2.
In one embodiment, q′=0, p=0, q=0, and p′ overhang nucleotides are complementary to the target mRNA.
In one embodiment, q′=0, p=0, q=0, and p′ overhang nucleotides are non-complementary to the target mRNA.
In one embodiment, the sense strand has a total of 21 nucleotides and the antisense strand has a total of 23 nucleotides.
In one embodiment, at least one np′ is linked to a neighboring nucleotide via a phosphorothioate linkage.
In one embodiment, all np′ are linked to neighboring nucleotides via phosphorothioate linkages.
In one embodiment, the RNAi agent is selected from the group of RNAi agents listed in Table 4, Table 18, Table 19, or Table 23. In another embodiment, the RNAi agent is selected from the group consisting of AD-58123, AD-58111, AD-58121, AD-58116, AD-58133, AD-58099, AD-58088, AD-58642, AD-58644, AD-58641, AD-58647, AD-58645, AD-58643, AD-58646, AD-62510, AD-62643, AD-62645, AD-62646, AD-62650, and AD-62651.
In one aspect, the present invention provides a double stranded RNAi agent capable of inhibiting the expression of complement component C5 in a cell, wherein said double stranded RNAi agent comprises a sense strand complementary to an antisense strand, wherein said antisense strand comprises a region complementary to part of an mRNA encoding complement component C5, wherein each strand is about 14 to about 30 nucleotides in length, wherein said double stranded RNAi agent is represented by formula (III):








sense:
(III)


5′ np-Na-(X X X)i-Nb-Y Y Y-Nb-(Z Z Z)j-Na-nq 3′



antisense:



3′ np′-Na′-(X′X′X′)k-Nb′-Y′Y′Y′-Nb′-(Z′Z′Z′)l-Na′-



nq′ 5′ 







wherein:
i, j, k, and l are each independently 0 or 1;
p, p′, q, and q′ are each independently 0-6;
each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;

    
    
        each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
        
            each np, np′, nq, and nq′, each of which may or may not be present independently represents an overhang nucleotide;
        
        
        XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and wherein the modifications are 2′-O-methyl or 2′-fluoro modifications;
        modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′; and
        wherein the sense strand is conjugated to at least one ligand.
    
    


In another aspect, the present invention provides a double stranded RNAi agent capable of inhibiting the expression of complement component C5 in a cell, wherein said double stranded RNAi agent comprises a sense strand complementary to an antisense strand, wherein said antisense strand comprises a region complementary to part of an mRNA encoding complement component C5, wherein each strand is about 14 to about 30 nucleotides in length, wherein said double stranded RNAi agent is represented by formula (III):








sense:
(III)


5′ np-Na-(X X X)i-Nb-Y Y Y-Nb-(Z Z Z)j-Na-nq 3′



antisense:



3′ np′-Na′-(X′X′X′)k-Nb′-Y′Y′Y′-Nb′-(Z′Z′Z′)l-Na′-



nq′ 5′







wherein:
i, j, k, and l are each independently 0 or 1;
each np, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;

    
    
        p, q, and q′ are each independently 0-6;
        np′>0 and at least one np′ is linked to a neighboring nucleotide via a phosphorothioate linkage;
    
    


each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;

    
    
        each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
        XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and wherein the modifications are 2′-O-methyl or 2′-fluoro modifications;
        modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′; and
        wherein the sense strand is conjugated to at least one ligand.
    
    


In another aspect, the present invention provides a double stranded RNAi agent capable of inhibiting the expression of complement component C5 in a cell, wherein said double stranded RNAi agent comprises a sense strand complementary to an antisense strand, wherein said antisense strand comprises a region complementary to part of an mRNA encoding complement component C5, wherein each strand is about 14 to about 30 nucleotides in length, wherein said double stranded RNAi agent is represented by formula (III):








sense:
(III)


5′ np-Na-(X X X)i-Nb-Y Y Y-Nb-(Z Z Z)j-Na-nq 3′



antisense:



3′ np′-Na′-(X′X′X′)k-Nb′-Y′Y′Y′-Nb′-(Z′Z′Z′)l-Na′-



nq′ 5′ 







wherein:
i, j, k, and l are each independently 0 or 1;
each np, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;

    
    
        p, q, and q′ are each independently 0-6;
        np′>0 and at least one np′ is linked to a neighboring nucleotide via a phosphorothioate linkage;
    
    


each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;

    
    
        each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
        
            XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and wherein the modifications are 2′-O-methyl or 2′-fluoro modifications;
        
        
        modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′; and
        wherein the sense strand is conjugated to at least one ligand, wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.
    
    


In yet another aspect, the present invention provides a double stranded RNAi agent capable of inhibiting the expression of complement component C5 in a cell, wherein said double stranded RNAi agent comprises a sense strand complementary to an antisense strand, wherein said antisense strand comprises a region complementary to part of an mRNA encoding complement component C5, wherein each strand is about 14 to about 30 nucleotides in length, wherein said double stranded RNAi agent is represented by formula (III):








sense:
(III)


5′ np-Na-(X X X)i-Nb-Y Y Y-Nb-(Z Z Z)j-Na-nq 3′



antisense:



3′ np′-Na′-(X′X′X′)k-Nb′-Y′Y′Y′-Nb′-(Z′Z′Z′)l-Na′-



nq′ 5′ 







wherein:
i, j, k, and l are each independently 0 or 1;

    
    
        each np, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;
        
            p, q, and q′ are each independently 0-6;
            np′>0 and at least one np′ is linked to a neighboring nucleotide via a phosphorothioate linkage;
        
        
        each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;
        each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
        
            XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and wherein the modifications are 2′-O-methyl or 2′-fluoro modifications;
        
        
        modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′;
        wherein the sense strand comprises at least one phosphorothioate linkage; and
        
            wherein the sense strand is conjugated to at least one ligand, wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.
        
        
    
    


In another aspect, the present invention provides a double stranded RNAi agent capable of inhibiting the expression of complement component C5 in a cell, wherein said double stranded RNAi agent comprises a sense strand complementary to an antisense strand, wherein said antisense strand comprises a region complementary to part of an mRNA encoding complement component C5, wherein each strand is about 14 to about 30 nucleotides in length, wherein said double stranded RNAi agent is represented by formula (III):











sense:
5′ np-Na-Y Y Y-Na-nq 3′
(IIIa)



 



antisense:
3′ np′-Na′-Y′Y′Y′-Na′-nq′ 5′







wherein:

    
    
        each np, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;
        
            p, q, and q′ are each independently 0-6;
            np′>0 and at least one np′ is linked to a neighboring nucleotide via a phosphorothioate linkage;
        
        
        each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;
        
            YYY and Y′Y′Y′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and wherein the modifications are 2′-O-methyl or 2′-fluoro modifications;
            wherein the sense strand comprises at least one phosphorothioate linkage; and
        
        
        wherein the sense strand is conjugated to at least one ligand, wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.
    
    


In one aspect, the present invention provides a double stranded RNAi agent for inhibiting expression of complement component C5, wherein the double stranded RNAi agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5, wherein substantially all of the nucleotides of the sense strand comprise a modification selected from the group consisting of a 2′-O-methyl modification and a 2′-fluoro modification, wherein the sense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus, wherein substantially all of the nucleotides of the antisense strand comprise a modification selected from the group consisting of a 2′-O-methyl modification and a 2′-fluoro modification, wherein the antisense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus and two phosphorothioate internucleotide linkages at the 3′-terminus, and wherein the sense strand is conjugated to one or more GalNAc derivatives attached through a branched bivalent or trivalent linker at the 3′-terminus.
In one embodiment, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides. In another embodiment, each strand has 19-30 nucleotides.
In one aspect, the present invention provides a cell containing a dsRNA agent of the invention.
In one aspect, the present invention provides a vector encoding at least one strand of a dsRNA agent, wherein the dsRNA agent comprises a region of complementarity to at least a part of an mRNA encoding complement component C5, wherein the dsRNA is 30 base pairs or less in length, and wherein the dsRNA agent targets the mRNA for cleavage.
In one embodiment, the region of complementarity is at least 15 nucleotides in length. In another embodiment, the region of complementarity is 19 to 21 nucleotides in length. In another embodiment, each strand has 19-30 nucleotides.
In one aspect, the present invention provides a cell comprising a vector of the invention.
In one aspect, the present invention provides a pharmaceutical composition for inhibiting expression of a complement component C5 gene comprising a dsRNA agent of the invention.
In one embodiment, the RNAi agent is administered in an unbuffered solution.
In one embodiment, the unbuffered solution is saline or water.
In one embodiment, the RNAi agent is administered with a buffer solution.
In one embodiment, the buffer solution comprises acetate, citrate, prolamine, carbonate, or phosphate or any combination thereof.
In another embodiment, the buffer solution is phosphate buffered saline (PBS).
In another aspect, the present invention provides a pharmaceutical composition comprising a double stranded RNAi agent of the invention and a lipid formulation.
In one embodiment, the lipid formulation comprises a LNP. In another embodiment, the lipid formulation comprises a MC3.
In one aspect, the present invention provides a composition comprising an antisense polynucleotide agent selected from the group consisting of the sequences listed in any one of Tables 3, 4, 5, 6, 19, 18, 20, 21, and 23.
In another aspect, the present invention provides a composition comprising a sense polynucleotide agent selected from the group consisting of the sequences listed in any one of Tables 3, 4, 5, 6, 19, 18, 20, 21, and 23.
In yet another aspect, the present invention provides a modified antisense polynucleotide agent selected from the group consisting of the antisense sequences listed in any one of Tables 4, 6, 18, 19, 21, and 23.
In a further aspect, the present invention provides a modified sense polynucleotide agent selected from the group consisting of the sense sequences listed in any one of Tables 4, 6, 18, 19, 21, and 23.
In one aspect the present invention provides methods of treating a subject having a disease or disorder that would benefit from reduction in complement component C5 expression. The methods include administering to the subject a therapeutically effective amount of a dsRNA agent comprising a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5, thereby treating the subject.
In another aspect, the present invention provides methods of preventing at least one symptom in a subject having a disease or disorder that would benefit from reduction in complement component C5 expression. The methods include administering to the subject a therapeutically effective amount of a dsRNA agent comprising a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5, thereby preventing at least one symptom in the subject having a disorder that would benefit from reduction in C5 expression.
In another aspect, the present invention provides methods of treating a subject having a disease or disorder that would benefit from reduction in complement component C5 expression. The methods include administering to the subject a therapeutically effective amount of a dsRNA agent comprising a sense strand and an antisense strand, the antisense strand comprising a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense sequences listed in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, 23, thereby treating the subject.
In yet another aspect, the present invention provides methods of preventing at least one symptom in a subject having a disease or disorder that would benefit from reduction in complement component C5 expression. The methods include administering to the subject a prophylactically effective amount of a dsRNA agent comprising a sense strand and an antisense strand, the antisense strand comprising a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense sequences listed in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23, thereby preventing at least one symptom in the subject having a disorder that would benefit from reduction in C5 expression.
In one aspect, the present invention provides methods of treating a subject having a disease or disorder that would benefit from reduction in complement component C5 expression which include administering to the subject a therapeutically effective amount of a double stranded RNAi agent, wherein the double stranded RNAi agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5, wherein substantially all of the nucleotides of the antisense strand and substantially all of the nucleotides of the sense strand are modified nucleotides and, wherein the sense strand is conjugated to one or more ligands at the 3′-terminus.
In one embodiment, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides.
In one embodiment, the administration is subcutaneous administration.
In one embodiment, substantially all of the nucleotides of the sense strand are modified nucleotides selected from the group consisting of a 2′-O-methyl modification, a 2′-fluoro modification and a 3′-terminal dT nucleotide. In another embodiment, substantially all of the nucleotides of the antisense strand are modified nucleotides selected from the group consisting of a 2′-O-methyl modification, a 2′-fluoro modification and a 3′-terminal dT nucleotide. In another embodiment, the modified nucleotides are a short sequence of deoxy-thymine (dT) nucleotides. In another embodiment, the sense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus. In one embodiment, the antisense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus and two phosphorothioate internucleotide linkages at the 3′-terminus. In yet another embodiment, the sense strand is conjugated to one or more GalNAc derivatives attached through a branched bivalent or trivalent linker at the 3′-terminus.
In another aspect, the present invention provides methods of preventing at least one symptom in a subject having a disease or disorder that would benefit from reduction in complement component C5 expression which include administering to the subject a prophylactically effective amount of a double stranded RNAi agent, wherein the double stranded RNAi agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5, wherein substantially all of the nucleotides of the antisense strand and substantially all of the nucleotides of the sense strand are modified nucleotides and, wherein the sense strand is conjugated to a ligand at the 3′-terminus.
In one embodiment, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides.
In one embodiment, the administration is subcutaneous administration.
In one embodiment, substantially all of the nucleotides of the sense strand are modified nucleotides selected from the group consisting of a 2′-O-methyl modification, a 2′-fluoro modification and a 3′-terminal dT nucleotide. In another embodiment, substantially all of the nucleotides of the antisense strand are modified nucleotides selected from the group consisting of a 2′-O-methyl modification, a 2′-fluoro modification and a 3′-terminal dT nucleotide. In another embodiment, the modified nucleotides are a short sequence of deoxy-thymine (dT) nucleotides. In another embodiment, the sense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus. In one embodiment, the antisense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus and two phosphorothioate internucleotide linkages at the 3′-terminus. In yet another embodiment, the sense strand is conjugated to one or more GalNAc derivatives attached through a branched bivalent or trivalent linker at the 3′-terminus.
In one aspect, the present invention provides methods of treating a subject having a disease or disorder that would benefit from reduction in complement component C5 expression. The methods include administering to the subject a therapeutically effective amount of a dsRNA agent comprising a sense strand complementary to an antisense strand, wherein the antisense strand comprises a region complementary to part of an mRNA encoding C5, wherein each strand is about 14 to about 30 nucleotides in length, wherein the double stranded RNAi agent is represented by formula (III):








sense:
(III)


5′ np-Na-(X X X)i-Nb-Y Y Y-Nb-(Z Z Z)j-Na-nq 3′



antisense:



3′ np′-Na′-(X′X′X′)k-Nb′-Y′Y′Y′-Nb′-(Z′Z′Z′)l-Na′-



nq′ 5′ 







    
    
        wherein:
        i, j, k, and l are each independently 0 or 1;
        p, p′, q, and q′ are each independently 0-6;
        each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;
        each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
        each np, np′, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;
        XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides;
        modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′; and
        wherein the sense strand is conjugated to at least one ligand, thereby treating the subject, thereby treating a subject having a disease or disorder that would benefit from reduction in complement component C5 expression.
    
    


In another aspect, the present invention provides methods of preventing at least one symptom in a subject having a disease or disorder that would benefit from reduction in complement component C5 expression. The methods include administering to the subject a prophylactically effective amount of a dsRNA agent comprising a sense strand complementary to an antisense strand, wherein the antisense strand comprises a region complementary to part of an mRNA encoding C5, wherein each strand is about 14 to about 30 nucleotides in length, wherein the double stranded RNAi agent is represented by formula (III):








sense:
(III)


5′ np-Na-(X X X)i-Nb-Y Y Y-Nb-(Z Z Z)j-Na-nq 3′



antisense:



3′ np′-Na′-(X′X′X′)k-Nb′-Y′Y′Y′-Nb′-(Z′Z′Z′)l-Na′-



nq′ 5′ 







    
    
        wherein:
        i, j, k, and l are each independently 0 or 1;
        p, p′, q, and q′ are each independently 0-6;
        each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;
        each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
        each np, np′, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;
        XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides;
        modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′; and
        wherein the sense strand is conjugated to at least one ligand, thereby preventing at least one symptom in the subject having a disorder that would benefit from reduction in C5 expression, thereby preventing at least one symptom in a subject having a disease or disorder that would benefit from reduction in complement component C5 expression.
    
    


In one embodiment, the administration of the dsRNA to the subject causes a decrease in intravascular hemolysis, a stabilization of hemoglobin levels and/or a decrease in C5 protein accumulation.
In one embodiment, the disorder is a complement component C5-associated disease. In one embodiment, the complement component C5-associated disease is selected from the group consisting of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), asthma, rheumatoid arthritis (RA); antiphospholipid antibody syndrome; lupus nephritis; ischemia-reperfusion injury; typical or infectious hemolytic uremic syndrome (tHUS); dense deposit disease (DDD); neuromyelitis optica (NMO); multifocal motor neuropathy (MMN); multiple sclerosis (MS); macular degeneration (e.g., age-related macular degeneration (AMD)); hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome; thrombotic thrombocytopenic purpura (TTP); spontaneous fetal loss; Pauci-immune vasculitis; epidermolysis bullosa; recurrent fetal loss; pre-eclampsia, traumatic brain injury, myasthenia gravis, cold agglutinin disease, dermatomyositis bullous pemphigoid, Shiga toxin E. coli-related hemolytic uremic syndrome, C3 nephropathy, anti-neutrophil cytoplasmic antibody-associated vasculitis, humoral and vascular transplant rejection, graft dysfunction, myocardial infarction, an allogenic transplant, sepsis, Coronary artery disease, dermatomyositis, Graves' disease, atherosclerosis, Alzheimer's disease, systemic inflammatory response sepsis, septic shock, spinal cord injury, glomerulonephritis, Hashimoto's thyroiditis, type I diabetes, psoriasis, pemphigus, autoimmune hemolytic anemia (AIHA), ITP, Goodpasture syndrome, Degos disease, antiphospholipid syndrome (APS), catastrophic APS (CAPS), a cardiovascular disorder, myocarditis, a cerebrovascular disorder, a peripheral vascular disorder, a renovascular disorder, a mesenteric/enteric vascular disorder, vasculitis, Henoch-Schönlein purpura nephritis, systemic lupus erythematosus-associated vasculitis, vasculitis associated with rheumatoid arthritis, immune complex vasculitis, Takayasu's disease, dilated cardiomyopathy, diabetic angiopathy, Kawasaki's disease (arteritis), venous gas embolus (VGE), and restenosis following stent placement, rotational atherectomy, membraneous nephropathy, Guillain-Barre syndrome, and percutaneous transluminal coronary angioplasty (PTCA). In another embodiment, the complement component C5-associated disease is paroxysmal nocturnal hemoglobinuria (PNH). In yet another embodiment, the complement component C5-associated disease is atypical hemolytic uremic syndrome (aHUS).
In one embodiment, the subject is human.
In another embodiment, the methods of the invention further include administering an anti-complement component C5 antibody, or antigen-binding fragment thereof, to the subject.
In one embodiment, the antibody, or antigen-binding fragment thereof, inhibits cleavage of complement component C5 into fragments C5a and C5b. In another embodiment, the anti-complement component C5 antibody is eculizumab.
In another embodiment, the methods of the invention further include administering a meningococcal vaccine to the subject.
In one embodiment, eculizumab is administered to the subject weekly at a dose less than about 600 mg for 4 weeks followed by a fifth dose at about one week later of less than about 900 mg, followed by a dose less than about 900 mg about every two weeks thereafter.
In another embodiment, eculizumab is administered to the subject weekly at a dose less than about 900 mg for 4 weeks followed by a fifth dose at about one week later of less than about 1200 mg, followed by a dose less than about 1200 mg about every two weeks thereafter.
In one embodiment, the subject is less than 18 years of age and eculizumab is administered to the subject weekly at a dose less than about 900 mg for 4 weeks followed by a fifth dose at about one week later of less than about 1200 mg, followed by a dose less than about 1200 mg about every two weeks thereafter.
In another embodiment, the subject is less than 18 years of age and eculizumab is administered to the subject weekly at a dose less than about 600 mg for 2 weeks followed by a third dose at about one week later of less than about 900 mg, followed by a dose less than about 900 mg about every two weeks thereafter.
In another embodiment, the subject is less than 18 years of age and eculizumab is administered to the subject weekly at a dose less than about 600 mg for 2 weeks followed by a third dose at about one week later of less than about 600 mg, followed by a dose less than about 600 mg about every two weeks thereafter.
In yet another embodiment, the subject is less than 18 years of age and eculizumab is administered to the subject weekly at a dose less than about 600 mg for 1 week followed by a second dose at about one week later of less than about 300 mg, followed by a dose less than about 300 mg about every two weeks thereafter.
In one embodiment, the subject is less than 18 years of age and eculizumab is administered to the subject weekly at a dose less than about 300 mg for 1 week followed by a second dose at about one week later of less than about 300 mg, followed by a dose less than about 300 mg about every two weeks thereafter.
In another embodiment, the methods of the invention further include plasmapheresis or plasma exchange in the subject. In one such embodiment, eculizumab is administered to the subject at a dose less than about 600 mg or at a dose less than about 300 mg.
In a further embodiment, the methods of the invention further include plasma infusion in the subject. In one such embodiment, eculizumab is administered to the subject at a dose less than about 300 mg.
In one embodiment, eculizumab is administered to the subject at a dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 15 mg/kg. In another embodiment, eculizumab is administered to the subject at a dose of about 5 mg/kg to about 15 mg/kg.
In one embodiment, eculizumab is administered to the subject at a dose selected from the group consisting of 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 3 mg/kg, 5 mg/kg, 7 mg/kg, 10 mg/kg, and 15 mg/kg.
In one embodiment, eculizumab is administered to the subject via an intravenous infusion.
In another embodiment, eculizumab is administered to the subject subcutaneously.
In one embodiment, the dsRNA agent is administered at a dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 50 mg/kg.
In another embodiment, dsRNA agent is administered at a dose of about 10 mg/kg to about 30 mg/kg.
In one embodiment, the dsRNA agent is administered at a dose selected from the group consisting of 0.5 mg/kg 1 mg/kg, 1.5 mg/kg, 3 mg/kg, 5 mg/kg, 10 mg/kg, and 30 mg/kg.
In one embodiment, the dsRNA agent is administered to the subject once a week. In another embodiment, the dsRNA agent is administered to the subject twice a week. In another embodiment, the dsRNA agent is administered to the subject twice a month.
In one embodiment, the dsRNA agent is administered to the subject subcutaneously.
In one embodiment, the dsRNA agent and the eculizumab are administered to the subject subcutaneously. In another embodiment, the dsRNA agent and the eculizumab are administered to the subject simultaneously.
In one embodiment, the dsRNA agent is administered to the subject first for a period of time sufficient to reduce the levels of complement component C5 in the subject, and eculizumab is administered subsequently at a dose less than about 600 mg.
In one embodiment, the levels of complement component C5 in the subject are reduced by at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%.
In one embodiment, eculizumab is administered at a dose of about 100-500 mg.
In one embodiment, the methods of the invention further include measuring hemoglobin and/or LDH levels in the subject.
In one embodiment, the dsRNA is conjugated to a ligand.
In one embodiment, the ligand is conjugated to the 3′-end of the sense strand of the dsRNA.
In one embodiment, the ligand is an N-acetylgalactosamine (GalNAc) derivative.
In one aspect, the present invention provides methods of inhibiting complement component C5 expression in a cell. The methods include contacting the cell with a dsRNA agent comprising a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5; and maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a C5 gene, thereby inhibiting expression of the C5 gene in the cell.
In another aspect, the present invention provides methods of inhibiting complement component C5 expression in a cell. The methods include contacting the cell with a dsRNA agent comprising a sense strand and an antisense strand, the antisense strand comprising a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense sequences listed in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23; and maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a C5 gene, thereby inhibiting expression of the C5 gene in the cell.
In another aspect, the present invention provides methods of inhibiting complement component C5 expression in a cell, which includes contacting the cell with a dsRNA agent comprising a sense strand and an antisense strand comprising a region of complementarity, the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5, wherein substantially all of the nucleotides of the antisense strand and substantially all of the nucleotides of the sense strand are modified nucleotides and, wherein the sense strand is conjugated to one or more ligands at the 3′-terminus; and maintaining the cell produced in the first step for a time sufficient to obtain degradation of the mRNA transcript of a C5 gene, thereby inhibiting expression of the C5 gene in the cell.
In one embodiment, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides.
In one embodiment, substantially all of the nucleotides of the sense strand are modified nucleotides selected from the group consisting of a 2′-O-methyl modification, a 2′-fluoro modification and a 3′-terminal dT nucleotide. In another embodiment, substantially all of the nucleotides of the antisense strand are modified nucleotides selected from the group consisting of a 2′-O-methyl modification, a 2′-fluoro modification and a 3′-terminal dT nucleotide. In another embodiment, the modified nucleotides are a short sequence of deoxy-thymine (dT) nucleotides. In another embodiment, the sense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus. In one embodiment, the antisense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus and two phosphorothioate internucleotide linkages at the 3′-terminus. In yet another embodiment, the sense strand is conjugated to one or more GalNAc derivatives attached through a branched bivalent or trivalent linker at the 3′-terminus.
In yet another aspect, the present invention provides methods of inhibiting complement component C5 expression in a cell. The methods include contacting the cell with a dsRNA agent comprising a sense strand complementary to an antisense strand, wherein the antisense strand comprises a region complementary to part of an mRNA encoding C5, wherein each strand is about 14 to about 30 nucleotides in length, wherein the double stranded RNAi agent is represented by formula (III):








sense:
(III)


5′ np-Na-(X X X)i-Nb-Y Y Y-Nb-(Z Z Z)j-Na-nq 3′



antisense:



3′ np′-Na′-(X′X′X′)k-Nb′-Y′Y′Y′-Nb′-(Z′Z′Z′)l-Na′-



nq′ 5′ 







    
    
        wherein:
        i, j, k, and l are each independently 0 or 1;
        p, p′, q, and q′ are each independently 0-6;
        each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;
        each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof; each np, np′, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;
        XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides;
        modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′; and
        wherein the sense strand is conjugated to at least one ligand; and maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a C5 gene, thereby inhibiting expression of the C5 gene in the cell.
    
    


In one embodiment, the cell is within a subject.
In one embodiment, the subject is a human.
In one embodiment, the human subject suffers from a complement component C5-associated disease.
In one embodiment, the complement component C5-associated disease is selected from the group consisting of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), asthma, rheumatoid arthritis (RA); antiphospholipid antibody syndrome; lupus nephritis; ischemia-reperfusion injury; typical or infectious hemolytic uremic syndrome (tHUS); dense deposit disease (DDD); neuromyelitis optica (NMO); multifocal motor neuropathy (MMN); multiple sclerosis (MS); macular degeneration (e.g., age-related macular degeneration (AMD)); hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome; thrombotic thrombocytopenic purpura (TTP); spontaneous fetal loss; Pauci-immune vasculitis; epidermolysis bullosa; recurrent fetal loss; pre-eclampsia, traumatic brain injury, myasthenia gravis, cold agglutinin disease, dermatomyositis bullous pemphigoid, Shiga toxin E. coli-related hemolytic uremic syndrome, C3 nephropathy, anti-neutrophil cytoplasmic antibody-associated vasculitis, humoral and vascular transplant rejection, graft dysfunction, myocardial infarction, an allogenic transplant, sepsis, Coronary artery disease, dermatomyositis, Graves' disease, atherosclerosis, Alzheimer's disease, systemic inflammatory response sepsis, septic shock, spinal cord injury, glomerulonephritis, Hashimoto's thyroiditis, type I diabetes, psoriasis, pemphigus, autoimmune hemolytic anemia (AIHA), ITP, Goodpasture syndrome, Degos disease, antiphospholipid syndrome (APS), catastrophic APS (CAPS), a cardiovascular disorder, myocarditis, a cerebrovascular disorder, a peripheral vascular disorder, a renovascular disorder, a mesenteric/enteric vascular disorder, vasculitis, Henoch-Schönlein purpura nephritis, systemic lupus erythematosus-associated vasculitis, vasculitis associated with rheumatoid arthritis, immune complex vasculitis, Takayasu's disease, dilated cardiomyopathy, diabetic angiopathy, Kawasaki's disease (arteritis), venous gas embolus (VGE), and restenosis following stent placement, rotational atherectomy, membraneous nephropathy, Guillain-Barre syndrome, and percutaneous transluminal coronary angioplasty (PTCA). In another embodiment, the complement component C5-associated disease is paroxysmal nocturnal hemoglobinuria (PNH). In another embodiment, the complement component C5-associated disease is atypical hemolytic uremic syndrome (aHUS).
In one embodiment, the methods further include contacting the cell with an anti-complement component C5 antibody, or antigen-binding fragment thereof.
In one embodiment, the antibody, or antigen-binding fragment thereof, inhibits cleavage of complement component C5 into fragments C5a and C5b.
In one embodiment, the anti-complement component C5 antibody, or antigen-binding fragment thereof, is eculizumab.
In one embodiment, the methods further include contacting the cell with a meningococcal vaccine.
In one embodiment, the cell is contacted with eculizumab weekly at a dose less than about 600 mg for 4 weeks followed by a fifth dose at about one week later of less than about 900 mg, followed by a dose less than about 900 mg about every two weeks thereafter.
In another embodiment, the cell is contacted with eculizumab weekly at a dose less than about 900 mg for 4 weeks followed by a fifth dose at about one week later of less than about 1200 mg, followed by a dose less than about 1200 mg about every two weeks thereafter.
In another embodiment, the cell is contacted with eculizumab weekly at a dose less than about 900 mg for 4 weeks followed by a fifth dose at about one week later of less than about 1200 mg, followed by a dose less than about 1200 mg about every two weeks thereafter.
In yet another embodiment, the cell is contacted with eculizumab weekly at a dose less than about 600 mg for 2 weeks followed by a third dose at about one week later of less than about 900 mg, followed by a dose less than about 900 mg about every two weeks thereafter.
In one embodiment, the cell is contacted with eculizumab weekly at a dose less than about 600 mg for 2 weeks followed by a third dose at about one week later of less than about 600 mg, followed by a dose less than about 600 mg about every two weeks thereafter.
In another embodiment, the cell is contacted with eculizumab weekly at a dose less than about 600 mg for 1 week followed by a second dose at about one week later of less than about 300 mg, followed by a dose less than about 300 mg about every two weeks thereafter.
In one embodiment, the cell is contacted with eculizumab weekly at a dose less than about 300 mg for 1 week followed by a second dose at about one week later of less than about 300 mg, followed by a dose less than about 300 mg about every two weeks thereafter.
In one embodiment, the cell is within a subject.
In one embodiment, the methods of the invention further include plasmapheresis or plasma exchange in the subject. In one embodiment, eculizumab is administered to the subject at a dose less than about 600 mg. In another embodiment, eculizumab is administered to the subject at a dose less than about 300 mg.
In one embodiment, the methods of the invention further include plasma infusion in the subject. In one embodiment, eculizumab is administered to the subject at a dose less than about 300 mg.
In one embodiment, the cell is contacted with eculizumab at a dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 15 mg/kg.
In another embodiment, the cell is contacted with eculizumab at a dose of about 5 mg/kg to about 15 mg/kg.
In one embodiment, the cell is contacted with eculizumab at a dose selected from the group consisting of 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 3 mg/kg, 5 mg/kg, 7 mg/kg, 10 mg/kg, and 15 mg/kg.
In one embodiment, eculizumab is administered to the subject via an intravenous infusion. In another embodiment, eculizumab is administered to the subject subcutaneously.
In one embodiment, the cell is contacted with the dsRNA agent at a dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 50 mg/kg.
In another embodiment, the cell is contacted with the dsRNA agent at a dose of about 10 mg/kg to about 30 mg/kg.
In one embodiment, the cell is contacted with the dsRNA agent at a dose selected from the group consisting of 0.5 mg/kg 1 mg/kg, 1.5 mg/kg, 3 mg/kg, 5 mg/kg, 10 mg/kg, and 30 mg/kg.
In one embodiment, the cell is contacted with the dsRNA agent once a week. In another embodiment, the dsRNA agent is administered to the subject twice a week. In another embodiment, the cell is contacted with the dsRNA agent twice a month.
In one embodiment, the dsRNA agent is administered to the subject subcutaneously.
In one embodiment, the dsRNA agent and the eculizumab are administered to the subject subcutaneously. In another embodiment, the dsRNA agent and the eculizumab are administered to the subject simultaneously.
In one embodiment, the cell is contacted with the dsRNA agent and the eculizumab simultaneously.
In one embodiment, the dsRNA agent is administered to the subject first for a period of time sufficient to reduce the levels of complement component C5 in the subject, and eculizumab is administered subsequently at a dose less than about 600 mg.
In one embodiment, the levels of complement component C5 in the subject are reduced by at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%.
In one embodiment, eculizumab is administered at a dose of about 100-500 mg.
In one embodiment, the cell is contacted with the dsRNA agent first for a period of time sufficient to reduce the levels of complement component C5 in the cell, and the cell is subsequently contacted with eculizumab at a dose less than about 600 mg.
In one embodiment, the levels of complement component C5 in the cell are reduced by at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%.
In one embodiment, the cell is contacted with eculizumab at a dose of about 100-500 mg.
In one aspect, the present invention provides methods of inhibiting the expression of C5 in a subject. The methods include administering to the subject a therapeutically effective amount of a dsRNA agent comprising a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5, thereby inhibiting the expression of C5 in the subject.
In another aspect, the present invention provides methods of inhibiting the expression of C5 in a subject. The methods include administering to the subject a therapeutically effective amount of a dsRNA agent comprising a sense strand and an antisense strand, the antisense strand comprising a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense sequences listed in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23, thereby inhibiting the expression of C5 in the subject.
In another aspect, the present invention provides methods of inhibiting complement component C5 expression in a subject which include administering to the subject a therapeutically effective amount of a dsRNA agent comprising a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5, wherein substantially all of the nucleotides of the antisense strand and substantially all of the nucleotides of the sense strand are modified nucleotides and, wherein the sense strand is conjugated to one or more ligands at the 3′-terminus, thereby inhibiting expression of the C5 gene in the subject.
In one embodiment, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides.
In one embodiment, the administration is subcutaneous administration.
In one embodiment, substantially all of the nucleotides of the sense strand are modified nucleotides selected from the group consisting of a 2′-O-methyl modification, a 2′-fluoro modification and a 3′-terminal dT nucleotide. In another embodiment, substantially all of the nucleotides of the antisense strand are modified nucleotides selected from the group consisting of a 2′-O-methyl modification, a 2′-fluoro modification and a 3′-terminal dT nucleotide. In another embodiment, the modified nucleotides are a short sequence of deoxy-thymine (dT) nucleotides. In another embodiment, the sense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus. In one embodiment, the antisense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus and two phosphorothioate internucleotide linkages at the 3′-terminus. In yet another embodiment, the sense strand is conjugated to one or more GalNAc derivatives attached through a branched bivalent or trivalent linker at the 3′-terminus.
In another aspect, the present invention provides methods of inhibiting the expression of C5 in a subject. The methods include administering to the subject a therapeutically effective amount of a dsRNA agent comprising a sense strand complementary to an antisense strand, wherein the antisense strand comprises a region complementary to part of an mRNA encoding C5, wherein each strand is about 14 to about 30 nucleotides in length, wherein the double stranded RNAi agent is represented by formula (III):








sense:
(III)


5′ np-Na-(X X X)i-Nb-Y Y Y-Nb-(Z Z Z)j-Na-nq 3′



antisense:



3′ np′-Na′-(X′X′X′)k-Nb′-Y′Y′Y′-Nb′-(Z′Z′Z′)l-Na′-



nq′ 5′ 







    
    
        wherein:
        i, j, k, and l are each independently 0 or 1;
        p, p′, q, and q′ are each independently 0-6;
        each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;
        each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
        each np, np′, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;
        XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides;
        modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′; and
        wherein the sense strand is conjugated to at least one ligand, thereby inhibiting the expression of C5 in the subject.
    
    


In one embodiment, the methods further include administration of an anti-complement component C5 antibody, or antigen-binding fragment thereof, to the subject.
In one embodiment, the anti-complement component C5 antibody, or antigen-binding fragment thereof, is eculizumab.
In one embodiment, the antibody, or antigen-binding fragment thereof, inhibits cleavage of complement component C5 into fragments C5a and C5b.
In one embodiment, the methods of the invention further include administering a meningococcal vaccine to the subject.
In one embodiment, eculizumab is administered to the subject weekly at a dose less than about 600 mg for 4 weeks followed by a fifth dose at about one week later of less than about 900 mg, followed by a dose less than about 900 mg about every two weeks thereafter.
In another embodiment, eculizumab is administered to the subject weekly at a dose less than about 900 mg for 4 weeks followed by a fifth dose at about one week later of less than about 1200 mg, followed by a dose less than about 1200 mg about every two weeks thereafter.
In one embodiment, the subject is less than 18 years of age and eculizumab is administered to the subject weekly at a dose less than about 900 mg for 4 weeks followed by a fifth dose at about one week later of less than about 1200 mg, followed by a dose less than about 1200 mg about every two weeks thereafter.
In another embodiment, the subject is less than 18 years of age and eculizumab is administered to the subject weekly at a dose less than about 600 mg for 2 weeks followed by a third dose at about one week later of less than about 900 mg, followed by a dose less than about 900 mg about every two weeks thereafter.
In one embodiment, the subject is less than 18 years of age and eculizumab is administered to the subject weekly at a dose less than about 600 mg for 2 weeks followed by a third dose at about one week later of less than about 600 mg, followed by a dose less than about 600 mg about every two weeks thereafter.
In another embodiment, the subject is less than 18 years of age and eculizumab is administered to the subject weekly at a dose less than about 600 mg for 1 week followed by a second dose at about one week later of less than about 300 mg, followed by a dose less than about 300 mg about every two weeks thereafter.
In yet another embodiment, the subject is less than 18 years of age and eculizumab is administered to the subject weekly at a dose less than about 300 mg for 1 week followed by a second dose at about one week later of less than about 300 mg, followed by a dose less than about 300 mg about every two weeks thereafter.
In one embodiment, the methods further include plasmapheresis or plasma exchange in the subject. In one embodiment, eculizumab is administered to the subject at a dose less than about 600 mg. In another embodiment, eculizumab is administered to the subject at a dose less than about 300 mg.
In one embodiment, the methods further include plasma infusion in the subject. In one embodiment, eculizumab is administered to the subject at a dose less than about 300 mg.
In one embodiment, eculizumab is administered to the subject at a dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 15 mg/kg. In another embodiment, eculizumab is administered to the subject at a dose of about 5 mg/kg to about 15 mg/kg.
In another embodiment, eculizumab is administered to the subject at a dose selected from the group consisting of 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 3 mg/kg, 5 mg/kg, 7 mg/kg, 10 mg/kg, and 30 mg/kg.
In one embodiment, eculizumab is administered to the subject via an intravenous infusion. In another embodiment, eculizumab is administered to the subject subcutaneously.
In one embodiment, the dsRNA agent is administered at a dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 15 mg/kg.
In one embodiment, the dsRNA agent is administered at a dose of about 10 mg/kg to about 30 mg/kg. In another embodiment, the dsRNA agent is administered at a dose selected from the group consisting of 0.5 mg/kg 1 mg/kg, 1.5 mg/kg, 3 mg/kg, 5 mg/kg, 10 mg/kg, and 30 mg/kg.
In one embodiment, the dsRNA agent is administered to the subject once a week. In another embodiment, the dsRNA agent is administered to the subject twice a week. In another embodiment, the dsRNA agent is administered to the subject twice a month.
In one embodiment, the dsRNA agent is administered to the subject subcutaneously.
In one embodiment, the dsRNA agent and the eculizumab are administered to the subject subcutaneously. In another embodiment, the dsRNA agent and the eculizumab are administered to the subject simultaneously.
In one embodiment, the dsRNA agent is administered to the subject first for a period of time sufficient to reduce the levels of complement component C5 in the subject, and eculizumab is administered subsequently at a dose less than about 600 mg.
In one embodiment, the levels of complement component C5 in the subject are reduced by at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%.
In one embodiment, eculizumab is administered at a dose of about 100-500 mg.
In one embodiment, the dsRNA agent is conjugated to a ligand.
In one embodiment, the ligand is conjugated to the 3′-end of the sense strand of the dsRNA agent.
In one embodiment, the ligand is an N-acetylgalactosamine (GalNAc) derivative.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic of the three complement pathways: alternative, classical and lectin.
FIG. 2 is a graph showing the percentage of complement component C5 remaining in C57BL/6 mice following a single 10 mg/kg dose of the indicated iRNAs.
FIG. 3 is a graph showing the percentage of complement component C5 remaining in C57BL/6 mice following a single 10 mg/kg dose of the indicated iRNAs.
FIG. 4 is a graph showing the percentage of complement component C5 remaining in C57BL/6 mice 48 hours after a single 10 mg/kg dose of the indicated iRNAs.
FIG. 5A is a graph showing the percentage of hemolysis remaining at days 4 and 7 in rats after a single 2.5 mg/kg, 10 mg/kg, or 25 mg/kg subcutaneous dose of AD-58642.
FIG. 5B is a Western blot showing the amount of complement component C5 remaining at day 7 in rats after a single 2.5 mg/kg, 10 mg/kg, or 25 mg/kg subcutaneous dose of AD-58642.
FIG. 6A is a graph showing the percentage of complement component C5 remaining in C57BL/6 mice 5 days after a single 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg or 25 mg/kg dose of AD-58642.
FIG. 6B is a graph showing the percentage of complement component C5 remaining in C57BL/6 mice 5 days after a single 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg or 25 mg/kg dose of AD-58642.
FIG. 7A is a graph showing the percentage of hemolysis remaining at day 5 in C57BL/6 mice after a single 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg or 25 mg/kg dose of AD-58642.
FIG. 7B is a graph showing the percentage of hemolysis remaining at day 5 in C57BL/6 mice after a single 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg or 25 mg/kg dose of AD-58642.
FIG. 8 is a Western blot showing the amount of complement component C5 remaining at day 5 in C57BL/6 mice after a single 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg or 25 mg/kg dose of AD-58642.
FIG. 9 is a graph showing the amount of complement component C5 protein remaining at days 5 and 9 in mouse serum after a single 0.625 mg/kg, 1.25 mg/kg, 2.5 mg/kg, 5.0 mg/kg, or 10 mg/kg dose of AD-58641. The lower limit of quantitation (LLOQ) of the assay is shown as a dashed line.
FIG. 10 is a is a graph showing the amount of complement component C5 protein remaining at day 8 in mouse serum after a 0.625 mg/kg, 1.25 mg/kg, or 2.5 mg/kg dose of AD-58641 at days 0, 1, 2, and 3. The lower limit of quantitation (LLOQ) of the assay is shown as a dashed line.
FIG. 11A is graph demonstrating the efficacy and cumulative effect of repeat administration of compound AD-58641 in rats and depicts the hemolytic activity remaining in the serum of rats on days 0, 4, 7, 11, 14, 18, 25, and 32 after repeat administration at 2.5 mg/kg/dose or 5.0 mg/kg/dose, q2w×3 (twice a week for 3 weeks).
FIG. 11B is a Western blot demonstrating the efficacy and cumulative effect of repeat administration of compound AD-58641 in rats and depicts the amount of complement component C5 protein remaining in the serum of the animals.
FIG. 12 is a graph showing the amount of complement component C5 protein in cynomolgus macaque serum at various time points before, during and after two rounds of subcutaneous dosing at 2.5 mg/kg or 5 mg/kg of AD-58641 every third day for eight doses. C5 protein levels were normalized to the average of the three pre-dose samples.
FIG. 13 is a graph showing the percentage of hemolysis remaining in cynomolgus macaque serum at various time points before, during and after two rounds of subcutaneous dosing at 2.5 mg/kg or 5 mg/kg of AD-58641 every third day for eight doses. Percent hemolysis was calculated relative to maximal hemolysis and to background hemolysis in control samples.
FIG. 14 is a graph showing the percentage of complement component C5 protein remaining at day 5 in the serum of C57BL/6 mice following a single 1 mg/kg dose of the indicated iRNAs.
FIG. 15 is a graph showing the percentage of complement component C5 protein remaining at day 5 in the serum of C57BL/6 mice following a single 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 2.0 mg/kg dose of the indicated iRNAs.
FIG. 16 is a graph showing the percentage of complement component C5 protein remaining in the serum of C57BL/6 mice at days 6, 13, 20, 27, and 34 following a single 1 mg/kg dose of the indicated iRNAs.
FIG. 17 is a graph showing the percentage of hemolysis remaining in rat serum at various time points following administration of a 5 mg/kg dose of the indicated compounds at days 0, 4, and 7.
FIG. 18A shows the nucleotide sequence of Homo sapiens Complement Component 5 (C5) (SEQ ID NO:1); FIG. 18B shows the nucleotide sequence of Macaca mulatta Complement Component 5 (C5) (SEQ ID NO:2); FIG. 18C shows the nucleotide sequence of Mus musculus Complement Component 5 (C5) (SEQ ID NO:3); FIG. 18D shows the nucleotide sequence of Rattus norvegicus Complement Component 5 (C5) (SEQ ID NO:4); FIG. 18E shows the reverse complement of SEQ ID NO:1 (SEQ ID NO:5); FIG. 18F shows the reverse complement of SEQ ID NO:2 (SEQ ID NO:6); FIG. 18G shows the reverse complement of SEQ ID NO:3 (SEQ ID NO:7); and FIG. 18H shows the reverse complement of SEQ ID NO:4 (SEQ ID NO:8).



DETAILED DESCRIPTION OF THE INVENTION
The present invention provides iRNA agents which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a complement component C5 gene.
The iRNAs of the invention include an RNA strand (the antisense strand) having a region which is about 30 nucleotides or less in length, e.g., 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length, which region is substantially complementary to at least part of an mRNA transcript of a C5 gene. The use of these iRNAs enables the targeted degradation of mRNAs of a C5 gene in mammals. Very low dosages of C5 iRNAs, in particular, can specifically and efficiently mediate RNA interference (RNAi), resulting in significant inhibition of expression of a C5 gene. The present inventors have demonstrated that iRNAs targeting C5 can mediate RNAi in vitro and in vivo, resulting in significant inhibition of expression of a C5 gene. Thus, methods and compositions including these iRNAs are useful for treating a subject who would benefit by a reduction in the levels and/or activity of a C5 protein, such as a subject having a complement component C5-associated disease, such as paroxysmal nocturnal hemoglobinuria (PNH).
The present invention also provides methods and combination therapies for treating a subject having a disorder that would benefit from inhibiting or reducing the expression of a C5 gene, e.g., a complement component C5-associated disease, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) using iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a complement component C5 gene.
The present invention also provides methods for preventing at least one symptom, e.g., hemolysis, in a subject having a disorder that would benefit from inhibiting or reducing the expression of a C5 gene, e.g., a complement component C5-associated disease, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The present invention further provides iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a complement component C5 gene. The C5 gene may be within a cell, e.g., a cell within a subject, such as a human.
The combination therapies of the present invention include administering to a subject having a complement component C5-associated disease, an RNAi agent of the invention and an additional therapeutic, such as anti-complement component C5 antibody, or antigen-binding fragment thereof, e.g., eculizumab. The combination therapies of the invention reduce C5 levels in the subject (e.g., by about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or about 99%) by targeting C5 mRNA with an iRNA agent of the invention and, accordingly, allow the therapeutically (or prophylactically) effective amount of eculizumab required to treat the subject to be reduced, thereby decreasing the costs of treatment and permitting easier and more convenient ways of administering eculizumab, such as subcutaneous administration.
The following detailed description discloses how to make and use compositions containing iRNAs to inhibit the expression of a C5 gene, as well as compositions, uses, and methods for treating subjects having diseases and disorders that would benefit from inhibition and/or reduction of the expression of this gene.
I. Definitions
In order that the present invention may be more readily understood, certain terms are first defined. In addition, it should be noted that whenever a value or range of values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are also intended to be part of this invention.
The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element, e.g., a plurality of elements.
The term “including” is used herein to mean, and is used interchangeably with, the phrase “including but not limited to”.
The term “or” is used herein to mean, and is used interchangeably with, the term “and/or,” unless context clearly indicates otherwise.
As used herein, “complement component C5,” used interchangeably with the term “C5” refers to the well-known gene and polypeptide, also known in the art as CPAMD4, C3 and PZP-like alpha-2-macroglobulin domain-containing protein, anaphtlatoxin C5a analog, hemolytic complement (Hc), and complement C5. The sequence of a human C5 mRNA transcript can be found at, for example, GenBank Accession No. GI:38016946 (NM—001735.2; SEQ ID NO:1). The sequence of rhesus C5 mRNA can be found at, for example, GenBank Accession No. GI:297270262 (XM—001095750.2; SEQ ID NO:2). The sequence of mouse C5 mRNA can be found at, for example, GenBank Accession No. GI:291575171 (NM—010406.2; SEQ ID NO:3). The sequence of rat C5 mRNA can be found at, for example, GenBank Accession No. GI:392346248 (XM—345342.4; SEQ ID NO:4). Additional examples of C5 mRNA sequences are readily available using publicly available databases, e.g., GenBank.
The term “C5,” as used herein, also refers to naturally occurring DNA sequence variations of the C5 gene, such as a single nucleotide polymorphism in the C5 gene. Numerous SNPs within the C5 gene have been identified and may be found at, for example, NCBI dbSNP (see, e.g., ncbi.nlm.nih.gov/snp). Non-limiting examples of SNPs within the C5 gene may be found at, NCBI dbSNP Accession Nos. rs121909588 and rs121909587.
As used herein, “target sequence” refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of a C5 gene, including mRNA that is a product of RNA processing of a primary transcription product. In one embodiment, the target portion of the sequence will be at least long enough to serve as a substrate for iRNA-directed cleavage at or near that portion of the nucleotide sequence of an mRNA molecule formed during the transcription of a C5 gene.
The target sequence may be from about 9-36 nucleotides in length, e.g., about 15-30 nucleotides in length. For example, the target sequence can be from about 15-30 nucleotides, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.
As used herein, the term “strand comprising a sequence” refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.
“G,” “C,” “A,” “T” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine and uracil as a base, respectively. However, it will be understood that the term “ribonucleotide” or “nucleotide” can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety (see, e.g., Table 2). The skilled person is well aware that guanine, cytosine, adenine, and uracil can be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of dsRNA featured in the invention by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the invention.
The terms “iRNA”, “RNAi agent,” “iRNA agent,”, “RNA interference agent” as used interchangeably herein, refer to an agent that contains RNA as that term is defined herein, and which mediates the targeted cleavage of an RNA transcript via an RNA-induced silencing complex (RISC) pathway. iRNA directs the sequence-specific degradation of mRNA through a process known as RNA interference (RNAi). The iRNA modulates, e.g., inhibits, the expression of C5 in a cell, e.g., a cell within a subject, such as a mammalian subject.
In one embodiment, an RNAi agent of the invention includes a single stranded RNA that interacts with a target RNA sequence, e.g., a C5 target mRNA sequence, to direct the cleavage of the target RNA. Without wishing to be bound by theory it is believed that long double stranded RNA introduced into cells is broken down into siRNA by a Type III endonuclease known as Dicer (Sharp et al. (2001) Genes Dev. 15:485). Dicer, a ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3′ overhangs (Bernstein, et al., (2001) Nature 409:363). The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition (Nykanen, et al., (2001) Cell 107:309). Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleave the target to induce silencing (Elbashir, et al., (2001) Genes Dev. 15:188). Thus, in one aspect the invention relates to a single stranded RNA (siRNA) generated within a cell and which promotes the formation of a RISC complex to effect silencing of the target gene, i.e., a C5 gene. Accordingly, the term “siRNA” is also used herein to refer to an RNAi as described above.
In another embodiment, the RNAi agent may be a single-stranded siRNA that is introduced into a cell or organism to inhibit a target mRNA. Single-stranded RNAi agents bind to the RISC endonuclease, Argonaute 2, which then cleaves the target mRNA. The single-stranded siRNAs are generally 15-30 nucleotides and are chemically modified. The design and testing of single-stranded siRNAs are described in U.S. Pat. No. 8,101,348 and in Lima et al., (2012) Cell 150: 883-894, the entire contents of each of which are hereby incorporated herein by reference. Any of the antisense nucleotide sequences described herein may be used as a single-stranded siRNA as described herein or as chemically modified by the methods described in Lima et al., (2012) Cell 150:883-894.
In another embodiment, an “iRNA” for use in the compositions, uses, and methods of the invention is a double-stranded RNA and is referred to herein as a “double stranded RNAi agent,” “double-stranded RNA (dsRNA) molecule,” “dsRNA agent,” or “dsRNA”. The term “dsRNA”, refers to a complex of ribonucleic acid molecules, having a duplex structure comprising two anti-parallel and substantially complementary nucleic acid strands, referred to as having “sense” and “antisense” orientations with respect to a target RNA, i.e., a C5 gene. In some embodiments of the invention, a double-stranded RNA (dsRNA) triggers the degradation of a target RNA, e.g., an mRNA, through a post-transcriptional gene-silencing mechanism referred to herein as RNA interference or RNAi.
In general, the majority of nucleotides of each strand of a dsRNA molecule are ribonucleotides, but as described in detail herein, each or both strands can also include one or more non-ribonucleotides, e.g., a deoxyribonucleotide and/or a modified nucleotide. In addition, as used in this specification, an “RNAi agent” may include ribonucleotides with chemical modifications; an RNAi agent may include substantial modifications at multiple nucleotides. Such modifications may include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a siRNA type molecule, are encompassed by “RNAi agent” for the purposes of this specification and claims.
The duplex region may be of any length that permits specific degradation of a desired target RNA through a RISC pathway, and may range from about 9 to 36 base pairs in length, e.g., about 15-30 base pairs in length, for example, about 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 base pairs in length, such as about 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.
The two strands forming the duplex structure may be different portions of one larger RNA molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′-end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a “hairpin loop.” A hairpin loop can comprise at least one unpaired nucleotide. In some embodiments, the hairpin loop can comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 23 or more unpaired nucleotides.
Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not, but can be covalently connected. Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′-end of the respective other strand forming the duplex structure, the connecting structure is referred to as a “linker.” The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, an RNAi may comprise one or more nucleotide overhangs.
In one embodiment, an RNAi agent of the invention is a dsRNA of 24-30 nucleotides that interacts with a target RNA sequence, e.g., a C5 target mRNA sequence, to direct the cleavage of the target RNA. Without wishing to be bound by theory, long double stranded RNA introduced into cells is broken down into siRNA by a Type III endonuclease known as Dicer (Sharp et al. (2001) Genes Dev. 15:485). Dicer, a ribonuclease-III-like enzyme, processes the dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3′ overhangs (Bernstein, et al., (2001) Nature 409:363). The siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition (Nykanen, et al., (2001) Cell 107:309). Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleave the target to induce silencing (Elbashir, et al., (2001) Genes Dev. 15:188).
As used herein, the term “nucleotide overhang” refers to at least one unpaired nucleotide that protrudes from the duplex structure of an iRNA, e.g., a dsRNA. For example, when a 3′-end of one strand of a dsRNA extends beyond the 5′-end of the other strand, or vice versa, there is a nucleotide overhang. A dsRNA can comprise an overhang of at least one nucleotide; alternatively the overhang can comprise at least two nucleotides, at least three nucleotides, at least four nucleotides, at least five nucleotides or more. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5′-end, 3′-end or both ends of either an antisense or sense strand of a dsRNA.
In one embodiment, the antisense strand of a dsRNA has a 1-10 nucleotide, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end and/or the 5′-end. In one embodiment, the sense strand of a dsRNA has a 1-10 nucleotide, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end and/or the 5′-end. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.
“Blunt” or “blunt end” means that there are no unpaired nucleotides at that end of the double stranded RNAi agent, i.e., no nucleotide overhang. A “blunt ended” RNAi agent is a dsRNA that is double-stranded over its entire length, i.e., no nucleotide overhang at either end of the molecule. The RNAi agents of the invention include RNAi agents with nucleotide overhangs at one end (i.e., agents with one overhang and one blunt end) or with nucleotide overhangs at both ends.
The term “antisense strand” or “guide strand” refers to the strand of an iRNA, e.g., a dsRNA, which includes a region that is substantially complementary to a target sequence, e.g., a C5 mRNA. As used herein, the term “region of complementarity” refers to the region on the antisense strand that is substantially complementary to a sequence, for example a target sequence, e.g., a C5 nucleotide sequence, as defined herein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches can be in the internal or terminal regions of the molecule. Generally, the most tolerated mismatches are in the terminal regions, e.g., within 5, 4, 3, or 2 nucleotides of the 5′- and/or 3′-terminus of the iRNA.
The term “sense strand,” or “passenger strand” as used herein, refers to the strand of an iRNA that includes a region that is substantially complementary to a region of the antisense strand as that term is defined herein.
As used herein, the term “cleavage region” refers to a region that is located immediately adjacent to the cleavage site. The cleavage site is the site on the target at which cleavage occurs. In some embodiments, the cleavage region comprises three bases on either end of, and immediately adjacent to, the cleavage site. In some embodiments, the cleavage region comprises two bases on either end of, and immediately adjacent to, the cleavage site. In some embodiments, the cleavage site specifically occurs at the site bound by nucleotides 10 and 11 of the antisense strand, and the cleavage region comprises nucleotides 11, 12 and 13.
As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize and form a duplex structure under certain conditions with an oligonucleotide or polynucleotide comprising the second nucleotide sequence, as will be understood by the skilled person. Such conditions can, for example, be stringent conditions, where stringent conditions can include: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50° C. or 70° C. for 12-16 hours followed by washing (see, e.g., “Molecular Cloning: A Laboratory Manual, Sambrook, et al. (1989) Cold Spring Harbor Laboratory Press). Other conditions, such as physiologically relevant conditions as can be encountered inside an organism, can apply. The skilled person will be able to determine the set of conditions most appropriate for a test of complementarity of two sequences in accordance with the ultimate application of the hybridized nucleotides.
Complementary sequences within an iRNA, e.g., within a dsRNA as described herein, include base-pairing of the oligonucleotide or polynucleotide comprising a first nucleotide sequence to an oligonucleotide or polynucleotide comprising a second nucleotide sequence over the entire length of one or both nucleotide sequences. Such sequences can be referred to as “fully complementary” with respect to each other herein. However, where a first sequence is referred to as “substantially complementary” with respect to a second sequence herein, the two sequences can be fully complementary, or they can form one or more, but generally not more than 5, 4, 3 or 2 mismatched base pairs upon hybridization for a duplex up to 30 base pairs, while retaining the ability to hybridize under the conditions most relevant to their ultimate application, e.g., inhibition of gene expression via a RISC pathway. However, where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs shall not be regarded as mismatches with regard to the determination of complementarity. For example, a dsRNA comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is fully complementary to the shorter oligonucleotide, can yet be referred to as “fully complementary” for the purposes described herein.
“Complementary” sequences, as used herein, can also include, or be formed entirely from, non-Watson-Crick base pairs and/or base pairs formed from non-natural and modified nucleotides, in so far as the above requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs include, but are not limited to, G:U Wobble or Hoogstein base pairing.
The terms “complementary,” “fully complementary” and “substantially complementary” herein can be used with respect to the base matching between the sense strand and the antisense strand of a dsRNA, or between the antisense strand of an iRNA agent and a target sequence, as will be understood from the context of their use.
As used herein, a polynucleotide that is “substantially complementary to at least part of” a messenger RNA (mRNA) refers to a polynucleotide that is substantially complementary to a contiguous portion of the mRNA of interest (e.g., an mRNA encoding C5). For example, a polynucleotide is complementary to at least a part of a C5 mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding C5.
In general, the majority of nucleotides of each strand are ribonucleotides, but as described in detail herein, each or both strands can also include one or more non-ribonucleotides, e.g., a deoxyribonucleotide and/or a modified nucleotide. In addition, an “iRNA” may include ribonucleotides with chemical modifications. Such modifications may include all types of modifications disclosed herein or known in the art. Any such modifications, as used in an iRNA molecule, are encompassed by “iRNA” for the purposes of this specification and claims.
In one aspect of the invention, an agent for use in the methods and compositions of the invention is a single-stranded antisense RNA molecule that inhibits a target mRNA via an antisense inhibition mechanism. The single-stranded antisense RNA molecule is complementary to a sequence within the target mRNA. The single-stranded antisense oligonucleotides can inhibit translation in a stoichiometric manner by base pairing to the mRNA and physically obstructing the translation machinery, see Dias, N. et al., (2002) Mol Cancer Ther 1:347-355. The single-stranded antisense RNA molecule may be about 15 to about 30 nucleotides in length and have a sequence that is complementary to a target sequence. For example, the single-stranded antisense RNA molecule may comprise a sequence that is at least about 15, 16, 17, 18, 19, 20, or more contiguous nucleotides from any one of the antisense sequences described herein.
The term “lipid nanoparticle” or “LNP” is a vesicle comprising a lipid layer encapsulating a pharmaceutically active molecule, such as a nucleic acid molecule, e.g., an iRNA or a plasmid from which an iRNA is transcribed. LNPs are described in, for example, U.S. Pat. Nos. 6,858,225, 6,815,432, 8,158,601, and 8,058,069, the entire contents of which are hereby incorporated herein by reference.
As used herein, a “subject” is an animal, such as a mammal, including a primate (such as a human, a non-human primate, e.g., a monkey, and a chimpanzee), a non-primate (such as a cow, a pig, a camel, a llama, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, a mouse, a horse, and a whale), or a bird (e.g., a duck or a goose). In an embodiment, the subject is a human, such as a human being treated or assessed for a disease, disorder or condition that would benefit from reduction in C5 expression; a human at risk for a disease, disorder or condition that would benefit from reduction in C5 expression; a human having a disease, disorder or condition that would benefit from reduction in C5 expression; and/or human being treated for a disease, disorder or condition that would benefit from reduction in C5 expression as described herein.
As used herein, the terms “treating” or “treatment” refer to a beneficial or desired result including, but not limited to, alleviation or amelioration of one or more symptoms associated with unwanted complement pathway activation (e.g., hemolysis and/or chronic inflammation); diminishing the extent of unwanted complement pathway activation; stabilization (i.e., not worsening) of the state of chronic inflammation and/or hemolysis; amelioration or palliation of unwanted complement pathway activation (e.g., chronic inflammation and/or hemolysis) whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival in the absence of treatment.
The term “lower” in the context of the level of a complement component C5 in a subject or a disease marker or symptom refers to a statistically significant decrease in such level. The decrease can be, for example, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or more and is preferably down to a level accepted as within the range of normal for an individual without such disorder.
As used herein, “prevention” or “preventing,” when used in reference to a disease, disorder or condition thereof, that would benefit from a reduction in expression of a C5 gene, refers to a reduction in the likelihood that a subject will develop a symptom associated with such a disease, disorder, or condition, e.g., a symptom of unwanted complement activation, such as a chronic inflammation, hemolysis and/or thrombosis. The likelihood of developing a thrombosis is reduced, for example, when an individual having one or more risk factors for a thrombosis either fails to develop a thrombosis or develops a thrombosis with less severity relative to a population having the same risk factors and not receiving treatment as described herein. The failure to develop a disease, disorder or condition, or the reduction in the development of a symptom associated with such a disease, disorder or condition (e.g., by at least about 10% on a clinically accepted scale for that disease or disorder), or the exhibition of delayed symptoms delayed (e.g., by days, weeks, months or years) is considered effective prevention.
As used herein, the term “complement component C5-associated disease” is a disease or disorder that is caused by, or associated with complement activation. Such diseases are typically associated with inflammation and/or immune system activation, e.g., membrane attack complex-mediated lysis, anaphylaxis, and/or hemolysis. Non-limiting examples of complement component C5-associated diseases include paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), asthma, rheumatoid arthritis (RA); antiphospholipid antibody syndrome; lupus nephritis; ischemia-reperfusion injury; typical or infectious hemolytic uremic syndrome (tHUS); dense deposit disease (DDD); neuromyelitis optica (NMO); multifocal motor neuropathy (MMN); multiple sclerosis (MS); macular degeneration (e.g., age-related macular degeneration (AMD)); hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome; thrombotic thrombocytopenic purpura (TTP); spontaneous fetal loss; Pauci-immune vasculitis; epidermolysis bullosa; recurrent fetal loss; pre-eclampsia, traumatic brain injury, myasthenia gravis, cold agglutinin disease, dermatomyositis bullous pemphigoid, Shiga toxin E. coli-related hemolytic uremic syndrome, C3 nephropathy, anti-neutrophil cytoplasmic antibody-associated vasculitis (e.g., granulomatosis with polyangiitis (previously known as Wegener granulomatosis), Churg-Strauss syndrome, and microscopic polyangiitis), humoral and vascular transplant rejection, graft dysfunction, myocardial infarction (e.g., tissue damage and ischemia in myocardial infarction), an allogenic transplant, sepsis (e.g., poor outcome in sepsis), Coronary artery disease, dermatomyositis, Graves' disease, atherosclerosis, Alzheimer's disease, systemic inflammatory response sepsis, septic shock, spinal cord injury, glomerulonephritis, Hashimoto's thyroiditis, type I diabetes, psoriasis, pemphigus, autoimmune hemolytic anemia (AIHA), ITP, Goodpasture syndrome, Degos disease, antiphospholipid syndrome (APS), catastrophic APS (CAPS), a cardiovascular disorder, myocarditis, a cerebrovascular disorder, a peripheral (e.g., musculoskeletal) vascular disorder, a renovascular disorder, a mesenteric/enteric vascular disorder, vasculitis, Henoch-Schönlein purpura nephritis, systemic lupus erythematosus-associated vasculitis, vasculitis associated with rheumatoid arthritis, immune complex vasculitis, Takayasu's disease, dilated cardiomyopathy, diabetic angiopathy, Kawasaki's disease (arteritis), venous gas embolus (VGE), and restenosis following stent placement, rotational atherectomy, membraneous nephropathy, Guillain-Barre syndrome, and percutaneous transluminal coronary angioplasty (PTCA) (see, e.g., Holers (2008) Immunological Reviews 223:300-316; Holers and Thurman (2004) Molecular Immunology 41:147-152; U.S. Patent Publication No. 20070172483).
In one embodiment, a complement component C5-associated disease is paroxysmal nocturnal hemoglobinuria (PNH). The PNH may be classical PNH or PNH in the setting of another bone marrow failure syndrome and/or myelodysplastic syndromes (MDS), e.g., cytopenias. In another embodiment, a complement component C5-associated disease is atypical hemolytic uremic syndrome (aHUS).
II. iRNAS of the Invention
The present invention provides iRNAs which inhibit the expression of a complement component C5 gene. In one embodiment, the iRNA agent includes double-stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of a C5 gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human having a complement component C5-associated disease, e.g., PNH. The dsRNA includes an antisense strand having a region of complementarity which is complementary to at least a part of an mRNA formed in the expression of a C5 gene. The region of complementarity is about 30 nucleotides or less in length (e.g., about 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, or 18 nucleotides or less in length). Upon contact with a cell expressing the C5 gene, the iRNA inhibits the expression of the C5 gene (e.g., a human, a primate, a non-primate, or a bird C5 gene) by at least about 10% as assayed by, for example, a PCR or branched DNA (bDNA)-based method, or by a protein-based method, such as by immunofluorescence analysis, using, for example, Western Blotting or flowcytometric techniques.
A dsRNA includes two RNA strands that are complementary and hybridize to form a duplex structure under conditions in which the dsRNA will be used. One strand of a dsRNA (the antisense strand) includes a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence. The target sequence can be derived from the sequence of an mRNA formed during the expression of a C5 gene. The other strand (the sense strand) includes a region that is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. As described elsewhere herein and as known in the art, the complementary sequences of a dsRNA can also be contained as self-complementary regions of a single nucleic acid molecule, as opposed to being on separate oligonucleotides.
Generally, the duplex structure is between 15 and 30 base pairs in length, e.g., between, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.
Similarly, the region of complementarity to the target sequence is between 15 and 30 nucleotides in length, e.g., between 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.
In some embodiments, the dsRNA is between about 15 and about 20 nucleotides in length, or between about 25 and about 30 nucleotides in length. In general, the dsRNA is long enough to serve as a substrate for the Dicer enzyme. For example, it is well-known in the art that dsRNAs longer than about 21-23 nucleotides in length may serve as substrates for Dicer. As the ordinarily skilled person will also recognize, the region of an RNA targeted for cleavage will most often be part of a larger RNA molecule, often an mRNA molecule. Where relevant, a “part” of an mRNA target is a contiguous sequence of an mRNA target of sufficient length to allow it to be a substrate for RNAi-directed cleavage (i.e., cleavage through a RISC pathway).
One of skill in the art will also recognize that the duplex region is a primary functional portion of a dsRNA, e.g., a duplex region of about 9 to 36 base pairs, e.g., about 10-36, 11-36, 12-36, 13-36, 14-36, 15-36, 9-35, 10-35, 11-35, 12-35, 13-35, 14-35, 15-35, 9-34, 10-34, 11-34, 12-34, 13-34, 14-34, 15-34, 9-33, 10-33, 11-33, 12-33, 13-33, 14-33, 15-33, 9-32, 10-32, 11-32, 12-32, 13-32, 14-32, 15-32, 9-31, 10-31, 11-31, 12-31, 13-32, 14-31, 15-31, 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs. Thus, in one embodiment, to the extent that it becomes processed to a functional duplex, of e.g., 15-30 base pairs, that targets a desired RNA for cleavage, an RNA molecule or complex of RNA molecules having a duplex region greater than 30 base pairs is a dsRNA. Thus, an ordinarily skilled artisan will recognize that in one embodiment, a miRNA is a dsRNA. In another embodiment, a dsRNA is not a naturally occurring miRNA. In another embodiment, an iRNA agent useful to target C5 expression is not generated in the target cell by cleavage of a larger dsRNA.
A dsRNA as described herein can further include one or more single-stranded nucleotide overhangs e.g., 1, 2, 3, or 4 nucleotides. dsRNAs having at least one nucleotide overhang can have unexpectedly superior inhibitory properties relative to their blunt-ended counterparts. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5′-end, 3′-end or both ends of either an antisense or sense strand of a dsRNA.
A dsRNA can be synthesized by standard methods known in the art as further discussed below, e.g., by use of an automated DNA synthesizer, such as are commercially available from, for example, Biosearch, Applied Biosystems, Inc.
iRNA compounds of the invention may be prepared using a two-step procedure. First, the individual strands of the double-stranded RNA molecule are prepared separately. Then, the component strands are annealed. The individual strands of the siRNA compound can be prepared using solution-phase or solid-phase organic synthesis or both. Organic synthesis offers the advantage that the oligonucleotide strands comprising unnatural or modified nucleotides can be easily prepared. Single-stranded oligonucleotides of the invention can be prepared using solution-phase or solid-phase organic synthesis or both.
In one aspect, a dsRNA of the invention includes at least two nucleotide sequences, a sense sequence and an anti-sense sequence. The sense strand is selected from the group of sequences provided in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23, and the corresponding antisense strand of the sense strand is selected from the group of sequences of any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23. In this aspect, one of the two sequences is complementary to the other of the two sequences, with one of the sequences being substantially complementary to a sequence of an mRNA generated in the expression of a C5 gene. As such, in this aspect, a dsRNA will include two oligonucleotides, where one oligonucleotide is described as the sense strand in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23, and the second oligonucleotide is described as the corresponding antisense strand of the sense strand in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23. In one embodiment, the substantially complementary sequences of the dsRNA are contained on separate oligonucleotides. In another embodiment, the substantially complementary sequences of the dsRNA are contained on a single oligonucleotide.
It will be understood that, although some of the sequences in Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23 are described as modified and/or conjugated sequences, the RNA of the iRNA of the invention e.g., a dsRNA of the invention, may comprise any one of the sequences set forth in Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23 that is un-modified, un-conjugated, and/or modified and/or conjugated differently than described therein.
The skilled person is well aware that dsRNAs having a duplex structure of between about 20 and 23 base pairs, e.g., 21, base pairs have been hailed as particularly effective in inducing RNA interference (Elbashir et al., EMBO 2001, 20:6877-6888). However, others have found that shorter or longer RNA duplex structures can also be effective (Chu and Rana (2007) RNA 14:1714-1719; Kim et al. (2005) Nat Biotech 23:222-226). In the embodiments described above, by virtue of the nature of the oligonucleotide sequences provided in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23, dsRNAs described herein can include at least one strand of a length of minimally 21 nucleotides. It can be reasonably expected that shorter duplexes having one of the sequences of any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23 minus only a few nucleotides on one or both ends can be similarly effective as compared to the dsRNAs described above. Hence, dsRNAs having a sequence of at least 15, 16, 17, 18, 19, 20, or more contiguous nucleotides derived from one of the sequences of any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23, and differing in their ability to inhibit the expression of a C5 gene by not more than about 5, 10, 15, 20, 25, or 30% inhibition from a dsRNA comprising the full sequence, are contemplated to be within the scope of the present invention.
In addition, the RNAs provided in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23 identify a site(s) in a C5 transcript that is susceptible to RISC-mediated cleavage. As such, the present invention further features iRNAs that target within one of these sites. As used herein, an iRNA is said to target within a particular site of an RNA transcript if the iRNA promotes cleavage of the transcript anywhere within that particular site. Such an iRNA will generally include at least about 15 contiguous nucleotides from one of the sequences provided in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23 coupled to additional nucleotide sequences taken from the region contiguous to the selected sequence in a C5 gene.
While a target sequence is generally about 15-30 nucleotides in length, there is wide variation in the suitability of particular sequences in this range for directing cleavage of any given target RNA. Various software packages and the guidelines set out herein provide guidance for the identification of optimal target sequences for any given gene target, but an empirical approach can also be taken in which a “window” or “mask” of a given size (as a non-limiting example, 21 nucleotides) is literally or figuratively (including, e.g., in silico) placed on the target RNA sequence to identify sequences in the size range that can serve as target sequences. By moving the sequence “window” progressively one nucleotide upstream or downstream of an initial target sequence location, the next potential target sequence can be identified, until the complete set of possible sequences is identified for any given target size selected. This process, coupled with systematic synthesis and testing of the identified sequences (using assays as described herein or as known in the art) to identify those sequences that perform optimally can identify those RNA sequences that, when targeted with an iRNA agent, mediate the best inhibition of target gene expression. Thus, while the sequences identified, for example, in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23 represent effective target sequences, it is contemplated that further optimization of inhibition efficiency can be achieved by progressively “walking the window” one nucleotide upstream or downstream of the given sequences to identify sequences with equal or better inhibition characteristics.
Further, it is contemplated that for any sequence identified, e.g., in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23, further optimization could be achieved by systematically either adding or removing nucleotides to generate longer or shorter sequences and testing those sequences generated by walking a window of the longer or shorter size up or down the target RNA from that point. Again, coupling this approach to generating new candidate targets with testing for effectiveness of iRNAs based on those target sequences in an inhibition assay as known in the art and/or as described herein can lead to further improvements in the efficiency of inhibition. Further still, such optimized sequences can be adjusted by, e.g., the introduction of modified nucleotides as described herein or as known in the art, addition or changes in overhang, or other modifications as known in the art and/or discussed herein to further optimize the molecule (e.g., increasing serum stability or circulating half-life, increasing thermal stability, enhancing transmembrane delivery, targeting to a particular location or cell type, increasing interaction with silencing pathway enzymes, increasing release from endosomes) as an expression inhibitor.
An iRNA as described herein can contain one or more mismatches to the target sequence. In one embodiment, an iRNA as described herein contains no more than 3 mismatches. If the antisense strand of the iRNA contains mismatches to a target sequence, it is preferable that the area of mismatch is not located in the center of the region of complementarity. If the antisense strand of the iRNA contains mismatches to the target sequence, it is preferable that the mismatch be restricted to be within the last 5 nucleotides from either the 5′- or 3′-end of the region of complementarity. For example, for a 23 nucleotide iRNA agent the strand which is complementary to a region of a C5 gene, generally does not contain any mismatch within the central 13 nucleotides. The methods described herein or methods known in the art can be used to determine whether an iRNA containing a mismatch to a target sequence is effective in inhibiting the expression of a C5 gene. Consideration of the efficacy of iRNAs with mismatches in inhibiting expression of a C5 gene is important, especially if the particular region of complementarity in a C5 gene is known to have polymorphic sequence variation within the population.
III. Modified iRNAS of the Invention
In one embodiment, the RNA of the iRNA of the invention e.g., a dsRNA, is un-modified, and does not comprise, e.g., chemical modifications and/or conjugations known in the art and described herein. In another embodiment, the RNA of an iRNA of the invention, e.g., a dsRNA, is chemically modified to enhance stability or other beneficial characteristics. In certain embodiments of the invention, substantially all of the nucleotides of an iRNA of the invention are modified. In other embodiments of the invention, all of the nucleotides of an iRNA of the invention are modified. iRNAs of the invention in which “substantially all of the nucleotides are modified” are largely but not wholly modified and can include not more than 5, 4, 3, 2, or 1 unmodified nucleotides.
The nucleic acids featured in the invention can be synthesized and/or modified by methods well established in the art, such as those described in “Current protocols in nucleic acid chemistry,” Beaucage, S. L. et al. (Edrs.), John Wiley & Sons, Inc., New York, N.Y., USA, which is hereby incorporated herein by reference. Modifications include, for example, end modifications, e.g., 5′-end modifications (phosphorylation, conjugation, inverted linkages) or 3′-end modifications (conjugation, DNA nucleotides, inverted linkages, etc.); base modifications, e.g., replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases; sugar modifications (e.g., at the 2′-position or 4′-position) or replacement of the sugar; and/or backbone modifications, including modification or replacement of the phosphodiester linkages. Specific examples of iRNA compounds useful in the embodiments described herein include, but are not limited to RNAs containing modified backbones or no natural internucleoside linkages. RNAs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In some embodiments, a modified iRNA will have a phosphorus atom in its internucleoside backbone.
Modified RNA backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′-linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts and free acid forms are also included.
Representative U.S. patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170; 6,172,209; 6,239,265; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and U.S. Pat. No. RE39464, the entire contents of each of which are hereby incorporated herein by reference.
Modified RNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts.
Representative U.S. patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and, 5,677,439, the entire contents of each of which are hereby incorporated herein by reference.
In other embodiments, suitable RNA mimetics are contemplated for use in iRNAs, in which both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an RNA mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an RNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, the entire contents of each of which are hereby incorporated herein by reference. Additional PNA compounds suitable for use in the iRNAs of the invention are described in, for example, in Nielsen et al., Science, 1991, 254, 1497-1500.
Some embodiments featured in the invention include RNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular —CH2—NH—CH2—, —CH2—N(CH3)—O—CH2-[known as a methylene (methylimino) or MMI backbone], —CH2—O—N(CH3)—CH2—, —CH2—N(CH3)—N(CH3)—CH2— and —N(CH3)—CH2—CH2-[wherein the native phosphodiester backbone is represented as —O—P—O—CH2—] of the above-referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above-referenced U.S. Pat. No. 5,602,240. In some embodiments, the RNAs featured herein have morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.
Modified RNAs can also contain one or more substituted sugar moieties. The iRNAs, e.g., dsRNAs, featured herein can include one of the following at the 2′-position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted C1 to C10 alkyl or C2 to C10 alkenyl and alkynyl. Exemplary suitable modifications include O[(CH2)nO]mCH3, O(CH2).nOCH3, O(CH2)nNH2, O(CH2)nCH3, O(CH2)nONH2, and O(CH2)nON[(CH2)nCH3)]2, where n and m are from 1 to about 10. In other embodiments, dsRNAs include one of the following at the 2′ position: C1 to C10 lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an iRNA, or a group for improving the pharmacodynamic properties of an iRNA, and other substituents having similar properties. In some embodiments, the modification includes a 2′-methoxyethoxy (2′-O—CH2CH2OCH3, also known as 2′-O-(2-methoxyethyl) or 2′-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78:486-504) i.e., an alkoxy-alkoxy group. Another exemplary modification is 2′-dimethylaminooxyethoxy, i.e., a O(CH2)2ON(CH3)2 group, also known as 2′-DMAOE, as described in examples herein below, and 2′-dimethylaminoethoxyethoxy (also known in the art as 2′-O-dimethylaminoethoxyethyl or 2′-DMAEOE), i.e., 2′-O—CH2—O—CH2—N(CH2)2.
Other modifications include 2′-methoxy (2′-OCH3), 2′-aminopropoxy (2′-OCH2CH2CH2NH2) and 2′-fluoro (2′-F). Similar modifications can also be made at other positions on the RNA of an iRNA, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked dsRNAs and the 5′ position of 5′ terminal nucleotide. iRNAs can also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative U.S. patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application. The entire contents of each of the foregoing are hereby incorporated herein by reference.
An iRNA can also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as deoxy-thymine (dT), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl anal other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008; those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. L, ed. John Wiley & Sons, 1990, these disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, dsRNA Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are exemplary base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications.
Representative U.S. patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. Nos. 3,687,808, 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, the entire contents of each of which are hereby incorporated herein by reference.
The RNA of an iRNA can also be modified to include one or more locked nucleic acids (LNA). A locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2′ and 4′ carbons. This structure effectively “locks” the ribose in the 3′-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33(1):439-447; Mook, O R. et al., (2007) Mol Canc Ther 6(3):833-843; Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193).
Representative U.S. patents that teach the preparation of locked nucleic acid nucleotides include, but are not limited to, the following: U.S. Pat. Nos. 6,268,490; 6,670,461; 6,794,499; 6,998,484; 7,053,207; 7,084,125; and 7,399,845, the entire contents of each of which are hereby incorporated herein by reference.
Potentially stabilizing modifications to the ends of RNA molecules can include N-(acetylaminocaproyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproyl-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2′-0-deoxythymidine (ether), N-(aminocaproyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3′′-phosphate, inverted base dT(idT) and others. Disclosure of this modification can be found in PCT Publication No. WO 2011/005861.
A. Modified iRNAs Comprising Motifs of the Invention
In certain aspects of the invention, the double-stranded RNAi agents of the invention include agents with chemical modifications as disclosed, for example, in U.S. Provisional Application No. 61/561,710, filed on Nov. 18, 2011, or in PCT/US2012/065691, filed on Nov. 16, 2012, the entire contents of each of which are incorporated herein by reference.
As shown herein and in Provisional Application No. 61/561,710 or PCT Application No. PCT/US2012/065691, a superior result may be obtained by introducing one or more motifs of three identical modifications on three consecutive nucleotides into a sense strand and/or antisense strand of an RNAi agent, particularly at or near the cleavage site. In some embodiments, the sense strand and antisense strand of the RNAi agent may otherwise be completely modified. The introduction of these motifs interrupts the modification pattern, if present, of the sense and/or antisense strand. The RNAi agent may be optionally conjugated with a GalNAc derivative ligand, for instance on the sense strand. The resulting RNAi agents present superior gene silencing activity.
More specifically, it has been surprisingly discovered that when the sense strand and antisense strand of the double-stranded RNAi agent are completely modified to have one or more motifs of three identical modifications on three consecutive nucleotides at or near the cleavage site of at least one strand of an RNAi agent, the gene silencing activity of the RNAi agent was superiorly enhanced.
Accordingly, the invention provides double-stranded RNAi agents capable of inhibiting the expression of a target gene (i.e., a complement component C5 (C5) gene) in vivo. The RNAi agent comprises a sense strand and an antisense strand. Each strand of the RNAi agent may range from 12-30 nucleotides in length. For example, each strand may be between 14-30 nucleotides in length, 17-30 nucleotides in length, 25-30 nucleotides in length, 27-30 nucleotides in length, 17-23 nucleotides in length, 17-21 nucleotides in length, 17-19 nucleotides in length, 19-25 nucleotides in length, 19-23 nucleotides in length, 19-21 nucleotides in length, 21-25 nucleotides in length, or 21-23 nucleotides in length.
The sense strand and antisense strand typically form a duplex double stranded RNA (“dsRNA”), also referred to herein as an “RNAi agent.” The duplex region of an RNAi agent may be 12-30 nucleotide pairs in length. For example, the duplex region can be between 14-30 nucleotide pairs in length, 17-30 nucleotide pairs in length, 27-30 nucleotide pairs in length, 17-23 nucleotide pairs in length, 17-21 nucleotide pairs in length, 17-19 nucleotide pairs in length, 19-25 nucleotide pairs in length, 19-23 nucleotide pairs in length, 19-21 nucleotide pairs in length, 21-25 nucleotide pairs in length, or 21-23 nucleotide pairs in length. In another example, the duplex region is selected from 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, and 27 nucleotides in length.
In one embodiment, the RNAi agent may contain one or more overhang regions and/or capping groups at the 3′-end, 5′-end, or both ends of one or both strands. The overhang can be 1-6 nucleotides in length, for instance 2-6 nucleotides in length, 1-5 nucleotides in length, 2-5 nucleotides in length, 1-4 nucleotides in length, 2-4 nucleotides in length, 1-3 nucleotides in length, 2-3 nucleotides in length, or 1-2 nucleotides in length. The overhangs can be the result of one strand being longer than the other, or the result of two strands of the same length being staggered. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence. The first and second strands can also be joined, e.g., by additional bases to form a hairpin, or by other non-base linkers.
In one embodiment, the nucleotides in the overhang region of the RNAi agent can each independently be a modified or unmodified nucleotide including, but no limited to 2′-sugar modified, such as, 2-F, 2′-Omethyl, thymidine (T), 2′-O-methoxyethyl-5-methyluridine (Teo), 2′-O-methoxyethyladenosine (Aeo), 2′-O-methoxyethyl-5-methylcytidine (m5Ceo), and any combinations thereof. For example, TT can be an overhang sequence for either end on either strand. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence.
The 5′- or 3′-overhangs at the sense strand, antisense strand or both strands of the RNAi agent may be phosphorylated. In some embodiments, the overhang region(s) contains two nucleotides having a phosphorothioate between the two nucleotides, where the two nucleotides can be the same or different. In one embodiment, the overhang is present at the 3′-end of the sense strand, antisense strand, or both strands. In one embodiment, this 3′-overhang is present in the antisense strand. In one embodiment, this 3′-overhang is present in the sense strand.
The RNAi agent may contain only a single overhang, which can strengthen the interference activity of the RNAi, without affecting its overall stability. For example, the single-stranded overhang may be located at the 3′-terminal end of the sense strand or, alternatively, at the 3′-terminal end of the antisense strand. The RNAi may also have a blunt end, located at the 5′-end of the antisense strand (or the 3′-end of the sense strand) or vice versa. Generally, the antisense strand of the RNAi has a nucleotide overhang at the 3′-end, and the 5′-end is blunt. While not wishing to be bound by theory, the asymmetric blunt end at the 5′-end of the antisense strand and 3′-end overhang of the antisense strand favor the guide strand loading into RISC process.
In one embodiment, the RNAi agent is a double ended bluntmer of 19 nucleotides in length, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 7, 8, 9 from the 5′end. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5′end.
In another embodiment, the RNAi agent is a double ended bluntmer of 20 nucleotides in length, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 8, 9, 10 from the 5′end. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5′end.
In yet another embodiment, the RNAi agent is a double ended bluntmer of 21 nucleotides in length, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 9, 10, 11 from the 5′end. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5′end.
In one embodiment, the RNAi agent comprises a 21 nucleotide sense strand and a 23 nucleotide antisense strand, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 9, 10, 11 from the 5′end; the antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5′end, wherein one end of the RNAi agent is blunt, while the other end comprises a 2 nucleotide overhang. Preferably, the 2 nucleotide overhang is at the 3′-end of the antisense strand. When the 2 nucleotide overhang is at the 3′-end of the antisense strand, there may be two phosphorothioate internucleotide linkages between the terminal three nucleotides, wherein two of the three nucleotides are the overhang nucleotides, and the third nucleotide is a paired nucleotide next to the overhang nucleotide. In one embodiment, the RNAi agent additionally has two phosphorothioate internucleotide linkages between the terminal three nucleotides at both the 5′-end of the sense strand and at the 5′-end of the antisense strand. In one embodiment, every nucleotide in the sense strand and the antisense strand of the RNAi agent, including the nucleotides that are part of the motifs are modified nucleotides. In one embodiment each residue is independently modified with a 2′-O-methyl or 3′-fluoro, e.g., in an alternating motif. Optionally, the RNAi agent further comprises a ligand (preferably GalNAc3).
In one embodiment, the RNAi agent comprises a sense and an antisense strand, wherein the sense strand is 25-30 nucleotide residues in length, wherein starting from the 5′ terminal nucleotide (position 1) positions 1 to 23 of the first strand comprise at least 8 ribonucleotides; the antisense strand is 36-66 nucleotide residues in length and, starting from the 3′ terminal nucleotide, comprises at least 8 ribonucleotides in the positions paired with positions 1-23 of sense strand to form a duplex; wherein at least the 3′ terminal nucleotide of antisense strand is unpaired with sense strand, and up to 6 consecutive 3′ terminal nucleotides are unpaired with sense strand, thereby forming a 3′ single stranded overhang of 1-6 nucleotides; wherein the 5′ terminus of antisense strand comprises from 10-30 consecutive nucleotides which are unpaired with sense strand, thereby forming a 10-30 nucleotide single stranded 5′ overhang; wherein at least the sense strand 5′ terminal and 3′ terminal nucleotides are base paired with nucleotides of antisense strand when sense and antisense strands are aligned for maximum complementarity, thereby forming a substantially duplexed region between sense and antisense strands; and antisense strand is sufficiently complementary to a target RNA along at least 19 ribonucleotides of antisense strand length to reduce target gene expression when the double stranded nucleic acid is introduced into a mammalian cell; and wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides, where at least one of the motifs occurs at or near the cleavage site. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at or near the cleavage site.
In one embodiment, the RNAi agent comprises sense and antisense strands, wherein the RNAi agent comprises a first strand having a length which is at least 25 and at most 29 nucleotides and a second strand having a length which is at most 30 nucleotides with at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at position 11, 12, 13 from the 5′ end; wherein the 3′ end of the first strand and the 5′ end of the second strand form a blunt end and the second strand is 1-4 nucleotides longer at its 3′ end than the first strand, wherein the duplex region which is at least 25 nucleotides in length, and the second strand is sufficiently complementary to a target mRNA along at least 19 nucleotide of the second strand length to reduce target gene expression when the RNAi agent is introduced into a mammalian cell, and wherein dicer cleavage of the RNAi agent preferentially results in an siRNA comprising the 3′ end of the second strand, thereby reducing expression of the target gene in the mammal. Optionally, the RNAi agent further comprises a ligand.
In one embodiment, the sense strand of the RNAi agent contains at least one motif of three identical modifications on three consecutive nucleotides, where one of the motifs occurs at the cleavage site in the sense strand.
In one embodiment, the antisense strand of the RNAi agent can also contain at least one motif of three identical modifications on three consecutive nucleotides, where one of the motifs occurs at or near the cleavage site in the antisense strand
For an RNAi agent having a duplex region of 17-23 nucleotide in length, the cleavage site of the antisense strand is typically around the 10, 11 and 12 positions from the 5′-end. Thus the motifs of three identical modifications may occur at the 9, 10, 11 positions; 10, 11, 12 positions; 11, 12, 13 positions; 12, 13, 14 positions; or 13, 14, 15 positions of the antisense strand, the count starting from the 1st nucleotide from the 5′-end of the antisense strand, or, the count starting from the 1st paired nucleotide within the duplex region from the 5′-end of the antisense strand. The cleavage site in the antisense strand may also change according to the length of the duplex region of the RNAi from the 5′-end.
The sense strand of the RNAi agent may contain at least one motif of three identical modifications on three consecutive nucleotides at the cleavage site of the strand; and the antisense strand may have at least one motif of three identical modifications on three consecutive nucleotides at or near the cleavage site of the strand. When the sense strand and the antisense strand form a dsRNA duplex, the sense strand and the antisense strand can be so aligned that one motif of the three nucleotides on the sense strand and one motif of the three nucleotides on the antisense strand have at least one nucleotide overlap, i.e., at least one of the three nucleotides of the motif in the sense strand forms a base pair with at least one of the three nucleotides of the motif in the antisense strand. Alternatively, at least two nucleotides may overlap, or all three nucleotides may overlap.
In one embodiment, the sense strand of the RNAi agent may contain more than one motif of three identical modifications on three consecutive nucleotides. The first motif may occur at or near the cleavage site of the strand and the other motifs may be a wing modification. The term “wing modification” herein refers to a motif occurring at another portion of the strand that is separated from the motif at or near the cleavage site of the same strand. The wing modification is either adjacent to the first motif or is separated by at least one or more nucleotides. When the motifs are immediately adjacent to each other then the chemistry of the motifs are distinct from each other and when the motifs are separated by one or more nucleotide than the chemistries can be the same or different. Two or more wing modifications may be present. For instance, when two wing modifications are present, each wing modification may occur at one end relative to the first motif which is at or near cleavage site or on either side of the lead motif.
Like the sense strand, the antisense strand of the RNAi agent may contain more than one motifs of three identical modifications on three consecutive nucleotides, with at least one of the motifs occurring at or near the cleavage site of the strand. This antisense strand may also contain one or more wing modifications in an alignment similar to the wing modifications that may be present on the sense strand.
In one embodiment, the wing modification on the sense strand or antisense strand of the RNAi agent typically does not include the first one or two terminal nucleotides at the 3′-end, 5′-end or both ends of the strand.
In another embodiment, the wing modification on the sense strand or antisense strand of the RNAi agent typically does not include the first one or two paired nucleotides within the duplex region at the 3′-end, 5′-end or both ends of the strand.
When the sense strand and the antisense strand of the RNAi agent each contain at least one wing modification, the wing modifications may fall on the same end of the duplex region, and have an overlap of one, two or three nucleotides.
When the sense strand and the antisense strand of the RNAi agent each contain at least two wing modifications, the sense strand and the antisense strand can be so aligned that two modifications each from one strand fall on one end of the duplex region, having an overlap of one, two or three nucleotides; two modifications each from one strand fall on the other end of the duplex region, having an overlap of one, two or three nucleotides; two modifications one strand fall on each side of the lead motif, having an overlap of one, two or three nucleotides in the duplex region.
In one embodiment, every nucleotide in the sense strand and antisense strand of the RNAi agent, including the nucleotides that are part of the motifs, may be modified. Each nucleotide may be modified with the same or different modification which can include one or more alteration of one or both of the non-linking phosphate oxygens and/or of one or more of the linking phosphate oxygens; alteration of a constituent of the ribose sugar, e.g., of the 2′ hydroxyl on the ribose sugar; wholesale replacement of the phosphate moiety with “dephospho” linkers; modification or replacement of a naturally occurring base; and replacement or modification of the ribose-phosphate backbone.
As nucleic acids are polymers of subunits, many of the modifications occur at a position which is repeated within a nucleic acid, e.g., a modification of a base, or a phosphate moiety, or a non-linking O of a phosphate moiety. In some cases the modification will occur at all of the subject positions in the nucleic acid but in many cases it will not. By way of example, a modification may only occur at a 3′ or 5′ terminal position, may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand. A modification may occur in a double strand region, a single strand region, or in both. A modification may occur only in the double strand region of a RNA or may only occur in a single strand region of a RNA. For example, a phosphorothioate modification at a non-linking O position may only occur at one or both termini, may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand, or may occur in double strand and single strand regions, particularly at termini. The 5′ end or ends can be phosphorylated.
It may be possible, e.g., to enhance stability, to include particular bases in overhangs, or to include modified nucleotides or nucleotide surrogates, in single strand overhangs, e.g., in a 5′ or 3′ overhang, or in both. For example, it can be desirable to include purine nucleotides in overhangs. In some embodiments all or some of the bases in a 3′ or 5′ overhang may be modified, e.g., with a modification described herein. Modifications can include, e.g., the use of modifications at the 2′ position of the ribose sugar with modifications that are known in the art, e.g., the use of deoxyribonucleotides, 2′-deoxy-2′-fluoro (2′-F) or 2′-O-methyl modified instead of the ribosugar of the nucleobase, and modifications in the phosphate group, e.g., phosphorothioate modifications. Overhangs need not be homologous with the target sequence.
In one embodiment, each residue of the sense strand and antisense strand is independently modified with LNA, HNA, CeNA, 2′-methoxyethyl, 2′-O-methyl, 2′-O-allyl, 2′-C-allyl, 2′-deoxy, 2′-hydroxyl, or 2′-fluoro. The strands can contain more than one modification. In one embodiment, each residue of the sense strand and antisense strand is independently modified with 2′-O-methyl or 2′-fluoro.
At least two different modifications are typically present on the sense strand and antisense strand. Those two modifications may be the 2′-O-methyl or 2′-fluoro modifications, or others.
In one embodiment, the Na and/or Nb comprise modifications of an alternating pattern. The term “alternating motif” as used herein refers to a motif having one or more modifications, each modification occurring on alternating nucleotides of one strand. The alternating nucleotide may refer to one per every other nucleotide or one per every three nucleotides, or a similar pattern. For example, if A, B and C each represent one type of modification to the nucleotide, the alternating motif can be “ABABABABABAB . . . ,” “AABBAABBAABB . . . ,” “AABAABAABAAB . . . ,” “AAABAAABAAAB . . . ,” “AAABBBAAABBB . . . ,” or “ABCABCABCABC . . . ,” etc.
The type of modifications contained in the alternating motif may be the same or different.
For example, if A, B, C, D each represent one type of modification on the nucleotide, the alternating pattern, i.e., modifications on every other nucleotide, may be the same, but each of the sense strand or antisense strand can be selected from several possibilities of modifications within the alternating motif such as “ABABAB . . . ”, “ACACAC . . . ” “BDBDBD . . . ” or “CDCDCD . . . ,” etc.
In one embodiment, the RNAi agent of the invention comprises the modification pattern for the alternating motif on the sense strand relative to the modification pattern for the alternating motif on the antisense strand is shifted. The shift may be such that the modified group of nucleotides of the sense strand corresponds to a differently modified group of nucleotides of the antisense strand and vice versa. For example, the sense strand when paired with the antisense strand in the dsRNA duplex, the alternating motif in the sense strand may start with “ABABAB” from 5′-3′ of the strand and the alternating motif in the antisense strand may start with “BABABA” from 5′-3′ of the strand within the duplex region. As another example, the alternating motif in the sense strand may start with “AABBAABB” from 5′-3′ of the strand and the alternating motif in the antisense strand may start with “BBAABBAA” from 5′-3′ of the strand within the duplex region, so that there is a complete or partial shift of the modification patterns between the sense strand and the antisense strand.
In one embodiment, the RNAi agent comprises the pattern of the alternating motif of 2′-O-methyl modification and 2′-F modification on the sense strand initially has a shift relative to the pattern of the alternating motif of 2′-O-methyl modification and 2′-F modification on the antisense strand initially, i.e., the 2′-O-methyl modified nucleotide on the sense strand base pairs with a 2′-F modified nucleotide on the antisense strand and vice versa. The 1 position of the sense strand may start with the 2′-F modification, and the 1 position of the antisense strand may start with the 2′-O-methyl modification.
The introduction of one or more motifs of three identical modifications on three consecutive nucleotides to the sense strand and/or antisense strand interrupts the initial modification pattern present in the sense strand and/or antisense strand. This interruption of the modification pattern of the sense and/or antisense strand by introducing one or more motifs of three identical modifications on three consecutive nucleotides to the sense and/or antisense strand surprisingly enhances the gene silencing activity to the target gene.
In one embodiment, when the motif of three identical modifications on three consecutive nucleotides is introduced to any of the strands, the modification of the nucleotide next to the motif is a different modification than the modification of the motif. For example, the portion of the sequence containing the motif is “ . . . NaYYYNb . . . ,” where “Y” represents the modification of the motif of three identical modifications on three consecutive nucleotide, and “Na” and “Nb” represent a modification to the nucleotide next to the motif “YYY” that is different than the modification of Y, and where Na and Nb can be the same or different modifications. Alternatively, Na and/or Nb may be present or absent when there is a wing modification present.
The RNAi agent may further comprise at least one phosphorothioate or methylphosphonate internucleotide linkage. The phosphorothioate or methylphosphonate internucleotide linkage modification may occur on any nucleotide of the sense strand or antisense strand or both strands in any position of the strand. For instance, the internucleotide linkage modification may occur on every nucleotide on the sense strand and/or antisense strand; each internucleotide linkage modification may occur in an alternating pattern on the sense strand and/or antisense strand; or the sense strand or antisense strand may contain both internucleotide linkage modifications in an alternating pattern. The alternating pattern of the internucleotide linkage modification on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the internucleotide linkage modification on the sense strand may have a shift relative to the alternating pattern of the internucleotide linkage modification on the antisense strand. In one embodiment, a double-stranded RNAi agent comprises 6-8 phosphorothioate internucleotide linkages. In one embodiment, the antisense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus and two phosphorothioate internucleotide linkages at the 3′-terminus, and the sense strand comprises at least two phosphorothioate internucleotide linkages at either the 5′-terminus or the 3′-terminus.
In one embodiment, the RNAi comprises a phosphorothioate or methylphosphonate internucleotide linkage modification in the overhang region. For example, the overhang region may contain two nucleotides having a phosphorothioate or methylphosphonate internucleotide linkage between the two nucleotides. Internucleotide linkage modifications also may be made to link the overhang nucleotides with the terminal paired nucleotides within the duplex region. For example, at least 2, 3, 4, or all the overhang nucleotides may be linked through phosphorothioate or methylphosphonate internucleotide linkage, and optionally, there may be additional phosphorothioate or methylphosphonate internucleotide linkages linking the overhang nucleotide with a paired nucleotide that is next to the overhang nucleotide. For instance, there may be at least two phosphorothioate internucleotide linkages between the terminal three nucleotides, in which two of the three nucleotides are overhang nucleotides, and the third is a paired nucleotide next to the overhang nucleotide. These terminal three nucleotides may be at the 3′-end of the antisense strand, the 3′-end of the sense strand, the 5′-end of the antisense strand, and/or the 5′end of the antisense strand.
In one embodiment, the 2 nucleotide overhang is at the 3′-end of the antisense strand, and there are two phosphorothioate internucleotide linkages between the terminal three nucleotides, wherein two of the three nucleotides are the overhang nucleotides, and the third nucleotide is a paired nucleotide next to the overhang nucleotide. Optionally, the RNAi agent may additionally have two phosphorothioate internucleotide linkages between the terminal three nucleotides at both the 5′-end of the sense strand and at the 5′-end of the antisense strand.
In one embodiment, the RNAi agent comprises mismatch(es) with the target, within the duplex, or combinations thereof. The mismatch may occur in the overhang region or the duplex region. The base pair may be ranked on the basis of their propensity to promote dissociation or melting (e.g., on the free energy of association or dissociation of a particular pairing, the simplest approach is to examine the pairs on an individual pair basis, though next neighbor or similar analysis can also be used). In terms of promoting dissociation: A:U is preferred over G:C; G:U is preferred over G:C; and I:C is preferred over G:C (I=inosine). Mismatches, e.g., non-canonical or other than canonical pairings (as described elsewhere herein) are preferred over canonical (A:T, A:U, G:C) pairings; and pairings which include a universal base are preferred over canonical pairings.
In one embodiment, the RNAi agent comprises at least one of the first 1, 2, 3, 4, or 5 base pairs within the duplex regions from the 5′-end of the antisense strand independently selected from the group of: A:U, G:U, I:C, and mismatched pairs, e.g., non-canonical or other than canonical pairings or pairings which include a universal base, to promote the dissociation of the antisense strand at the 5′-end of the duplex.
In one embodiment, the nucleotide at the 1 position within the duplex region from the 5′-end in the antisense strand is selected from the group consisting of A, dA, dU, U, and dT. Alternatively, at least one of the first 1, 2 or 3 base pair within the duplex region from the 5′-end of the antisense strand is an AU base pair. For example, the first base pair within the duplex region from the 5′-end of the antisense strand is an AU base pair.
In another embodiment, the nucleotide at the 3′-end of the sense strand is deoxy-thymine (dT). In another embodiment, the nucleotide at the 3′-end of the antisense strand is deoxy-thymine (dT). In one embodiment, there is a short sequence of deoxy-thymine nucleotides, for example, two dT nucleotides on the 3′-end of the sense and/or antisense strand.
In one embodiment, the sense strand sequence may be represented by formula (I):









5′ np-Na-(X X X)i-Nb-Y Y Y-Nb-(Z Z Z)j-Na-nq 3′
(I)







wherein:
i and j are each independently 0 or 1;
p and q are each independently 0-6;
each Na independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides; each Nb independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;
each np and nq independently represent an overhang nucleotide;
wherein Nb and Y do not have the same modification; and
XXX, YYY and ZZZ each independently represent one motif of three identical modifications on three consecutive nucleotides. Preferably YYY is all 2′-F modified nucleotides.
In one embodiment, the Na and/or Nb comprise modifications of alternating pattern.
In one embodiment, the YYY motif occurs at or near the cleavage site of the sense strand. For example, when the RNAi agent has a duplex region of 17-23 nucleotides in length, the YYY motif can occur at or the vicinity of the cleavage site (e.g.: can occur at positions 6, 7, 8, 7, 8, 9, 8, 9, 10, 9, 10, 11, 10, 11, 12 or 11, 12, 13) of—the sense strand, the count starting from the 1st nucleotide, from the 5′-end; or optionally, the count starting at the 1st paired nucleotide within the duplex region, from the 5′-end.
In one embodiment, i is 1 and j is 0, or i is 0 and j is 1, or both i and j are 1. The sense strand can therefore be represented by the following formulas:










5′np-Na-YYY-Nb-ZZZ-Na-nq3′;
(Ib)



 



5′np-Na-XXX-Nb-YYY-Na-nq3′; or
(Ic)



 



5′np-Na-XXX-Nb-YYY-Nb-ZZZ-Na-nq3′.
(Id)






When the sense strand is represented by formula (Ib), Nb represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each Na independently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.
When the sense strand is represented as formula (Ic), Nb represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each Na can independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.
When the sense strand is represented as formula (Id), each Nb independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Preferably, Nb is 0, 1, 2, 3, 4, 5 or 6 Each Na can independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.
Each of X, Y and Z may be the same or different from each other.
In other embodiments, i is 0 and j is 0, and the sense strand may be represented by the formula:










5' np-Na-YYY-Na-nq 3'. 
(Ia)






When the sense strand is represented by formula (Ia), each Na independently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.
In one embodiment, the antisense strand sequence of the RNAi may be represented by formula (II):








5'
(II)


nq,-Na'-(Z'Z'Z')k-Nb'-Y'Y'Y'-Nb'-(X'X'X')l-



N'a-np' 3'







wherein:
k and l are each independently 0 or 1;
p′ and q′ are each independently 0-6;
each Na′ independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;
each Nb′ independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;
each np′ and nq′ independently represent an overhang nucleotide;
wherein Nb′ and Y′ do not have the same modification;
and
X′X′X′, Y′Y′Y′ and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides.
In one embodiment, the Na′ and/or Nb′comprise modifications of alternating pattern.
The Y′Y′Y′ motif occurs at or near the cleavage site of the antisense strand. For example, when the RNAi agent has a duplex region of 17-23 nucleotide in length, the Y′Y′Y′ motif can occur at positions 9, 10, 11; 10, 11, 12; 11, 12, 13; 12, 13, 14; or 13, 14, 15 of the antisense strand, with the count starting from the 1st nucleotide, from the 5′-end; or optionally, the count starting at the 1st paired nucleotide within the duplex region, from the 5′-end. Preferably, the Y′Y′Y′ motif occurs at positions 11, 12, 13.
In one embodiment, Y′Y′Y′ motif is all 2′-OMe modified nucleotides.
In one embodiment, k is 1 and 1 is 0, or k is 0 and l is 1, or both k and l are 1.
The antisense strand can therefore be represented by the following formulas:








5'nq,-Na'-Z'Z'Z'-Nb'-Y'Y'Y'-Na'-np, 3'; 
(IIb)


 


5'nq,-Na'-Y'Y'Y'-Nb'-X'X'X'-np,3'; or
(IIc)


 


5'
(IId)


nq,-Na'-Z'Z'Z'-Nb'-Y'Y'Y'-Nb'-X'X'X'-Na'-np,3'.







When the antisense strand is represented by formula (IIb), Nb′ represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each Na′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.
When the antisense strand is represented as formula (IIc), Nb′represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each Na′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.
When the antisense strand is represented as formula (IId), each Nb′ independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each Na′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Preferably, Nb is 0, 1, 2, 3, 4, 5 or 6.
In other embodiments, k is 0 and 1 is 0 and the antisense strand may be represented by the formula:










5'np'-Na'-Y'Y'Y'-Na'-nq'3'.
(Ia).






When the antisense strand is represented as formula (IIa), each Na′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.
Each of X, Y′ and Z′ may be the same or different from each other.
Each nucleotide of the sense strand and antisense strand may be independently modified with LNA, HNA, CeNA, 2′-methoxyethyl, 2′-O-methyl, 2′-O-allyl, 2′-C-allyl, 2′-hydroxyl, or 2′-fluoro. For example, each nucleotide of the sense strand and antisense strand is independently modified with 2′-O-methyl or 2′-fluoro. Each X, Y, Z, X, Y′ and Z′, in particular, may represent a 2′-O-methyl modification or a 2′-fluoro modification.
In one embodiment, the sense strand of the RNAi agent may contain YYY motif occurring at 9, 10 and 11 positions of the strand when the duplex region is 21 nt, the count starting from the 1st nucleotide from the 5′-end, or optionally, the count starting at the 1st paired nucleotide within the duplex region, from the 5′-end; and Y represents 2′-F modification. The sense strand may additionally contain XXX motif or ZZZ motifs as wing modifications at the opposite end of the duplex region; and XXX and ZZZ each independently represents a 2′-OMe modification or 2′-F modification.
In one embodiment the antisense strand may contain Y′Y′Y′ motif occurring at positions 11, 12, 13 of the strand, the count starting from the 1st nucleotide from the 5′-end, or optionally, the count starting at the 1st paired nucleotide within the duplex region, from the 5′-end; and Y′represents 2′-O-methyl modification. The antisense strand may additionally contain X′X′X′ motif or Z′Z′Z′ motifs as wing modifications at the opposite end of the duplex region; and X′X′X′ and Z′Z′Z′ each independently represents a 2′-OMe modification or 2′-F modification.
The sense strand represented by any one of the above formulas (Ia), (Ib), (Ic), and (Id) forms a duplex with a antisense strand being represented by any one of formulas (IIa), (IIb), (IIc), and (IId), respectively.
Accordingly, the RNAi agents for use in the methods of the invention may comprise a sense strand and an antisense strand, each strand having 14 to 30 nucleotides, the RNAi duplex represented by formula (III):










sense:
5'np-Na-(XXX)i-Nb-YYY-Nb-(ZZZ)j-Na-nq3' 
(III)



 


antisense:
3'np'-Na-(X'X'X')k-Nb-Y'Y'Y'-Nb-(Z'Z'Z')i-Na-nq5'








wherein:
i, j, k, and l are each independently 0 or 1;
p, p′, q, and q′ are each independently 0-6;
each Na and Na independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;
each Nb and Nb independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;
wherein
each np, np′, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide; and
XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides.
In one embodiment, i is 0 and j is 0; or i is 1 and j is 0; or i is 0 and j is 1; or both i and j are 0; or both i and j are 1. In another embodiment, k is 0 and 1 is 0; or k is 1 and 1 is 0; k is 0 and l is 1; or both k and l are 0; or both k and l are 1.
Exemplary combinations of the sense strand and antisense strand forming a RNAi duplex include the formulas below:








5'np-Na-YYY-Na-nq3'
(IIIa)


3'np'-Na'-Y'Y'Y'-Na'nq'5'



5'np-Na-YYY-Nb-ZZZ-Na-nq3'
(IIIb)


3'np'-Na'-Y'Y'Y'-Nb'-Z'Z'Z'-Na'nq'5'



5'np-Na-XXX-Nb-YYY-Na-nq3'
(IIIc)


3'np'-Na'-X'X'X'-Nb'-Y'Y'Y'-Na'-nq'5'



5'np-Na-XXX-Nb-YYY-Nb-ZZZ-Na-nq3'
(IIId)


 


5'np-Na-X'X'X'-Nb-Y'Y'Y'-Nb-Z'Z'Z'-Na-nq3'







When the RNAi agent is represented by formula (IIIa), each Na independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.
When the RNAi agent is represented by formula (IIIb), each Nb independently represents an oligonucleotide sequence comprising 1-10, 1-7, 1-5 or 1-4 modified nucleotides. Each Na independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.
When the RNAi agent is represented as formula (IIIc), each Nb, Nb′ independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0modified nucleotides. Each Na independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.
When the RNAi agent is represented as formula (IIId), each Nb, Nb′ independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0modified nucleotides. Each Na, Na′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Each of Na, Na, Nb and Nb independently comprises modifications of alternating pattern.
Each of X, Y and Z in formulas (III), (IIIa), (IIIb), (IIIc), and (IIId) may be the same or different from each other.
When the RNAi agent is represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), at least one of the Y nucleotides may form a base pair with one of the Y′ nucleotides. Alternatively, at least two of the Y nucleotides form base pairs with the corresponding Y′ nucleotides; or all three of the Y nucleotides all form base pairs with the corresponding Y′ nucleotides.
When the RNAi agent is represented by formula (IIIb) or (IIId), at least one of the Z nucleotides may form a base pair with one of the Z′ nucleotides. Alternatively, at least two of the Z nucleotides form base pairs with the corresponding Z′ nucleotides; or all three of the Z nucleotides all form base pairs with the corresponding Z′ nucleotides.
When the RNAi agent is represented as formula (IIIc) or (IIId), at least one of the X nucleotides may form a base pair with one of the X′ nucleotides. Alternatively, at least two of the X nucleotides form base pairs with the corresponding X′ nucleotides; or all three of the X nucleotides all form base pairs with the corresponding X′ nucleotides.
In one embodiment, the modification on the Y nucleotide is different than the modification on the Y′ nucleotide, the modification on the Z nucleotide is different than the modification on the Z′ nucleotide, and/or the modification on the X nucleotide is different than the modification on the X′ nucleotide.
In one embodiment, when the RNAi agent is represented by formula (IIId), the Na modifications are 2′-O-methyl or 2′-fluoro modifications. In another embodiment, when the RNAi agent is represented by formula (IIId), the Na modifications are 2′-O-methyl or 2′-fluoro modifications and np′>0 and at least one np′ is linked to a neighboring nucleotide a via phosphorothioate linkage. In yet another embodiment, when the RNAi agent is represented by formula (IIId), the Na modifications are 2′-O-methyl or 2′-fluoro modifications, np′>0 and at least one np′ is linked to a neighboring nucleotide via phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker (described below). In another embodiment, when the RNAi agent is represented by formula (IIId), the Na modifications are 2′-O-methyl or 2′-fluoro modifications, np′>0 and at least one np′ is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.
In one embodiment, when the RNAi agent is represented by formula (IIIa), the Na modifications are 2′-O-methyl or 2′-fluoro modifications, np′>0 and at least one np′ is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.
In one embodiment, the RNAi agent is a multimer containing at least two duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.
In one embodiment, the RNAi agent is a multimer containing three, four, five, six or more duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.
In one embodiment, two RNAi agents represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId) are linked to each other at the 5′ end, and one or both of the 3′ ends and are optionally conjugated to a ligand. Each of the agents can target the same gene or two different genes; or each of the agents can target same gene at two different target sites.
Various publications describe multimeric RNAi agents that can be used in the methods of the invention. Such publications include WO2007/091269, U.S. Pat. No. 7,858,769, WO2010/141511, WO2007/117686, WO2009/014887 and WO2011/031520 the entire contents of each of which are hereby incorporated herein by reference.
As described in more detail below, the RNAi agent that contains conjugations of one or more carbohydrate moieties to a RNAi agent can optimize one or more properties of the RNAi agent. In many cases, the carbohydrate moiety will be attached to a modified subunit of the RNAi agent. For example, the ribose sugar of one or more ribonucleotide subunits of a dsRNA agent can be replaced with another moiety, e.g., a non-carbohydrate (preferably cyclic) carrier to which is attached a carbohydrate ligand. A ribonucleotide subunit in which the ribose sugar of the subunit has been so replaced is referred to herein as a ribose replacement modification subunit (RRMS). A cyclic carrier may be a carbocyclic ring system, i.e., all ring atoms are carbon atoms, or a heterocyclic ring system, i.e., one or more ring atoms may be a heteroatom, e.g., nitrogen, oxygen, sulfur. The cyclic carrier may be a monocyclic ring system, or may contain two or more rings, e.g. fused rings. The cyclic carrier may be a fully saturated ring system, or it may contain one or more double bonds.
The ligand may be attached to the polynucleotide via a carrier. The carriers include (i) at least one “backbone attachment point,” preferably two “backbone attachment points” and (ii) at least one “tethering attachment point.” A “backbone attachment point” as used herein refers to a functional group, e.g. a hydroxyl group, or generally, a bond available for, and that is suitable for incorporation of the carrier into the backbone, e.g., the phosphate, or modified phosphate, e.g., sulfur containing, backbone, of a ribonucleic acid. A “tethering attachment point” (TAP) in some embodiments refers to a constituent ring atom of the cyclic carrier, e.g., a carbon atom or a heteroatom (distinct from an atom which provides a backbone attachment point), that connects a selected moiety. The moiety can be, e.g., a carbohydrate, e.g. monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide and polysaccharide. Optionally, the selected moiety is connected by an intervening tether to the cyclic carrier. Thus, the cyclic carrier will often include a functional group, e.g., an amino group, or generally, provide a bond, that is suitable for incorporation or tethering of another chemical entity, e.g., a ligand to the constituent ring.
The RNAi agents may be conjugated to a ligand via a carrier, wherein the carrier can be cyclic group or acyclic group; preferably, the cyclic group is selected from pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolane, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl and decalin; preferably, the acyclic group is selected from serinol backbone or diethanolamine backbone.
In certain specific embodiments, the RNAi agent for use in the methods of the invention is an agent selected from the group of agents listed in any one of Tables 3, 4, 5, 6, 18, 19, 20, 21, and 23. These agents may further comprise a ligand.
IV. iRNAS Conjugated to Ligands
Another modification of the RNA of an iRNA of the invention involves chemically linking to the RNA one or more ligands, moieties or conjugates that enhance the activity, cellular distribution or cellular uptake of the iRNA. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86: 6553-6556), cholic acid (Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060), a thioether, e.g., beryl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med. Chem. Let., 1993, 3:2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10:1111-1118; Kabanov et al., FEBS Lett., 1990, 259:327-330; Svinarchuk et al., Biochimie, 1993, 75:49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654; Shea et al., Nucl. Acids Res., 1990, 18:3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923-937).
In one embodiment, a ligand alters the distribution, targeting or lifetime of an iRNA agent into which it is incorporated. In preferred embodiments a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand. Preferred ligands will not take part in duplex pairing in a duplexed nucleic acid.
Ligands can include a naturally occurring substance, such as a protein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, N-acetylgalactosamine, or hyaluronic acid); or a lipid. The ligand can also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, or polyphosphazine. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.
Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g., an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucoseamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, vitamin A, biotin, or an RGD peptide or RGD peptide mimetic.
Other examples of ligands include dyes, intercalating agents (e.g. acridines), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g. EDTA), lipophilic molecules, e.g., cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, bomeol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine) and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG]2, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g. biotin), transport/absorption facilitators (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.
Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a hepatic cell. Ligands can also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF-κB.
The ligand can be a substance, e.g., a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell's cytoskeleton, e.g., by disrupting the cell's microtubules, microfilaments, and/or intermediate filaments. The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.
In some embodiments, a ligand attached to an iRNA as described herein acts as a pharmacokinetic modulator (PK modulator). PK modulators include lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents, PEG, vitamins etc. Exemplary PK modulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin etc. Oligonucleotides that comprise a number of phosphorothioate linkages are also known to bind to serum protein, thus short oligonucleotides, e.g., oligonucleotides of about 5 bases, 10 bases, 15 bases or 20 bases, comprising multiple of phosphorothioate linkages in the backbone are also amenable to the present invention as ligands (e.g. as PK modulating ligands). In addition, aptamers that bind serum components (e.g. serum proteins) are also suitable for use as PK modulating ligands in the embodiments described herein.
Ligand-conjugated oligonucleotides of the invention may be synthesized by the use of an oligonucleotide that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the oligonucleotide (described below). This reactive oligonucleotide may be reacted directly with commercially-available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto.
The oligonucleotides used in the conjugates of the present invention may be conveniently and routinely made through the well-known technique of solid-phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides, such as the phosphorothioates and alkylated derivatives.
In the ligand-conjugated oligonucleotides and ligand-molecule bearing sequence-specific linked nucleosides of the present invention, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.
When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then reacted with the linking moiety to form the ligand-conjugated oligonucleotide.
In some embodiments, the oligonucleotides or linked nucleosides of the present invention are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.
A. Lipid Conjugates
In one embodiment, the ligand or conjugate is a lipid or lipid-based molecule. Such a lipid or lipid-based molecule preferably binds a serum protein, e.g., human serum albumin (HSA). An HSA binding ligand allows for distribution of the conjugate to a target tissue, e.g., a non-kidney target tissue of the body. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands. For example, naproxen or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, and/or (c) can be used to adjust binding to a serum protein, e.g., HSA.
A lipid based ligand can be used to inhibit, e.g., control the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.
In a preferred embodiment, the lipid based ligand binds HSA. Preferably, it binds HSA with a sufficient affinity such that the conjugate will be preferably distributed to a non-kidney tissue. However, it is preferred that the affinity not be so strong that the HSA-ligand binding cannot be reversed.
In another preferred embodiment, the lipid based ligand binds HSA weakly or not at all, such that the conjugate will be preferably distributed to the kidney. Other moieties that target to kidney cells can also be used in place of or in addition to the lipid based ligand.
In another aspect, the ligand is a moiety, e.g., a vitamin, which is taken up by a target cell, e.g., a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells.
Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include are B vitamin, e.g., folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by target cells such as liver cells. Also included are HSA and low density lipoprotein (LDL).
B. Cell Permeation Agents
In another aspect, the ligand is a cell-permeation agent, preferably a helical cell-permeation agent. Preferably, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennopedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. The helical agent is preferably an alpha-helical agent, which preferably has a lipophilic and a lipophobic phase.
The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to iRNA agents can affect pharmacokinetic distribution of the iRNA, such as by enhancing cellular recognition and absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.
A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g., consisting primarily of Tyr, Trp or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 9). An RFGF analogue (e.g., amino acid sequence AALLPVLLAAP (SEQ ID NO: 10) containing a hydrophobic MTS can also be a targeting moiety. The peptide moiety can be a “delivery” peptide, which can carry large polar molecules including peptides, oligonucleotides, and protein across cell membranes. For example, sequences from the HIV Tat protein (GRKKRRQRRRPPQ (SEQ ID NO: 11) and the Drosophila Antennapedia protein (RQIKIWFQNRRMKWKK (SEQ ID NO: 12) have been found to be capable of functioning as delivery peptides. A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature, 354:82-84, 1991). Examples of a peptide or peptidomimetic tethered to a dsRNA agent via an incorporated monomer unit for cell targeting purposes is an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.
An RGD peptide for use in the compositions and methods of the invention may be linear or cyclic, and may be modified, e.g., glycosylated or methylated, to facilitate targeting to a specific tissue(s). RGD-containing peptides and peptidiomimemtics may include D-amino acids, as well as synthetic RGD mimics. In addition to RGD, one can use other moieties that target the integrin ligand. Preferred conjugates of this ligand target PECAM-1 or VEGF.
A “cell permeation peptide” is capable of permeating a cell, e.g., a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell. A microbial cell-permeating peptide can be, for example, a α-helical linear peptide (e.g., LL-37 or Ceropin P1), a disulfide bond-containing peptide (e.g., α-defensin, β-defensin or bactenecin), or a peptide containing only one or two dominating amino acids (e.g., PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni et al., Nucl. Acids Res. 31:2717-2724, 2003).
C. Carbohydrate Conjugates
In some embodiments of the compositions and methods of the invention, an iRNA oligonucleotide further comprises a carbohydrate. The carbohydrate conjugated iRNA are advantageous for the in vivo delivery of nucleic acids, as well as compositions suitable for in vivo therapeutic use, as described herein. As used herein, “carbohydrate” refers to a compound which is either a carbohydrate per se made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom; or a compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which can be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom. Representative carbohydrates include the sugars (mono-, di-, tri- and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides such as starches, glycogen, cellulose and polysaccharide gums. Specific monosaccharides include C5 and above (e.g., C5, C6, C7, or C8) sugars; di- and trisaccharides include sugars having two or three monosaccharide units (e.g., C5, C6, C7, or C8).
In one embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is a monosaccharide. In one embodiment, the monosaccharide is an N-acetylgalactosamine, such as




In another embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is selected from the group consisting of:













Another representative carbohydrate conjugate for use in the embodiments described herein includes, but is not limited to




when one of X or Y is an oligonucleotide, the other is a hydrogen.

In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modulator and/or a cell permeation peptide.
D. Linkers
In some embodiments, the conjugate or ligand described herein can be attached to an iRNA oligonucleotide with various linkers that can be cleavable or non-cleavable.
The term “linker” or “linking group” means an organic moiety that connects two parts of a compound, e.g., covalently attaches two parts of a compound. Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NR8, C(O), C(O)NH, SO, SO2, SO2NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylhereroaryl, which one or more methylenes can be interrupted or terminated by O, S, S(O), SO2, N(R8), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; where R8 is hydrogen, acyl, aliphatic or substituted aliphatic. In one embodiment, the linker is between about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18 atoms, 7-17, 8-17, 6-16, 7-16, or 8-16 atoms.
A cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In a preferred embodiment, the cleavable linking group is cleaved at least about 10 times, 20, times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times or more, or at least about 100 times faster in a target cell or under a first reference condition (which can, e.g., be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, e.g., be selected to mimic or represent conditions found in the blood or serum).
Cleavable linking groups are susceptible to cleavage agents, e.g., pH, redox potential or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction; esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.
A cleavable linkage group, such as a disulfide bond can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0. Some linkers will have a cleavable linking group that is cleaved at a preferred pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.
A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. For example, a liver-targeting ligand can be linked to a cationic lipid through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in esterases include cells of the lung, renal cortex, and testis.
Linkers that contain peptide bonds can be used when targeting cell types rich in peptidases, such as liver cells and synoviocytes.
In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, e.g., blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In preferred embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).
i. Redox Cleavable Linking Groups
In one embodiment, a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulphide linking group (—S—S—). To determine if a candidate cleavable linking group is a suitable “reductively cleavable linking group,” or for example is suitable for use with a particular iRNA moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents know in the art, which mimic the rate of cleavage which would be observed in a cell, e.g., a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In one, candidate compounds are cleaved by at most about 10% in the blood. In other embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood (or under in vitro conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.
ii. Phosphate-Based Cleavable Linking Groups
In another embodiment, a cleavable linker comprises a phosphate-based cleavable linking group. A phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are —O—P(O)(ORk)-O—, —O—P(S)(ORk)-O—, —O—P(S)(SRk)-O—, —S—P(O)(ORk)-O—, —O—P(O)(ORk)-S—, —S—P(O)(ORk)-S—, —O—P(S)(ORk)-S—, —S—P(S)(ORk)-O—, —O—P(O)(Rk)-O—, —O—P(S)(Rk)-O—, —S—P(O)(Rk)-O—, —S—P(S)(Rk)-O—, —S—P(O)(Rk)-S—, —O—P(S)(Rk)-S—. Preferred embodiments are —O—P(O)(OH)—O—, —O—P(S)(OH)—O—, —O—P(S)(SH)—O—, —S—P(O)(OH)—O—, —O—P(O)(OH)—S—, —S—P(O)(OH)—S—, —O—P(S)(OH)—S—, —S—P(S)(OH)—O—, —O—P(O)(H)—O—, —O—P(S)(H)—O—, —S—P(O)(H)—O, —S—P(S)(H)—O—, —S—P(O)(H)—S—, —O—P(S)(H)—S—. A preferred embodiment is —O—P(O)(OH)—O—. These candidates can be evaluated using methods analogous to those described above.
iii. Acid Cleavable Linking Groups
In another embodiment, a cleavable linker comprises an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In preferred embodiments acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.75, 5.5, 5.25, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula —C═NN—, C(O)O, or —OC(O). A preferred embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.
iv. Ester-Based Linking Groups
In another embodiment, a cleavable linker comprises an ester-based cleavable linking group. An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable linking groups include but are not limited to esters of alkylene, alkenylene and alkynylene groups. Ester cleavable linking groups have the general formula —C(O)O—, or —OC(O)—. These candidates can be evaluated using methods analogous to those described above.
v. Peptide-Based Cleaving Groups
In yet another embodiment, a cleavable linker comprises a peptide-based cleavable linking group. A peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (e.g., dipeptides, tripeptides etc.) and polypeptides. Peptide-based cleavable groups do not include the amide group (—C(O)NH—). The amide group can be formed between any alkylene, alkenylene or alkynelene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide based cleavage group is generally limited to the peptide bond (i.e., the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula —NHCHRAC(O)NHCHRBC(O)—, where RA and RB are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.
In one embodiment, an iRNA of the invention is conjugated to a carbohydrate through a linker. Non-limiting examples of iRNA carbohydrate conjugates with linkers of the compositions and methods of the invention include, but are not limited to,







when one of X or Y is an oligonucleotide, the other is a hydrogen.

In certain embodiments of the compositions and methods of the invention, a ligand is one or more “GalNAc” (N-acetylgalactosamine) derivatives attached through a bivalent or trivalent branched linker.
In one embodiment, a dsRNA of the invention is conjugated to a bivalent or trivalent branched linker selected from the group of structures shown in any of formula (XXXI)-(XXXIV):




wherein:

q2A, q2B, q3A, q3B, q4A, q4B, q5A, q5B and q5C represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;

p2A, p2B, p3A, p3B, p4A, p4B, p5A, p5B, p5C, T2A, T2B, T3A, T3B, T4A, T4B, T4A, T5B, T5C are each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH2, CH2NH or CH2O;

Q2A, Q2B, Q3A, Q3B, Q4A, Q4B, Q5A, Q5B, Q5C are independently for each occurrence absent, alkylene, substituted alkylene wherein one or more methylenes can be interrupted or terminated by one or more of O, S, S(O), SO2, N(RN), C(R′)═C(R′′), C≡C or C(O);

R2A, R2B, R3A, R3B, R4A, R4B, R5A, R5B, R5C are each independently for each occurrence absent, NH, O, S, CH2, C(O)O, C(O)NH, NHCH(Ra)C(O), —C(O)—CH(Ra)—NH—, CO, CH═N—O,





heterocyclyl;

L2A, L2B, L3A, L3B, L4A, L4B, L5A, L5B and L5C represent the ligand; i.e. each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; and Ra is H or amino acid side chain. Trivalent conjugating GalNAc derivatives are particularly useful for use with RNAi agents for inhibiting the expression of a target gene, such as those of formula (XXXV):




    
    
        wherein L5A, L5B and L5C represent a monosaccharide, such as GalNAc derivative.
    
    


Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc derivatives include, but are not limited to, the structures recited above as formulas II, VII, XI, X, and XIII.
Representative U.S. patents that teach the preparation of RNA conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941; 6,294,664; 6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; 8,106,022, the entire contents of each of which are hereby incorporated herein by reference.
It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications can be incorporated in a single compound or even at a single nucleoside within an iRNA. The present invention also includes iRNA compounds that are chimeric compounds.
“Chimeric” iRNA compounds or “chimeras,” in the context of this invention, are iRNA compounds, preferably dsRNAs, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of a dsRNA compound. These iRNAs typically contain at least one region wherein the RNA is modified so as to confer upon the iRNA increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the iRNA can serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of iRNA inhibition of gene expression. Consequently, comparable results can often be obtained with shorter iRNAs when chimeric dsRNAs are used, compared to phosphorothioate deoxy dsRNAs hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.
In certain instances, the RNA of an iRNA can be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to iRNAs in order to enhance the activity, cellular distribution or cellular uptake of the iRNA, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Kubo, T. et al., Biochem. Biophys. Res. Comm., 2007, 365(1):54-61; Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10:111; Kabanov et al., FEBS Lett., 1990, 259:327; Svinarchuk et al., Biochimie, 1993, 75:49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651; Shea et al., Nucl. Acids Res., 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923). Representative United States patents that teach the preparation of such RNA conjugates have been listed above. Typical conjugation protocols involve the synthesis of an RNAs bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction can be performed either with the RNA still bound to the solid support or following cleavage of the RNA, in solution phase. Purification of the RNA conjugate by HPLC typically affords the pure conjugate.
IV. Delivery of an iRNA of the Invention
The delivery of an iRNA of the invention to a cell e.g., a cell within a subject, such as a human subject (e.g., a subject in need thereof, such as a subject having a complement component C5-associated disease) can be achieved in a number of different ways. For example, delivery may be performed by contacting a cell with an iRNA of the invention either in vitro or in vivo. In vivo delivery may also be performed directly by administering a composition comprising an iRNA, e.g., a dsRNA, to a subject. Alternatively, in vivo delivery may be performed indirectly by administering one or more vectors that encode and direct the expression of the iRNA. These alternatives are discussed further below.
In general, any method of delivering a nucleic acid molecule (in vitro or in vivo) can be adapted for use with an iRNA of the invention (see e.g., Akhtar S. and Julian R L. (1992) Trends Cell. Biol. 2(5):139-144 and WO94/02595, which are incorporated herein by reference in their entireties). For in vivo delivery, factors to consider in order to deliver an iRNA molecule include, for example, biological stability of the delivered molecule, prevention of non-specific effects, and accumulation of the delivered molecule in the target tissue. The non-specific effects of an iRNA can be minimized by local administration, for example, by direct injection or implantation into a tissue or topically administering the preparation. Local administration to a treatment site maximizes local concentration of the agent, limits the exposure of the agent to systemic tissues that can otherwise be harmed by the agent or that can degrade the agent, and permits a lower total dose of the iRNA molecule to be administered. Several studies have shown successful knockdown of gene products when an iRNA is administered locally. For example, intraocular delivery of a VEGF dsRNA by intravitreal injection in cynomolgus monkeys (Tolentino, M J., et al (2004) Retina 24:132-138) and subretinal injections in mice (Reich, S J., et al (2003) Mol. Vis. 9:210-216) were both shown to prevent neovascularization in an experimental model of age-related macular degeneration. In addition, direct intratumoral injection of a dsRNA in mice reduces tumor volume (Pille, J., et al (2005) Mol. Ther. 11:267-274) and can prolong survival of tumor-bearing mice (Kim, W J., et al (2006) Mol. Ther. 14:343-350; Li, S., et al (2007) Mol. Ther. 15:515-523). RNA interference has also shown success with local delivery to the CNS by direct injection (Dorn, G., et al. (2004) Nucleic Acids 32:e49; Tan, P H., et al (2005) Gene Ther. 12:59-66; Makimura, H., et al (2002) BMC Neurosci. 3:18; Shishkina, G T., et al (2004) Neuroscience 129:521-528; Thakker, E R., et al (2004) Proc. Natl. Acad. Sci. U.S.A. 101:17270-17275; Akaneya, Y., et al (2005) J. Neurophysiol. 93:594-602) and to the lungs by intranasal administration (Howard, K A., et al (2006) Mol. Ther. 14:476-484; Zhang, X., et al (2004) J. Biol. Chem. 279:10677-10684; Bitko, V., et al (2005) Nat. Med. 11:50-55). For administering an iRNA systemically for the treatment of a disease, the RNA can be modified or alternatively delivered using a drug delivery system; both methods act to prevent the rapid degradation of the dsRNA by endo- and exo-nucleases in vivo. Modification of the RNA or the pharmaceutical carrier can also permit targeting of the iRNA composition to the target tissue and avoid undesirable off-target effects. iRNA molecules can be modified by chemical conjugation to lipophilic groups such as cholesterol to enhance cellular uptake and prevent degradation. For example, an iRNA directed against ApoB conjugated to a lipophilic cholesterol moiety was injected systemically into mice and resulted in knockdown of apoB mRNA in both the liver and jejunum (Soutschek, J., et al (2004) Nature 432:173-178). Conjugation of an iRNA to an aptamer has been shown to inhibit tumor growth and mediate tumor regression in a mouse model of prostate cancer (McNamara, J O., et al (2006) Nat. Biotechnol. 24:1005-1015). In an alternative embodiment, the iRNA can be delivered using drug delivery systems such as a nanoparticle, a dendrimer, a polymer, liposomes, or a cationic delivery system. Positively charged cationic delivery systems facilitate binding of an iRNA molecule (negatively charged) and also enhance interactions at the negatively charged cell membrane to permit efficient uptake of an iRNA by the cell. Cationic lipids, dendrimers, or polymers can either be bound to an iRNA, or induced to form a vesicle or micelle (see e.g., Kim S H., et al (2008) Journal of Controlled Release 129(2):107-116) that encases an iRNA. The formation of vesicles or micelles further prevents degradation of the iRNA when administered systemically. Methods for making and administering cationic-iRNA complexes are well within the abilities of one skilled in the art (see e.g., Sorensen, D R., et al (2003) J. Mol. Biol 327:761-766; Verma, U N., et al (2003) Clin. Cancer Res. 9:1291-1300; Arnold, A S et al (2007) J. Hypertens. 25:197-205, which are incorporated herein by reference in their entirety). Some non-limiting examples of drug delivery systems useful for systemic delivery of iRNAs include DOTAP (Sorensen, D R., et al (2003), supra; Verma, U N., et al (2003), supra), Oligofectamine, “solid nucleic acid lipid particles” (Zimmermann, T S., et al (2006) Nature 441:111-114), cardiolipin (Chien, P Y., et al (2005) Cancer Gene Ther. 12:321-328; Pal, A., et al (2005) Int J. Oncol. 26:1087-1091), polyethyleneimine (Bonnet M E., et al (2008) Pharm. Res. August 16 Epub ahead of print; Aigner, A. (2006) J. Biomed. Biotechnol. 71659), Arg-Gly-Asp (RGD) peptides (Liu, S. (2006) Mol. Pharm. 3:472-487), and polyamidoamines (Tomalia, D A., et al (2007) Biochem. Soc. Trans. 35:61-67; Yoo, H., et al (1999) Pharm. Res. 16:1799-1804). In some embodiments, an iRNA forms a complex with cyclodextrin for systemic administration. Methods for administration and pharmaceutical compositions of iRNAs and cyclodextrins can be found in U.S. Pat. No. 7,427,605, which is herein incorporated by reference in its entirety.
A. Vector encoded iRNAs of the Invention
iRNA targeting the C5 gene can be expressed from transcription units inserted into DNA or RNA vectors (see, e.g., Couture, A, et al., TIG. (1996), 12:5-10; Skillern, A., et al., International PCT Publication No. WO 00/22113, Conrad, International PCT Publication No. WO 00/22114, and Conrad, U.S. Pat. No. 6,054,299). Expression can be transient (on the order of hours to weeks) or sustained (weeks to months or longer), depending upon the specific construct used and the target tissue or cell type. These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be an integrating or non-integrating vector. The transgene can also be constructed to permit it to be inherited as an extrachromosomal plasmid (Gassmann, et al., Proc. Natl. Acad. Sci. USA (1995) 92:1292).
The individual strand or strands of an iRNA can be transcribed from a promoter on an expression vector. Where two separate strands are to be expressed to generate, for example, a dsRNA, two separate expression vectors can be co-introduced (e.g., by transfection or infection) into a target cell. Alternatively each individual strand of a dsRNA can be transcribed by promoters both of which are located on the same expression plasmid. In one embodiment, a dsRNA is expressed as inverted repeat polynucleotides joined by a linker polynucleotide sequence such that the dsRNA has a stem and loop structure.
iRNA expression vectors are generally DNA plasmids or viral vectors. Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can be used to produce recombinant constructs for the expression of an iRNA as described herein. Eukaryotic cell expression vectors are well known in the art and are available from a number of commercial sources. Typically, such vectors are provided containing convenient restriction sites for insertion of the desired nucleic acid segment. Delivery of iRNA expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that allows for introduction into a desired target cell.
iRNA expression plasmids can be transfected into target cells as a complex with cationic lipid carriers (e.g., Oligofectamine) or non-cationic lipid-based carriers (e.g., Transit-TKOTM). Multiple lipid transfections for iRNA-mediated knockdowns targeting different regions of a target RNA over a period of a week or more are also contemplated by the invention. Successful introduction of vectors into host cells can be monitored using various known methods. For example, transient transfection can be signaled with a reporter, such as a fluorescent marker, such as Green Fluorescent Protein (GFP). Stable transfection of cells ex vivo can be ensured using markers that provide the transfected cell with resistance to specific environmental factors (e.g., antibiotics and drugs), such as hygromycin B resistance.
Viral vector systems which can be utilized with the methods and compositions described herein include, but are not limited to, (a) adenovirus vectors; (b) retrovirus vectors, including but not limited to lentiviral vectors, moloney murine leukemia virus, etc.; (c) adeno-associated virus vectors; (d) herpes simplex virus vectors; (e) SV 40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) pox virus vectors such as an orthopox, e.g., vaccinia virus vectors or avipox, e.g. canary pox or fowl pox; and (j) a helper-dependent or gutless adenovirus. Replication-defective viruses can also be advantageous. Different vectors will or will not become incorporated into the cells' genome. The constructs can include viral sequences for transfection, if desired. Alternatively, the construct can be incorporated into vectors capable of episomal replication, e.g. EPV and EBV vectors. Constructs for the recombinant expression of an iRNA will generally require regulatory elements, e.g., promoters, enhancers, etc., to ensure the expression of the iRNA in target cells. Other aspects to consider for vectors and constructs are further described below.
Vectors useful for the delivery of an iRNA will include regulatory elements (promoter, enhancer, etc.) sufficient for expression of the iRNA in the desired target cell or tissue. The regulatory elements can be chosen to provide either constitutive or regulated/inducible expression.
Expression of the iRNA can be precisely regulated, for example, by using an inducible regulatory sequence that is sensitive to certain physiological regulators, e.g., circulating glucose levels, or hormones (Docherty et al., 1994, FASEB J. 8:20-24). Such inducible expression systems, suitable for the control of dsRNA expression in cells or in mammals include, for example, regulation by ecdysone, by estrogen, progesterone, tetracycline, chemical inducers of dimerization, and isopropyl-beta-D1-thiogalactopyranoside (IPTG). A person skilled in the art would be able to choose the appropriate regulatory/promoter sequence based on the intended use of the iRNA transgene.
Viral vectors that contain nucleic acid sequences encoding an iRNA can be used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding an iRNA are cloned into one or more vectors, which facilitate delivery of the nucleic acid into a patient. More detail about retroviral vectors can be found, for example, in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the mdr1 gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110-114 (1993). Lentiviral vectors contemplated for use include, for example, the HIV based vectors described in U.S. Pat. Nos. 6,143,520; 5,665,557; and 5,981,276, which are herein incorporated by reference.
Adenoviruses are also contemplated for use in delivery of iRNAs of the invention. Adenoviruses are especially attractive vehicles, e.g., for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). A suitable AV vector for expressing an iRNA featured in the invention, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells, are described in Xia H et al. (2002), Nat. Biotech. 20: 1006-1010.
Adeno-associated virus (AAV) vectors may also be used to delivery an iRNA of the invention (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Pat. No. 5,436,146). In one embodiment, the iRNA can be expressed as two separate, complementary single-stranded RNA molecules from a recombinant AAV vector having, for example, either the U6 or H1 RNA promoters, or the cytomegalovirus (CMV) promoter. Suitable AAV vectors for expressing the dsRNA featured in the invention, methods for constructing the recombinant AV vector, and methods for delivering the vectors into target cells are described in Samulski R et al. (1987), J. Virol. 61: 3096-3101; Fisher K J et al. (1996), J. Virol, 70: 520-532; Samulski R et al. (1989), J. Virol. 63: 3822-3826; U.S. Pat. No. 5,252,479; U.S. Pat. No. 5,139,941; International Patent Application No. WO 94/13788; and International Patent Application No. WO 93/24641, the entire disclosures of which are herein incorporated by reference.
Another viral vector suitable for delivery of an iRNA of the inevtion is a pox virus such as a vaccinia virus, for example an attenuated vaccinia such as Modified Virus Ankara (MVA) or NYVAC, an avipox such as fowl pox or canary pox.
The tropism of viral vectors can be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses, or by substituting different viral capsid proteins, as appropriate. For example, lentiviral vectors can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like. AAV vectors can be made to target different cells by engineering the vectors to express different capsid protein serotypes; see, e.g., Rabinowitz J E et al. (2002), J Virol 76:791-801, the entire disclosure of which is herein incorporated by reference.
The pharmaceutical preparation of a vector can include the vector in an acceptable diluent, or can include a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
V. Pharmaceutical Compositions of the Invention
The present invention also includes pharmaceutical compositions and formulations which include the iRNAs of the invention. In one embodiment, provided herein are pharmaceutical compositions containing an iRNA, as described herein, and a pharmaceutically acceptable carrier.
The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human subjects and animal subjects without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The phrase “pharmaceutically-acceptable carrier” as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject being treated. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium state, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; and (22) other non-toxic compatible substances employed in pharmaceutical formulations.
The pharmaceutical compositions containing the iRNA are useful for treating a disease or disorder associated with the expression or activity of a C5 gene, e.g. a complement component C5-associated disease. Such pharmaceutical compositions are formulated based on the mode of delivery. One example is compositions that are formulated for systemic administration via parenteral delivery, e.g., by subcutaneous (SC) or intravenous (IV) delivery. Another example is compositions that are formulated for direct delivery into the brain parenchyma, e.g., by infusion into the brain, such as by continuous pump infusion. The pharmaceutical compositions of the invention may be administered in dosages sufficient to inhibit expression of a C5 gene. In general, a suitable dose of an iRNA of the invention will be in the range of about 0.001 to about 200.0 milligrams per kilogram body weight of the recipient per day, generally in the range of about 1 to 50 mg per kilogram body weight per day. For example, the dsRNA can be administered at about 0.01 mg/kg, about 0.05 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 1.5 mg/kg, about 2 mg/kg, about 3 mg/kg, about 10 mg/kg, about 20 mg/kg, about 30 mg/kg, about 40 mg/kg, or about 50 mg/kg per single dose.
For example, the dsRNA may be administered at a dose of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or about 10 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.
In another embodiment, the dsRNA is administered at a dose of about 0.1 to about 50 mg/kg, about 0.25 to about 50 mg/kg, about 0.5 to about 50 mg/kg, about 0.75 to about 50 mg/kg, about 1 to about 50 mg/mg, about 1.5 to about 50 mg/kb, about 2 to about 50 mg/kg, about 2.5 to about 50 mg/kg, about 3 to about 50 mg/kg, about 3.5 to about 50 mg/kg, about 4 to about 50 mg/kg, about 4.5 to about 50 mg/kg, about 5 to about 50 mg/kg, about 7.5 to about 50 mg/kg, about 10 to about 50 mg/kg, about 15 to about 50 mg/kg, about 20 to about 50 mg/kg, about 20 to about 50 mg/kg, about 25 to about 50 mg/kg, about 25 to about 50 mg/kg, about 30 to about 50 mg/kg, about 35 to about 50 mg/kg, about 40 to about 50 mg/kg, about 45 to about 50 mg/kg, about 0.1 to about 45 mg/kg, about 0.25 to about 45 mg/kg, about 0.5 to about 45 mg/kg, about 0.75 to about 45 mg/kg, about 1 to about 45 mg/mg, about 1.5 to about 45 mg/kb, about 2 to about 45 mg/kg, about 2.5 to about 45 mg/kg, about 3 to about 45 mg/kg, about 3.5 to about 45 mg/kg, about 4 to about 45 mg/kg, about 4.5 to about 45 mg/kg, about 5 to about 45 mg/kg, about 7.5 to about 45 mg/kg, about 10 to about 45 mg/kg, about 15 to about 45 mg/kg, about 20 to about 45 mg/kg, about 20 to about 45 mg/kg, about 25 to about 45 mg/kg, about 25 to about 45 mg/kg, about 30 to about 45 mg/kg, about 35 to about 45 mg/kg, about 40 to about 45 mg/kg, about 0.1 to about 40 mg/kg, about 0.25 to about 40 mg/kg, about 0.5 to about 40 mg/kg, about 0.75 to about 40 mg/kg, about 1 to about 40 mg/mg, about 1.5 to about 40 mg/kb, about 2 to about 40 mg/kg, about 2.5 to about 40 mg/kg, about 3 to about 40 mg/kg, about 3.5 to about 40 mg/kg, about 4 to about 40 mg/kg, about 4.5 to about 40 mg/kg, about 5 to about 40 mg/kg, about 7.5 to about 40 mg/kg, about 10 to about 40 mg/kg, about 15 to about 40 mg/kg, about 20 to about 40 mg/kg, about 20 to about 40 mg/kg, about 25 to about 40 mg/kg, about 25 to about 40 mg/kg, about 30 to about 40 mg/kg, about 35 to about 40 mg/kg, about 0.1 to about 30 mg/kg, about 0.25 to about 30 mg/kg, about 0.5 to about 30 mg/kg, about 0.75 to about 30 mg/kg, about 1 to about 30 mg/mg, about 1.5 to about 30 mg/kb, about 2 to about 30 mg/kg, about 2.5 to about 30 mg/kg, about 3 to about 30 mg/kg, about 3.5 to about 30 mg/kg, about 4 to about 30 mg/kg, about 4.5 to about 30 mg/kg, about 5 to about 30 mg/kg, about 7.5 to about 30 mg/kg, about 10 to about 30 mg/kg, about 15 to about 30 mg/kg, about 20 to about 30 mg/kg, about 20 to about 30 mg/kg, about 25 to about 30 mg/kg, about 0.1 to about 20 mg/kg, about 0.25 to about 20 mg/kg, about 0.5 to about 20 mg/kg, about 0.75 to about 20 mg/kg, about 1 to about 20 mg/mg, about 1.5 to about 20 mg/kb, about 2 to about 20 mg/kg, about 2.5 to about 20 mg/kg, about 3 to about 20 mg/kg, about 3.5 to about 20 mg/kg, about 4 to about 20 mg/kg, about 4.5 to about 20 mg/kg, about 5 to about 20 mg/kg, about 7.5 to about 20 mg/kg, about 10 to about 20 mg/kg, or about 15 to about 20 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.
For example, the dsRNA may be administered at a dose of about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or about 10 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.
In another embodiment, the dsRNA is administered at a dose of about 0.5 to about 50 mg/kg, about 0.75 to about 50 mg/kg, about 1 to about 50 mg/mg, about 1.5 to about 50 mg/kb, about 2 to about 50 mg/kg, about 2.5 to about 50 mg/kg, about 3 to about 50 mg/kg, about 3.5 to about 50 mg/kg, about 4 to about 50 mg/kg, about 4.5 to about 50 mg/kg, about 5 to about 50 mg/kg, about 7.5 to about 50 mg/kg, about 10 to about 50 mg/kg, about 15 to about 50 mg/kg, about 20 to about 50 mg/kg, about 20 to about 50 mg/kg, about 25 to about 50 mg/kg, about 25 to about 50 mg/kg, about 30 to about 50 mg/kg, about 35 to about 50 mg/kg, about 40 to about 50 mg/kg, about 45 to about 50 mg/kg, about 0.5 to about 45 mg/kg, about 0.75 to about 45 mg/kg, about 1 to about 45 mg/mg, about 1.5 to about 45 mg/kb, about 2 to about 45 mg/kg, about 2.5 to about 45 mg/kg, about 3 to about 45 mg/kg, about 3.5 to about 45 mg/kg, about 4 to about 45 mg/kg, about 4.5 to about 45 mg/kg, about 5 to about 45 mg/kg, about 7.5 to about 45 mg/kg, about 10 to about 45 mg/kg, about 15 to about 45 mg/kg, about 20 to about 45 mg/kg, about 20 to about 45 mg/kg, about 25 to about 45 mg/kg, about 25 to about 45 mg/kg, about 30 to about 45 mg/kg, about 35 to about 45 mg/kg, about 40 to about 45 mg/kg, about 0.5 to about 40 mg/kg, about 0.75 to about 40 mg/kg, about 1 to about 40 mg/mg, about 1.5 to about 40 mg/kb, about 2 to about 40 mg/kg, about 2.5 to about 40 mg/kg, about 3 to about 40 mg/kg, about 3.5 to about 40 mg/kg, about 4 to about 40 mg/kg, about 4.5 to about 40 mg/kg, about 5 to about 40 mg/kg, about 7.5 to about 40 mg/kg, about 10 to about 40 mg/kg, about 15 to about 40 mg/kg, about 20 to about 40 mg/kg, about 20 to about 40 mg/kg, about 25 to about 40 mg/kg, about 25 to about 40 mg/kg, about 30 to about 40 mg/kg, about 35 to about 40 mg/kg, about 0.5 to about 30 mg/kg, about 0.75 to about 30 mg/kg, about 1 to about 30 mg/mg, about 1.5 to about 30 mg/kb, about 2 to about 30 mg/kg, about 2.5 to about 30 mg/kg, about 3 to about 30 mg/kg, about 3.5 to about 30 mg/kg, about 4 to about 30 mg/kg, about 4.5 to about 30 mg/kg, about 5 to about 30 mg/kg, about 7.5 to about 30 mg/kg, about 10 to about 30 mg/kg, about 15 to about 30 mg/kg, about 20 to about 30 mg/kg, about 20 to about 30 mg/kg, about 25 to about 30 mg/kg, about 0.5 to about 20 mg/kg, about 0.75 to about 20 mg/kg, about 1 to about 20 mg/mg, about 1.5 to about 20 mg/kb, about 2 to about 20 mg/kg, about 2.5 to about 20 mg/kg, about 3 to about 20 mg/kg, about 3.5 to about 20 mg/kg, about 4 to about 20 mg/kg, about 4.5 to about 20 mg/kg, about 5 to about 20 mg/kg, about 7.5 to about 20 mg/kg, about 10 to about 20 mg/kg, or about 15 to about 20 mg/kg. In one embodiment, the dsRNA is administered at a dose of about 10 mg/kg to about 30 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.
For example, subjects can be administered, e.g., subcutaneously or intravenously, a single therapeutic amount of iRNA, such as about 0.1, 0.125, 0.15, 0.175, 0.2, 0.225, 0.25, 0.275, 0.3, 0.325, 0.35, 0.375, 0.4, 0.425, 0.45, 0.475, 0.5, 0.525, 0.55, 0.575, 0.6, 0.625, 0.65, 0.675, 0.7, 0.725, 0.75, 0.775, 0.8, 0.825, 0.85, 0.875, 0.9, 0.925, 0.95, 0.975, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 31, 32, 33, 34, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or about 50 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.
In some embodiments, subjects are administered, e.g., subcutaneously or intravenously, multiple doses of a therapeutic amount of iRNA, such as a dose about 0.1, 0.125, 0.15, 0.175, 0.2, 0.225, 0.25, 0.275, 0.3, 0.325, 0.35, 0.375, 0.4, 0.425, 0.45, 0.475, 0.5, 0.525, 0.55, 0.575, 0.6, 0.625, 0.65, 0.675, 0.7, 0.725, 0.75, 0.775, 0.8, 0.825, 0.85, 0.875, 0.9, 0.925, 0.95, 0.975, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 31, 32, 33, 34, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or about 50 mg/kg. A multi-dose regimine may include administration of a therapeutic amount of iRNA daily, such as for two days, three days, four days, five days, six days, seven days, or longer.
In other embodiments, subjects are administered, e.g., subcutaneously or intravenously, a repeat dose of a therapeutic amount of iRNA, such as a dose about 0.1, 0.125, 0.15, 0.175, 0.2, 0.225, 0.25, 0.275, 0.3, 0.325, 0.35, 0.375, 0.4, 0.425, 0.45, 0.475, 0.5, 0.525, 0.55, 0.575, 0.6, 0.625, 0.65, 0.675, 0.7, 0.725, 0.75, 0.775, 0.8, 0.825, 0.85, 0.875, 0.9, 0.925, 0.95, 0.975, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 31, 32, 33, 34, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or about 50 mg/kg. A repeat-dose regimine may include administration of a therapeutic amount of iRNA on a regular basis, such as every other day, every third day, every fourth day, twice a week, once a week, every other week, or once a month.
The pharmaceutical composition can be administered by intravenous infusion over a period of time, such as over a 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21, 22, 23, 24, or about a 25 minute period. The administration may be repeated, for example, on a regular basis, such as weekly, biweekly (i.e., every two weeks) for one month, two months, three months, four months or longer. After an initial treatment regimen, the treatments can be administered on a less frequent basis. For example, after administration weekly or biweekly for three months, administration can be repeated once per month, for six months or a year or longer.
The pharmaceutical composition can be administered once daily, or the iRNA can be administered as two, three, or more sub-doses at appropriate intervals throughout the day or even using continuous infusion or delivery through a controlled release formulation. In that case, the iRNA contained in each sub-dose must be correspondingly smaller in order to achieve the total daily dosage. The dosage unit can also be compounded for delivery over several days, e.g., using a conventional sustained release formulation which provides sustained release of the iRNA over a several day period. Sustained release formulations are well known in the art and are particularly useful for delivery of agents at a particular site, such as could be used with the agents of the present invention. In this embodiment, the dosage unit contains a corresponding multiple of the daily dose.
In other embodiments, a single dose of the pharmaceutical compositions can be long lasting, such that subsequent doses are administered at not more than 3, 4, or 5 day intervals, or at not more than 1, 2, 3, or 4 week intervals. In some embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered once per week. In other embodiments of the invention, a single dose of the pharmaceutical compositions of the invention is administered bi-monthly.
The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a composition can include a single treatment or a series of treatments. Estimates of effective dosages and in vivo half-lives for the individual iRNAs encompassed by the invention can be made using conventional methodologies or on the basis of in vivo testing using an appropriate animal model, as described elsewhere herein.
Advances in mouse genetics have generated a number of mouse models for the study of various human diseases, such as a disorder that would benefit from reduction in the expression of C5. Such models can be used for in vivo testing of iRNA, as well as for determining a therapeutically effective dose. Suitable mouse models are known in the art and include, for example, collagen-induced arthritis mouse model (Courtenay, J. S., et al. (1980) Nature 283, 666-668), myocardial ischemia (Homeister J W and Lucchesi B R (1994) Annu Rev Pharmacol Toxicol 34:17-40), ovalbumin induced asthma mouse models (e.g., Tomkinson A., et al. (2001). J. Immunol. 166, 5792-5800), (NZB×NZW)F1, MRL/Faslpr (MRL/lpr) and BXSB mouse models (Theofilopoulos, A. N. and Kono, D. H. 1999. Murine lupus models: gene-specific and genome-wide studies. In Lahita R. G., ed., Systemic Lupus Erythematosus, 3rd edn, p. 145. Academic Press, San Diego, Calif.), mouse aHUS model (Goicoechea de Jorge et al. (2011) The development of atypical hemolytic uremic syndrome depends on complement C5, J Am Soc Nephrol 22:137-145.
The pharmaceutical compositions of the present invention can be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration can be topical (e.g., by a transdermal patch), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal, oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; subdermal, e.g., via an implanted device; or intracranial, e.g., by intraparenchymal, intrathecal or intraventricular, administration.
The iRNA can be delivered in a manner to target a particular tissue, such as the liver (e.g., the hepatocytes of the liver).
Pharmaceutical compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like can be necessary or desirable. Coated condoms, gloves and the like can also be useful. Suitable topical formulations include those in which the iRNAs featured in the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Suitable lipids and liposomes include neutral (e.g., dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearolyphosphatidyl choline) negative (e.g., dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g., dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). iRNAs featured in the invention can be encapsulated within liposomes or can form complexes thereto, in particular to cationic liposomes. Alternatively, iRNAs can be complexed to lipids, in particular to cationic lipids. Suitable fatty acids and esters include but are not limited to arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C1-20 alkyl ester (e.g., isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof). Topical formulations are described in detail in U.S. Pat. No. 6,747,014, which is incorporated herein by reference.
A. iRNA Formulations Comprising Membranous Molecular Assemblies
An iRNA for use in the compositions and methods of the invention can be formulated for delivery in a membranous molecular assembly, e.g., a liposome or a micelle. As used herein, the term “liposome” refers to a vesicle composed of amphiphilic lipids arranged in at least one bilayer, e.g., one bilayer or a plurality of bilayers. Liposomes include unilamellar and multilamellar vesicles that have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the iRNA composition. The lipophilic material isolates the aqueous interior from an aqueous exterior, which typically does not include the iRNA composition, although in some examples, it may. Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomal bilayer fuses with bilayer of the cellular membranes. As the merging of the liposome and cell progresses, the internal aqueous contents that include the iRNA are delivered into the cell where the iRNA can specifically bind to a target RNA and can mediate RNAi. In some cases the liposomes are also specifically targeted, e.g., to direct the iRNA to particular cell types.
A liposome containing a RNAi agent can be prepared by a variety of methods. In one example, the lipid component of a liposome is dissolved in a detergent so that micelles are formed with the lipid component. For example, the lipid component can be an amphipathic cationic lipid or lipid conjugate. The detergent can have a high critical micelle concentration and may be nonionic. Exemplary detergents include cholate, CHAPS, octylglucoside, deoxycholate, and lauroyl sarcosine. The RNAi agent preparation is then added to the micelles that include the lipid component. The cationic groups on the lipid interact with the RNAi agent and condense around the RNAi agent to form a liposome. After condensation, the detergent is removed, e.g., by dialysis, to yield a liposomal preparation of RNAi agent.
If necessary a carrier compound that assists in condensation can be added during the condensation reaction, e.g., by controlled addition. For example, the carrier compound can be a polymer other than a nucleic acid (e.g., spermine or spermidine). pH can also adjusted to favor condensation.
Methods for producing stable polynucleotide delivery vehicles, which incorporate a polynucleotide/cationic lipid complex as structural components of the delivery vehicle, are further described in, e.g., WO 96/37194, the entire contents of which are incorporated herein by reference. Liposome formation can also include one or more aspects of exemplary methods described in Felgner, P. L. et al., Proc. Natl. Acad. Sci., USA 8:7413-7417, 1987; U.S. Pat. No. 4,897,355; U.S. Pat. No. 5,171,678; Bangham, et al. M. Mol. Biol. 23:238, 1965; Olson, et al. Biochim. Biophys. Acta 557:9, 1979; Szoka, et al. Proc. Natl. Acad. Sci. 75: 4194, 1978; Mayhew, et al. Biochim. Biophys. Acta 775:169, 1984; Kim, et al. Biochim. Biophys. Acta 728:339, 1983; and Fukunaga, et al. Endocrinol. 115:757, 1984. Commonly used techniques for preparing lipid aggregates of appropriate size for use as delivery vehicles include sonication and freeze-thaw plus extrusion (see, e.g., Mayer, et al. Biochim. Biophys. Acta 858:161, 1986). Microfluidization can be used when consistently small (50 to 200 nm) and relatively uniform aggregates are desired (Mayhew, et al. Biochim. Biophys. Acta 775:169, 1984). These methods are readily adapted to packaging RNAi agent preparations into liposomes.
Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged nucleic acid molecules to form a stable complex. The positively charged nucleic acid/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., Biochem. Biophys. Res. Commun., 1987, 147, 980-985).
Liposomes which are pH-sensitive or negatively-charged, entrap nucleic acids rather than complex with it. Since both the nucleic acid and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some nucleic acid is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver nucleic acids encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., Journal of Controlled Release, 1992, 19, 269-274).
One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.
Examples of other methods to introduce liposomes into cells in vitro and in vivo include U.S. Pat. No. 5,283,185; U.S. Pat. No. 5,171,678; WO 94/00569; WO 93/24640; WO 91/16024; Felgner, J. Biol. Chem. 269:2550, 1994; Nabel, Proc. Natl. Acad. Sci. 90:11307, 1993; Nabel, Human Gene Ther. 3:649, 1992; Gershon, Biochem. 32:7143, 1993; and Strauss EMBO J. 11:417, 1992.
Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising NovasomeTM I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and NovasomeTM II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporine A into different layers of the skin (Hu et al. S.T.P. Pharma. Sci., 1994, 4(6) 466).
Liposomes also include “sterically stabilized” liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside GM1, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., FEBS Letters, 1987, 223, 42; Wu et al., Cancer Research, 1993, 53, 3765).
Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (Ann. N.Y. Acad. Sci., 1987, 507, 64) reported the ability of monosialoganglioside GM1, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (Proc. Natl. Acad. Sci. U.S.A., 1988, 85, 6949). U.S. Pat. No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside GM1 or a galactocerebroside sulfate ester. U.S. Pat. No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al).
In one embodiment, cationic liposomes are used. Cationic liposomes possess the advantage of being able to fuse to the cell membrane. Non-cationic liposomes, although not able to fuse as efficiently with the plasma membrane, are taken up by macrophages in vivo and can be used to deliver RNAi agents to macrophages.
Further advantages of liposomes include: liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated RNAi agents in their internal compartments from metabolism and degradation (Rosoff, in “Pharmaceutical Dosage Forms,” Lieberman, Rieger and Banker (Eds.), 1988, volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.
A positively charged synthetic cationic lipid, N-[1-(2,3-dioleyloxyl)propyl]-N,N,N-trimethylammonium chloride (DOTMA) can be used to form small liposomes that interact spontaneously with nucleic acid to form lipid-nucleic acid complexes which are capable of fusing with the negatively charged lipids of the cell membranes of tissue culture cells, resulting in delivery of RNAi agent (see, e.g., Felgner, P. L. et al., Proc. Natl. Acad. Sci., USA 8:7413-7417, 1987 and U.S. Pat. No. 4,897,355 for a description of DOTMA and its use with DNA).
A DOTMA analogue, 1,2-bis(oleoyloxy)-3-(trimethylammonia)propane (DOTAP) can be used in combination with a phospholipid to form DNA-complexing vesicles. LipofectinTM Bethesda Research Laboratories, Gaithersburg, Md.) is an effective agent for the delivery of highly anionic nucleic acids into living tissue culture cells that comprise positively charged DOTMA liposomes which interact spontaneously with negatively charged polynucleotides to form complexes. When enough positively charged liposomes are used, the net charge on the resulting complexes is also positive. Positively charged complexes prepared in this way spontaneously attach to negatively charged cell surfaces, fuse with the plasma membrane, and efficiently deliver functional nucleic acids into, for example, tissue culture cells. Another commercially available cationic lipid, 1,2-bis(oleoyloxy)-3,3-(trimethylammonia)propane (“DOTAP”) (Boehringer Mannheim, Indianapolis, Ind.) differs from DOTMA in that the oleoyl moieties are linked by ester, rather than ether linkages.
Other reported cationic lipid compounds include those that have been conjugated to a variety of moieties including, for example, carboxyspermine which has been conjugated to one of two types of lipids and includes compounds such as 5-carboxyspermylglycine dioctaoleoylamide (“DOGS”) (TransfectamTM, Promega, Madison, Wis.) and dipalmitoylphosphatidylethanolamine 5-carboxyspermyl-amide (“DPPES”) (see, e.g., U.S. Pat. No. 5,171,678).
Another cationic lipid conjugate includes derivatization of the lipid with cholesterol (“DC-Chol”) which has been formulated into liposomes in combination with DOPE (See, Gao, X. and Huang, L., Biochim. Biophys. Res. Commun. 179:280, 1991). Lipopolylysine, made by conjugating polylysine to DOPE, has been reported to be effective for transfection in the presence of serum (Zhou, X. et al., Biochim. Biophys. Acta 1065:8, 1991). For certain cell lines, these liposomes containing conjugated cationic lipids, are said to exhibit lower toxicity and provide more efficient transfection than the DOTMA-containing compositions. Other commercially available cationic lipid products include DMRIE and DMRIE-HP (Vical, La Jolla, Calif.) and Lipofectamine (DOSPA) (Life Technology, Inc., Gaithersburg, Md.). Other cationic lipids suitable for the delivery of oligonucleotides are described in WO 98/39359 and WO 96/37194.
Liposomal formulations are particularly suited for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer RNAi agent into the skin. In some implementations, liposomes are used for delivering RNAi agent to epidermal cells and also to enhance the penetration of RNAi agent into dermal tissues, e.g., into skin. For example, the liposomes can be applied topically. Topical delivery of drugs formulated as liposomes to the skin has been documented (see, e.g., Weiner et al., Journal of Drug Targeting, 1992, vol. 2, 405-410 and du Plessis et al., Antiviral Research, 18, 1992, 259-265; Mannino, R. J. and Fould-Fogerite, S., Biotechniques 6:682-690, 1988; Itani, T. et al. Gene 56:267-276. 1987; Nicolau, C. et al. Meth. Enz. 149:157-176, 1987; Straubinger, R. M. and Papahadjopoulos, D. Meth. Enz. 101:512-527, 1983; Wang, C. Y. and Huang, L., Proc. Natl. Acad. Sci. USA 84:7851-7855, 1987).
Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver a drug into the dermis of mouse skin. Such formulations with RNAi agent are useful for treating a dermatological disorder.
Liposomes that include iRNA can be made highly deformable. Such deformability can enable the liposomes to penetrate through pore that are smaller than the average radius of the liposome. For example, transfersomes are a type of deformable liposomes. Transferosomes can be made by adding surface edge activators, usually surfactants, to a standard liposomal composition. Transfersomes that include RNAi agent can be delivered, for example, subcutaneously by infection in order to deliver RNAi agent to keratinocytes in the skin. In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. In addition, due to the lipid properties, these transferosomes can be self-optimizing (adaptive to the shape of pores, e.g., in the skin), self-repairing, and can frequently reach their targets without fragmenting, and often self-loading.
Other formulations amenable to the present invention are described in U.S. provisional application Ser. No. 61/018,616, filed Jan. 2, 2008; 61/018,611, filed Jan. 2, 2008; 61/039,748, filed Mar. 26, 2008; 61/047,087, filed Apr. 22, 2008 and 61/051,528, filed May 8, 2008. PCT application no PCT/US2007/080331, filed Oct. 3, 2007 also describes formulations that are amenable to the present invention.
Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes can be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g., they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.
Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the “head”) provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in “Pharmaceutical Dosage Forms”, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).
If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.
If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.
If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.
If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.
The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in “Pharmaceutical Dosage Forms”, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).
The iRNA for use in the methods of the invention can also be provided as micellar formulations. “Micelles” are defined herein as a particular type of molecular assembly in which amphipathic molecules are arranged in a spherical structure such that all the hydrophobic portions of the molecules are directed inward, leaving the hydrophilic portions in contact with the surrounding aqueous phase. The converse arrangement exists if the environment is hydrophobic.
A mixed micellar formulation suitable for delivery through transdermal membranes may be prepared by mixing an aqueous solution of the siRNA composition, an alkali metal C8 to C22 alkyl sulphate, and a micelle forming compounds. Exemplary micelle forming compounds include lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof, chenodeoxycholate, deoxycholate, and mixtures thereof. The micelle forming compounds may be added at the same time or after addition of the alkali metal alkyl sulphate. Mixed micelles will form with substantially any kind of mixing of the ingredients but vigorous mixing in order to provide smaller size micelles.
In one method a first micellar composition is prepared which contains the siRNA composition and at least the alkali metal alkyl sulphate. The first micellar composition is then mixed with at least three micelle forming compounds to form a mixed micellar composition. In another method, the micellar composition is prepared by mixing the siRNA composition, the alkali metal alkyl sulphate and at least one of the micelle forming compounds, followed by addition of the remaining micelle forming compounds, with vigorous mixing.
Phenol and/or m-cresol may be added to the mixed micellar composition to stabilize the formulation and protect against bacterial growth. Alternatively, phenol and/or m-cresol may be added with the micelle forming ingredients. An isotonic agent such as glycerin may also be added after formation of the mixed micellar composition.
For delivery of the micellar formulation as a spray, the formulation can be put into an aerosol dispenser and the dispenser is charged with a propellant. The propellant, which is under pressure, is in liquid form in the dispenser. The ratios of the ingredients are adjusted so that the aqueous and propellant phases become one, i.e., there is one phase. If there are two phases, it is necessary to shake the dispenser prior to dispensing a portion of the contents, e.g., through a metered valve. The dispensed dose of pharmaceutical agent is propelled from the metered valve in a fine spray.
Propellants may include hydrogen-containing chlorofluorocarbons, hydrogen-containing fluorocarbons, dimethyl ether and diethyl ether. In certain embodiments, HFA 134a (1,1,1,2 tetrafluoroethane) may be used.
The specific concentrations of the essential ingredients can be determined by relatively straightforward experimentation. For absorption through the oral cavities, it is often desirable to increase, e.g., at least double or triple, the dosage for through injection or administration through the gastrointestinal tract.
B. Lipid Particles
iRNAs, e.g., dsRNAs of in the invention may be fully encapsulated in a lipid formulation, e.g., a LNP, or other nucleic acid-lipid particle.
As used herein, the term “LNP” refers to a stable nucleic acid-lipid particle. LNPs typically contain a cationic lipid, a non-cationic lipid, and a lipid that prevents aggregation of the particle (e.g., a PEG-lipid conjugate). LNPs are extremely useful for systemic applications, as they exhibit extended circulation lifetimes following intravenous (i.v.) injection and accumulate at distal sites (e.g., sites physically separated from the administration site). LNPs include “pSPLP,” which include an encapsulated condensing agent-nucleic acid complex as set forth in PCT Publication No. WO 00/03683. The particles of the present invention typically have a mean diameter of about 50 nm to about 150 nm, more typically about 60 nm to about 130 nm, more typically about 70 nm to about 110 nm, most typically about 70 nm to about 90 nm, and are substantially nontoxic. In addition, the nucleic acids when present in the nucleic acid-lipid particles of the present invention are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., U.S. Pat. Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; 6,815,432; U.S. Publication No. 2010/0324120 and PCT Publication No. WO 96/40964.
In one embodiment, the lipid to drug ratio (mass/mass ratio) (e.g., lipid to dsRNA ratio) will be in the range of from about 1:1 to about 50:1, from about 1:1 to about 25:1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5:1 to about 9:1, or about 6:1 to about 9:1. Ranges intermediate to the above recited ranges are also contemplated to be part of the invention.
The cationic lipid can be, for example, N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N—(I-2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N—(I-(2,3-dioleyloxyl)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3-dioleyloxy)propylamine (DODMA), 1,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-Dilinoleyoxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2-Dilinoleyoxy-3-morpholinopropane (DLin-MA), 1,2-Dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-Linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-Dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.C1), 1,2-Dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-Dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), or 3-(N,N-Dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-Dioleylamino)-1,2-propanedio (DOAP), 1,2-Dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA) or analogs thereof, (3aR,5s,6aS)—N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3), 1,1′-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediyl)didodecan-2-ol (Tech GI), or a mixture thereof. The cationic lipid can comprise from about 20 mol % to about 50 mol % or about 40 mol % of the total lipid present in the particle.
In another embodiment, the compound 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane can be used to prepare lipid-siRNA nanoparticles. Synthesis of 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane is described in U.S. provisional patent application No. 61/107,998 filed on Oct. 23, 2008, which is herein incorporated by reference.
In one embodiment, the lipid-siRNA particle includes 40% 2, 2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane: 10% DSPC: 40% Cholesterol: 10% PEG-C-DOMG (mole percent) with a particle size of 63.0±20 nm and a 0.027 siRNA/Lipid Ratio.
The ionizable/non-cationic lipid can be an anionic lipid or a neutral lipid including, but not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), cholesterol, or a mixture thereof. The non-cationic lipid can be from about 5 mol % to about 90 mol %, about 10 mol %, or about 58 mol % if cholesterol is included, of the total lipid present in the particle.
The conjugated lipid that inhibits aggregation of particles can be, for example, a polyethyleneglycol (PEG)-lipid including, without limitation, a PEG-diacylglycerol (DAG), a PEG-dialkyloxypropyl (DAA), a PEG-phospholipid, a PEG-ceramide (Cer), or a mixture thereof. The PEG-DAA conjugate can be, for example, a PEG-dilauryloxypropyl (Ci2), a PEG-dimyristyloxypropyl (Ci4), a PEG-dipalmityloxypropyl (Ci6), or a PEG-distearyloxypropyl (C]8). The conjugated lipid that prevents aggregation of particles can be from 0 mol % to about 20 mol % or about 2 mol % of the total lipid present in the particle.
In some embodiments, the nucleic acid-lipid particle further includes cholesterol at, e.g., about 10 mol % to about 60 mol % or about 48 mol % of the total lipid present in the particle.
In one embodiment, the lipidoid ND98.4HCl (MW 1487) (see U.S. patent application Ser. No. 12/056,230, filed Mar. 26, 2008, which is incorporated herein by reference), Cholesterol (Sigma-Aldrich), and PEG-Ceramide C16 (Avanti Polar Lipids) can be used to prepare lipid-dsRNA nanoparticles (i.e., LNP01 particles). Stock solutions of each in ethanol can be prepared as follows: ND98, 133 mg/ml; Cholesterol, 25 mg/ml, PEG-Ceramide C16, 100 mg/ml. The ND98, Cholesterol, and PEG-Ceramide C16 stock solutions can then be combined in a, e.g., 42:48:10 molar ratio. The combined lipid solution can be mixed with aqueous dsRNA (e.g., in sodium acetate pH 5) such that the final ethanol concentration is about 35-45% and the final sodium acetate concentration is about 100-300 mM. Lipid-dsRNA nanoparticles typically form spontaneously upon mixing. Depending on the desired particle size distribution, the resultant nanoparticle mixture can be extruded through a polycarbonate membrane (e.g., 100 nm cut-off) using, for example, a thermobarrel extruder, such as Lipex Extruder (Northern Lipids, Inc). In some cases, the extrusion step can be omitted. Ethanol removal and simultaneous buffer exchange can be accomplished by, for example, dialysis or tangential flow filtration. Buffer can be exchanged with, for example, phosphate buffered saline (PBS) at about pH 7, e.g., about pH 6.9, about pH 7.0, about pH 7.1, about pH 7.2, about pH 7.3, or about pH 7.4.




LNP01 formulations are described, e.g., in International Application Publication No. WO 2008/042973, which is hereby incorporated by reference.
Additional exemplary lipid-dsRNA formulations are described in Table 1.









TABLE 1







cationic lipid/non-cationic




lipid/cholesterol/PEG-lipid conjugate



Ionizable/Cationic Lipid
Lipid:siRNA ratio







SNALP-1
1,2-Dilinolenyloxy-N,N-dimethylaminopropane
DLinDMA/DPPC/Cholesterol/PEG-cDMA



(DLinDMA)
(57.1/7.1/34.4/1.4)




lipid:siRNA ~7:1


2-XTC
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-
XTC/DPPC/Cholesterol/PEG-cDMA



dioxolane (XTC)
57.1/7.1/34.4/1.4




lipid:siRNA ~7:1


LNP05
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-
XTC/DSPC/Cholesterol/PEG-DMG



dioxolane (XTC)
57.5/7.5/31.5/3.5




lipid:siRNA ~6:1


LNP06
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-
XTC/DSPC/Cholesterol/PEG-DMG



dioxolane (XTC)
57.5/7.5/31.5/3.5




lipid:siRNA ~11:1


LNP07
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-
XTC/DSPC/Cholesterol/PEG-DMG



dioxolane (XTC)
60/7.5/31/1.5,




lipid:siRNA ~6:1


LNP08
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-
XTC/DSPC/Cholesterol/PEG-DMG



dioxolane (XTC)
60/7.5/31/1.5,




lipid:siRNA ~11:1


LNP09
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-
XTC/DSPC/Cholesterol/PEG-DMG



dioxolane (XTC)
50/10/38.5/1.5




Lipid:siRNA 10:1


LNP10
(3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z,12Z)-
ALN100/DSPC/Cholesterol/PEG-DMG



octadeca-9,12-dienyl)tetrahydro-3aH-
50/10/38.5/1.5



cyclopenta[d][1,3]dioxol-5-amine (ALN100)
Lipid:siRNA 10:1


LNP11
(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-
MC-3/DSPC/Cholesterol/PEG-DMG



tetraen-19-yl 4-(dimethylamino)butanoate
50/10/38.5/1.5



(MC3)
Lipid:siRNA 10:1


LNP12
1,1′-(2-(4-(2-((2-(bis(2-
Tech G1/DSPC/Cholesterol/PEG-DMG



hydroxydodecyl)amino)ethyl)(2-
50/10/38.5/1.5



hydroxydodecyl)amino)ethyl)piperazin-1-
Lipid:siRNA 10:1



yl)ethylazanediyl)didodecan-2-ol (Tech G1)


LNP13
XTC
XTC/DSPC/Chol/PEG-DMG




50/10/38.5/1.5




Lipid:siRNA: 33:1


LNP14
MC3
MC3/DSPC/Chol/PEG-DMG




40/15/40/5




Lipid:siRNA: 11:1


LNP15
MC3
MC3/DSPC/Chol/PEG-DSG/GalNAc-PEG-DSG




50/10/35/4.5/0.5




Lipid:siRNA: 11:1


LNP16
MC3
MC3/DSPC/Chol/PEG-DMG




50/10/38.5/1.5




Lipid:siRNA: 7:1


LNP17
MC3
MC3/DSPC/Chol/PEG-DSG




50/10/38.5/1.5




Lipid:siRNA: 10:1


LNP18
MC3
MC3/DSPC/Chol/PEG-DMG




50/10/38.5/1.5




Lipid:siRNA: 12:1


LNP19
MC3
MC3/DSPC/Chol/PEG-DMG




50/10/35/5




Lipid:siRNA: 8:1


LNP20
MC3
MC3/DSPC/Chol/PEG-DPG




50/10/38.5/1.5




Lipid:siRNA: 10:1


LNP21
C12-200
C12-200/DSPC/Chol/PEG-DSG




50/10/38.5/1.5




Lipid:siRNA: 7:1


LNP22
XTC
XTC/DSPC/Chol/PEG-DSG




50/10/38.5/1.5




Lipid:siRNA: 10:1





DSPC: distearoylphosphatidylcholine


DPPC: dipalmitoylphosphatidylcholine


PEG-DMG: PEG-didimyristoyl glycerol (C14-PEG, or PEG-C14) (PEG with avg mol wt of 2000)


PEG-DSG: PEG-distyryl glycerol (C18-PEG, or PEG-C18) (PEG with avg mol wt of 2000)


PEG-cDMA: PEG-carbamoyl-1,2-dimyristyloxypropylamine (PEG with avg mol wt of 2000)


SNALP (1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA)) comprising formulations are described in International Publication No. WO2009/127060, filed Apr. 15, 2009, which is hereby incorporated by reference.


XTC comprising formulations are described, e.g., in U.S. Provisional Serial No. 61/148,366, filed Jan. 29, 2009; U.S. Provisional Serial No. 61/156,851, filed Mar. 2, 2009; U.S. Provisional Serial No. filed Jun. 10, 2009; U.S. Provisional Serial No. 61/228,373, filed Jul. 24, 2009; U.S. Provisional Serial No. 61/239,686, filed Sep. 3, 2009, and International Application No. PCT/US2010/022614, filed Jan. 29, 2010, which are hereby incorporated by reference.


MC3 comprising formulations are described, e.g., in U.S. Publication No. 2010/0324120, filed Jun. 10, 2010, the entire contents of which are hereby incorporated by reference.


ALNY-100 comprising formulations are described, e.g., International patent application number PCT/US09/63933, filed on Nov. 10, 2009, which is hereby incorporated by reference.


C12-200 comprising formulations are described in U.S. Provisional Serial No. 61/175,770, filed May 5, 2009 and International Application No. PCT/US10/33777, filed May 5, 2010, which are hereby incorporated by reference.






Synthesis of Ionizable/Cationic Lipids

Any of the compounds, e.g., cationic lipids and the like, used in the nucleic acid-lipid particles of the invention can be prepared by known organic synthesis techniques, including the methods described in more detail in the Examples. All substituents are as defined below unless indicated otherwise.
“Alkyl” means a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms. Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and the like; while saturated branched alkyls include isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like. Representative saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturated cyclic alkyls include cyclopentenyl and cyclohexenyl, and the like.
“Alkenyl” means an alkyl, as defined above, containing at least one double bond between adjacent carbon atoms. Alkenyls include both cis and trans isomers. Representative straight chain and branched alkenyls include ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like.
“Alkynyl” means any alkyl or alkenyl, as defined above, which additionally contains at least one triple bond between adjacent carbons. Representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1 butynyl, and the like.
“Acyl” means any alkyl, alkenyl, or alkynyl wherein the carbon at the point of attachment is substituted with an oxo group, as defined below. For example, —C(═O)alkyl, —C(═O)alkenyl, and —C(═O)alkynyl are acyl groups.
“Heterocycle” means a 5- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains from 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, and the nitrogen heteroatom can be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring. The heterocycle can be attached via any heteroatom or carbon atom. Heterocycles include heteroaryls as defined below. Heterocycles include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperizynyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
The terms “optionally substituted alkyl”, “optionally substituted alkenyl”, “optionally substituted alkynyl”, “optionally substituted acyl”, and “optionally substituted heterocycle” means that, when substituted, at least one hydrogen atom is replaced with a substituent. In the case of an oxo substituent (═O) two hydrogen atoms are replaced. In this regard, substituents include oxo, halogen, heterocycle, —CN, —ORx, —NRxRy, —NRxC(═O)Ry, —NRxSO2Ry, —C(═O)Rx, —C(═O)ORx, —C(═O)NRxRy, —SOnRx and —SOnNRxRy, wherein n is 0, 1 or 2, Rx and Ry are the same or different and independently hydrogen, alkyl or heterocycle, and each of said alkyl and heterocycle substituents can be further substituted with one or more of oxo, halogen, —OH, —CN, alkyl, —ORx, heterocycle, —NRxRy, —NRxC(═O)Ry, —NRxSO2Ry, —C(═O)Rx, —C(═O)ORx, —C(═O)NRxRy, —SOnRx and —SOnNRxRy.
“Halogen” means fluoro, chloro, bromo and iodo.
In some embodiments, the methods of the invention can require the use of protecting groups. Protecting group methodology is well known to those skilled in the art (see, for example, Protective Groups in Organic Synthesis, Green, T. W. et al., Wiley-Interscience, New York City, 1999). Briefly, protecting groups within the context of this invention are any group that reduces or eliminates unwanted reactivity of a functional group. A protecting group can be added to a functional group to mask its reactivity during certain reactions and then removed to reveal the original functional group. In some embodiments an “alcohol protecting group” is used. An “alcohol protecting group” is any group which decreases or eliminates unwanted reactivity of an alcohol functional group. Protecting groups can be added and removed using techniques well known in the art.
Synthesis of Formula A
In some embodiments, nucleic acid-lipid particles of the invention are formulated using a cationic lipid of formula A:




where R1 and R2 are independently alkyl, alkenyl or alkynyl, each can be optionally substituted, and R3 and R4 are independently lower alkyl or R3 and R4 can be taken together to form an optionally substituted heterocyclic ring. In some embodiments, the cationic lipid is XTC (2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane). In general, the lipid of formula A above can be made by the following Reaction Schemes 1 or 2, wherein all substituents are as defined above unless indicated otherwise.





Lipid A, where R1 and R2 are independently alkyl, alkenyl or alkynyl, each can be optionally substituted, and R3 and R4 are independently lower alkyl or R3 and R4 can be taken together to form an optionally substituted heterocyclic ring, can be prepared according to Scheme 1. Ketone 1 and bromide 2 can be purchased or prepared according to methods known to those of ordinary skill in the art. Reaction of 1 and 2 yields ketal 3. Treatment of ketal 3 with amine 4 yields lipids of formula A. The lipids of formula A can be converted to the corresponding ammonium salt with an organic salt of formula 5, where X is anion counter ion selected from halogen, hydroxide, phosphate, sulfate, or the like.





Alternatively, the ketone 1 starting material can be prepared according to Scheme 2. Grignard reagent 6 and cyanide 7 can be purchased or prepared according to methods known to those of ordinary skill in the art. Reaction of 6 and 7 yields ketone 1. Conversion of ketone 1 to the corresponding lipids of formula A is as described in Scheme 1.

Synthesis of MC3

Preparation of DLin-M-C3-DMA (i.e., (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate) was as follows. A solution of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-ol (0.53 g), 4-N,N-dimethylaminobutyric acid hydrochloride (0.51 g), 4-N,N-dimethylaminopyridine (0.61 g) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.53 g) in dichloromethane (5 mL) was stirred at room temperature overnight. The solution was washed with dilute hydrochloric acid followed by dilute aqueous sodium bicarbonate. The organic fractions were dried over anhydrous magnesium sulphate, filtered and the solvent removed on a rotovap. The residue was passed down a silica gel column (20 g) using a 1-5% methanol/dichloromethane elution gradient.
Fractions containing the purified product were combined and the solvent removed, yielding a colorless oil (0.54 g).
Synthesis of ALNY-100
Synthesis of ketal 519 [ALNY-100] was performed using the following scheme 3:




Synthesis of 515

To a stirred suspension of LiAlH4 (3.74 g, 0.09852 mol) in 200 ml anhydrous THF in a two neck RBF (IL), was added a solution of 514 (10 g, 0.04926 mol) in 70 mL of THF slowly at 0 0 C under nitrogen atmosphere. After complete addition, reaction mixture was warmed to room temperature and then heated to reflux for 4 h. Progress of the reaction was monitored by TLC. After completion of reaction (by TLC) the mixture was cooled to 0 0 C and quenched with careful addition of saturated Na2SO4 solution. Reaction mixture was stirred for 4 h at room temperature and filtered off. Residue was washed well with THF. The filtrate and washings were mixed and diluted with 400 mL dioxane and 26 mL conc. HCl and stirred for 20 minutes at room temperature. The volatilities were stripped off under vacuum to furnish the hydrochloride salt of 515 as a white solid. Yield: 7.12 g 1H-NMR (DMSO, 400 MHz): δ=9.34 (broad, 2H), 5.68 (s, 2H), 3.74 (m, 1H), 2.66-2.60 (m, 2H), 2.50-2.45 (m, 5H).
Synthesis of 516
To a stirred solution of compound 515 in 100 mL dry DCM in a 250 mL two neck RBF, was added NEt3 (37.2 mL, 0.2669 mol) and cooled to 0 0 C under nitrogen atmosphere. After a slow addition of N-(benzyloxy-carbonyloxy)-succinimide (20 g, 0.08007 mol) in 50 mL dry DCM, reaction mixture was allowed to warm to room temperature. After completion of the reaction (2-3 h by TLC) mixture was washed successively with 1N HCl solution (1×100 mL) and saturated NaHCO3 solution (1×50 mL). The organic layer was then dried over anhyd. Na2SO4 and the solvent was evaporated to give crude material which was purified by silica gel column chromatography to get 516 as sticky mass. Yield: 11 g (89%). 1H-NMR (CDCl3, 400 MHz): δ=7.36-7.27 (m, 5H), 5.69 (s, 2H), 5.12 (s, 2H), 4.96 (br., 1H) 2.74 (s, 3H), 2.60 (m, 2H), 2.30-2.25 (m, 2H). LC-MS [M+H]-232.3 (96.94%).
Synthesis of 517A and 517B
The cyclopentene 516 (5 g, 0.02164 mol) was dissolved in a solution of 220 mL acetone and water (10:1) in a single neck 500 mL RBF and to it was added N-methyl morpholine-N-oxide (7.6 g, 0.06492 mol) followed by 4.2 mL of 7.6% solution of OsO4 (0.275 g, 0.00108 mol) in tert-butanol at room temperature. After completion of the reaction ( ̃3 h), the mixture was quenched with addition of solid Na2SO3 and resulting mixture was stirred for 1.5 h at room temperature. Reaction mixture was diluted with DCM (300 mL) and washed with water (2×100 mL) followed by saturated NaHCO3 (1×50 mL) solution, water (1×30 mL) and finally with brine (1×50 mL). Organic phase was dried over an. Na2SO4 and solvent was removed in vacuum. Silica gel column chromatographic purification of the crude material was afforded a mixture of diastereomers, which were separated by prep HPLC. Yield: −6 g crude
517A—Peak-1 (white solid), 5.13 g (96%). 1H-NMR (DMSO, 400 MHz): δ=7.39-7.31 (m, 5H), 5.04 (s, 2H), 4.78-4.73 (m, 1H), 4.48-4.47 (d, 2H), 3.94-3.93 (m, 2H), 2.71 (s, 3H), 1.72-1.67 (m, 4H). LC-MS—[M+H]-266.3, [M+NH4+]-283.5 present, HPLC-97.86%. Stereochemistry confirmed by X-ray.
Synthesis of 518
Using a procedure analogous to that described for the synthesis of compound 505, compound 518 (1.2 g, 41%) was obtained as a colorless oil. 1H-NMR (CDCl3, 400 MHz): δ=7.35-7.33 (m, 4H), 7.30-7.27 (m, 1H), 5.37-5.27 (m, 8H), 5.12 (s, 2H), 4.75 (m, 1H), 4.58-4.57 (m, 2H), 2.78-2.74 (m, 7H), 2.06-2.00 (m, 8H), 1.96-1.91 (m, 2H), 1.62 (m, 4H), 1.48 (m, 2H), 1.37-1.25 (br m, 36H), 0.87 (m, 6H). HPLC-98.65%.
General Procedure for the Synthesis of Compound 519
A solution of compound 518 (1 eq) in hexane (15 mL) was added in a drop-wise fashion to an ice-cold solution of LAH in THF (1 M, 2 eq). After complete addition, the mixture was heated at 40° C. over 0.5 h then cooled again on an ice bath. The mixture was carefully hydrolyzed with saturated aqueous Na2SO4 then filtered through celite and reduced to an oil. Column chromatography provided the pure 519 (1.3 g, 68%) which was obtained as a colorless oil. 13C NMR 8=130.2, 130.1 (×2), 127.9 (×3), 112.3, 79.3, 64.4, 44.7, 38.3, 35.4, 31.5, 29.9 (×2), 29.7, 29.6 (×2), 29.5 (×3), 29.3 (×2), 27.2 (×3), 25.6, 24.5, 23.3, 226, 14.1; Electrospray MS (+ve): Molecular weight for C44H80NO2 (M+H)+ Calc. 654.6. Found 654.6.
Formulations prepared by either the standard or extrusion-free method can be characterized in similar manners. For example, formulations are typically characterized by visual inspection. They should be whitish translucent solutions free from aggregates or sediment. Particle size and particle size distribution of lipid-nanoparticles can be measured by light scattering using, for example, a Malvern Zetasizer Nano ZS (Malvern, USA). Particles should be about 20-300 nm, such as 40-100 nm in size. The particle size distribution should be unimodal. The total dsRNA concentration in the formulation, as well as the entrapped fraction, is estimated using a dye exclusion assay. A sample of the formulated dsRNA can be incubated with an RNA-binding dye, such as Ribogreen (Molecular Probes) in the presence or absence of a formulation disrupting surfactant, e.g., 0.5% Triton-X100. The total dsRNA in the formulation can be determined by the signal from the sample containing the surfactant, relative to a standard curve. The entrapped fraction is determined by subtracting the “free” dsRNA content (as measured by the signal in the absence of surfactant) from the total dsRNA content. Percent entrapped dsRNA is typically >85%. For SNALP formulation, the particle size is at least 30 nm, at least 40 nm, at least 50 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at least 100 nm, at least 110 nm, and at least 120 nm. The suitable range is typically about at least 50 nm to about at least 110 nm, about at least 60 nm to about at least 100 nm, or about at least 80 nm to about at least 90 nm.
Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders can be desirable. In some embodiments, oral formulations are those in which dsRNAs featured in the invention are administered in conjunction with one or more penetration enhancer surfactants and chelators. Suitable surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Suitable bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucholic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Suitable fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g., sodium). In some embodiments, combinations of penetration enhancers are used, for example, fatty acids/salts in combination with bile acids/salts. One exemplary combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. DsRNAs featured in the invention can be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. DsRNA complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Suitable complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyomithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylaminomethylethylene P(TDAE), polyaminostyrene (e.g., p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcynaoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for dsRNAs and their preparation are described in detail in U.S. Pat. No. 6,887,906, US Publn. No. 20030027780, and U.S. Pat. No. 6,747,014, each of which is incorporated herein by reference.
Compositions and formulations for parenteral, intraparenchymal (into the brain), intrathecal, intraventricular or intrahepatic administration can include sterile aqueous solutions which can also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.
Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. Particularly preferred are formulations that target the liver when treating hepatic disorders such as hepatic carcinoma.
The pharmaceutical formulations of the present invention, which can conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
The compositions of the present invention can be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention can also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions can further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension can also contain stabilizers.
C. Additional Formulations
i. Emulsions
The compositions of the present invention can be prepared and formulated as emulsions. Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 301). Emulsions are often biphasic systems comprising two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions can be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions can contain additional components in addition to the dispersed phases, and the active drug which can be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants can also be present in emulsions as needed. Pharmaceutical emulsions can also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.
Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion can be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that can be incorporated into either phase of the emulsion. Emulsifiers can broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).
Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants can be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y. Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).
Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.
A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).
Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.
Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that can readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used can be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.
The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of ease of formulation, as well as efficacy from an absorption and bioavailability standpoint (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.
ii. Microemulsions
In one embodiment of the present invention, the compositions of iRNAs and nucleic acids are formulated as microemulsions. A microemulsion can be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: Controlled Release of Drugs: Polymers and Aggregate Systems, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 271).
The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.
Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions can, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase can typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase can include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.
Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (see e.g., U.S. Pat. Nos. 6,191,105; 7,063,860; 7,070,802; 7,157,099; Constantinides et al., Pharmaceutical Research, 1994, 11, 1385-1390; Ritschel, Meth. Find. Exp. Clin. Pharmacol., 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (see e.g., U.S. Pat. Nos. 6,191,105; 7,063,860; 7,070,802; 7,157,099; Constantinides et al., Pharmaceutical Research, 1994, 11, 1385; Ho et al., J. Pharm. Sci., 1996, 85, 138-143). Often microemulsions can form spontaneously when their components are brought together at ambient temperature. This can be particularly advantageous when formulating thermolabile drugs, peptides or iRNAs. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of iRNAs and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of iRNAs and nucleic acids.
Microemulsions of the present invention can also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the iRNAs and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention can be classified as belonging to one of five broad categories—surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of these classes has been discussed above.
iii. Microparticles
an RNAi agent of the invention may be incorporated into a particle, e.g., a microparticle. Microparticles can be produced by spray-drying, but may also be produced by other methods including lyophilization, evaporation, fluid bed drying, vacuum drying, or a combination of these techniques.
iv. Penetration Enhancers
In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly iRNAs, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs can cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.
Penetration enhancers can be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.
Surfactants (or “surface-active agents”) are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of iRNAs through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., J. Pharm. Pharmacol., 1988, 40, 252).
Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C1-20 alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (see e.g., Touitou, E., et al. Enhancement in Drug Delivery, CRC Press, Danvers, Mass., 2006; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; El Hariri et al., J. Pharm. Pharmacol., 1992, 44, 651-654).
The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Brunton, Chapter 38 in: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term “bile salts” includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. Suitable bile salts include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucholic acid (sodium glucholate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Swinyard, Chapter 39 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Yamamoto et al., J. Pharm. Exp. Ther., 1992, 263, 25; Yamashita et al., J. Pharm. Sci., 1990, 79, 579-583).
Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of iRNAs through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, J. Chromatogr., 1993, 618, 315-339). Suitable chelating agents include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines)(see e.g., Katdare, A. et al., Excipient development for pharmaceutical, biotechnology, and drug delivery, CRC Press, Danvers, Mass., 2006; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Buur et al., J. Control Rel., 1990, 14, 43-51).
As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of iRNAs through the alimentary mucosa (see e.g., Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33). This class of penetration enhancers includes, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., J. Pharm. Pharmacol., 1987, 39, 621-626).
Agents that enhance uptake of iRNAs at the cellular level can also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of dsRNAs. Examples of commercially available transfection reagents include, for example LipofectamineTM (Invitrogen; Carlsbad, Calif.), Lipofectamine 2000TM (Invitrogen; Carlsbad, Calif.), 293fectinTM (Invitrogen; Carlsbad, Calif.), CellfectinTM (Invitrogen; Carlsbad, Calif.), DMRIE-CTM (Invitrogen; Carlsbad, Calif.), FreeStyleTMMAX (Invitrogen; Carlsbad, Calif.), LipofectamineTM 2000 CD (Invitrogen; Carlsbad, Calif.), LipofectamineTM (Invitrogen; Carlsbad, Calif.), RNAiMAX (Invitrogen; Carlsbad, Calif.), OligofectamineTM (Invitrogen; Carlsbad, Calif.), OptifectTM (Invitrogen; Carlsbad, Calif.), X-tremeGENE Q2 Transfection Reagent (Roche; Grenzacherstrasse, Switzerland), DOTAP Liposomal Transfection Reagent (Grenzacherstrasse, Switzerland), DOSPER Liposomal Transfection Reagent (Grenzacherstrasse, Switzerland), or Fugene (Grenzacherstrasse, Switzerland), Transfectam® Reagent (Promega; Madison, Wis.), TransFastTM Transfection Reagent (Promega; Madison, Wis.), TfxTM-20 Reagent (Promega; Madison, Wis.), TfxTM-50 Reagent (Promega; Madison, Wis.), DreamFectTM (OZ Biosciences; Marseille, France), EcoTransfect (OZ Biosciences; Marseille, France), TransPassa D1 Transfection Reagent (New England Biolabs; Ipswich, Mass., USA), LyoVecTM/LipoGenTM (Invitrogen; San Diego, Calif., USA), PerFectin Transfection Reagent (Genlantis; San Diego, Calif., USA), NeuroPORTER Transfection Reagent (Genlantis; San Diego, Calif., USA), GenePORTER Transfection reagent (Genlantis; San Diego, Calif., USA), GenePORTER 2 Transfection reagent (Genlantis; San Diego, Calif., USA), Cytofectin Transfection Reagent (Genlantis; San Diego, Calif., USA), BaculoPORTER Transfection Reagent (Genlantis; San Diego, Calif., USA), TroganPORTERTM transfection Reagent (Genlantis; San Diego, Calif., USA), RiboFect (Bioline; Taunton, Mass., USA), PlasFect (Bioline; Taunton, Mass., USA), UniFECTOR (B-Bridge International; Mountain View, Calif., USA), SureFECTOR (B-Bridge International; Mountain View, Calif., USA), or HiFectTM (B-Bridge International, Mountain View, Calif., USA), among others.
Other agents can be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.
v. Carriers
Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, “carrier compound” or “carrier” can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate dsRNA in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4′isothiocyano-stilbene-2,2′-disulfonic acid (Miyao et al., DsRNA Res. Dev., 1995, 5, 115-121; Takakura et al., DsRNA & Nucl. Acid Drug Dev., 1996, 6, 177-183.
vi. Excipients
In contrast to a carrier compound, a “pharmaceutical carrier” or “excipient” is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient can be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc).
Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.
Formulations for topical administration of nucleic acids can include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions can also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.
Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.
vii. Other Components
The compositions of the present invention can additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions can contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or can contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.
Aqueous suspensions can contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension can also contain stabilizers.
In some embodiments, pharmaceutical compositions featured in the invention include (a) one or more iRNA compounds and (b) one or more agents which function by a non-RNAi mechanism and which are useful in treating a hemolytic disorder. Examples of such agents include, but are not limited to an anti-inflammatory agent, anti-steatosis agent, anti-viral, and/or anti-fibrosis agent. In addition, other substances commonly used to protect the liver, such as silymarin, can also be used in conjunction with the iRNAs described herein. Other agents useful for treating liver diseases include telbivudine, entecavir, and protease inhibitors such as telaprevir and other disclosed, for example, in Tung et al., U.S. Application Publication Nos. 2005/0148548, 2004/0167116, and 2003/0144217; and in Hale et al., U.S. Application Publication No. 2004/0127488.
Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds that exhibit high therapeutic indices are preferred.
The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of compositions featured herein in the invention lies generally within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods featured in the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range of the compound or, when appropriate, of the polypeptide product of a target sequence (e.g., achieving a decreased concentration of the polypeptide) that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.
In addition to their administration, as discussed above, the iRNAs featured in the invention can be administered in combination with other known agents effective in treatment of pathological processes mediated by C5 expression. In any event, the administering physician can adjust the amount and timing of iRNA administration on the basis of results observed using standard measures of efficacy known in the art or described herein.
VI. Methods for Inhibiting C5 Expression
The present invention provides methods of inhibiting expression of C5 in a cell. The methods include contacting a cell with an RNAi agent, e.g., a double stranded RNAi agent, in an amount effective to inhibit expression of the C5 in the cell, thereby inhibiting expression of the C5 in the cell.
Contacting of a cell with a double stranded RNAi agent may be done in vitro or in vivo. Contacting a cell in vivo with the RNAi agent includes contacting a cell or group of cells within a subject, e.g., a human subject, with the RNAi agent. Combinations of in vitro and in vivo methods of contacting are also possible. Contacting may be direct or indirect, as discussed above. Furthermore, contacting a cell may be accomplished via a targeting ligand, including any ligand described herein or known in the art. In preferred embodiments, the targeting ligand is a carbohydrate moiety, e.g., a GalNAc3 ligand, or any other ligand that directs the RNAi agent to a site of interest, e.g., the liver of a subject.
The term “inhibiting,” as used herein, is used interchangeably with “reducing,” “silencing,” “downregulating” and other similar terms, and includes any level of inhibition.
The phrase “inhibiting expression of a C5” is intended to refer to inhibition of expression of any C5 gene (such as, e.g., a mouse C5 gene, a rat C5 gene, a monkey C5 gene, or a human C5 gene) as well as variants or mutants of a C5 gene. Thus, the C5 gene may be a wild-type C5 gene, a mutant C5 gene, or a transgenic C5 gene in the context of a genetically manipulated cell, group of cells, or organism.
“Inhibiting expression of a C5 gene” includes any level of inhibition of a C5 gene, e.g., at least partial suppression of the expression of a C5 gene. The expression of the C5 gene may be assessed based on the level, or the change in the level, of any variable associated with C5 gene expression, e.g., C5 mRNA level, C5 protein level, or for example, CH50 activity as a measure of total hemolytic complement, AH50 to measure the hemolytic activity of the alternate pathway of complement, and/or lactate dehydrogenase (LDH) levels as a measure of intravascular hemolysis, and/or hemoglobin levels. Levels of C5a, C5b, and soluble C5b-9 complex may also be measured to assess C5 expression. This level may be assessed in an individual cell or in a group of cells, including, for example, a sample derived from a subject.
Inhibition may be assessed by a decrease in an absolute or relative level of one or more variables that are associated with C5 expression compared with a control level. The control level may be any type of control level that is utilized in the art, e.g., a pre-dose baseline level, or a level determined from a similar subject, cell, or sample that is untreated or treated with a control (such as, e.g., buffer only control or inactive agent control).
In some embodiments of the methods of the invention, expression of a C5 gene is inhibited by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%. at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.
Inhibition of the expression of a C5 gene may be manifested by a reduction of the amount of mRNA expressed by a first cell or group of cells (such cells may be present, for example, in a sample derived from a subject) in which a C5 gene is transcribed and which has or have been treated (e.g., by contacting the cell or cells with an RNAi agent of the invention, or by administering an RNAi agent of the invention to a subject in which the cells are or were present) such that the expression of a C5 gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has not or have not been so treated (control cell(s)). In preferred embodiments, the inhibition is assessed by expressing the level of mRNA in treated cells as a percentage of the level of mRNA in control cells, using the following formula:




  
    
      
        
          (
          
            mRNA
            ⁢
            
              
            
            ⁢
            in
            ⁢
            
              
            
            ⁢
            control
            ⁢
            
              
            
            ⁢
            cells
          
          )
        
        -
        
          (
          
            mRNA
            ⁢
            
              
            
            ⁢
            in
            ⁢
            
              
            
            ⁢
            treated
            ⁢
            
              
            
            ⁢
            cells
          
          )
        
      
      
        (
        
          mRNA
          ⁢
          
            
          
          ⁢
          in
          ⁢
          
            
          
          ⁢
          control
          ⁢
          
            
          
          ⁢
          cells
        
        )
      
    
    ·
    100
  
  ⁢
  
    
  
  ⁢
  %




Alternatively, inhibition of the expression of a C5 gene may be assessed in terms of a reduction of a parameter that is functionally linked to C5 gene expression, e.g., C5 protein expression, hepcidin gene or protein expression, or iron levels in tissues or serum. C5 gene silencing may be determined in any cell expressing C5, either constitutively or by genomic engineering, and by any assay known in the art. The liver is the major site of C5 expression. Other significant sites of expression include the kidneys and the uterus.
Inhibition of the expression of a C5 protein may be manifested by a reduction in the level of the C5 protein that is expressed by a cell or group of cells (e.g., the level of protein expressed in a sample derived from a subject). As explained above for the assessment of mRNA suppression, the inhibition of protein expression levels in a treated cell or group of cells may similarly be expressed as a percentage of the level of protein in a control cell or group of cells.
A control cell or group of cells that may be used to assess the inhibition of the expression of a C5 gene includes a cell or group of cells that has not yet been contacted with an RNAi agent of the invention. For example, the control cell or group of cells may be derived from an individual subject (e.g., a human or animal subject) prior to treatment of the subject with an RNAi agent.
The level of C5 mRNA that is expressed by a cell or group of cells may be determined using any method known in the art for assessing mRNA expression. In one embodiment, the level of expression of C5 in a sample is determined by detecting a transcribed polynucleotide, or portion thereof, e.g., mRNA of the C5 gene. RNA may be extracted from cells using RNA extraction techniques including, for example, using acid phenol/guanidine isothiocyanate extraction (RNAzol B; Biogenesis), RNeasy RNA preparation kits (Qiagen) or PAXgene (PreAnalytix, Switzerland). Typical assay formats utilizing ribonucleic acid hybridization include nuclear run-on assays, RT-PCR, RNase protection assays (Melton et al., Nuc. Acids Res. 12:7035), Northern blotting, in situ hybridization, and microarray analysis.
In one embodiment, the level of expression of C5 is determined using a nucleic acid probe. The term “probe”, as used herein, refers to any molecule that is capable of selectively binding to a specific C5. Probes can be synthesized by one of skill in the art, or derived from appropriate biological preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.
Isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction (PCR) analyses and probe arrays. One method for the determination of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to C5 mRNA. In one embodiment, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative embodiment, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in determining the level of C5 mRNA.
An alternative method for determining the level of expression of C5 in a sample involves the process of nucleic acid amplification and/or reverse transcriptase (to prepare cDNA) of for example mRNA in the sample, e.g., by RT-PCR (the experimental embodiment set forth in Mullis, 1987, U.S. Pat. No. 4,683,202), ligase chain reaction (Barany (1991) Proc. Natl. Acad. Sci. USA 88:189-193), self sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6:1197), rolling circle replication (Lizardi et al., U.S. Pat. No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In particular aspects of the invention, the level of expression of C5 is determined by quantitative fluorogenic RT-PCR (i.e., the TaqManTM System).
The expression levels of C5 mRNA may be monitored using a membrane blot (such as used in hybridization analysis such as Northern, Southern, dot, and the like), or microwells, sample tubes, gels, beads or fibers (or any solid support comprising bound nucleic acids). See U.S. Pat. Nos. 5,770,722, 5,874,219, 5,744,305, 5,677,195 and 5,445,934, which are incorporated herein by reference. The determination of C5 expression level may also comprise using nucleic acid probes in solution.
In preferred embodiments, the level of mRNA expression is assessed using branched DNA (bDNA) assays or real time PCR (qPCR). The use of these methods is described and exemplified in the Examples presented herein.
The level of C5 protein expression may be determined using any method known in the art for the measurement of protein levels. Such methods include, for example, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, fluid or gel precipitin reactions, absorption spectroscopy, a colorimetric assays, spectrophotometric assays, flow cytometry, immunodiffusion (single or double), immunoelectrophoresis, Western blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, electrochemiluminescence assays, and the like.
The term “sample” as used herein refers to a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present within a subject. Examples of biological fluids include blood, serum and serosal fluids, plasma, lymph, urine, cerebrospinal fluid, saliva, ocular fluids, and the like. Tissue samples may include samples from tissues, organs or localized regions. For example, samples may be derived from particular organs, parts of organs, or fluids or cells within those organs. In certain embodiments, samples may be derived from the liver (e.g., whole liver or certain segments of liver or certain types of cells in the liver, such as, e.g., hepatocytes). In preferred embodiments, a “sample derived from a subject” refers to blood or plasma drawn from the subject. In further embodiments, a “sample derived from a subject” refers to liver tissue derived from the subject.
In some embodiments of the methods of the invention, the RNAi agent is administered to a subject such that the RNAi agent is delivered to a specific site within the subject. The inhibition of expression of C5 may be assessed using measurements of the level or change in the level of C5 mRNA or C5 protein in a sample derived from fluid or tissue from the specific site within the subject. In preferred embodiments, the site is the liver. The site may also be a subsection or subgroup of cells from any one of the aforementioned sites. The site may also include cells that express a particular type of receptor.
The phrase “contacting a cell with an RNAi agent,” such as a dsRNA, as used herein, includes contacting a cell by any possible means. Contacting a cell with an RNAi agent includes contacting a cell in vitro with the iRNA or contacting a cell in vivo with the iRNA. The contacting may be done directly or indirectly. Thus, for example, the RNAi agent may be put into physical contact with the cell by the individual performing the method, or alternatively, the RNAi agent may be put into a situation that will permit or cause it to subsequently come into contact with the cell.
Contacting a cell in vitro may be done, for example, by incubating the cell with the RNAi agent. Contacting a cell in vivo may be done, for example, by injecting the RNAi agent into or near the tissue where the cell is located, or by injecting the RNAi agent into another area, e.g., the bloodstream or the subcutaneous space, such that the agent will subsequently reach the tissue where the cell to be contacted is located. For example, the RNAi agent may contain and/or be coupled to a ligand, e.g., GalNAc3, that directs the RNAi agent to a site of interest, e.g., the liver. Combinations of in vitro and in vivo methods of contacting are also possible. For example, a cell may also be contacted in vitro with an RNAi agent and subsequently transplanted into a subject.
In one embodiment, contacting a cell with an iRNA includes “introducing” or “delivering the iRNA into the cell” by facilitating or effecting uptake or absorption into the cell. Absorption or uptake of an iRNA can occur through unaided diffusive or active cellular processes, or by auxiliary agents or devices. Introducing an iRNA into a cell may be in vitro and/or in vivo. For example, for in vivo introduction, iRNA can be injected into a tissue site or administered systemically. In vivo delivery can also be done by a beta-glucan delivery system, such as those described in U.S. Pat. Nos. 5,032,401 and 5,607,677, and U.S. Publication No. 2005/0281781, the entire contents of which are hereby incorporated herein by reference. In vitro introduction into a cell includes methods known in the art such as electroporation and lipofection. Further approaches are described herein below and/or are known in the art.
VII. Methods for Treating or Preventing a Complement Component C5-Associated Disorder
The present invention also provides therapeutic and prophylactic methods which include administering to a subject having a complement component C5-associated disease, e.g., PNH or aHUS, an iRNA agent, pharmaceutical compositions comprising an iRNA agent, or vector comprising an iRNA of the invention. In some aspects of the invention, the methods further include administering to the subject an additional therapeutic agent, such as an anti-complement component C5 antibody, or antigen-binding fragment thereof (e.g., eculizumab).
In one aspect, the present invention provides methods of treating a subject having a disorder that would benefit from reduction in C5 expression, e.g., a complement component C5-associated disease, e.g., PNH or aHUS. The treatment methods (and uses) of the invention include administering to the subject, e.g., a human, a therapeutically effective amount of an iRNA agent targeting a C5 gene or a pharmaceutical composition comprising an iRNA agent targeting a C5 gene, thereby treating the subject having a disorder that would benefit from reduction in C5 expression.
In another aspect, the present invention provides methods of treating a subject having a disorder that would benefit from reduction in C5 expression, e.g., a complement component C5-associated disease, e.g., PNH or aHUS, which include administering to the subject, e.g., a human, a therapeutically effective amount of an iRNA agent targeting a C5 gene or a pharmaceutical composition comprising an iRNA agent targeting a C5 gene, and an additional therapeutic agent, such as an anti-complement component C5 antibody, or antigen-binding fragment thereof (e.g., eculizumab), thereby treating the subject having a disorder that would benefit from reduction in C5 expression.
In one aspect, the invention provides methods of preventing at least one symptom in a subject having a disorder that would benefit from reduction in C5 expression, e.g., a complement component C5-associated disease, e.g., PNH or aHUS. The methods include administering to the subject a prohpylactically effective amount of the iRNA agent, e.g., dsRNA, or vector of the invention, thereby preventing at least one symptom in the subject having a disorder that would benefit from reduction in C5 expression. For example, the invention provides methods for preventing hemolysis in a subject suffering from a disorder that would benefit from reduction in C5 expression, e.g., a complement component C5-associated disease, e.g., PNH or aHUS.
In another aspect, the invention provides methods of preventing at least one symptom in a subject having a disorder that would benefit from reduction in C5 expression, e.g., a complement component C5-associated disease, e.g., PNH or aHUS. The methods include administering to the subject a prohpylactically effective amount of the iRNA agent, e.g., dsRNA, or vector of the invention, and an additional therapeutic agent, such as an anti-complement component C5 antibody, or antigen-binding fragment thereof (e.g., eculizumab), thereby preventing at least one symptom in the subject having a disorder that would benefit from reduction in C5 expression.
“Therapeutically effective amount,” as used herein, is intended to include the amount of an RNAi agent or anti-complement component C5 antibody, or antigen-binding fragment thereof (e.g., eculizumab), that, when administered to a subject having a complement component C5-associated disease, is sufficient to effect treatment of the disease (e.g., by diminishing, ameliorating or maintaining the existing disease or one or more symptoms of disease). The “therapeutically effective amount” may vary depending on the RNAi agent or antibody, or antigen-binding fragment thereof, how the agent is administered, the disease and its severity and the history, age, weight, family history, genetic makeup, the types of preceding or concomitant treatments, if any, and other individual characteristics of the subject to be treated.
“Prophylactically effective amount,” as used herein, is intended to include the amount of an iRNA agent or anti-complement component C5 antibody, or antigen-binding fragment thereof (e.g., eculizumab), that, when administered to a subject having a complement component C5-associate disease but not yet (or currently) experiencing or displaying symptoms of the disease, and/or a subject at risk of developing a complement component C5-associated disease, e.g., a subject having a graft and/or transplant, e.g., a sensitized or allogenic recipient, a subject having sepsis, and/or a subject having a myocardial infarction, is sufficient to prevent or ameliorate the disease or one or more symptoms of the disease. Ameliorating the disease includes slowing the course of the disease or reducing the severity of later-developing disease. The “prophylactically effective amount” may vary depending on the iRNA agent or anti-complement component C5 antibody, or antigen-binding fragment thereof, how the agent or anti-complement component C5 antibody, or antigen-binding fragment thereof, is administered, the degree of risk of disease, and the history, age, weight, family history, genetic makeup, the types of preceding or concomitant treatments, if any, and other individual characteristics of the patient to be treated.
A “therapeutically effective amount” or “prophylactically effective amount” also includes an amount of an RNAi agent or anti-complement component C5 antibody, or antigen-binding fragment thereof (e.g., eculizumab), that produces some desired local or systemic effect at a reasonable benefit/risk ratio applicable to any treatment. iRNA agents employed in the methods of the present invention may be administered in a sufficient amount to produce a reasonable benefit/risk ratio applicable to such treatment.
In another aspect, the present invention provides uses of a therapeutically effective amount of an iRNA agent of the invention for treating a subject, e.g., a subject that would benefit from a reduction and/or inhibition of C5 expression.
In another aspect, the present invention provides uses of a therapeutically effective amount of an iRNA agent of the invention and an additional therapeutic agent, such as an anti-complement component C5 antibody, or antigen-binding fragment thereof (e.g., eculizumab), for treating a subject, e.g., a subject that would benefit from a reduction and/or inhibition of C5 expression.
In yet another aspect, the present invention provides use of an iRNA agent, e.g., a dsRNA, of the invention targeting a C5 gene or a pharmaceutical composition comprising an iRNA agent targeting a C5 gene in the manufacture of a medicament for treating a subject, e.g., a subject that would benefit from a reduction and/or inhibition of C5 expression, such as a subject having a disorder that would benefit from reduction in C5 expression, e.g., a complement component C5-associated disease, e.g., PNH or aHUS.
In another aspect, the present invention provides uses of an iRNA agent, e.g., a dsRNA, of the invention targeting a C5 gene or a pharmaceutical composition comprising an iRNA agent targeting a C5 gene in the manufacture of a medicament for use in combination with an additional therapeutic agent, such as an anti-complement component C5 antibody, or antigen-binding fragment thereof (e.g., eculizumab), for treating a subject, e.g., a subject that would benefit from a reduction and/or inhibition of C5 expression, e.g., a complement component C5-associated disease, e.g., PNH or aHUS.
In another aspect, the invention provides uses of an iRNA, e.g., a dsRNA, of the invention for preventing at least one symptom in a subject suffering from a disorder that would benefit from a reduction and/or inhibition of C5 expression, such as a complement component C5-associated disease, e.g., PNH or aHUS.
In yet another aspect, the invention provides uses of an iRNA agent, e.g., a dsRNA, of the invention, and an additional therapeutic agent, such as an anti-complement component C5 antibody, or antigen-binding fragment thereof (e.g., eculizumab), for preventing at least one symptom in a subject suffering from a disorder that would benefit from a reduction and/or inhibition of C5 expression, such as a complement component C5-associated disease, e.g., PNH or aHUS.
In a further aspect, the present invention provides uses of an iRNA agent of the invention in the manufacture of a medicament for preventing at least one symptom in a subject suffering from a disorder that would benefit from a reduction and/or inhibition of C5 expression, such as a a complement component C5-associated disease, e.g., PNH or aHUS.
In a further aspect, the present invention provides uses of an iRNA agent of the invention in the manufacture of a medicament for use in combination with an additional therapeutic agent, such as an anti-complement component C5 antibody, or antigen-binding fragment thereof (e.g., eculizumab), for preventing at least one symptom in a subject suffering from a disorder that would benefit from a reduction and/or inhibition of C5 expression, such as a complement component C5-associated disease, e.g., PNH or aHUS.
In one embodiment, an iRNA agent targeting C5 is administered to a subject having a complement component C5-associated disease such that C5 levels, e.g., in a cell, tissue, blood, urine or other tissue or fluid of the subject are reduced by at least about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 62%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% or more and, subsequently, an additional therapeutic (as described below) is administered to the subject.
The additional therapeutic may be an anti-complement component C5 antibody, or antigen-binding fragment or derivative thereof. In one embodiment, the anti-complement component C5 antibody is eculizumab (SOLIRIS®), or antigen-binding fragment or derivative thereof. Eculizumab is a humanized monoclonal IgG2/4, kappa light chain antibody that specifically binds complement component C5 with high affinity and inhibits cleavage of C5 to C5a and C5b, thereby inhibiting the generation of the terminal complement complex C5b-9. Eculizumab is described in U.S. Pat. No. 6,355,245, the entire contents of which are incorporated herein by reference.
The methods of the invention comprising administration of an iRNA agent of the invention and eculizumab to a subject may further comprise administration of a meningococcal vaccine to the subject.
The additional therapeutic, e.g., eculizumab and/or a meningococcal vaccine, may be administered to the subject at the same time as the iRNA agent targeting C5 or at a different time.
Moreover, the additional therapeutic, e.g., eculizumab, may be administered to the subject in the same formulation as the iRNA agent targeting C5 or in a different formulation as the iRNA agent targeting C5.
Eculizumab dosage regimens are described in, for example, the product insert for eculizumab (SOLIRIS®) and in U.S. Patent Application No. 2012/0225056, the entire contents of each of which are incorporated herein by reference. In exemplary methods of the invention for treating a complement component C5-associated disease, e.g., PNH or aHUS, an iRNA agent targeting C5 is administered (e.g., subcutaneously) to the subject first, such that the C5 levels in the subject are reduced (e.g., by at least about 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 62%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% or more) and subsequently eculizumab is administered at doses lower than the ones described in the product insert for SOLIRIS®. For example, eculizumab may be administered to the subject weekly at a dose less than about 600 mg for 4 weeks followed by a fifth dose at about one week later of less than about 900 mg, followed by a dose less than about 900 mg about every two weeks thereafter. Eculizumab may also be administered to the subject weekly at a dose less than about 900 mg for 4 weeks followed by a fifth dose at about one week later of less than about 1200 mg, followed by a dose less than about 1200 mg about every two weeks thereafter. If the subject is less than 18 years of age, eculizumab may be administered to the subject weekly at a dose less than about 900 mg for 4 weeks followed by a fifth dose at about one week later of less than about 1200 mg, followed by a dose less than about 1200 mg about every two weeks thereafter; or if the subject is less than 18 years of age, eculizumab may be administered to the subject weekly at a dose less than about 600 mg for 2 weeks followed by a third dose at about one week later of less than about 900 mg, followed by a dose less than about 900 mg about every two weeks thereafter; or if the subject is less than 18 years of age, eculizumab may be administered to the subject weekly at a dose less than about 600 mg for 2 weeks followed by a third dose at about one week later of less than about 600 mg, followed by a dose less than about 600 mg about every two weeks thereafter; or if the subject is less than 18 years of age, eculizumab may be administered to the subject weekly at a dose less than about 600 mg for 1 week followed by a second dose at about one week later of less than about 300 mg, followed by a dose less than about 300 mg about every two weeks thereafter; or if the subject is less than 18 years of age, eculizumab may be administered to the subject weekly at a dose less than about 300 mg for 1 week followed by a second dose at about one week later of less than about 300 mg, followed by a dose less than about 300 mg about every two weeks thereafter. If the subject is receiving plamapheresis or plasma exchange, eculizumab may be administered to the subject at a dose less than about 300 mg (e.g., if the most recent does of eculizumab was about 300 mg) or less than about 600 mg (e.g., if the most recent does of eculizumab was about 600 mg or more). If the subject is receiving plasma infusion, eculizumab may be administered to the subject at a dose less than about 300 mg (e.g., if the most recent does of eculizumab was about 300 mg or more). The lower doses of eculizumab allow for either subcutaneous or intravenous administration of eculizumab.
In the combination therapies of the present invention comprising eculizumab, eculizumab may be administered to the subject, e.g., subcutaneously, at a dose of about 0.01 mg/kg to about 10 mg/kg, or about 5 mg/kg to about 10 mg/kg, or about 0.5 mg/kg to about 15 mg/kg. For example, eculizumab may be administered to the subject, e.g., subcutaneously, at a dose of 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 2.5 mg/kg, 3 mg/kg, 3.5 mg/kg, 4 mg/kg, 4.5 mg/kg, 5 mg/kg, 5.5 mg/kg, 6 mg/kg, 6.5 mg/kg, 7 mg/kg, 7.5 mg/kg, 8 mg/kg, 8.5 mg/kg, 9 mg/kg, 9.5 mg/kg, 10 mg/kg, 10.5 mg/kg, 11 mg/kg, 11.5 mg/kg, 12 mg/kg, 12.5 mg/kg, 13 mg/kg, 13.5 mg/kg, 14 mg/kg, 14.5 mg/kg, or 15 mg/kg.
The methods and uses of the invention include administering a composition described herein such that expression of the target C5 gene is decreased, such as for about 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 18, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, or about 80 hours. In one embodiment, expression of the target C5 gene is decreased for an extended duration, e.g., at least about two, three, four, five, six, seven days or more, e.g., about one week, two weeks, three weeks, or about four weeks or longer.
Administration of the dsRNA according to the methods and uses of the invention may result in a reduction of the severity, signs, symptoms, and/or markers of such diseases or disorders in a patient with a complement component C5-associated disease. By “reduction” in this context is meant a statistically significant decrease in such level. The reduction can be, for example, at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or about 100%.
Efficacy of treatment or prevention of disease can be assessed, for example by measuring disease progression, disease remission, symptom severity, reduction in pain, quality of life, dose of a medication required to sustain a treatment effect, level of a disease marker or any other measurable parameter appropriate for a given disease being treated or targeted for prevention. It is well within the ability of one skilled in the art to monitor efficacy of treatment or prevention by measuring any one of such parameters, or any combination of parameters. For example, efficacy of treatment of a hemolytic disorder may be assessed, for example, by periodic monitoring of LDH and CH50 levels. Comparisons of the later readings with the initial readings provide a physician an indication of whether the treatment is effective. It is well within the ability of one skilled in the art to monitor efficacy of treatment or prevention by measuring any one of such parameters, or any combination of parameters. In connection with the administration of an iRNA targeting C5 or pharmaceutical composition thereof, “effective against” a complement component C5-associated disease indicates that administration in a clinically appropriate manner results in a beneficial effect for at least a statistically significant fraction of patients, such as improvement of symptoms, a cure, a reduction in disease, extension of life, improvement in quality of life, or other effect generally recognized as positive by medical doctors familiar with treating a complement component C5-associated disease and the related causes.
A treatment or preventive effect is evident when there is a statistically significant improvement in one or more parameters of disease status, or by a failure to worsen or to develop symptoms where they would otherwise be anticipated. As an example, a favorable change of at least 10% in a measurable parameter of disease, and preferably at least 20%, 30%, 40%, 50% or more can be indicative of effective treatment. Efficacy for a given iRNA drug or formulation of that drug can also be judged using an experimental animal model for the given disease as known in the art. When using an experimental animal model, efficacy of treatment is evidenced when a statistically significant reduction in a marker or symptom is observed.
Alternatively, the efficacy can be measured by a reduction in the severity of disease as determined by one skilled in the art of diagnosis based on a clinically accepted disease severity grading scale, as but one example the Rheumatoid Arthritis Severity Scale (RASS). Any positive change resulting in e.g., lessening of severity of disease measured using the appropriate scale, represents adequate treatment using an iRNA or iRNA formulation as described herein.
Subjects can be administered a therapeutic amount of iRNA, such as about 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.15 mg/kg, 0.2 mg/kg, 0.25 mg/kg, 0.3 mg/kg, 0.35 mg/kg, 0.4 mg/kg, 0.45 mg/kg, 0.5 mg/kg, 0.55 mg/kg, 0.6 mg/kg, 0.65 mg/kg, 0.7 mg/kg, 0.75 mg/kg, 0.8 mg/kg, 0.85 mg/kg, 0.9 mg/kg, 0.95 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg, 1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg, 1.9 mg/kg, 2.0 mg/kg, 2.1 mg/kg, 2.2 mg/kg, 2.3 mg/kg, 2.4 mg/kg, 2.5 mg/kg dsRNA, 2.6 mg/kg dsRNA, 2.7 mg/kg dsRNA, 2.8 mg/kg dsRNA, 2.9 mg/kg dsRNA, 3.0 mg/kg dsRNA, 3.1 mg/kg dsRNA, 3.2 mg/kg dsRNA, 3.3 mg/kg dsRNA, 3.4 mg/kg dsRNA, 3.5 mg/kg dsRNA, 3.6 mg/kg dsRNA, 3.7 mg/kg dsRNA, 3.8 mg/kg dsRNA, 3.9 mg/kg dsRNA, 4.0 mg/kg dsRNA, 4.1 mg/kg dsRNA, 4.2 mg/kg dsRNA, 4.3 mg/kg dsRNA, 4.4 mg/kg dsRNA, 4.5 mg/kg dsRNA, 4.6 mg/kg dsRNA, 4.7 mg/kg dsRNA, 4.8 mg/kg dsRNA, 4.9 mg/kg dsRNA, 5.0 mg/kg dsRNA, 5.1 mg/kg dsRNA, 5.2 mg/kg dsRNA, 5.3 mg/kg dsRNA, 5.4 mg/kg dsRNA, 5.5 mg/kg dsRNA, 5.6 mg/kg dsRNA, 5.7 mg/kg dsRNA, 5.8 mg/kg dsRNA, 5.9 mg/kg dsRNA, 6.0 mg/kg dsRNA, 6.1 mg/kg dsRNA, 6.2 mg/kg dsRNA, 6.3 mg/kg dsRNA, 6.4 mg/kg dsRNA, 6.5 mg/kg dsRNA, 6.6 mg/kg dsRNA, 6.7 mg/kg dsRNA, 6.8 mg/kg dsRNA, 6.9 mg/kg dsRNA, 7.0 mg/kg dsRNA, 7.1 mg/kg dsRNA, 7.2 mg/kg dsRNA, 7.3 mg/kg dsRNA, 7.4 mg/kg dsRNA, 7.5 mg/kg dsRNA, 7.6 mg/kg dsRNA, 7.7 mg/kg dsRNA, 7.8 mg/kg dsRNA, 7.9 mg/kg dsRNA, 8.0 mg/kg dsRNA, 8.1 mg/kg dsRNA, 8.2 mg/kg dsRNA, 8.3 mg/kg dsRNA, 8.4 mg/kg dsRNA, 8.5 mg/kg dsRNA, 8.6 mg/kg dsRNA, 8.7 mg/kg dsRNA, 8.8 mg/kg dsRNA, 8.9 mg/kg dsRNA, 9.0 mg/kg dsRNA, 9.1 mg/kg dsRNA, 9.2 mg/kg dsRNA, 9.3 mg/kg dsRNA, 9.4 mg/kg dsRNA, 9.5 mg/kg dsRNA, 9.6 mg/kg dsRNA, 9.7 mg/kg dsRNA, 9.8 mg/kg dsRNA, 9.9 mg/kg dsRNA, 9.0 mg/kg dsRNA, 10 mg/kg dsRNA, 15 mg/kg dsRNA, 20 mg/kg dsRNA, 25 mg/kg dsRNA, 30 mg/kg dsRNA, 35 mg/kg dsRNA, 40 mg/kg dsRNA, 45 mg/kg dsRNA, or about 50 mg/kg dsRNA. Values and ranges intermediate to the recited values are also intended to be part of this invention.
In certain embodiments, for example, when a composition of the invention comprises a dsRNA as described herein and a lipid, subjects can be administered a therapeutic amount of iRNA, such as about 0.01 mg/kg to about 5 mg/kg, about 0.01 mg/kg to about 10 mg/kg, about 0.05 mg/kg to about 5 mg/kg, about 0.05 mg/kg to about 10 mg/kg, about 0.1 mg/kg to about 5 mg/kg, about 0.1 mg/kg to about 10 mg/kg, about 0.2 mg/kg to about 5 mg/kg, about 0.2 mg/kg to about 10 mg/kg, about 0.3 mg/kg to about 5 mg/kg, about 0.3 mg/kg to about 10 mg/kg, about 0.4 mg/kg to about 5 mg/kg, about 0.4 mg/kg to about 10 mg/kg, about 0.5 mg/kg to about 5 mg/kg, about 0.5 mg/kg to about 10 mg/kg, about 1 mg/kg to about 5 mg/kg, about 1 mg/kg to about 10 mg/kg, about 1.5 mg/kg to about 5 mg/kg, about 1.5 mg/kg to about 10 mg/kg, about 2 mg/kg to about 2.5 mg/kg, about 2 mg/kg to about 10 mg/kg, about 3 mg/kg to about 5 mg/kg, about 3 mg/kg to about 10 mg/kg, about 3.5 mg/kg to about 5 mg/kg, about 4 mg/kg to about 5 mg/kg, about 4.5 mg/kg to about 5 mg/kg, about 4 mg/kg to about 10 mg/kg, about 4.5 mg/kg to about 10 mg/kg, about 5 mg/kg to about 10 mg/kg, about 5.5 mg/kg to about 10 mg/kg, about 6 mg/kg to about 10 mg/kg, about 6.5 mg/kg to about 10 mg/kg, about 7 mg/kg to about 10 mg/kg, about 7.5 mg/kg to about 10 mg/kg, about 8 mg/kg to about 10 mg/kg, about 8.5 mg/kg to about 10 mg/kg, about 9 mg/kg to about 10 mg/kg, or about 9.5 mg/kg to about 10 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.
For example, the dsRNA may be administered at a dose of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or about 10 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.
In other embodiments, for example, when a composition of the invention comprises a dsRNA as described herein and an N-acetylgalactosamine, subjects can be administered a therapeutic amount of iRNA, such as a dose of about 0.1 to about 50 mg/kg, about 0.25 to about 50 mg/kg, about 0.5 to about 50 mg/kg, about 0.75 to about 50 mg/kg, about 1 to about 50 mg/mg, about 1.5 to about 50 mg/kb, about 2 to about 50 mg/kg, about 2.5 to about 50 mg/kg, about 3 to about 50 mg/kg, about 3.5 to about 50 mg/kg, about 4 to about 50 mg/kg, about 4.5 to about 50 mg/kg, about 5 to about 50 mg/kg, about 7.5 to about 50 mg/kg, about 10 to about 50 mg/kg, about 15 to about 50 mg/kg, about 20 to about 50 mg/kg, about 20 to about 50 mg/kg, about 25 to about 50 mg/kg, about 25 to about 50 mg/kg, about 30 to about 50 mg/kg, about 35 to about 50 mg/kg, about 40 to about 50 mg/kg, about 45 to about 50 mg/kg, about 0.1 to about 45 mg/kg, about 0.25 to about 45 mg/kg, about 0.5 to about 45 mg/kg, about 0.75 to about 45 mg/kg, about 1 to about 45 mg/mg, about 1.5 to about 45 mg/kb, about 2 to about 45 mg/kg, about 2.5 to about 45 mg/kg, about 3 to about 45 mg/kg, about 3.5 to about 45 mg/kg, about 4 to about 45 mg/kg, about 4.5 to about 45 mg/kg, about 5 to about 45 mg/kg, about 7.5 to about 45 mg/kg, about 10 to about 45 mg/kg, about 15 to about 45 mg/kg, about 20 to about 45 mg/kg, about 20 to about 45 mg/kg, about 25 to about 45 mg/kg, about 25 to about 45 mg/kg, about 30 to about 45 mg/kg, about 35 to about 45 mg/kg, about 40 to about 45 mg/kg, about 0.1 to about 40 mg/kg, about 0.25 to about 40 mg/kg, about 0.5 to about 40 mg/kg, about 0.75 to about 40 mg/kg, about 1 to about 40 mg/mg, about 1.5 to about 40 mg/kb, about 2 to about 40 mg/kg, about 2.5 to about 40 mg/kg, about 3 to about 40 mg/kg, about 3.5 to about 40 mg/kg, about 4 to about 40 mg/kg, about 4.5 to about 40 mg/kg, about 5 to about 40 mg/kg, about 7.5 to about 40 mg/kg, about 10 to about 40 mg/kg, about 15 to about 40 mg/kg, about 20 to about 40 mg/kg, about 20 to about 40 mg/kg, about 25 to about 40 mg/kg, about 25 to about 40 mg/kg, about 30 to about 40 mg/kg, about 35 to about 40 mg/kg, about 0.1 to about 30 mg/kg, about 0.25 to about 30 mg/kg, about 0.5 to about 30 mg/kg, about 0.75 to about 30 mg/kg, about 1 to about 30 mg/mg, about 1.5 to about 30 mg/kb, about 2 to about 30 mg/kg, about 2.5 to about 30 mg/kg, about 3 to about 30 mg/kg, about 3.5 to about 30 mg/kg, about 4 to about 30 mg/kg, about 4.5 to about 30 mg/kg, about 5 to about 30 mg/kg, about 7.5 to about 30 mg/kg, about 10 to about 30 mg/kg, about 15 to about 30 mg/kg, about 20 to about 30 mg/kg, about 20 to about 30 mg/kg, about 25 to about 30 mg/kg, about 0.1 to about 20 mg/kg, about 0.25 to about 20 mg/kg, about 0.5 to about 20 mg/kg, about 0.75 to about 20 mg/kg, about 1 to about 20 mg/mg, about 1.5 to about 20 mg/kb, about 2 to about 20 mg/kg, about 2.5 to about 20 mg/kg, about 3 to about 20 mg/kg, about 3.5 to about 20 mg/kg, about 4 to about 20 mg/kg, about 4.5 to about 20 mg/kg, about 5 to about 20 mg/kg, about 7.5 to about 20 mg/kg, about 10 to about 20 mg/kg, or about 15 to about 20 mg/kg. In one embodiment, when a composition of the invention comprises a dsRNA as described herein and an N-acetylgalactosamine, subjects can be administered a therapeutic amount of about 10 to about 30 mg/kg of dsRNA. Values and ranges intermediate to the recited values are also intended to be part of this invention.
For example, subjects can be administered a therapeutic amount of iRNA, such as about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 31, 32, 33, 34, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or about 50 mg/kg. Values and ranges intermediate to the recited values are also intended to be part of this invention.
The iRNA can be administered by intravenous infusion over a period of time, such as over a 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or about a 25 minute period. The administration may be repeated, for example, on a regular basis, such as weekly, biweekly (i.e., every two weeks) for one month, two months, three months, four months or longer. After an initial treatment regimen, the treatments can be administered on a less frequent basis. For example, after administration weekly or biweekly for three months, administration can be repeated once per month, for six months or a year or longer.
Administration of the iRNA can reduce C5 levels, e.g., in a cell, tissue, blood, urine or other compartment of the patient by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% or more.
Before administration of a full dose of the iRNA, patients can be administered a smaller dose, such as a 5% infusion, and monitored for adverse effects, such as an allergic reaction. In another example, the patient can be monitored for unwanted immunostimulatory effects, such as increased cytokine (e.g., TNF-alpha or INF-alpha) levels.
Owing to the inhibitory effects on C5 expression, a composition according to the invention or a pharmaceutical composition prepared therefrom can enhance the quality of life.
An iRNA of the invention may be administered in “naked” form, or as a “free iRNA.” A naked iRNA is administered in the absence of a pharmaceutical composition. The naked iRNA may be in a suitable buffer solution. The buffer solution may comprise acetate, citrate, prolamine, carbonate, or phosphate, or any combination thereof. In one embodiment, the buffer solution is phosphate buffered saline (PBS). The pH and osmolarity of the buffer solution containing the iRNA can be adjusted such that it is suitable for administering to a subject.
Alternatively, an iRNA of the invention may be administered as a pharmaceutical composition, such as a dsRNA liposomal formulation.
Subjects that would benefit from a reduction and/or inhibition of C5 gene expression are those having a complement component C5-associated disease or disorder as described herein. In one embodiment, a subject having a complement component C5-associated disease has paroxysmal nocturnal hemoglobinuria (PNH). In another embodiment, a subject having a complement component C5-associated disease has asthma. In another embodiment, a subject having a complement component C5-associated disease has rheumatoid arthritis. In yet another embodiment, a subject having a complement component C5-associated disease has systemic lupus erythmatosis. In one embodiment, a subject having a complement component C5-associated disease has glomerulonephritis. In another embodiment, a subject having a complement component C5-associated disease has psoriasis. In yet another embodiment, a subject having a complement component C5-associated disease has dermatomyositis bullous pemphigoid. In one embodiment, a subject having a complement component C5-associated disease has atypical hemolytic uremic syndrome. In another embodiment, a subject having a complement component C5-associated disease has Shiga toxin E. coli-related hemolytic uremic syndrome. In another embodiment, a subject having a complement component C5-associated disease has myasthenia gravis. In yet another embodiment, a subject having a complement component C5-associated disease has neuromyelistis optica. In one embodiment, a subject having a complement component C5-associated disease has dense deposit disease. In one embodiment, a subject having a complement component C5-associated disease has C3 neuropathy. In another embodiment, a subject having a complement component C5-associated disease has age-related macular degeneration. In another embodiment, a subject having a complement component C5-associated disease has cold agglutinin disease. In one embodiment, a subject having a complement component C5-associated disease has anti-neutrophil cytoplasmic antibody-associated vasculitis. In another embodiment, a subject having a complement component C5-associated disease has humoral and vascular transplant rejection. In one embodiment, a subject having a complement component C5-associated disease has graft dysfunction. In one embodiment, a subject having a complement component C5-associated disease has had a myocardial infarction. In another embodiment, a subject having a complement component C5-associated disease is a sensitized recipient of a transplant. In yet another embodiment, a subject having a complement component C5-associated disease has sepsis.
Treatment of a subject that would benefit from a reduction and/or inhibition of C5 gene expression includes therapeutic and prophylactic (e.g., the subject is to undergo sensitized (or allogenic) transplant surgery) treatment.
The invention further provides methods and uses of an iRNA agent or a pharmaceutical composition thereof (including methods and uses of an iRNA agent or a pharmaceutical composition comprising an iRNA agent and an anti-complement component C5 antibody, or antigen-binding fragment thereof) for treating a subject that would benefit from reduction and/or inhibition of C5 expression, e.g., a subject having a complement component C5-associated disease, in combination with other pharmaceuticals and/or other therapeutic methods, e.g., with known pharmaceuticals and/or known therapeutic methods, such as, for example, those which are currently employed for treating these disorders. For example, in certain embodiments, an iRNA targeting C5 is administered in combination with, e.g., an agent useful in treating a complement component C5-associated disease as described elsewhere herein.
For example, additional therapeutics and therapeutic methods suitable for treating a subject that would benefit from reduction in C5 expression, e.g., a subject having a complement component C5-associated disease, include plasmaphoresis, thrombolytic therapy (e.g., streptokinase), antiplatelet agents, folic acid, corticosteroids; immunosuppressive agents; estrogens, methotrexate, 6-MP, azathioprine sulphasalazine, mesalazine, olsalazine, chloroquinine/hydroxychloroquine, pencillamine, aurothiomalate (intramuscular and oral), azathioprine, cochicine, corticosteroids (oral, inhaled and local injection), beta-2 adrenoreceptor agonists (salbutamol, terbutaline, salmeteral), xanthines (theophylline, aminophylline), cromoglycate, nedocromil, ketotifen, ipratropium and oxitropium, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, for example, ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors, adensosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, agents which interfere with signalling by proinflammatory cytokines, such as TNF-α or IL-1 (e.g., IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL-1β (converting enzyme inhibitors, TNFα converting enzyme (TACE) inhibitors, T-cell signalling inhibitors, such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof (e.g., soluble p55 or p75 TNF receptors and the derivatives p75TNFRIgG (EnbrelTM and p55TNFRIgG (Lenercept)), sIL-1RI, sIL-1RII, and sIL-6R), antiinflammatory cytokines (e.g., IL-4, IL-10, IL-11, IL-13 and TGFβ), celecoxib, folic acid, hydroxychloroquine sulfate, rofecoxib, etanercept, infliximonoclonal antibody, naproxen, valdecoxib, sulfasalazine, methylprednisolone, meloxicam, methylprednisolone acetate, gold sodium thiomalate, aspirin, triamcinolone acetonide, propoxyphene napsylate/apap, folate, nabumetone, diclofenac, piroxicam, etodolac, diclofenac sodium, oxaprozin, oxycodone hcl, hydrocodone bitartrate/apap, diclofenac sodium/misoprostol, fentanyl, anakinra, human recombinant, tramadol hcl, salsalate, sulindac, cyanocobalamin/fa/pyridoxine, acetaminophen, alendronate sodium, prednisolone, morphine sulfate, lidocaine hydrochloride, indomethacin, glucosamine sulf/chondroitin, amitriptyline hcl, sulfadiazine, oxycodone hcl/acetaminophen, olopatadine hcl, misoprostol, naproxen sodium, omeprazole, cyclophosphamide, rituximonoclonal antibody, IL-1 TRAP, MRA, CTLA4-IG, IL-18 BP, anti-IL-18, Anti-IL15, BIRB-796, SCIO-469, VX-702, AMG-548, VX-740, Roflumilast, IC-485, CDC-801, Mesopram, cyclosporine, cytokine suppressive anti-inflammatory drug(s) (CSAIDs); CDP-571/BAY-10-3356 (humanized anti-TNFα antibody; Celltech/Bayer); cA2/infliximonoclonal antibody (chimeric anti-TNFα antibody; Centocor); 75 kdTNFR-IgG/etanercept (75 kD TNF receptor-IgG fusion protein; Immunex; see e.g., (1994) Arthr. Rheum. 37: S295; (1996) J. Invest. Med. 44: 235A); 55 kdTNF-IgG (55 kD TNF receptor-IgG fusion protein; Hoffmann-LaRoche); IDEC-CE9.1/SB 210396 (non-depleting primatized anti-CD4 antibody; IDEC/SmithKline; see e.g., (1995) Arthr. Rheum. 38: S185); DAB 486-IL-2 and/or DAB 389-IL-2 (IL-2 fusion proteins; Seragen; see e.g., (1993) Arthrit. Rheum. 36: 1223); Anti-Tac (humanized anti-IL-2RcL; Protein Design Labs/Roche); IL-4 (anti-inflammatory cytokine; DNAX/Schering); IL-10 (SCH 52000; recombinant IL-10, anti-inflammatory cytokine; DNAX/Schering); IL-4; IL-10 and/or IL-4 agonists (e.g., agonist antibodies); IL-RA (IL-1 receptor antagonist; Synergen/Amgen); anakinra (Kineret®/Amgen); TNF-bp/s-TNF (soluble TNF binding protein; see e.g., (1996) Arthr. Rheum. 39(9 (supplement)): S284; (1995) Amer. J. Physiol.—Heart and Circ. Physiol. 268: 37-42); R973401 (phosphodiesterase Type IV inhibitor; see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S282); MK-966 (COX-2 Inhibitor; see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S81); Iloprost (see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S82); methotrexate; thalidomide (see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S282) and thalidomide-related drugs (e.g., Celgen); leflunomide (anti-inflammatory and cytokine inhibitor; see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S131; (1996) Inflamm. Res. 45: 103-107); tranexamic acid (inhibitor of plasminogen activation; see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S284); T-614 (cytokine inhibitor; see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S282); prostaglandin E1 (see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S282); Tenidap (non-steroidal anti-inflammatory drug; see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S280); Naproxen (non-steroidal anti-inflammatory drug; see e.g., (1996) Neuro. Report 7: 1209-1213); Meloxicam (non-steroidal anti-inflammatory drug); Ibuprofen (non-steroidal anti-inflammatory drug); Piroxicam (non-steroidal anti-inflammatory drug); Diclofenac (non-steroidal anti-inflammatory drug); Indomethacin (non-steroidal anti-inflammatory drug); Sulfasalazine (see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S281); Azathioprine (see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S281); ICE inhibitor (inhibitor of the enzyme interleukin-1β converting enzyme); zap-70 and/or lck inhibitor (inhibitor of the tyrosine kinase zap-70 or lck); VEGF inhibitor and/or VEGF-R inhibitor (inhibitors of vascular endothelial cell growth factor or vascular endothelial cell growth factor receptor; inhibitors of angiogenesis); corticosteroid anti-inflammatory drugs (e.g., SB203580); TNF-convertase inhibitors; anti-IL-12 antibodies; anti-IL-18 antibodies; interleukin-11 (see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S296); interleukin-13 (see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S308); interleukin-17 inhibitors (see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S120); gold; penicillamine; chloroquine; chlorambucil; hydroxychloroquine; cyclosporine; cyclophosphamide; total lymphoid irradiation; anti-thymocyte globulin; anti-CD4 antibodies; CD5-toxins; orally-administered peptides and collagen; lobenzarit disodium; Cytokine Regulating Agents (CRAs) HP228 and HP466 (Houghten Pharmaceuticals, Inc.); ICAM-1 antisense phosphorothioate oligo-deoxynucleotides (ISIS 2302; Isis Pharmaceuticals, Inc.); soluble complement receptor 1 (TP10; T Cell Sciences, Inc.); prednisone; orgotein; glycosaminoglycan polysulphate; minocycline; anti-IL2R antibodies; marine and botanical lipids (fish and plant seed fatty acids; see e.g., DeLuca et al. (1995) Rheum. Dis. Clin. North Am. 21: 759-777); auranofin; phenylbutazone; meclofenamic acid; flufenamic acid; intravenous immune globulin; zileuton; azaribine; mycophenolic acid (RS-61443); tacrolimus (FK-506); sirolimus (rapamycin); amiprilose (therafectin); cladribine (2-chlorodeoxyadenosine); methotrexate; bcl-2 inhibitors (see Bruncko, M. et al. (2007) J. Med. Chem. 50(4): 641-662); antivirals and immune-modulating agents, small molecule inhibitor of KDR, small molecule inhibitor of Tie-2; methotrexate; prednisone; celecoxib; folic acid; hydroxychloroquine sulfate; rofecoxib; etanercept; infliximonoclonal antibody; leflunomide; naproxen; valdecoxib; sulfasalazine; methylprednisolone; ibuprofen; meloxicam; methylprednisolone acetate; gold sodium thiomalate; aspirin; azathioprine; triamcinolone acetonide; propxyphene napsylate/apap; folate; nabumetone; diclofenac; piroxicam; etodolac; diclofenac sodium; oxaprozin; oxycodone hcl; hydrocodone bitartrate/apap; diclofenac sodium/misoprostol; fentanyl; anakinra, human recombinant; tramadol hcl; salsalate; sulindac; cyanocobalamin/fa/pyridoxine; acetaminophen; alendronate sodium; prednisolone; morphine sulfate; lidocaine hydrochloride; indomethacin; glucosamine sulfate/chondroitin; cyclosporine; amitriptyline hcl; sulfadiazine; oxycodone hcl/acetaminophen; olopatadine hcl; misoprostol; naproxen sodium; omeprazole; mycophenolate mofetil; cyclophosphamide; rituximonoclonal antibody; IL-1 TRAP; MRA; CTLA4-IG; IL-18 BP; IL-12/23; anti-IL 18; anti-IL 15; BIRB-796; SCIO-469; VX-702; AMG-548; VX-740; Roflumilast; IC-485; CDC-801; mesopram, albuterol, salmeterol/fluticasone, montelukast sodium, fluticasone propionate, budesonide, prednisone, salmeterol xinafoate, levalbuterol hcl, albuterol sulfate/ipratropium, prednisolone sodium phosphate, triamcinolone acetonide, beclomethasone dipropionate, ipratropium bromide, azithromycin, pirbuterol acetate, prednisolone, theophylline anhydrous, methylprednisolone sodium succinate, clarithromycin, zafirlukast, formoterol fumarate, influenza virus vaccine, methylprednisolone, amoxicillin trihydrate, flunisolide, allergy injection, cromolyn sodium, fexofenadine hydrochloride, flunisolide/menthol, amoxicillin/clavulanate, levofloxacin, inhaler assist device, guaifenesin, dexamethasone sodium phosphate, moxifloxacin hcl, doxycycline hyclate, guaifenesin/d-methorphan, p-ephedrine/cod/chlorphenir, gatifloxacin, cetirizine hydrochloride, mometasone furoate, salmeterol xinafoate, benzonatate, cephalexin, pe/hydrocodone/chlorphenir, cetirizine hcl/pseudoephed, phenylephrine/cod/promethazine, codeine/promethazine, cefprozil, dexamethasone, guaifenesin/pseudoephedrine, chlorpheniramine/hydrocodone, nedocromil sodium, terbutaline sulfate, epinephrine, methylprednisolone, metaproterenol sulfate, aspirin, nitroglycerin, metoprolol tartrate, enoxaparin sodium, heparin sodium, clopidogrel bisulfate, carvedilol, atenolol, morphine sulfate, metoprolol succinate, warfarin sodium, lisinopril, isosorbide mononitrate, digoxin, furosemide, simvastatin, ramipril, tenecteplase, enalapril maleate, torsemide, retavase, losartan potassium, quinapril hcl/mag carb, bumetanide, alteplase, enalaprilat, amiodarone hydrochloride, tirofiban hcl m-hydrate, diltiazem hydrochloride, captopril, irbesartan, valsartan, propranolol hydrochloride, fosinopril sodium, lidocaine hydrochloride, eptifibatide, cefazolin sodium, atropine sulfate, aminocaproic acid, spironolactone, interferon, sotalol hydrochloride, potassium chloride, docusate sodium, dobutamine hcl, alprazolam, pravastatin sodium, atorvastatin calcium, midazolam hydrochloride, meperidine hydrochloride, isosorbide dinitrate, epinephrine, dopamine hydrochloride, bivalirudin, rosuvastatin, ezetimibe/simvastatin, avasimibe, and cariporide.
The iRNA agent (and/or an anti-complement component C5 antibody) and an additional therapeutic agent and/or treatment may be administered at the same time and/or in the same combination, e.g., parenterally, or the additional therapeutic agent can be administered as part of a separate composition or at separate times and/or by another method known in the art or described herein.
The present invention also provides methods of using an iRNA agent of the invention and/or a composition containing an iRNA agent of the invention to reduce and/or inhibit complement component C5 expression in a cell. In other aspects, the present invention provides an iRNA of the invention and/or a composition comprising an iRNA of the invention for use in reducing and/or inhibiting C5 expression in a cell. In yet other aspects, use of an iRNA of the invention and/or a composition comprising an iRNA of the invention for the manufacture of a medicament for reducing and/or inhibiting C5 expression in a cell are provided.
The methods and uses include contacting the cell with an iRNA, e.g., a dsRNA, of the invention and maintaining the cell for a time sufficient to obtain degradation of the mRNA transcript of a C5 gene, thereby inhibiting expression of the C5 gene in the cell.
Reduction in gene expression can be assessed by any methods known in the art. For example, a reduction in the expression of C5 may be determined by determining the mRNA expression level of C5 using methods routine to one of ordinary skill in the art, e.g., Northern blotting, qRT-PCR, by determining the protein level of C5 using methods routine to one of ordinary skill in the art, such as Western blotting, immunological techniques, flow cytometry methods, ELISA, and/or by determining a biological activity of C5, such as CH50 or AH50 hemolysis assay, and/or by determining the biological activity of one or more molecules associated with the complement system, e.g., C5 products, such as C5a and C5b (or, in an in vivo setting, e.g., hemolysis).
In the methods and uses of the invention the cell may be contacted in vitro or in vivo, i.e., the cell may be within a subject. In embodiments of the invention in which the cell is within a subject, the methods may include further contacting the cell with an anti-complement component C5 antibody, e.g., eculizumab.
A cell suitable for treatment using the methods of the invention may be any cell that expresses a C5 gene. A cell suitable for use in the methods and uses of the invention may be a mammalian cell, e.g., a primate cell (such as a human cell or a non-human primate cell, e.g., a monkey cell or a chimpanzee cell), a non-primate cell (such as a cow cell, a pig cell, a camel cell, a llama cell, a horse cell, a goat cell, a rabbit cell, a sheep cell, a hamster, a guinea pig cell, a cat cell, a dog cell, a rat cell, a mouse cell, a lion cell, a tiger cell, a bear cell, or a buffalo cell), a bird cell (e.g., a duck cell or a goose cell), or a whale cell. In one embodiment, the cell is a human cell, e.g., a human liver cell.
C5 expression may be inhibited in the cell by at least about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100%.
The in vivo methods and uses of the invention may include administering to a subject a composition containing an iRNA, where the iRNA includes a nucleotide sequence that is complementary to at least a part of an RNA transcript of the C5 gene of the mammal to be treated. When the organism to be treated is a mammal such as a human, the composition can be administered by any means known in the art including, but not limited to subcutaneous, intravenous, oral, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, rectal, and topical (including buccal and sublingual) administration. In certain embodiments, the compositions are administered by subcutaneous or intravenous infusion or injection.
In some embodiments, the administration is via a depot injection. A depot injection may release the iRNA in a consistent way over a prolonged time period. Thus, a depot injection may reduce the frequency of dosing needed to obtain a desired effect, e.g., a desired inhibition of C5, or a therapeutic or prophylactic effect. A depot injection may also provide more consistent serum concentrations. Depot injections may include subcutaneous injections or intramuscular injections. In preferred embodiments, the depot injection is a subcutaneous injection.
In some embodiments, the administration is via a pump. The pump may be an external pump or a surgically implanted pump. In certain embodiments, the pump is a subcutaneously implanted osmotic pump. In other embodiments, the pump is an infusion pump. An infusion pump may be used for intravenous, subcutaneous, arterial, or epidural infusions. In preferred embodiments, the infusion pump is a subcutaneous infusion pump. In other embodiments, the pump is a surgically implanted pump that delivers the iRNA to the liver.
The mode of administration may be chosen based upon whether local or systemic treatment is desired and based upon the area to be treated. The route and site of administration may be chosen to enhance targeting.
In one aspect, the present invention also provides methods for inhibiting the expression of a C5 gene in a mammal, e.g., a human. The present invention also provides a composition comprising an iRNA, e.g., a dsRNA, that targets a C5 gene in a cell of a mammal for use in inhibiting expression of the C5 gene in the mammal. In another aspect, the present invention provides use of an iRNA, e.g., a dsRNA, that targets a C5 gene in a cell of a mammal in the manufacture of a medicament for inhibiting expression of the C5 gene in the mammal.
The methods and uses include administering to the mammal, e.g., a human, a composition comprising an iRNA, e.g., a dsRNA, that targets a C5 gene in a cell of the mammal and maintaining the mammal for a time sufficient to obtain degradation of the mRNA transcript of the C5 gene, thereby inhibiting expression of the C5 gene in the mammal. In some embodiment, the methods further comprise administering an anti-complement component C5 antibody, e.g., eculizumab, to the subject.
Reduction in gene expression can be assessed by any methods known it the art and by methods, e.g. qRT-PCR, described herein. Reduction in protein production can be assessed by any methods known it the art and by methods, e.g., ELISA or Western blotting, described herein. In one embodiment, a puncture liver biopsy sample serves as the tissue material for monitoring the reduction in C5 gene and/or protein expression. In another embodiment, a blood sample serves as the tissue material for monitoring the reduction in C5 gene and/or protein expression. In other embodiments, inhibition of the expression of a C5 gene is monitored indirectly by, for example, determining the expression and/or activity of a gene in a C5 pathway, including, for example, C5a, C5b, and soluble C5b-9 (see, e.g., FIG. 1). For example, the activity of CD59 may be monitored to determine the inhibition of expression of a C5 gene. CH50, AH50, clot formation and/or serum lactate dehydrogenase (LDH), in a sample, e.g., a blood or liver sample, may also be measured. Suitable assays are further described in the Examples section below.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the iRNAs and methods featured in the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
EXAMPLES
Example 1
iRNA Synthesis
Source of Reagents
Where the source of a reagent is not specifically given herein, such reagent can be obtained from any supplier of reagents for molecular biology at a quality/purity standard for application in molecular biology.
Transcripts
siRNA design was carried out to identify siRNAs targeting human, rhesus (Macaca mulatta), mouse, and rat C5 transcripts annotated in the NCBI Gene database (http://www.ncbi.nlm.nih.gov/gene/). Design used the following transcripts from the NCBI RefSeq collection: Human—NM—001735.2; Rhesus—XM—001095750.2; Mouse—NM—010406.2; Rat—XM—345342.4. SiRNA duplexes were designed in several separate batches, including but not limited to batches containing duplexes matching human and rhesus transcripts only; human, rhesus, and mouse transcripts only; human, rhesus, mouse, and rat transcripts only; and mouse and rat transcripts only. All siRNA duplexes were designed that shared 100% identity with the listed human transcript and other species transcripts considered in each design batch (above).
siRNA Design, Specificity, and Efficacy Prediction
The predicted specificity of all possible 19mers was predicted from each sequence. Candidate 19mers were then selected that lacked repeats longer than 7 nucleotides. These 2971 candidate human/rhesus, 142 human/rhesus/mouse, 54 human/rhesus/mouse/rat, and 807 mouse/rat siRNAs were used in comprehensive searches against the appropriate transcriptomes (defined as the set of NM_ and XM_records within the human, rhesus, dog, mouse, or rat NCBI Refseq sets) using an exhaustive “brute-force” algorithm implemented in the python script BruteForce.py. The script next parsed the transcript-oligo alignments to generate a score based on the position and number of mismatches between the siRNA and any potential off-target transcript. The off-target score is weighted to emphasize differences in the ‘seed’ region of siRNAs, in positions 2-9 from the 5′-end of the molecule.
Each oligo-transcript pair from the brute-force search was given a mismatch score by summing the individual mismatch scores; mismatches in the position 2-9 were counted as 2.8, mismatches in the cleavage site positions 10-11 were counted as 1.2, and mismatches in region 12-19 counted as 1.0. An additional off-target prediction was carried out by comparing the frequency of heptamers and octomers derived from 3 distinct, seed-derived hexamers of each oligo. The hexamers from positions 2-7 relative to the 5′ start were used to create 2 heptamers and one octamer. ‘Heptamer1’ was created by adding a 3′-A to the hexamer; heptamer2 was created by adding a 5′-A to the hexamer; the octomer was created by adding an A to both 5′- and 3′-ends of the hexamer. The frequency of octamers and heptamers in the human, rhesus, mouse, or rat 3′-UTRome (defined as the subsequence of the transcriptome from NCBI's Refseq database where the end of the coding region, the ‘CDS’, is clearly defined) was pre-calculated. The octamer frequency was normalized to the heptamer frequency using the median value from the range of octamer frequencies. A ‘mirSeedScore’ was then calculated by calculating the sum of ((3× normalized octamer count)+(2× heptamer2 count)+(1× heptamer1 count)).
Both siRNAs strands were assigned to a category of specificity according to the calculated scores: a score above 3 qualifies as highly specific, equal to 3 as specific and between 2.2 and 2.8 as moderately specific. The duplexes were sorted by the specificity of the antisense strand and those duplexes whose antisense oligos lacked GC at the first position, lacked G at both positions 13 and 14, and had 3 or more Us or As in the seed region were selected.
For GalNaC-conjugated duplexes, sense 21mer and antisense 23mer oligos were designed by extending antisense 19mers (described above) to 23 nucleotides of target-complementary sequence. All species transcripts included in the design batch were checked for complementarity. Only 23mers that preserved 100% sequence complementarity in at least 2 species were used. For each duplex, the sense 21mer was specified as the reverse complement of the first 21 nucleotides of the antisense strand.
siRNA Sequence Selection
A total of 23 sense and 23 antisense derived human/rhesus, 6 sense and 6 antisense human/rhesus/mouse, 6 sense and 6 antisense derived human/rhesus/mouse/mouse/rat, and 13 sense and 13 antisense derived mouse/rat siRNA 19mer oligos were synthesized and formed into duplexes.
The above 19mer sets were extended to 21/23mer duplexes for GalNac conjugate design and re-classified according to their new species matches. Twenty-seven sense and 27 antisense derived human/rhesus, 1 sense and 1 sense derived human/rhesus/mouse, 3 sense and 3 antisense derived human/rhesus/rat, 4 sense and 4 antisense derived human/rhesus/mouse/rat, and 13 sense and 13 antisense derived mouse/rat 21mer (sense) and 23mer (antisense) oligos were synthesized and formed into duplexes.
A detailed list of C5 sense and antisense strand sequences is shown in Tables 3-6.
siRNA Synthesis
General Small and Medium Scale RNA Synthesis Procedure
RNA oligonucleotides were synthesized at scales between 0.2-500 μmol using commercially available 5′-O-(4,4′-dimethoxytrityl)-2′-O-t-butyldimethylsilyl-3′-O-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite monomers of uridine, 4-N-acetylcytidine, 6-N-benzoyladenosine and 2-N-isobutyrylguanosine and the corresponding 2′-O-methyl and 2′-fluoro phosphoramidites according to standard solid phase oligonucleotide synthesis protocols. The amidite solutions were prepared at 0.1-0.15 M concentration and 5-ethylthio-1H-tetrazole (0.25-0.6 M in acetonitrile) was used as the activator. Phosphorothioate backbone modifications were introduced during synthesis using 0.2 M phenylacetyl disulfide (PADS) in lutidine:acetonitrile (1:1) (v;v) or 0.1 M 3-(dimethylaminomethylene) amino-3H-1,2,4-dithiazole-5-thione (DDTT) in pyridine for the oxidation step. After completion of synthesis, the sequences were cleaved from the solid support and deprotected using methylamine followed by triethylamine.3HF to remove any 2′-O-t-butyldimethylsilyl protecting groups present.
For synthesis scales between 5-500 μmol and fully 2′ modified sequences (2′-fluoro and/or 2′-O-methyl or combinations thereof) the oligonucleotides where deprotected using 3:1 (v/v) ethanol and concentrated (28-32%) aqueous ammonia either at 35° C. 16 h or 55° C. for 5.5 h. Prior to ammonia deprotection the oligonucleotides where treated with 0.5 M piperidine in acetonitrile for 20 min on the solid support. The crude oligonucleotides were analyzed by LC-MS and anion-exchange HPLC (IEX-HPLC). Purification of the oligonucleotides was carried out by IEX HPLC using: 20 mM phosphate, 10%-15% ACN, pH=8.5 (buffer A) and 20 mM phosphate, 10%-15% ACN, 1 M NaBr, pH=8.5 (buffer B). Fractions were analyzed for purity by analytical HPLC. The product-containing fractions with suitable purity were pooled and concentrated on a rotary evaporator prior to desalting. The samples were desalted by size exclusion chromatography and lyophilized to dryness. Equal molar amounts of sense and antisense strands were annealed in 1×PBS buffer to prepare the corresponding siRNA duplexes.
For small scales (0.2-1 μmol), synthesis was performed on a MerMade 192 synthesizer in a 96 well format. In case of fully 2′-modified sequences (2′-fluoro and/or 2′-O-methyl or combinations thereof) the oligonucleotides where deprotected using methylamine at room temperature for 30-60 min followed by incubation at 60° C. for 30 min or using 3:1 (v/v) ethanol and concentrated (28-32%) aqueous ammonia at room temperature for 30-60 min followed by incubation at 40° C. for 1.5 hours. The crude oligonucleotides were then precipitated in a solution of acetonitrile:acetone (9:1) and isolated by centrifugation and decanting the supernatant. The crude oligonucleotide pellet was re-suspended in 20 mM NaOAc buffer and analyzed by LC-MS and anion exchange HPLC. The crude oligonucleotide sequences were desalted in 96 deep well plates on a 5 mL HiTrap Sephadex G25 column (GE Healthcare). In each well about 1.5 mL samples corresponding to an individual sequence was collected. These purified desalted oligonucleotides were analyzed by LC-MS and anion exchange chromatography. Duplexes were prepared by annealing equimolar amounts of sense and antisense sequences on a Tecan robot. Concentration of duplexes was adjusted to 10 μM in 1×PBS buffer.
Synthesis of GalNAc-Conjugated Oligonucleotides for In Vivo Analysis
Oligonucleotides conjugated with GalNAc ligand at their 3′-terminus were synthesized at scales between 0.2-500 μmol using a solid support pre-loaded with a Y-shaped linker bearing a 4,4′-dimethoxytrityl (DMT)-protected primary hydroxy group for oligonucleotide synthesis and a GalNAc ligand attached through a tether.
For synthesis of GalNAc conjugates in the scales between 5-500 μmol, the above synthesis protocol for RNA was followed with the following adaptions: For polystyrene-based synthesis supports 5% dichloroacetic acid in toluene was used for DMT-cleavage during synthesis. Cleavage from the support and deprotection was performed as described above. Phosphorothioate-rich sequences (usually >5 phorphorothioates) were synthesized without removing the final 5′-DMT group (“DMT-on”) and, after cleavage and deprotection as described above, purified by reverse phase HPLC using 50 mM ammonium acetate in water (buffer A) and 50 mM ammoniumacetate in 80% acetonitirile (buffer B). Fractions were analyzed for purity by analytical HPLC and/or LC-MS. The product-containing fractions with suitable purity were pooled and concentrated on a rotary evaporator. The DMT-group was removed using 20%-25% acetic acid in water until completion. The samples were desalted by size exclusion chromatography and lyophilized to dryness. Equal molar amounts of sense and antisense strands were annealed in 1×PBS buffer to prepare the corresponding siRNA duplexes.
For small scale synthesis of GalNAc conjugates (0.2-1 μmol), including sequences with multiple phosphorothioate linkages, the protocols described above for synthesis of RNA or fully 2′-F/2′-OMe-containing sequences on MerMade platform were applied. Synthesis was performed on pre-packed columns containing GalNAc-functionalized controlled pore glass support.
Example 2
In Vitro Screening
Cell Culture and Transfections
Hep3B cells (ATCC, Manassas, Va.) were grown to near confluence at 37° C. in an atmosphere of 5% CO2 in Eagle's Minimum Essential Medium (ATCC) supplemented with 10% FBS, streptomycin, and glutamine (ATCC) before being released from the plate by trypsinization. Cells were washed and re-suspended at 0.25×106 cells/ml. During transfections, cells were plated onto a 96-well plate with about 20,000 cells per well.
Primary mouse hepatocytes (PMH) were freshly isolated from a C57BL/6 female mouse (Charles River Labortories International, Inc. Willmington, Mass.) less than 1 hour prior to transfections and grown in primary hepatocyte media. Cells were resuspended at 0.11×106 cells/ml in InVitroGRO CP Rat (plating) medium (Celsis In Vitro Technologies, catalog number S01494). During transfections, cells were plated onto a BD BioCoat 96 well collagen plate (BD, 356407) at 10,000 cells per well and incubated at 37° C. in an atmosphere of 5% CO2.
Cryopreserved Primary Cynomolgus Hepatocytes (Celsis In Vitro Technologies, M003055-P) were thawed at 37° C. water bath immediately prior to usage and re-suspended at 0.26×106 cells/ml in InVitroGRO CP (plating) medium (Celsis In Vitro Technologies, catalog number Z99029). During transfections, cells were plated onto a BD BioCoat 96 well collagen plate (BD, 356407) at 25,000 cells per well and incubated at 37° C. in an atmosphere of 5% CO2.
For Hep3B, PMH, and primary Cynomolgus hepatocytes, transfection was carried out by adding 14.8 μl of Opti-MEM plus 0.2 μl of Lipofectamine RNAiMax per well (Invitrogen, Carlsbad Calif. catalog number13778-150) to 5 μl of each siRNA duplex to an individual well in a 96-well plate. The mixture was then incubated at room temperature for 20 minutes. Eighty μl of complete growth media without antibiotic containing the appropriate cell number were then added to the siRNA mixture. Cells were incubated for 24 hours prior to RNA purification.
Single dose experiments were performed at 10 nM and 0.1 nM final duplex concentration for GalNAc modified sequences or at 1 nM and 0.01 nM final duplex concentration for all other sequences. Dose response experiments were done at 3, 1, 0.3, 0.1, 0.037, 0.0123, 0.00412, and 0.00137 nM final duplex concentration for primary mouse hepatocytes and at 3, 1, 0.3, 0.1, 0.037, 0.0123, 0.00412, 0.00137, 0.00046, 0.00015, 0.00005, and 0.000017 nM final duplex concentration for Hep3B cells.
Free Uptake Transfection
Free uptake experiments were performed by adding 10 μl of siRNA duplexes in PBS per well into a 96 well plate. Ninety μl of complete growth media containing appropriate cell number for the cell type was then added to the siRNA. Cells were incubated for 24 hours prior to RNA purification. Single dose experiments were performed at 500 nM and 5 nM final duplex concentration and dose response experiments were done at 1000, 333, 111, 37, 12.3, 4.12, 1.37, 0.46 nM final duplex concentration.
Total RNA Isolation Using DYNABEADS mRNA Isolation Kit (Invitrogen, Part #: 610-12)
Cells were harvested and lysed in 150 μl of Lysis/Binding Buffer then mixed for 5 minutes at 850 rpm using an Eppendorf Thermomixer (the mixing speed was the same throughout the process). Ten microliters of magnetic beads and 80 μl Lysis/Binding Buffer mixture were added to a round bottom plate and mixed for 1 minute. Magnetic beads were captured using a magnetic stand and the supernatant was removed without disturbing the beads. After removing the supernatant, the lysed cells were added to the remaining beads and mixed for 5 minutes. After removing the supernatant, magnetic beads were washed 2 times with 150 μl Wash Buffer A and mixed for 1 minute. The beads were capturedagain and the supernatant was removed. The beads were then washed with 150 μl Wash Buffer B, captured and the supernatant was removed. The beads were next washed with 150 μl Elution Buffer, captured and the supernatant removed. Finally, the beads were allowed to dry for 2 minutes. After drying, 50 μl of Elution Buffer was added and mixed for 5 minutes at 70° C. The beads were captured on magnet for 5 minutes. Forty-five μl of supernatant was removed and added to another 96 well plate.
cDNA Synthesis Using ABI High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, Calif., Cat #4368813)
A master mix of 2 μl 10× Buffer, 0.8 μl 25×dNTPs, 2 μl Random primers, 1 μl Reverse Transcriptase, 1 μl RNase inhibitor and 3.2 μl of H2O per reaction as prepared. Equal volumes master mix and RNA were mixed for a final volume of 12 μl for in vitro screened or 20 μl for in vivo screened samples. cDNA was generated using a Bio-Rad C-1000 or S-1000 thermal cycler (Hercules, Calif.) through the following steps: 25° C. for 10 minutes, 37° C. for 120 minutes, 85° C. for 5 seconds, and 4° C. hold.
Real Time PCR
Two μl of cDNA were added to a master mix containing 2 μl of H2O, 0.51 μl GAPDH TaqMan Probe (Life Technologies catalog number 4326317E for Hep3B cells, catalog number 352339E for primary mouse hepatocytes or custom probe for cynomolgus primary hepatocytes), 0.5 μl C5 TaqMan probe (Life Technologies c catalog number Hs00156197_m1 for Hep3B cells or mm00439275_m1 for Primary Mouse Hepatoctyes or custom probe for cynomolgus primary hepatocytes) and 5 μl Lightcycler 480 probe master mix (Roche catalog number 04887301001) per well in a 384 well plates (Roche catalog number 04887301001). Real time PCR was performed in an Roche LC480 Real Time PCR system (Roche) using the ΔΔCt(RQ) assay. For in vitro screening, each duplex was tested with two biological replicates unless otherwise noted and each Real Time PCR was performed in duplicate technical replicates. For in vivo screening, each duplex was tested in one or more experiments (3 mice per group) and each Real Time PCR was run in duplicate technical replicates.
To calculate relative fold change in C5 mRNA levels, real time data were analyzed using the ΔΔCt method and normalized to assays performed with cells transfected with 10 nM AD-1955, or mock transfected cells. IC50s were calculated using a 4 parameter fit model using XLFit and normalized to cells transfected with AD-1955 over the same dose range, or to its own lowest dose.
The sense and antisense sequences of AD-1955 are:









SENSE:







(SEQ ID NO: 13)









cuuAcGcuGAGuAcuucGAdTsdT;


 



ANTISENSE:







(SEQ ID NO: 14)









UCGAAGuACUcAGCGuAAGdTsdT.






Table 7 shows the results of a single dose screen in Hep3B cells transfected with the indicated GalNAC conjugated modified iRNAs. Data are expressed as percent of message remaining relative to untreated cells.
Table 8 shows the results of a single dose transfection screen in primary mouse hepatocytes transfected with the indicated GalNAC conjugated modified iRNAs. Data are expressed as percent of message remaining relative to untreated cells.
Table 9 shows the results of a single dose free uptake screen in primary Cynomolgus hepatocytes with the indicated GalNAC conjugated modified iRNAs. Data are expressed as percent of message remaining relative to untreated cells.
Table 10 shows the results of a single dose free uptake screen in primary mouse hepatocytes with the indicated GalNAC conjugated modified iRNAs. Data are expressed as percent of message remaining relative to untreated cells.
Table 11 shows the dose response of a free uptake screen in primary Cynomolgus hepatocytes with the indicated GalNAC conjugated modified iRNAs. The indicated IC50 values represent the IC50 values relative to untreated cells.
Table 12 shows the dose response of a free uptake screen in primary mouse hepatocytes with the indicated GalNAC conjugated modified iRNAs. The indicated IC50 values represent the IC50 values relative to untreated cells.
Table 13 shows the results of a single dose screen in Hep3B cells transfected with the indicated modified and unmodified iRNAs. Data are expressed as percent of message remaining relative to untreated cells. The 0.01 nM dose was a single biological transfection and the 1 nM dose was a duplicate biological transfection.
Table 14 shows the results of a single dose screen in primary mouse hepatocytes transfected with the indicated modified and unmodified iRNAs. Data are expressed as percent of message remaining relative to untreated cells.
Table 15 shows the dose response in Hep3B cells transfected with the indicated modified and unmodified iRNAs. The indicated IC50 values represent the IC50 values relative to untreated cells.
Table 16 shows the dose response in primary mouse hepatocytes transfected with the indicated modified and unmodified iRNAs. The indicated IC50 values represent the IC50 values relative to untreated cells.







TABLE 2







Abbreviations of nucleotide monomers used in nucleic acid sequence


representation. It will be understood that these monomers, when present


in an oligonucleotide, are mutually linked by 5′-3′-phosphodiester bonds.








Abbreviation
Nucleotide(s)





A
Adenosine-3′-phosphate


Af
2′-fluoroadenosine-3′-phosphate


Afs
2′-fluoroadenosine-3′-phosphorothioate


As
adenosine-3′-phosphorothioate


C
cytidine-3′-phosphate


Cf
2′-fluorocytidine-3′-phosphate


Cfs
2′-fluorocytidine-3′-phosphorothioate


Cs
cytidine-3′-phosphorothioate


G
guanosine-3′-phosphate


Gf
2′-fluoroguanosine-3′-phosphate


Gfs
2′-fluoroguanosine-3′-phosphorothioate


Gs
guanosine-3′-phosphorothioate


T
5′-methyluridine-3′-phosphate


Tf
2′-fluoro-5-methyluridine-3′-phosphate


Tfs
2′-fluoro-5-methyluridine-3′-phosphorothioate


Ts
5-methyluridine-3′-phosphorothioate


U
Uridine-3′-phosphate


Uf
2′-fluorouridine-3′-phosphate


Ufs
2′-fluorouridine-3′-phosphorothioate


Us
uridine-3′-phosphorothioate


N
any nucleotide (G, A, C, T or U)


a
2′-O-methyladenosine-3′-phosphate


as
2′-O-methyladenosine-3′-phosphorothioate


c
2′-O-methylcytidine-3′-phosphate


cs
2′-O-methylcytidine-3′-phosphorothioate


g
2′-O-methylguanosine-3′-phosphate


gs
2′-O-methylguanosine-3′-phosphorothioate


t
2′-O-methyl-5-methyluridine-3′-phosphate


ts
2′-O-methyl-5-methyluridine-3′-phosphorothioate


u
2′-O-methyluridine-3′-phosphate


us
2′-O-methyluridine-3′-phosphorothioate


s
phosphorothioate linkage


L96
N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol



Hyp-(GalNAc-alkyl)3


(dt)
deoxy-thymine
















TABLE 3







Unmodified Sense and Antisense Strand Sequences of C5 dsRNAs




















SEQ ID



Duplex ID
Sense strand
Sense Unmodified Sequence
SEQ ID NO:
Antisense
Antisense Unmodified Sequence
NO:
Species_Oligo name1

















AD-58093.12 UM3
A-118310.1
AAUAACUCACUAUAAUUACUU
15
A-118311.1
AAGUAAUUAUAGUGAGUUAUUUU
66
NM_001735.2_1517-1539_as


 


AD-58099.1 UM
A-118312.1
UGACAAAAUAACUCACUAUAA
16
A-118313.1
UUAUAGUGAGUUAUUUUGUCAAU
67
NM_001735.2_1511-1533_as


 


AD-58105.1 UM
A-118314.1
CUUCCUCUGGAAAUUGGCCUU
17
A-118315.1
AAGGCCAAUUUCCAGAGGAAGCA
68
NM_001735.2_2733-2755_as


 


AD-58111.1 UM
A-118316.1
GACAAAAUAACUCACUAUAAU
18
A-118317.1
AUUAUAGUGAGUUAUUUUGUCAA
69
NM_001735.2_1512-1534_as


 


AD-58117.1 UM
A-118318.1
UCCUCUGGAAAUUGGCCUUCA
19
A-118319.1
UGAAGGCCAAUUUCCAGAGGAAG
70
NM_001735.2_2735-2757_as


 


AD-58123.1 UM
A-118320.1
AAGCAAGAUAUUUUUAUAAUA
20
A-118321.1
UAUUAUAAAAAUAUCUUGCUUUU
71
NM_001735.2_784-806_as


 


AD-58129.1 UM
A-118322.1
AAAAUGUUUUUGUCAAGUACA
21
A-118323.1
UGUACUUGACAAAAACAUUUUCU
72
NM_001735.2_4744-4766_as


 


AD-58088.1 UM
A-118324.1
AUUUAAACAACAAGUACCUUU
22
A-118325.1
AAAGGUACUUGUUGUUUAAAUCU
73
NM_001735.2_982-1004_as


 


AD-58094.1 UM
A-118326.1
AUUCAGAAAGUCUGUGAAGGA
23
A-118327.1
UCCUUCACAGACUUUCUGAAUUU
74
NM_001735.2_4578-4600_as


 


AD-58100.1 UM
A-118328.1
ACACUGAAGCAUUUGAUGCAA
24
A-118329.1
UUGCAUCAAAUGCUUCAGUGUAU
75
NM_001735.2_169-191_as


 


AD-58106.1 UM
A-118330.1
GCAGUUCUGUGUUAAAAUGUC
25
A-118331.1
GACAUUUUAACACAGAACUGCAU
76
NM_001735.2_2591-2613_as


 


AD-58112.1 UM
A-118332.1
AGGAUUUUGAGUGUAAAAGGA
26
A-118333.1
UCCUUUUACACUCAAAAUCCUUU
77
NM_001735.2_2955-2977_as


 


AD-58118.1 UM
A-118334.1
AAUGAUGAACCUUGUAAAGAA
27
A-118335.1
UUCUUUACAAGGUUCAUCAUUUU
78
NM_001735.2_2025-2047_as


 


AD-58124.1 UM
A-118336.1
AUCAUUGGAACAUUUUUCAUU
28
A-118337.1
AAUGAAAAAUGUUCCAAUGAUUU
79
NM_001735.2_3118-3140_as


 


AD-58130.1 UM
A-118338.1
AGCCAGAAAUUCGGAGUUAUU
29
A-118339.1
AAUAACUCCGAAUUUCUGGCUUG
80
NM_001735.2_2317-2339_as


 


AD-58089.1 UM
A-118340.1
UCCCUGGGAGAUAAAACUCAC
30
A-118341.1
GUGAGUUUUAUCUCCCAGGGAAA
81
NM_001735.2_3618-3640_as


 


AD-58095.1 UM
A-118342.1
GAAAAUGAUGAACCUUGUAAA
31
A-118343.1
UUUACAAGGUUCAUCAUUUUCUU
82
NM_001735.2_2022-2044_as


 


AD-58101.1 UM
A-118344.1
AUUGCUCAAGUCACAUUUGAU
32
A-118345.1
AUCAAAUGUGACUUGAGCAAUUC
83
NM_001735.2_918-940_as


 


AD-58107.1 UM
A-118346.1
GAGAUUGCAUAUGCUUAUAAA
33
A-118347.1
UUUAUAAGCAUAUGCAAUCUCUG
84
NM_001735.2_4698-4720_as


 


AD-58113.1 UM
A-118348.1
GUUAUCCUGAUAAAAAAUUUA
34
A-118349.1
UAAAUUUUUUAUCAGGAUAACUU
85
NM_001735.2_205-227_as


 


AD-58119.1 UM
A-118350.1
AGGAAGUUUGCAGCUUUUAUU
35
A-118351.1
AAUAAAAGCUGCAAACUUCCUCA
86
NM_001735.2_4147-4169_as


 


AD-58125.1 UM
A-118352.1
GAAGAAAUUGAUCAUAUUGGA
36
A-118353.1
UCCAAUAUGAUCAAUUUCUUCUA
87
NM_001735.2_555-577_as


 


AD-58131.1 UM
A-118354.1
AUCCUGAUAAAAAAUUUAGUU
37
A-118355.1
AACUAAAUUUUUUAUCAGGAUAA
88
NM_001735.2_208-230_as


 


AD-58090.1 UM
A-118356.1
UGGAAAAGAAAUCUUAGUAAA
38
A-118357.1
UUUACUAAGAUUUCUUUUCCAAA
89
NM_001735.2_2786-2808_as


 


AD-58096.1 UM
A-118358.1
UCUUAUCAAAGUAUAAACAUU
39
A-118359.1
AAUGUUUAUACUUUGAUAAGAUG
90
NM_001735.2_1596-1618_as


 


AD-58102.1 UM
A-118360.1
UCCCUACAAACUGAAUUUGGU
40
A-118361.1
ACCAAAUUCAGUUUGUAGGGAGA
91
NM_001735.2_1082-1104_as


 


AD-58108.1 UM
A-118362.1
CAGGAGCAAACAUAUGUCAUU
41
A-118363.1
AAUGACAUAUGUUUGCUCCUGUC
92
NM_001735.2_87-109_as


 


AD-58114.1 UM
A-118364.1
ACAUGUAACAACUGUAGUUCA
42
A-118365.1
UGAACUACAGUUGUUACAUGUAC
93
NM_001735.2_4109-4131_as


 


AD-58120.1 UM
A-118366.1
CAGGAAAUCAUUGGAACAUUU
43
A-118367.1
AAAUGUUCCAAUGAUUUCCUGUU
94
NM_001735.2_3112-3134_as


 


AD-58126.1 UM
A-118368.1
UUUAAGAAUUUUGAAAUUACU
44
A-118369.1
AGUAAUUUCAAAAUUCUUAAAGU
95
NM_001735.2_759-781_as


 


AD-58132.1 UM
A-118370.1
UAUUCUGCAACUGAAUUCGAU
45
A-118371.1
AUCGAAUUCAGUUGCAGAAUAAC
96
NM_001735.2_4412-4434_as


 


AD-58091.1 UM
A-118372.1
GCCCUUGGAAAGAGUAUUUCA
46
A-118373.1
UGAAAUACUCUUUCCAAGGGCUU
97
NM_001735.2_1886-1908_as


 


AD-58097.1 UM
A-118374.1
CCUGAUAAAAAAUUUAGUUAC
47
A-118375.1
GUAACUAAAUUUUUUAUCAGGAU
98
NM_001735.2_210-232_as


 


AD-58103.1 UM
A-118376.1
CCCUUGGAAAGAGUAUUUCAA
48
A-118377.1
UUGAAAUACUCUUUCCAAGGGCU
99
NM_001735.2_1887-1909_as


 


AD-58121.1 UM
A-118382.1
UGCAGAUCAAACACAAUUUCA
49
A-118383.1
UGAAAUUGUGUUUGAUCUGCAGA
100
NM_010406.2_4943-4965_as


 


AD-58133.1 UM
A-118386.1
CAGAUCAAACACAAUUUCAGU
50
A-118387.1
ACUGAAAUUGUGUUUGAUCUGCA
101
NM_010406.2_4945-4967_as


 


AD-58116.1 UM
A-118396.1
GUUCCGGAUAUUUGAACUUUU
51
A-118397.1
AAAAGUUCAAAUAUCCGGAACCG
102
NM_010406.2_4500-4522_as


 


AD-58644.1 UM
A-119328.1
AUUUAAACAACAAGUACCUUU
52
A-119329.1
AAAGGUACUUGUUGUUUAAAUCU
103
NM_001735.2_982-1004_as


 


AD-58651.1 UM
A-119328.2
AUUUAAACAACAAGUACCUUU
53
A-119339.1
AAAGGUACUUGUUGUUUAAAUCU
104
NM_001735.2_982-1004_as


 


AD-58641.1 UM
A-119322.1
UGACAAAAUAACUCACUAUAA
54
A-119323.1
UUAUAGUGAGUUAUUUUGUCAAU
105
NM_001735.2_1511-1533_as


 


AD-58648.1 UM
A-119322.2
UGACAAAAUAACUCACUAUAA
55
A-119336.1
UUAUAGUGAGUUAUUUUGUCAAU
106
NM_001735.2_1511-1533_as


 


AD-58642.1 UM
A-119324.1
GACAAAAUAACUCACUAUAAU
56
A-119325.1
AUUAUAGUGAGUUAUUUUGUCAA
107
NM_001735.2_1512-1534_as


 


AD-58649.1 UM
A-119324.2
GACAAAAUAACUCACUAUAAU
57
A-119337.1
AUUAUAGUGAGUUAUUUUGUCAA
108
NM_001735.2_1512-1534_as


 


AD-58647.1 UM
A-119334.1
GUUCCGGAUAUUUGAACUUUU
58
A-119335.1
AAAAGUUCAAAUAUCCGGAACCG
109
NM_010406.2_4500-4522_as


 


AD-58654.1 UM
A-119334.2
GUUCCGGAUAUUUGAACUUUU
59
A-119342.1
AAAAGUUCAAAUAUCCGGAACCG
110
NM_010406.2_4500-4522_as


 


AD-58645.1 UM
A-119330.1
UGCAGAUCAAACACAAUUUCA
60
A-119331.1
UGAAAUUGUGUUUGAUCUGCAGA
111
NM_010406.2_4943-4965_as


 


AD-58652.1 UM
A-119330.2
UGCAGAUCAAACACAAUUUCA
61
A-119340.1
UGAAAUUGUGUUUGAUCUGCAGA
112
NM_010406.2_4943-4965_as


 


AD-58643.1 UM
A-119326.1
AAGCAAGAUAUUUUUAUAAUA
62
A-119327.1
UAUUAUAAAAAUAUCUUGCUUUU
113
NM_001735.2_784-806_as


 


AD-58650.1 UM
A-119326.2
AAGCAAGAUAUUUUUAUAAUA
63
A-119338.1
UAUUAUAAAAAUAUCUUGCUUUU
114
NM_001735.2_784-806_as


 


AD-58646.1 UM
A-119332.1
CAGAUCAAACACAAUUUCAGU
64
A-119333.1
ACUGAAAUUGUGUUUGAUCUGCA
115
NM_010406.2_4945-4967_as


 


AD-58653.1 UM
A-119332.2
CAGAUCAAACACAAUUUCAGU
65
A-119341.1
ACUGAAAUUGUGUUUGAUCUGCA
116
NM_010406.2_4945-4967_as





1The Species Oligo name reflects the GenBank record (e.g., NM_001735.2) and the position in the nucleotide sequence of the GenBank record (e.g., 1517-1539) that the antisense strand targets.


2The number following the decimal point refers to the lot number.


3UM = unmodified













TABLE 4







GalNAC Conujugated Modified Sense and Antisense Strand Sequences of C5 dsRNAs

















SEQ


SEQ






ID


ID
Species_Oligo


Duplex ID
Sense strand
Sense sequence
NO:
Antisense
Antisense sequence
NO:
name4





AD-58093.1
A-118310.1
AfaUfaAfcUfcAfCfUfaUfaAfuUfaCfuUfL96
117
A-118311.1
aAfgUfaAfuUfaUfaguGfaGfuUfaUfusUfsu
168



 


AD-58099.1
A-118312.1
UfgAfcAfaAfaUfAfAfcUfcAfcUfaUfaAfL96
118
A-118313.1
uUfaUfaGfuGfaGfuuaUfuUfuGfuCfasAfsu
169



 


AD-58105.1
A-118314.1
CfuUfcCfuCfuGfGfAfaAfuUfgGfcCfuUfL96
119
A-118315.1
aAfgGfcCfaAfuUfuccAfgAfgGfaAfgsCfsa
170



 


AD-58111.1
A-118316.1
GfaCfaAfaAfuAfAfCfuCfaCfuAfuAfaUfL96
120
A-118317.1
aUfuAfuAfgUfgAfguuAfuUfuUfgUfcsAfsa
171



 


AD-58117.1
A-118318.1
UfcCfuCfuGfgAfAfAfuUfgGfcCfuUfcAfL96
121
A-118319.1
uGfaAfgGfcCfaAfuuuCfcAfgAfgGfasAfsg
172



 


AD-58123.1
A-118320.1
AfaGfcAfaGfaUfAfUfuUfuUfaUfaAfuAfL96
122
A-118321.1
uAfuUfaUfaAfaAfauaUfcUfuGfcUfusUfsu
173



 


AD-58129.1
A-118322.1
AfaAfaUfgUfuUfUfUfgUfcAfaGfuAfcAfL96
123
A-118323.1
uGfuAfcUfuGfaCfaaaAfaCfaUfuUfusCfsu
174



 


AD-58088.1
A-118324.1
AfuUfuAfaAfcAfAfCfaAfgUfaCfcUfuUfL96
124
A-118325.1
aAfaGfgUfaCfuUfguuGfuUfuAfaAfusCfsu
175



 


AD-58094.1
A-118326.1
AfuUfcAfgAfaAfGfUfcUfgUfgAfaGfgAfL96
125
A-118327.1
uCfcUfuCfaCfaGfacuUfuCfuGfaAfusUfsu
176



 


AD-58100.1
A-118328.1
AfcAfcUfgAfaGfCfAfuUfuGfaUfgCfaAfL96
126
A-118329.1
uUfgCfaUfcAfaAfugcUfuCfaGfuGfusAfsu
177



 


AD-58106.1
A-118330.1
GfcAfgUfuCfuGfUfGfuUfaAfaAfuGfuCfL96
127
A-118331.1
gAfcAfuUfuUfaAfcacAfgAfaCfuGfcsAfsu
178



 


AD-58112.1
A-118332.1
AfgGfaUfuUfuGfAfGfuGfuAfaAfaGfgAfL96
128
A-118333.1
uCfcUfuUfuAfcAfcucAfaAfaUfcCfusUfsu
179



 


AD-58118.1
A-118334.1
AfaUfgAfuGfaAfCfCfuUfgUfaAfaGfaAfL96
129
A-118335.1
uUfcUfuUfaCfaAfgguUfcAfuCfaUfusUfsu
180



 


AD-58124.1
A-118336.1
AfuCfaUfuGfgAfAfCfaUfuUfuUfcAfuUfL96
130
A-118337.1
aAfuGfaAfaAfaUfguuCfcAfaUfgAfusUfsu
181



 


AD-58130.1
A-118338.1
AfgCfcAfgAfaAfUfUfcGfgAfgUfuAfuUfL96
131
A-118339.1
aAfuAfaCfuCfcGfaauUfuCfuGfgCfusUfsg
182



 


AD-58089.1
A-118340.1
UfcCfcUfgGfgAfGfAfuAfaAfaCfuCfaCfL96
132
A-118341.1
gUfgAfgUfuUfuAfucuCfcCfaGfgGfasAfsa
183



 


AD-58095.1
A-118342.1
GfaAfaAfuGfaUfGfAfaCfcUfuGfuAfaAfL96
133
A-118343.1
uUfuAfcAfaGfgUfucaUfcAfuUfuUfcsUfsu
184



 


AD-58101.1
A-118344.1
AfuUfgCfuCfaAfGfUfcAfcAfuUfuGfaUfL96
134
A-118345.1
aUfcAfaAfuGfuGfacuUfgAfgCfaAfusUfsc
185



 


AD-58107.1
A-118346.1
GfaGfaUfuGfcAfUfAfuGfcUfuAfuAfaAfL96
135
A-118347.1
uUfuAfuAfaGfcAfuauGfcAfaUfcUfcsUfsg
186



 


AD-58113.1
A-118348.1
GfuUfaUfcCfuGfAfUfaAfaAfaAfuUfuAfL96
136
A-118349.1
uAfaAfuUfuUfuUfaucAfgGfaUfaAfcsUfsu
187



 


AD-58119.1
A-118350.1
AfgGfaAfgUfuUfGfCfaGfcUfuUfuAfuUfL96
137
A-118351.1
aAfuAfaAfaGfcUfgcaAfaCfuUfcCfusCfsa
188



 


AD-58125.1
A-118352.1
GfaAfgAfaAfuUfGfAfuCfaUfaUfuGfgAfL96
138
A-118353.1
uCfcAfaUfaUfgAfucaAfuUfuCfuUfcsUfsa
189



 


AD-58131.1
A-118354.1
AfuCfcUfgAfuAfAfAfaAfaUfuUfaGfuUfL96
139
A-118355.1
aAfcUfaAfaUfuUfuuuAfuCfaGfgAfusAfsa
190



 


AD-58090.1
A-118356.1
UfgGfaAfaAfgAfAfAfuCfuUfaGfuAfaAfL96
140
A-118357.1
uUfuAfcUfaAfgAfuuuCfuUfuUfcCfasAfsa
191



 


AD-58096.1
A-118358.1
UfcUfuAfuCfaAfAfGfuAfuAfaAfcAfuUfL96
141
A-118359.1
aAfuGfuUfuAfuAfcuuUfgAfuAfaGfasUfsg
192



 


AD-58102.1
A-118360.1
UfcCfcUfaCfaAfAfCfuGfaAfuUfuGfgUfL96
142
A-118361.1
aCfcAfaAfuUfcAfguuUfgUfaGfgGfasGfsa
193



 


AD-58108.1
A-118362.1
CfaGfgAfgCfaAfAfCfaUfaUfgUfcAfuUfL96
143
A-118363.1
aAfuGfaCfaUfaUfguuUfgCfuCfcUfgsUfsc
194



 


AD-58114.1
A-118364.1
AfcAfuGfuAfaCfAfAfcUfgUfaGfuUfcAfL96
144
A-118365.1
uGfaAfcUfaCfaGfuugUfuAfcAfuGfusAfsc
195



 


AD-58120.1
A-118366.1
CfaGfgAfaAfuCfAfUfuGfgAfaCfaUfuUfL96
145
A-118367.1
aAfaUfgUfuCfcAfaugAfuUfuCfcUfgsUfsu
196



 


AD-58126.1
A-118368.1
UfuUfaAfgAfaUfUfUfuGfaAfaUfuAfcUfL96
146
A-118369.1
aGfuAfaUfuUfcAfaaaUfuCfuUfaAfasGfsu
197



 


AD-58132.1
A-118370.1
UfaUfuCfuGfcAfAfCfuGfaAfuUfcGfaUfL96
147
A-118371.1
aUfcGfaAfuUfcAfguuGfcAfgAfaUfasAfsc
198



 


AD-58091.1
A-118372.1
GfcCfcUfuGfgAfAfAfgAfgUfaUfuUfcAfL96
148
A-118373.1
uGfaAfaUfaCfuCfuuuCfcAfaGfgGfcsUfsu
199



 


AD-58097.1
A-118374.1
CfcUfgAfuAfaAfAfAfaUfuUfaGfuUfaCfL96
149
A-118375.1
gUfaAfcUfaAfaUfuuuUfuAfuCfaGfgsAfsu
200



 


AD-58103.1
A-118376.1
CfcCfuUfgGfaAfAfGfaGfuAfuUfuCfaAfL96
150
A-118377.1
uUfgAfaAfuAfcUfcuuUfcCfaAfgGfgsCfsu
201



 


AD-58121.1
A-118382.1
UfgCfaGfaUfcAfAfAfcAfcAfaUfuUfcAfL96
151
A-118383.1
uGfaAfaUfuGfuGfuuuGfaUfcUfgCfasGfsa
202



 


AD-58133.1
A-118386.1
CfaGfaUfcAfaAfCfAfcAfaUfuUfcAfgUfL96
152
A-118387.1
aCfuGfaAfaUfuGfuguUfuGfaUfcUfgsCfsa
203



 


AD-58116.1
A-118396.1
GfuUfcCfgGfaUfAfUfuUfgAfaCfuUfuUfL96
153
A-118397.1
aAfaAfgUfuCfaAfauaUfcCfgGfaAfcsCfsg
204



 


AD-58644.1
A-119328.1
AfsusUfuAfaAfcAfAfCfaAfgUfaCfcUfuUfL96
154
A-119329.1
asAfsaGfgUfaCfuUfguuGfuUfuAfaAfuscsu
205



 


AD-58651.1
A-119328.2
AfsusUfuAfaAfcAfAfCfaAfgUfaCfcUfuUfL96
155
A-119339.1
asAfsaGfsgUfsaCfsuUfsguuGfsuUfsuAfsaAfsuscsu
206



 


AD-58641.1
A-119322.1
UfsgsAfcAfaAfaUfAfAfcUfcAfcUfaUfaAfL96
156
A-119323.1
usUfsaUfaGfuGfaGfuuaUfuUfuGfuCfasasu
207



 


AD-58648.1
A-119322.2
UfsgsAfcAfaAfaUfAfAfcUfcAfcUfaUfaAfL96
157
A-119336.1
usUfsaUfsaGfsuGfsaGfsuuaUfsuUfsuGfsuCfsasasu
208



 


AD-58642.1
A-119324.1
GfsasCfaAfaAfuAfAfCfuCfaCfuAfuAfaUfL96
158
A-119325.1
asUfsuAfuAfgUfgAfguuAfuUfuUfgUfcsasa
209



 


AD-58649.1
A-119324.2
GfsasCfaAfaAfuAfAfCfuCfaCfuAfuAfaUfL96
159
A-119337.1
asUfsuAfsuAfsgUfsgAfsguuAfsuUfsuUfsgUfscsasa
210



 


AD-58647.1
A-119334.1
GfsusUfcCfgGfaUfAfUfuUfgAfaCfuUfuUfL96
160
A-119335.1
asAfsaAfgUfuCfaAfauaUfcCfgGfaAfcscsg
211



 


AD-58654.1
A-119334.2
GfsusUfcCfgGfaUfAfUfuUfgAfaCfuUfuUfL96
161
A-119342.1
asAfsaAfsgUfsuCfsaAfsauaUfscCfsgGfsaAfscscsg
212



 


AD-58645.1
A-119330.1
UfsgsCfaGfaUfcAfAfAfcAfcAfaUfuUfcAfL96
162
A-119331.1
usGfsaAfaUfuGfuGfuuuGfaUfcUfgCfasgsa
213



 


AD-58652.1
A-119330.2
UfsgsCfaGfaUfcAfAfAfcAfcAfaUfuUfcAfL96
163
A-119340.1
usGfsaAfsaUfsuGfsuGfsuuuGfsaUfscUfsgCfsasgsa
214



 


AD-58643.1
A-119326.1
AfsasGfcAfaGfaUfAfUfuUfuUfaUfaAfuAfL96
164
A-119327.1
usAfsuUfaUfaAfaAfauaUfcUfuGfcUfususu
215



 


AD-58650.1
A-119326.2
AfsasGfcAfaGfaUfAfUfuUfuUfaUfaAfuAfL96
165
A-119338.1
usAfsuUfsaUfsaAfsaAfsauaUfscUfsuGfscUfsususu
216



 


AD-58646.1
A-119332.1
CfsasGfaUfcAfaAfCfAfcAfaUfuUfcAfgUfL96
166
A-119333.1
asCfsuGfaAfaUfuGfuguUfuGfaUfcUfgscsa
217



 


AD-58653.1
A-119332.2
CfsasGfaUfcAfaAfCfAfcAfaUfuUfcAfgUfL96
167
A-119341.1
asCfsuGfsaAfsaUfsuGfsuguUfsuGfsaUfscUfsgscsa
218





4The Species Oligo name and the position in the nucleotide sequence of the GenBank record that the antisense strand targets correspond to those shown in Table 3.













TABLE 5







Unmodified Sense and Antisense Strand Sequences of C5 dsRNAs














Duplex ID
Sense strand
Sense Unmodified Sequence
SEQ ID NO:
Antisense
Antisense Unmodified Sequence
SEQ ID NO:
Species_Oligo name





AD-58143.1 UM
A-118423.1
CACUAUAAUUACUUGAUUU
219
A-118424.1
AAAUCAAGUAAUUAUAGUG
302
NM_001735.2_1522-1540_as


 


AD-58149.1 UM
A-118425.1
UAACUCACUAUAAUUACUU
220
A-118426.1
AAGUAAUUAUAGUGAGUUA
303
NM_001735.2_1517-1535_as


 


AD-58155.1 UM
A-118427.1
ACAAAAUAACUCACUAUAA
221
A-118428.1
UUAUAGUGAGUUAUUUUGU
304
NM_001735.2_1511-1529_as


 


AD-58161.1 UM
A-118429.1
UCCUCUGGAAAUUGGCCUU
222
A-118430.1
AAGGCCAAUUUCCAGAGGA
305
NM_001735.2_2733-2751_as


 


AD-58167.1 UM
A-118431.1
CAAAAUAACUCACUAUAAU
223
A-118432.1
AUUAUAGUGAGUUAUUUUG
306
NM_001735.2_1512-1530_as


 


AD-58173.1 UM
A-118433.1
CUCUGGAAAUUGGCCUUCA
224
A-118434.1
UGAAGGCCAAUUUCCAGAG
307
NM_001735.2_2735-2753_as


 


AD-58179.1 UM
A-118435.1
GCAAGAUAUUUUUAUAAUA
225
A-118436.1
UAUUAUAAAAAUAUCUUGC
308
NM_001735.2_784-802_as


 


AD-58185.1 UM
A-118437.1
AAUGUUUUUGUCAAGUACA
226
A-118438.1
UGUACUUGACAAAAACAUU
309
NM_001735.2_4744-4762_as


 


AD-58144.1 UM
A-118439.1
UUAAACAACAAGUACCUUU
227
A-118440.1
AAAGGUACUUGUUGUUUAA
310
NM_001735.2_982-1000_as


 


AD-58150.1 UM
A-118441.1
UCAGAAAGUCUGUGAAGGA
228
A-118442.1
UCCUUCACAGACUUUCUGA
311
NM_001735.2_4578-4596_as


 


AD-58156.1 UM
A-118443.1
ACUGAAGCAUUUGAUGCAA
229
A-118444.1
UUGCAUCAAAUGCUUCAGU
312
NM_001735.2_169-187_as


 


AD-58162.1 UM
A-118445.1
AGUUCUGUGUUAAAAUGUC
230
A-118446.1
GACAUUUUAACACAGAACU
313
NM_001735.2_2591-2609_as


 


AD-58168.1 UM
A-118447.1
GAUUUUGAGUGUAAAAGGA
231
A-118448.1
UCCUUUUACACUCAAAAUC
314
NM_001735.2_2955-2973_as


 


AD-58174.1 UM
A-118449.1
UGAUGAACCUUGUAAAGAA
232
A-118450.1
UUCUUUACAAGGUUCAUCA
315
NM_001735.2_2025-2043_as


 


AD-58180.1 UM
A-118451.1
CAUUGGAACAUUUUUCAUU
233
A-118452.1
AAUGAAAAAUGUUCCAAUG
316
NM_001735.2_3118-3136_as


 


AD-58186.1 UM
A-118453.1
CCAGAAAUUCGGAGUUAUU
234
A-118454.1
AAUAACUCCGAAUUUCUGG
317
NM_001735.2_2317-2335_as


 


AD-58145.1 UM
A-118455.1
CCUGGGAGAUAAAACUCAC
235
A-118456.1
GUGAGUUUUAUCUCCCAGG
318
NM_001735.2_3618-3636_as


 


AD-58151.1 UM
A-118457.1
AAAUGAUGAACCUUGUAAA
236
A-118458.1
UUUACAAGGUUCAUCAUUU
319
NM_001735.2_2022-2040_as


 


AD-58157.1 UM
A-118459.1
UGCUCAAGUCACAUUUGAU
237
A-118460.1
AUCAAAUGUGACUUGAGCA
320
NM_001735.2_918-936_as


 


AD-58163.1 UM
A-118461.1
GAUUGCAUAUGCUUAUAAA
238
A-118462.1
UUUAUAAGCAUAUGCAAUC
321
NM_001735.2_4698-4716_as


 


AD-58169.1 UM
A-118463.1
UAUCCUGAUAAAAAAUUUA
239
A-118464.1
UAAAUUUUUUAUCAGGAUA
322
NM_001735.2_205-223_as


 


AD-58175.1 UM
A-118465.1
GAAGUUUGCAGCUUUUAUU
240
A-118466.1
AAUAAAAGCUGCAAACUUC
323
NM_001735.2_4147-4165_as


 


AD-58181.1 UM
A-118467.1
AGAAAUUGAUCAUAUUGGA
241
A-118468.1
UCCAAUAUGAUCAAUUUCU
324
NM_001735.2_555-573_as


 


AD-58187.1 UM
A-118469.1
CCUGAUAAAAAAUUUAGUU
242
A-118470.1
AACUAAAUUUUUUAUCAGG
325
NM_001735.2_208-226_as


 


AD-58146.1 UM
A-118471.1
GAAAAGAAAUCUUAGUAAA
243
A-118472.1
UUUACUAAGAUUUCUUUUC
326
NM_001735.2_2786-2804_as


 


AD-58152.1 UM
A-118473.1
UUAUCAAAGUAUAAACAUU
244
A-118474.1
AAUGUUUAUACUUUGAUAA
327
NM_001735.2_1596-1614_as


 


AD-58158.1 UM
A-118475.1
CCUACAAACUGAAUUUGGU
245
A-118476.1
ACCAAAUUCAGUUUGUAGG
328
NM_001735.2_1082-1100_as


 


AD-58164.1 UM
A-118477.1
GGAGCAAACAUAUGUCAUU
246
A-118478.1
AAUGACAUAUGUUUGCUCC
329
NM_001735.2_87-105_as


 


AD-58170.1 UM
A-118479.1
AUGUAACAACUGUAGUUCA
247
A-118480.1
UGAACUACAGUUGUUACAU
330
NM_001735.2_4109-4127_as


 


AD-58176.1 UM
A-118481.1
GGAAAUCAUUGGAACAUUU
248
A-118482.1
AAAUGUUCCAAUGAUUUCC
331
NM_001735.2_3112-3130_as


 


AD-58182.1 UM
A-118483.1
UAAGAAUUUUGAAAUUACU
249
A-118484.1
AGUAAUUUCAAAAUUCUUA
332
NM_001735.2_759-777_as


 


AD-58188.1 UM
A-118485.1
UUCUGCAACUGAAUUCGAU
250
A-118486.1
AUCGAAUUCAGUUGCAGAA
333
NM_001735.2_4412-4430_as


 


AD-58147.1 UM
A-118487.1
CCUUGGAAAGAGUAUUUCA
251
A-118488.1
UGAAAUACUCUUUCCAAGG
334
NM_001735.2_1886-1904_as


 


AD-58153.1 UM
A-118489.1
UGAUAAAAAAUUUAGUUAC
252
A-118490.1
GUAACUAAAUUUUUUAUCA
335
NM_001735.2_210-228_as


 


AD-58159.1 UM
A-118491.1
CUUGGAAAGAGUAUUUCAA
253
A-118492.1
UUGAAAUACUCUUUCCAAG
336
NM_001735.2_1887-1905_as


 


AD-58190.1 UM
A-118519.1
CACUAUAAUUACUUGAUUU
254
A-118520.1
AAAUCAAGUAAUUAUAGUG
337
NM_001735.2_1522-1540_as


 


AD-58196.1 UM
A-118521.1
UAACUCACUAUAAUUACUU
255
A-118522.1
AAGUAAUUAUAGUGAGUUA
338
NM_001735.2_1517-1535_as


 


AD-58202.1 UM
A-118523.1
ACAAAAUAACUCACUAUAA
256
A-118524.1
UUAUAGUGAGUUAUUUUGU
339
NM_001735.2_1511-1529_as


 


AD-58208.1 UM
A-118525.1
UCCUCUGGAAAUUGGCCUU
257
A-118526.1
AAGGCCAAUUUCCAGAGGA
340
NM_001735.2_2733-2751_as


 


AD-58214.1 UM
A-118527.1
CAAAAUAACUCACUAUAAU
258
A-118528.1
AUUAUAGUGAGUUAUUUUG
341
NM_001735.2_1512-1530_as


 


AD-58220.1 UM
A-118529.1
CUCUGGAAAUUGGCCUUCA
259
A-118530.1
UGAAGGCCAAUUUCCAGAG
342
NM_001735.2_2735-2753_as


 


AD-58226.1 UM
A-118531.1
GCAAGAUAUUUUUAUAAUA
260
A-118532.1
UAUUAUAAAAAUAUCUUGC
343
NM_001735.2_784-802_as


 


AD-58231.1 UM
A-118533.1
AAUGUUUUUGUCAAGUACA
261
A-118534.1
UGUACUUGACAAAAACAUU
344
NM_001735.2_4744-4762_as


 


AD-58191.1 UM
A-118535.1
UUAAACAACAAGUACCUUU
262
A-118536.1
AAAGGUACUUGUUGUUUAA
345
NM_001735.2_982-1000_as


 


AD-58197.1 UM
A-118537.1
UCAGAAAGUCUGUGAAGGA
263
A-118538.1
UCCUUCACAGACUUUCUGA
346
NM_001735.2_4578-4596_as


 


AD-58203.1 UM
A-118539.1
ACUGAAGCAUUUGAUGCAA
264
A-118540.1
UUGCAUCAAAUGCUUCAGU
347
NM_001735.2_169-187_as


 


AD-58209.1 UM
A-118541.1
AGUUCUGUGUUAAAAUGUC
265
A-118542.1
GACAUUUUAACACAGAACU
348
NM_001735.2_2591-2609_as


 


AD-58233.1 UM
A-118565.1
CACUAUAAUUACUUGAUUU
266
A-118566.1
AAAUCAAGUAAUUAUAGUG
349
NM_001735.2_1522-1540_as


 


AD-58193.1 UM
A-118567.1
UAACUCACUAUAAUUACUU
267
A-118568.1
AAGUAAUUAUAGUGAGUUA
350
NM_001735.2_1517-1535_as


 


AD-58199.1 UM
A-118569.1
ACAAAAUAACUCACUAUAA
268
A-118570.1
UUAUAGUGAGUUAUUUUGU
351
NM_001735.2_1511-1529_as


 


AD-58205.1 UM
A-118571.1
UCCUCUGGAAAUUGGCCUU
269
A-118572.1
AAGGCCAAUUUCCAGAGGA
352
NM_001735.2_2733-2751_as


 


AD-58211.1 UM
A-118573.1
CAAAAUAACUCACUAUAAU
270
A-118574.1
AUUAUAGUGAGUUAUUUUG
353
NM_001735.2_1512-1530_as


 


AD-58217.1 UM
A-118575.1
CUCUGGAAAUUGGCCUUCA
271
A-118576.1
UGAAGGCCAAUUUCCAGAG
354
NM_001735.2_2735-2753_as


 


AD-58223.1 UM
A-118577.1
GCAAGAUAUUUUUAUAAUA
272
A-118578.1
UAUUAUAAAAAUAUCUUGC
355
NM_001735.2_784-802_as


 


AD-58229.1 UM
A-118579.1
AAUGUUUUUGUCAAGUACA
273
A-118580.1
UGUACUUGACAAAAACAUU
356
NM_001735.2_4744-4762_as


 


AD-58234.1 UM
A-118581.1
UUAAACAACAAGUACCUUU
274
A-118582.1
AAAGGUACUUGUUGUUUAA
357
NM_001735.2_982-1000_as


 


AD-58194.1 UM
A-118583.1
UCAGAAAGUCUGUGAAGGA
275
A-118584.1
UCCUUCACAGACUUUCUGA
358
NM_001735.2_4578-4596_as


 


AD-58200.1 UM
A-118585.1
ACUGAAGCAUUUGAUGCAA
276
A-118586.1
UUGCAUCAAAUGCUUCAGU
359
NM_001735.2_169-187_as


 


AD-58206.1 UM
A-118587.1
AGUUCUGUGUUAAAAUGUC
277
A-118588.1
GACAUUUUAACACAGAACU
360
NM_001735.2_2591-2609_as


 


AD-58236.1 UM
A-118423.2
CACUAUAAUUACUUGAUUU
278
A-118644.1
AAAUCAAGUAAUUAUAGUG
361
NM_001735.2_1522-1540_as


 


AD-58242.1 UM
A-118425.2
UAACUCACUAUAAUUACUU
279
A-118645.1
AAGUAAUUAUAGUGAGUUA
362
NM_001735.2_1517-1535_as


 


AD-58248.1 UM
A-118427.2
ACAAAAUAACUCACUAUAA
280
A-118646.1
UUAUAGUGAGUUAUUUUGU
363
NM_001735.2_1511-1529_as


 


AD-58254.1 UM
A-118429.2
UCCUCUGGAAAUUGGCCUU
281
A-118647.1
AAGGCCAAUUUCCAGAGGA
364
NM_001735.2_2733-2751_as


 


AD-58260.1 UM
A-118431.2
CAAAAUAACUCACUAUAAU
282
A-118648.1
AUUAUAGUGAGUUAUUUUG
365
NM_001735.2_1512-1530_as


 


AD-58266.1 UM
A-118433.2
CUCUGGAAAUUGGCCUUCA
283
A-118649.1
UGAAGGCCAAUUUCCAGAG
366
NM_001735.2_2735-2753_as


 


AD-58272.1 UM
A-118435.2
GCAAGAUAUUUUUAUAAUA
284
A-118650.1
UAUUAUAAAAAUAUCUUGC
367
NM_001735.2_784-802_as


 


AD-58277.1 UM
A-118437.2
AAUGUUUUUGUCAAGUACA
285
A-118651.1
UGUACUUGACAAAAACAUU
368
NM_001735.2_4744-4762_as


 


AD-58237.1 UM
A-118439.2
UUAAACAACAAGUACCUUU
286
A-118652.1
AAAGGUACUUGUUGUUUAA
369
NM_001735.2_982-1000_as


 


AD-58243.1 UM
A-118441.2
UCAGAAAGUCUGUGAAGGA
287
A-118653.1
UCCUUCACAGACUUUCUGA
370
NM_001735.2_4578-4596_as


 


AD-58249.1 UM
A-118443.2
ACUGAAGCAUUUGAUGCAA
288
A-118654.1
UUGCAUCAAAUGCUUCAGU
371
NM_001735.2_169-187_as


 


AD-58255.1 UM
A-118445.2
AGUUCUGUGUUAAAAUGUC
289
A-118655.1
GACAUUUUAACACAGAACU
372
NM_001735.2_2591-2609_as


 


AD-58279.1 UM
A-118423.3
CACUAUAAUUACUUGAUUU
290
A-118667.1
AAAUCAAGUAAUUAUAGUG
373
NM_001735.2_1522-1540_as


 


AD-58239.1 UM
A-118425.3
UAACUCACUAUAAUUACUU
291
A-118668.1
AAGUAAUUAUAGUGAGUUA
374
NM_001735.2_1517-1535_as


 


AD-58245.1 UM
A-118427.3
ACAAAAUAACUCACUAUAA
292
A-118669.1
UUAUAGUGAGUUAUUUUGU
375
NM_001735.2_1511-1529_as


 


AD-58251.1 UM
A-118429.3
UCCUCUGGAAAUUGGCCUU
293
A-118670.1
AAGGCCAAUUUCCAGAGGA
376
NM_001735.2_2733-2751_as


 


AD-58257.1 UM
A-118431.3
CAAAAUAACUCACUAUAAU
294
A-118671.1
AUUAUAGUGAGUUAUUUUG
377
NM_001735.2_1512-1530_as


 


AD-58263.1 UM
A-118433.3
CUCUGGAAAUUGGCCUUCA
295
A-118672.1
UGAAGGCCAAUUUCCAGAG
378
NM_001735.2_2735-2753_as


 


AD-58269.1 UM
A-118435.3
GCAAGAUAUUUUUAUAAUA
296
A-118673.1
UAUUAUAAAAAUAUCUUGC
379
NM_001735.2_784-802_as


 


AD-58275.1 UM
A-118437.3
AAUGUUUUUGUCAAGUACA
297
A-118674.1
UGUACUUGACAAAAACAUU
380
NM_001735.2_4744-4762_as


 


AD-58280.1 UM
A-118439.3
UUAAACAACAAGUACCUUU
298
A-118675.1
AAAGGUACUUGUUGUUUAA
381
NM_001735.2_982-1000_as


 


AD-58240.1 UM
A-118441.3
UCAGAAAGUCUGUGAAGGA
299
A-118676.1
UCCUUCACAGACUUUCUGA
382
NM_001735.2_4578-4596_as


 


AD-58246.1 UM
A-118443.3
ACUGAAGCAUUUGAUGCAA
300
A-118677.1
UUGCAUCAAAUGCUUCAGU
383
NM_001735.2_169-187_as


 


AD-58252.1 UM
A-118445.3
AGUUCUGUGUUAAAAUGUC
301
A-118678.1
GACAUUUUAACACAGAACU
384
NM_001735.2_2591-2609_as
















TABLE 6







Modified Sense and Antisense Strand Sequences of C5 dsRNAs














Duplex ID
Sense strand
Sense sequence
SEQ ID NO:
Antisense
Antisense sequence
SEQ ID NO:
Species_Oligo name5





AD-58143.1
A-118423.1
cAcuAuAAuuAcuuGAuuudTsdT
385
A-118424.1
AAAUcAAGuAAUuAuAGUGdTsdT
468



 


AD-58149.1
A-118425.1
uAAcucAcuAuAAuuAcuudTsdT
386
A-118426.1
AAGuAAUuAuAGUGAGUuAdTsdT
469



 


AD-58155.1
A-118427.1
AcAAAAuAAcucAcuAuAAdTsdT
387
A-118428.1
UuAuAGUGAGUuAUUUUGUdTsdT
470



 


AD-58161.1
A-118429.1
uccucuGGAAAuuGGccuudTsdT
388
A-118430.1
AAGGCcAAUUUCcAGAGGAdTsdT
471



 


AD-58167.1
A-118431.1
cAAAAuAAcucAcuAuAAudTsdT
389
A-118432.1
AUuAuAGUGAGUuAUUUUGdTsdT
472



 


AD-58173.1
A-118433.1
cucuGGAAAuuGGccuucAdTsdT
390
A-118434.1
UGAAGGCcAAUUUCcAGAGdTsdT
473



 


AD-58179.1
A-118435.1
GcAAGAuAuuuuuAuAAuAdTsdT
391
A-118436.1
uAUuAuAAAAAuAUCUUGCdTsdT
474



 


AD-58185.1
A-118437.1
AAuGuuuuuGucAAGuAcAdTsdT
392
A-118438.1
UGuACUUGAcAAAAAcAUUdTsdT
475



 


AD-58144.1
A-118439.1
uuAAAcAAcAAGuAccuuudTsdT
393
A-118440.1
AAAGGuACUUGUUGUUuAAdTsdT
476



 


AD-58150.1
A-118441.1
ucAGAAAGucuGuGAAGGAdTsdT
394
A-118442.1
UCCUUcAcAGACUUUCUGAdTsdT
477



 


AD-58156.1
A-118443.1
AcuGAAGcAuuuGAuGcAAdTsdT
395
A-118444.1
UUGcAUcAAAUGCUUcAGUdTsdT
478



 


AD-58162.1
A-118445.1
AGuucuGuGuuAAAAuGucdTsdT
396
A-118446.1
GAcAUUUuAAcAcAGAACUdTsdT
479



 


AD-58168.1
A-118447.1
GAuuuuGAGuGuAAAAGGAdTsdT
397
A-118448.1
UCCUUUuAcACUcAAAAUCdTsdT
480



 


AD-58174.1
A-118449.1
uGAuGAAccuuGuAAAGAAdTsdT
398
A-118450.1
UUCUUuAcAAGGUUcAUcAdTsdT
481



 


AD-58180.1
A-118451.1
cAuuGGAAcAuuuuucAuudTsdT
399
A-118452.1
AAUGAAAAAUGUUCcAAUGdTsdT
482



 


AD-58186.1
A-118453.1
ccAGAAAuucGGAGuuAuudTsdT
400
A-118454.1
AAuAACUCCGAAUUUCUGGdTsdT
483



 


AD-58145.1
A-118455.1
ccuGGGAGAuAAAAcucAcdTsdT
401
A-118456.1
GUGAGUUUuAUCUCCcAGGdTsdT
484



 


AD-58151.1
A-118457.1
AAAuGAuGAAccuuGuAAAdTsdT
402
A-118458.1
UUuAcAAGGUUcAUcAUUUdTsdT
485



 


AD-58157.1
A-118459.1
uGcucAAGucAcAuuuGAudTsdT
403
A-118460.1
AUcAAAUGUGACUUGAGcAdTsdT
486



 


AD-58163.1
A-118461.1
GAuuGcAuAuGcuuAuAAAdTsdT
404
A-118462.1
UUuAuAAGcAuAUGcAAUCdTsdT
487



 


AD-58169.1
A-118463.1
uAuccuGAuAAAAAAuuuAdTsdT
405
A-118464.1
uAAAUUUUUuAUcAGGAuAdTsdT
488



 


AD-58175.1
A-118465.1
GAAGuuuGcAGcuuuuAuudTsdT
406
A-118466.1
AAuAAAAGCUGcAAACUUCdTsdT
489



 


AD-58181.1
A-118467.1
AGAAAuuGAucAuAuuGGAdTsdT
407
A-118468.1
UCcAAuAUGAUcAAUUUCUdTsdT
490



 


AD-58187.1
A-118469.1
ccuGAuAAAAAAuuuAGuudTsdT
408
A-118470.1
AACuAAAUUUUUuAUcAGGdTsdT
491



 


AD-58146.1
A-118471.1
GAAAAGAAAucuuAGuAAAdTsdT
409
A-118472.1
UUuACuAAGAUUUCUUUUCdTsdT
492



 


AD-58152.1
A-118473.1
uuAucAAAGuAuAAAcAuudTsdT
410
A-118474.1
AAUGUUuAuACUUUGAuAAdTsdT
493



 


AD-58158.1
A-118475.1
ccuAcAAAcuGAAuuuGGudTsdT
411
A-118476.1
ACcAAAUUcAGUUUGuAGGdTsdT
494



 


AD-58164.1
A-118477.1
GGAGcAAAcAuAuGucAuudTsdT
412
A-118478.1
AAUGAcAuAUGUUUGCUCCdTsdT
495



 


AD-58170.1
A-118479.1
AuGuAAcAAcuGuAGuucAdTsdT
413
A-118480.1
UGAACuAcAGUUGUuAcAUdTsdT
496



 


AD-58176.1
A-118481.1
GGAAAucAuuGGAAcAuuudTsdT
414
A-118482.1
AAAUGUUCcAAUGAUUUCCdTsdT
497



 


AD-58182.1
A-118483.1
uAAGAAuuuuGAAAuuAcudTsdT
415
A-118484.1
AGuAAUUUcAAAAUUCUuAdTsdT
498



 


AD-58188.1
A-118485.1
uucuGcAAcuGAAuucGAudTsdT
416
A-118486.1
AUCGAAUUcAGUUGcAGAAdTsdT
499



 


AD-58147.1
A-118487.1
ccuuGGAAAGAGuAuuucAdTsdT
417
A-118488.1
UGAAAuACUCUUUCcAAGGdTsdT
500



 


AD-58153.1
A-118489.1
uGAuAAAAAAuuuAGuuAcdTsdT
418
A-118490.1
GuAACuAAAUUUUUuAUcAdTsdT
501



 


AD-58159.1
A-118491.1
cuuGGAAAGAGuAuuucAAdTsdT
419
A-118492.1
UUGAAAuACUCUUUCcAAGdTsdT
502



 


AD-58190.1
A-118519.1
CACUAUAAUUACUUGAUUUdTdT
420
A-118520.1
AAAUCAAGUAAUUAUAGUGdTdT
503



 


AD-58196.1
A-118521.1
UAACUCACUAUAAUUACUUdTdT
421
A-118522.1
AAGUAAUUAUAGUGAGUUAdTdT
504



 


AD-58202.1
A-118523.1
ACAAAAUAACUCACUAUAAdTdT
422
A-118524.1
UUAUAGUGAGUUAUUUUGUdTdT
505



 


AD-58208.1
A-118525.1
UCCUCUGGAAAUUGGCCUUdTdT
423
A-118526.1
AAGGCCAAUUUCCAGAGGAdTdT
506



 


AD-58214.1
A-118527.1
CAAAAUAACUCACUAUAAUdTdT
424
A-118528.1
AUUAUAGUGAGUUAUUUUGdTdT
507



 


AD-58220.1
A-118529.1
CUCUGGAAAUUGGCCUUCAdTdT
425
A-118530.1
UGAAGGCCAAUUUCCAGAGdTdT
508



 


AD-58226.1
A-118531.1
GCAAGAUAUUUUUAUAAUAdTdT
426
A-118532.1
UAUUAUAAAAAUAUCUUGCdTdT
509



 


AD-58231.1
A-118533.1
AAUGUUUUUGUCAAGUACAdTdT
427
A-118534.1
UGUACUUGACAAAAACAUUdTdT
510



 


AD-58191.1
A-118535.1
UUAAACAACAAGUACCUUUdTdT
428
A-118536.1
AAAGGUACUUGUUGUUUAAdTdT
511



 


AD-58197.1
A-118537.1
UCAGAAAGUCUGUGAAGGAdTdT
429
A-118538.1
UCCUUCACAGACUUUCUGAdTdT
512



 


AD-58203.1
A-118539.1
ACUGAAGCAUUUGAUGCAAdTdT
430
A-118540.1
UUGCAUCAAAUGCUUCAGUdTdT
513



 


AD-58209.1
A-118541.1
AGUUCUGUGUUAAAAUGUCdTdT
431
A-118542.1
GACAUUUUAACACAGAACUdTdT
514



 


AD-58233.1
A-118565.1
CfACfUfAUfAAUfUfACfUfUfGAUfUfUfdTsdT
432
A-118566.1
AAAUCfAAGUfAAUUfAUfAGUGdTsdT
515



 


AD-58193.1
A-118567.1
UfAACfUfCfACfUfAUfAAUfUfACfUfUfdTsdT
433
A-118568.1
AAGUfAAUUfAUfAGUGAGUUfAdTsdT
516



 


AD-58199.1
A-118569.1
ACfAAAAUfAACfUfCfACfUfAUfAAdTsdT
434
A-118570.1
UUfAUfAGUGAGUUfAUUUUGUdTsdT
517



 


AD-58205.1
A-118571.1
UfCfCfUfCfUfGGAAAUfUfGGCfCfUfUfdTsdT
435
A-118572.1
AAGGCCfAAUUUCCfAGAGGAdTsdT
518



 


AD-58211.1
A-118573.1
CfAAAAUfAACfUfCfACfUfAUfAAUfdTsdT
436
A-118574.1
AUUfAUfAGUGAGUUfAUUUUGdTsdT
519



 


AD-58217.1
A-118575.1
CfUfCfUfGGAAAUfUfGGCfCfUfUfCfAdTsdT
437
A-118576.1
UGAAGGCCfAAUUUCCfAGAGdTsdT
520



 


AD-58223.1
A-118577.1
GCfAAGAUfAUfUfUfUfUfAUfAAUfAdTsdT
438
A-118578.1
UfAUUfAUfAAAAAUfAUCUUGCdTsdT
521



 


AD-58229.1
A-118579.1
AAUfGUfUfUfUfUfGUfCfAAGUfACfAdTsdT
439
A-118580.1
UGUfACUUGACfAAAAACfAUUdTsdT
522



 


AD-58234.1
A-118581.1
UfUfAAACfAACfAAGUfACfCfUfUfUfdTsdT
440
A-118582.1
AAAGGUfACUUGUUGUUUfAAdTsdT
523



 


AD-58194.1
A-118583.1
UfCfAGAAAGUfCfUfGUfGAAGGAdTsdT
441
A-118584.1
UCCUUCfACfAGACUUUCUGAdTsdT
524



 


AD-58200.1
A-118585.1
ACfUfGAAGCfAUfUfUfGAUfGCfAAdTsdT
442
A-118586.1
UUGCfAUCfAAAUGCUUCfAGUdTsdT
525



 


AD-58206.1
A-118587.1
AGUfUfCfUfGUfGUfUfAAAAUfGUfCfdTsdT
443
A-118588.1
GACfAUUUUfAACfACfAGAACUdTsdT
526



 


AD-58236.1
A-118423.2
cAcuAuAAuuAcuuGAuuudTsdT
444
A-118644.1
AAAUcAAGuAAUuAuAGuGdTsdT
527



 


AD-58242.1
A-118425.2
uAAcucAcuAuAAuuAcuudTsdT
445
A-118645.1
AAGuAAUuAuAGuGAGUuAdTsdT
528



 


AD-58248.1
A-118427.2
AcAAAAuAAcucAcuAuAAdTsdT
446
A-118646.1
UuAuAGuGAGUuAuUuuGUdTsdT
529



 


AD-58254.1
A-118429.2
uccucuGGAAAuuGGccuudTsdT
447
A-118647.1
AAGGCcAAuUUCcAGAGGAdTsdT
530



 


AD-58260.1
A-118431.2
cAAAAuAAcucAcuAuAAudTsdT
448
A-118648.1
AUuAuAGuGAGUuAuUuuGdTsdT
531



 


AD-58266.1
A-118433.2
cucuGGAAAuuGGccuucAdTsdT
449
A-118649.1
uGAAGGCcAAuUUCcAGAGdTsdT
532



 


AD-58272.1
A-118435.2
GcAAGAuAuuuuuAuAAuAdTsdT
450
A-118650.1
uAUuAuAAAAAuAUCuuGCdTsdT
533



 


AD-58277.1
A-118437.2
AAuGuuuuuGucAAGuAcAdTsdT
451
A-118651.1
uGuACuuGAcAAAAAcAuUdTsdT
534



 


AD-58237.1
A-118439.2
uuAAAcAAcAAGuAccuuudTsdT
452
A-118652.1
AAAGGuACuuGuuGuUuAAdTsdT
535



 


AD-58243.1
A-118441.2
ucAGAAAGucuGuGAAGGAdTsdT
453
A-118653.1
UCCuUcAcAGACuUUCuGAdTsdT
536



 


AD-58249.1
A-118443.2
AcuGAAGcAuuuGAuGcAAdTsdT
454
A-118654.1
uuGcAUcAAAuGCuUcAGUdTsdT
537



 


AD-58255.1
A-118445.2
AGuucuGuGuuAAAAuGucdTsdT
455
A-118655.1
GAcAuUUuAAcAcAGAACUdTsdT
538



 


AD-58279.1
A-118423.3
cAcuAuAAuuAcuuGAuuudTsdT
456
A-118667.1
AAAUCAAGuAAuuAuAgugdTsdT
539



 


AD-58239.1
A-118425.3
uAAcucAcuAuAAuuAcuudTsdT
457
A-118668.1
AAGuAAuUAuAGuGAGuuadTsdT
540



 


AD-58245.1
A-118427.3
AcAAAAuAAcucAcuAuAAdTsdT
458
A-118669.1
UuAuAGuGAGuuAuuuugudTsdT
541



 


AD-58251.1
A-118429.3
uccucuGGAAAuuGGccuudTsdT
459
A-118670.1
AAGGCCAAuUuCCAGAggadTsdT
542



 


AD-58257.1
A-118431.3
cAAAAuAAcucAcuAuAAudTsdT
460
A-118671.1
AuUAuAGuGAGuuAuuuugdTsdT
543



 


AD-58263.1
A-118433.3
cucuGGAAAuuGGccuucAdTsdT
461
A-118672.1
UGAAGGCCAAuuuCCAgagdTsdT
544



 


AD-58269.1
A-118435.3
GcAAGAuAuuuuuAuAAuAdTsdT
462
A-118673.1
UAuUAuAAAAAuAuCuugcdTsdT
545



 


AD-58275.1
A-118437.3
AAuGuuuuuGucAAGuAcAdTsdT
463
A-118674.1
UGuACuUGACAAAAACauudTsdT
546



 


AD-58280.1
A-118439.3
uuAAAcAAcAAGuAccuuudTsdT
464
A-118675.1
AAAGGuACuUGuuGuuuaadTsdT
547



 


AD-58240.1
A-118441.3
ucAGAAAGucuGuGAAGGAdTsdT
465
A-118676.1
UCCuUCACAGACuuuCugadTsdT
548



 


AD-58246.1
A-118443.3
AcuGAAGcAuuuGAuGcAAdTsdT
466
A-118677.1
UuGCAUCAAAuGCuuCagudTsdT
549



 


AD-58252.1
A-118445.3
AGuucuGuGuuAAAAuGucdTsdT
467
A-118678.1
GACAuUuUAACACAGAacudTsdT
550





5The Species Oligo name and the position in the nucleotide sequence of the GenBank record that the antisense strand targets correspond to those shown in Table 5.













TABLE 7







C5 single dose screen in Hep3B cells with GalNAC conjugated iRNAs














10 nM
0.1 nM
10 nM
0.1 nM



Duplex ID
AVG
AVG
STDEV
STDEV

















AD-58093.1
15.62
21.60
7.48
6.52



AD-58099.1
9.07
14.70
1.18
4.65



AD-58105.1
36.71
60.23
5.07
19.83



AD-58111.1
11.83
22.78
3.51
12.75



AD-58117.1
12.43
33.46
2.00
23.56



AD-58123.1
8.05
15.18
2.89
7.94



AD-58129.1
10.77
40.06
1.30
19.66



AD-58088.1
6.55
16.40
1.24
4.58



AD-58094.1
19.59
40.68
7.64
12.30



AD-58100.1
10.92
20.12
0.74
8.38



AD-58106.1
10.97
37.23
2.49
19.95



AD-58112.1
13.24
29.32
2.90
14.08



AD-58118.1
6.63
15.23
0.54
5.72



AD-58124.1
7.17
13.00
1.44
6.48



AD-58130.1
10.38
17.92
2.36
6.92



AD-58089.1
8.81
30.67
2.91
10.53



AD-58095.1
8.72
14.66
1.04
3.37



AD-58101.1
8.17
19.36
1.30
5.69



AD-58107.1
4.84
18.10
1.66
7.21



AD-58113.1
8.78
14.62
1.77
7.89



AD-58119.1
8.90
15.01
0.91
7.35



AD-58125.1
11.13
17.04
2.61
9.03



AD-58131.1
13.50
40.14
1.08
12.07



AD-58090.1
7.90
21.57
2.95
6.61



AD-58096.1
8.02
16.56
1.54
6.68



AD-58102.1
12.40
27.93
1.83
11.78



AD-58108.1
12.02
15.07
2.88
5.74



AD-58114.1
11.86
25.05
1.48
9.46



AD-58120.1
7.65
10.57
0.58
3.56



AD-58126.1
8.45
15.39
2.08
7.42



AD-58132.1
8.50
19.26
2.52
9.38



AD-58091.1
8.68
18.05
2.95
6.62



AD-58097.1
9.31
23.02
0.67
10.10



AD-58103.1
8.53
17.23
2.90
7.27



AD-1955
57.41
81.16
10.76
5.29



Mock
78.61
75.97
5.70
2.76



Untreated
100
100
6.13
5.98

















TABLE 8







C5 single dose transfection screen in primary mouse hepatocytes with


GalNAC conjugated iRNAs














10 nM
0.1 nM
10 nM
0.1 nM



Duplex ID
AVG
AVG
STDEV
STDEV

















AD-58093.1
1.53
1.65
0.17
0.25



AD-58099.1
1.65
1.50
0.61
0.22



AD-58105.1
11.20
46.95
0.08
3.89



AD-58111.1
2.49
2.13
0.26
0.20



AD-58117.1
3.57
31.91
0.93
0.62



AD-58123.1
4.29
2.97
0.11
2.22



AD-58129.1
1.19
8.53
0.23
0.72



AD-58088.1
0.84
1.34
0.68
0.07



AD-58094.1
11.34
66.82
0.17
3.01



AD-58100.1
2.78
1.51
0.43
0.33



AD-58106.1
6.79
52.91
4.42
6.78



AD-58121.1
1.94
2.15
0.04
0.91



AD-58133.1
1.74
3.25
0.19
1.64



AD-58116.1
1.76
2.21
1.27
0.78



AD-1955
87.39
91.71
5.77
4.68



Mock
79.67
89.02
1.51
3.91



Untreated
100
100
6.39
13.11

















TABLE 9







C5 single dose screen in primary Cynomolgus hepatocytes with GalNAC


conjugated iRNAs














500 nM
5 nM


Duplex ID
500 nM AVG
5 nM AVG
STDEV
STDEV














AD-58093.1
63.94
83.09
2.14
12.65


AD-58099.1
61.34
85.85
12.32
21.95


AD-58105.1
91.98
97.57
6.09
11.48


AD-58111.1
71.27
92.28
1.93
12.72


AD-58117.1
73.42
88.82
3.24
11.08


AD-58123.1
75.14
73.06
7.72
9.71


AD-58129.1
81.66
90.62
2.13
4.77


AD-58088.1
53.63
87.03
5.93
19.86


AD-58094.1
89.62
93.65
0.87
14.76


AD-58100.1
79.56
96.70
4.31
1.10


AD-58106.1
116.24
125.99
14.28
40.65


AD-58112.1
97.19
107.81
N/A
3.13


AD-58118.1
67.40
97.38
5.28
22.64


AD-58124.1
58.04
96.14
8.72
10.64


AD-58130.1
84.19
88.65
10.50
4.34


AD-58089.1
83.83
83.44
1.91
12.26


AD-58095.1
58.53
78.02
15.07
12.45


AD-58101.1
76.68
76.73
3.95
6.35


AD-58107.1
57.37
86.78
14.71
2.99


AD-58113.1
37.79
71.10
8.27
7.76


AD-58119.1
36.77
83.16
3.42
9.66


AD-58125.1
72.40
96.53
4.46
4.96


AD-58131.1
95.58
101.69
10.17
2.21


AD-58090.1
56.37
75.00
3.21
4.97


AD-58096.1
44.33
57.99
11.46
25.17


AD-58102.1
95.46
89.35
0.83
1.76


AD-58108.1
41.54
56.41
8.41
0.14


AD-58114.1
88.32
101.88
20.02
30.29


AD-58120.1
37.34
56.41
0.73
2.14


AD-58126.1
84.97
105.90
2.39
7.96


AD-58132.1
81.55
85.12
12.93
8.94


AD-58091.1
78.88
84.60
44.66
17.40


AD-58097.1
106.06
98.16
13.74
3.14


AD-58103.1
57.21
89.46
6.40
5.93


Untreated
100
100
8.77
10.33
















TABLE 10







C5 single dose free uptake screen in primary mouse hepatocytes with


GalNAC conjugated iRNAs














500 nM
5 nM


Duplex ID
500 nM AVG
5 nM AVG
STDEV
STDEV














AD-58093.1
31.62
64.91
7.13
8.39


AD-58099.1
9.46
29.63
1.29
5.66


AD-58105.1
84.77
96.41
5.22
1.89


AD-58111.1
17.35
50.95
1.21
3.16


AD-58117.1
94.95
139.52
15.43
43.39


AD-58123.1
13.07
44.58
2.11
3.49


AD-58129.1
68.87
85.04
2.62
4.42


AD-58088.1
17.61
48.22
2.22
3.40


AD-58094.1
95.92
104.23
4.16
6.53


AD-58100.1
34.92
61.71
1.30
2.15


AD-58106.1
85.26
107.53
2.30
3.38


AD-58121.1
12.88
43.76
1.41
1.28


AD-58133.1
20.97
42.76
0.24
0.11


AD-58116.1
8.35
38.04
1.35
1.40


Untreated
100.00
100.00
3.85
4.38
















TABLE 11







IC50 data in primary Cynomolgus hepatocytes with GalNAC conjugated


iRNAs











Duplex ID
IC50 (nM)
STDEV















AD-58099.1
3.131
1.141



AD-58111.1
12.750
5.280



AD-58123.1
0.679
7.587



AD-58088.1
0.218
3.487



AD-58113.1
7.296
3.540



AD-58119.1
33.240
14.740



AD-58096.1
10.380
4.199



AD-58108.1
0.953
10.080



AD-58120.1
36.170
88.070

















TABLE 12







IC50 data in primary mouse hepatocytes with GalNAC conjugated iRNAs











Duplex ID
IC50 (nM)
STDEV















AD-58099
3.777
0.122



AD-58111
0.622
2.421



AD-58123
0.549
1.626



AD-58088
9.513
2.588



AD-58121
2.169
1.176



AD-58133
3.802
1.006



AD-58116
2.227
0.604



AD-58644.1
4.596
0.3506



AD-58651.1
59.76
51.99



AD-58641.1
0.82
0.2618



AD-58648.1
7.031
1.256



AD-58642.1
0.5414
0.7334



AD-58649.1
3.32
4.922



AD-58647.1
1.356
0.5215



AD-58654.1
2.09
0.8338



AD-58645.1
2.944
0.3315



AD-58652.1
5.316
2.477



AD-58643.1
2.179
1.112



AD-58650.1
8.223
3.76



AD-58646.1
2.581
0.8186



AD-58653.1
2.451
1.249

















TABLE 13







C5 single dose screen in Hep3B cells with modified and unmodified


iRNAs














1 nM
0.01 nM


Duplex
1 nM AVG
0.01 nM AVG
STDEV
STDEV














AD-58143.1
12.13
100.58
3.47
3.94


AD-58149.1
10.46
64.97
0.98
0.00


AD-58155.1
44.88
76.24
1.56
3.74


AD-58161.1
8.51
102.30
1.06
0.50


AD-58167.1
6.54
76.24
1.15
3.74


AD-58173.1
6.85
107.44
0.85
4.74


AD-58179.1
10.19
78.07
0.59
1.15


AD-58185.1
29.46
79.99
3.64
0.78


AD-58144.1
16.82
81.95
1.09
0.40


AD-58150.1
11.05
76.20
2.55
0.00


AD-58156.1
25.92
76.73
2.72
1.50


AD-58162.1
13.25
71.89
0.43
3.87


AD-58168.1
9.74
45.16
0.52
1.11


AD-58174.1
4.84
70.14
0.25
2.75


AD-58180.1
9.41
56.77
1.91
1.95


AD-58186.1
9.97
68.91
1.03
0.34


AD-58145.1
14.29
103.38
1.94
2.03


AD-58151.1
10.16
81.17
1.71
4.77


AD-58157.1
4.72
63.19
1.05
0.00


AD-58163.1
4.95
40.13
1.65
0.59


AD-58169.1
17.02
83.10
1.88
2.04


AD-58175.1
8.30
62.54
0.28
0.31


AD-58181.1
21.89
55.26
4.22
3.52


AD-58187.1
61.96
71.12
2.61
2.79


AD-58146.1
14.25
95.23
2.64
6.53


AD-58152.1
11.22
70.09
0.80
7.88


AD-58158.1
7.96
98.86
0.76
4.36


AD-58164.1
11.60
43.83
2.06
3.43


AD-58170.1
12.28
39.59
0.96
1.36


AD-58176.1
6.89
38.77
1.04
1.33


AD-58182.1
18.65
55.78
0.96
0.55


AD-58188.1
5.40
69.39
1.07
0.34


AD-58147.1
8.22
106.66
0.77
2.61


AD-58153.1
68.10
104.17
4.44
18.29


AD-58159.1
8.76
81.41
1.54
2.79


AD-58190.1
21.94
77.26
2.23
0.76


AD-58196.1
15.97
72.43
1.07
5.32


AD-58202.1
11.99
93.83
5.34
2.76


AD-58208.1
18.63
52.07
12.88
2.55


AD-58214.1
6.85
94.15
0.51
2.31


AD-58220.1
11.50
78.34
3.85
0.77


AD-58226.1
5.77
57.75
1.71
1.13


AD-58231.1
7.23
75.67
1.07
0.74


AD-58191.1
35.40
66.17
5.50
4.21


AD-58197.1
12.05
67.49
1.70
0.33


AD-58203.1
15.16
66.80
1.46
1.31


AD-58209.1
7.58
71.23
3.58
6.28


AD-58233.1
27.01
86.02
0.86
0.42


AD-58193.1
15.37
99.85
1.44
0.00


AD-58199.1
21.52
78.39
6.02
16.40


AD-58205.1
24.13
78.88
5.46
0.77


AD-58211.1
16.38
32.37
2.61
0.48


AD-58217.1
12.23
70.16
0.29
3.44


AD-58223.1
8.51
72.85
3.01
1.79


AD-58229.1
5.50
75.93
1.96
0.37


AD-58234.1
46.86
101.94
15.59
0.00


AD-58194.1
14.49
107.05
2.47
4.20


AD-58200.1
16.21
61.04
0.96
1.20


AD-58206.1
13.25
37.73
2.82
2.03


AD-58236.1
8.29
119.17
1.16
2.92


AD-58242.1
12.05
102.69
0.44
4.03


AD-58248.1
62.78
83.41
15.22
3.27


AD-58254.1
11.18
100.54
1.59
0.00


AD-58260.1
8.42
71.84
1.10
0.35


AD-58266.1
14.05
92.21
1.91
2.26


AD-58272.1
22.63
81.11
1.62
1.59


AD-58277.1
70.51
75.67
4.80
0.74


AD-58237.1
28.10
98.56
1.96
5.79


AD-58243.1
14.16
86.05
1.11
2.95


AD-58249.1
77.08
96.45
15.14
0.95


AD-58255.1
12.27
47.89
2.58
0.00


AD-58279.1
25.78
94.13
5.52
0.46


AD-58239.1
22.98
83.45
0.28
4.91


AD-58245.1
89.60
90.93
15.24
0.45


AD-58251.1
28.39
86.32
7.29
0.00


AD-58257.1
48.97
64.53
9.10
1.90


AD-58263.1
9.14
83.39
1.27
1.63


AD-58269.1
83.84
75.94
15.90
1.12


AD-58275.1
10.29
86.32
0.73
0.85


AD-58280.1
72.77
110.04
7.44
3.24


AD-58240.1
65.42
75.69
3.82
2.23


AD-58246.1
59.19
65.88
28.95
0.65


AD-58252.1
15.35
97.26
1.14
7.62


Mock
76.53
66.57
14.26
4.72


AD-1955
72.30
82.72
19.54
49.99


Untreated
100.00
100.00
21.68
26.78
















TABLE 14







C5 single dose screen in primary mouse hepatocytes with modified and


unmodified iRNAs












1 nM





Duplex ID
AVG
0.1 nM AVG
1 nM STDEV
0.1 nM STDEV














AD-58143.1
4.51
81.77
3.13
8.75


AD-58149.1
4.65
73.16
3.14
20.17


AD-58155.1
65.56
79.74
4.66
9.36


AD-58161.1
16.82
81.11
6.22
7.43


AD-58167.1
4.72
77.12
1.17
14.25


AD-58173.1
5.57
76.00
3.14
13.52


AD-58179.1
14.55
77.88
1.44
18.40


AD-58185.1
15.69
72.59
8.67
7.81


AD-58144.1
8.70
91.49
0.90
7.08


AD-58150.1
12.51
84.01
1.64
8.20


AD-58156.1
18.23
97.32
1.47
19.50


AD-58162.1
7.72
78.89
5.19
13.80


AD-58190.1
11.86
92.80
2.82
4.41


AD-58196.1
7.27
82.71
1.39
31.81


AD-58202.1
10.67
87.11
1.04
35.79


AD-58208.1
32.21
74.39
8.60
27.45


AD-58214.1
4.24
67.63
0.45
17.85


AD-58220.1
13.64
96.14
4.56
14.36


AD-58226.1
3.83
63.44
1.30
11.94


AD-58231.1
5.95
82.24
2.80
17.36


AD-58191.1
14.50
99.50
5.48
5.53


AD-58197.1
16.12
93.09
0.81
3.21


AD-58203.1
12.52
104.63
5.98
6.02


AD-58209.1
8.79
59.35
3.05
13.07


AD-58233.1
9.50
64.26
5.69
8.70


AD-58193.1
8.88
89.60
3.36
3.08


AD-58199.1
13.56
87.14
2.18
6.44


AD-58205.1
46.84
89.13
4.48
17.16


AD-58211.1
13.10
111.62
1.10
21.54


AD-58217.1
29.79
117.49
11.85
20.41


AD-58223.1
20.53
105.44
1.94
2.98


AD-58229.1
13.76
98.15
1.05
9.03


AD-58234.1
12.33
71.34
0.72
4.17


AD-58194.1
14.02
90.60
1.39
15.64


AD-58200.1
5.25
90.95
1.37
31.70


AD-58206.1
8.19
109.47
3.99
21.75


AD-58236.1
2.07
70.19
0.80
20.59


AD-58242.1
4.76
53.26
1.59
11.56


AD-58248.1
62.42
78.23
5.47
25.85


AD-58254.1
16.47
70.22
2.92
21.74


AD-58260.1
2.84
75.65
0.38
11.59


AD-58266.1
40.70
89.88
16.05
11.57


AD-58272.1
21.42
59.44
13.29
10.98


AD-58277.1
71.72
121.44
16.35
21.16


AD-58237.1
11.85
112.68
9.22
12.88


AD-58243.1
10.46
90.64
3.42
4.33


AD-58249.1
71.47
113.30
4.30
3.84


AD-58255.1
6.86
78.55
2.22
28.37


AD-58279.1
7.15
74.96
2.84
4.72


AD-58239.1
13.64
106.45
1.87
8.25


AD-58245.1
68.67
112.08
21.89
7.73


AD-58251.1
47.01
133.20
4.69
7.14


AD-58257.1
30.68
87.51
2.87
32.84


AD-58263.1
7.22
83.23
2.55
37.50


AD-58269.1
78.90
106.06
5.07
3.04


AD-58275.1
8.92
95.77
1.91
7.14


AD-58280.1
16.67
78.47
4.15
6.06


AD-58240.1
71.03
138.54
5.32
10.87


AD-58246.1
71.87
89.02
4.95
8.63


AD-58252.1
4.04
56.10
1.23
12.02


Mock
66.84
82.81
2.75
17.19


AD-1955
87.44
102.07
3.64
4.08


Untreated
100.00
100.00
15.25
18.37
















TABLE 15







IC50 data in Hep3B cells with modified and unmodified iRNAs











Duplex ID
IC50 (pM)
STDEV















AD-58143.1
36.35
12.26



AD-58149.1
5.735
6.196



AD-58161.1
78.12
26.64



AD-58167.1
31.03
18.14



AD-58173.1
29.12
16.53



AD-58236.1
52.73
32.02



AD-58242.1
8.859
4.321



AD-58260.1
7.706
5.094



AD-58263.1
96.64
47.61

















TABLE 16







IC50 data in primary mouse hepatocytes with modified and unmodified


iRNAs











Duplex ID
IC50 (pM)
STDEV















AD-58260.1
1.015
0.9676



AD-58149.1
1.309
1.749



AD-58167.1
1.991
2.477



AD-58242.1
0.5866
1.8



AD-58236.1
0.4517
0.06392



AD-58143.1
0.8876
0.1613



AD-58279.1
3.116
0.7368



AD-58252.1
7.153
1.021



AD-58173.1
7.144
19.88



AD-58263.1
3.224
5.478










Example 3
In Vivo Screening
A subset of seven GalNAC conjugated iRNAs was selected for further in vivo evaluation.
C57BL/6 mice (N=3 per group) were injected subcutaneously with 10 mg/kg of GalNAc conjugated duplexes or an equal volume of 1× Dulbecco's Phosphate-Buffered Saline (DPBS) (Life Technologies, Cat#14040133). Forty-eight hours later, mice were euthanized and the livers were dissected and flash frozen in liquid nitrogen. Livers were ground in a 2000 Geno/Grinder (SPEX SamplePrep, Metuchen, N.J.). Approximately 10 mg of liver powder per sample was used for RNA isolation. Samples were first homogenized in a TissueLyserII (Qiagen Inc, Valencia, Calif.) and then RNA was extracted using a RNeasy 96 Universal Tissue Kit (Qiagen Inc., Cat#74881) following manufacturer's protocol using vacuum/spin technology. RNA concentration was measured by a NanoDrop 8000 (Thermo Scientific, Wilmington, Del.) and was adjusted to 100 ng/μl. cDNA and RT-PCR were performed as described above.
The results of the single dose screen are depicted in FIG. 2. Table 17 shows the results of an in vivo single dose screen with the indicated GalNAC conjugated modified iRNAs. Data are expressed as percent of mRNA remaining relative to DPBS treated mice. The “Experiments” column lists the number of experiments from which the average was calculated. The standard deviation is calculated from all mice in a group across all experiments analyzed.







TABLE 17







In vivo C5 single dose screen












Duplex ID
Experiments
AVG
STDEV
















AD-58088.2
2
82.66
13.54



AD-58644.1
1
37.79
9.63



AD-58651.1
1
75.33
5.21



AD-58099.2
2
71.94
15.45



AD-58641.1
1
20.09
4.09



AD-58648.1
1
48.43
9.07



AD-58111.2
3
67.17
13.60



AD-58642.1
2
21.78
5.32



AD-58649.1
1
45.30
14.02



AD-58116.2
2
70.16
10.32



AD-58647.1
1
26.77
4.14



AD-58654.1
1
50.06
27.85



AD-58121.2
2
52.56
13.00



AD-58645.1
1
24.60
1.29



AD-58652.1
1
52.67
3.87



AD-58123.2
2
65.70
9.60



AD-58643.1
1
23.21
2.41



AD-58650.1
1
46.75
14.10



AD-58133.2
3
51.98
13.45



AD-58646.1
2
28.67
5.34



AD-58653.1
1
43.02
10.61



PBS
3
100.00
9.03










Two of the most efficacious GalNAC conjugated iRNAs were further modified to include additional phosphorothioate linkages (Table 18) and the efficacy of these duplexes was determined in vivo as described above. The results of the single dose screen are depicted in FIG. 3 and demonstrate that the iRNA agents with additional phosphorothiate linkages are more efficacious than those iRNA agents without or with fewer phosphorothioate linkages.







TABLE 18







Phosphorothioate Modifed GalNAC Conjugated C5 iRNAs

















SEQ


SEQ






ID


ID



Duplex ID
Sense strand
Sense sequence
NO:
Antisense
Antisense sequence
NO:
Cross Reactivity





AD-58642.1
A-119324.1
GfsasCfaAfaAfuAfAfCfu
551
A-119325.1
asUfsuAfuAfgUfgAfguu
555
HumRheMusRat




CfaCfuAfuAfaUfL96


AfuUfuUfgUfcsasa




 


AD-58111.2
A-118316.1
GfaCfaAfaAfuAfAfCfuCfa
552
A-118317.1
aUfuAfuAfgUfgAfguu
556
HumRheMusRat




CfuAfuAfaUfL96


AfuUfuUfgUfcsAfsa




 


AD-58646.1
A-119332.1
CfsasGfaUfcAfaAfCfAfc
553
A-119333.1
asCfsuGfaAfaUfuGfugu
557
MusRat




AfaUfuUfcAfgUfL96


UfuGfaUfcUfgscsa




 


AD-58133.2
A-118386.1
CfaGfaUfcAfaAfCfAfc
554
A-118387.1
aCfuGfaAfaUfuGfugu
558
MusRat




AfaUfuUfcAfgUfL96


UfuGfaUfcUfgsCfsa









Given the impact of the additional phosphorothioate linkages on the silencing ability of the iRNA agents described above, the efficacy of additional GalNAC conjugated iRNA duplexes including phosphoriothioate linkages (Table 19) was determined in vivo as described above. The results of this single dose screen are depicted in FIG. 4.
The duration of silencing of AD-58642 in vivo was determined by administering a single 2.5 mg/kg, 10 mg/kg, or 25 mg/kg dose to rats and determining the amount of C5 protein (FIG. 5B) present on day 7 and the activity of C5 protein (FIG. 5A) present on days 4 and 7. As demonstrated in FIG. 5, there is a 50% reduction in the activity of C5 protein by Day 4 at a 25 mg/kg dose and at Day 7, a greater than 70% reduction in the activity of C5 protein.
The amount of C5 protein was determined by Western blot analysis of whole serum. The activity of C5 protein was determined by a hemolysis assay. Briefly, a fixed dilution of human C5 depleted human serum was mixed with mouse serum and incubated with antibody-coated sheep red blood cells for 1 hour. The hemoglobin absorbance was measured and the % hemolysis as compared to a reference curve (prepared using a dilution series of mouse serum) was calculated.
The efficacy of AD-58642 in vivo was also assayed in mice following a single subcutaneous injection of 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, and 25 mg/kg of AD-58642. At day 5 C5 mRNA was assayed in liver samples using qPCR, C5 activity was assayed for hemolysis, and the amount of C5 protein was determined by Western blot analysis of whole serum.
As depicted in FIGS. 6A and 6B, although there is only a minor improvement (i.e., about 5%) in efficacy of AD-58642 to inhibit C5 mRNA at a dose of 25 mg/kg as compared to a 10 mg/kg dose, there is an average of 85% silencing with a 25 mg/kg dose. In addition, there is a dose response effect with an IC50 of about 2.5 mg/kg.
FIGS. 7A and 7B and 8 demonstrate that AD-58642 is efficacious for decreasing the amount of C5 protein (FIG. 8) and C5 protein activity (FIGS. 7A and 7B).
The duration of silencing of AD-58641 in vivo was also determined by subcutaneously administering a single 0.625 mg/kg, 1.25 mg/kg, 2.5 mg/kg, 5.0 mg/kg, or 10 mg/kg dose of AD-58641 to C57Bl/6 (n=3) mice and determining the amount of C5 protein present in these animals on days 5 and 9 by ELISA. Briefly, serum was collected on day 0, pre-bleed, day 5, and day 9 and the levels of C5 proteins were quantified by ELISA. C5 protein levels were normalized to the day 0 pre-bleed level. As depicted in FIG. 9, the results demonstrate that there is a dose dependent potent and durable knock-down of C5 serum protein. (The single dose ED50 was 0.6 mg/kg).
Compound AD-58641 was also tested for efficacy in C57Bl/6 mice using a multi-dosing administration protocol. Mice were subcutaneously administered compound AD-58641 at a 0.625 mg/kg, 1.25 mg/kg, or 2.5 mg/kg dose at days 0, 1, 2, and 3. Serum was collected at days 0 and 8 as illustrated in FIG. 10 and analyzed for C5 protein levels by ELISA. C5 levels were normalized to the day 0 pre-bleed level. FIG. 10 shows that multi-dosing of AD-58641 achieves silencing of C5 protein at all of the does tested, with a greater than 90% silencing of C5 protein at a dose of 2.5 mg/kg.
Compound AD-58641 was further tested for efficacy and to evaluate the cumulative effect of the compound in rats using a repeat administration protocol. Wild-type Sprague Dawley rats were subcutaneously injected with compound AD-58641 at a 2.5 mg/kg/dose or 5.0 mg/kg/dose twice a week for 3 weeks (q2w×3). Serum was collected on days 0, 4, 7, 11, 14, 18, 25, and 32. Serum hemolytic activity was quantified using a hemolysis assay in which a 1:150 dilution of rat serum was incubated with sensitized sheep rat blood cells in GVB++ buffer for 1 hour and hemoglobin release was quantified by measuring absorbance at 415 nm (see FIG. 11A). The amount of C5 protein present in the samples was also determined by ELISA (FIG. 11B). The results demonstrate a dose dependent potent and durable decrease in hemolytic activity, achieving about 90% hemolytic activity inhibition.







TABLE 19







Additional Phosphorothioate Modifed GalNAC Conjugated C5 iRNAs



















SEQ


SEQ






Sense

ID


ID
Start




Duplex ID
strand
Sense sequence
NO:
Antisense
Antisense sequence
NO:
position
Cross Reactivity
PS#



















AD-58088.2
A-118324.1
AfuUfuAfaAfcAfAfCfaAfgUfaCfcUfuUfL96
559
A-118325.1
aAfaGfgUfaCfuUfguuGfuUfuAfaAfusCfsu
580
984
HumRheMus
2


 


AD-58644.1
A-119328.1
AfsusUfuAfaAfcAfAfCfaAfgUfaCfcUfuUfL96
560
A-119329.1
asAfsaGfgUfaCfuUfguuGfuUfuAfaAfuscsu
581
984
HumRheMus
6


 


AD-58651.1
A-119328.2
AfsusUfuAfaAfcAfAfCfaAfgUfaCfcUfuUfL96
561
A-119339.1
asAfsaGfsgUfsaCfsuUfsguuGfsuUfsu
582
984
HumRheMus
14







AfsaAfsuscsu






 


AD-58099.2
A-118312.1
UfgAfcAfaAfaUfAfAfcUfcAfcUfaUfaAfL96
562
A-118313.1
uUfaUfaGfuGfaGfuuaUfuUfuGfuCfasAfsu
583
1513
HumRheMusRat
2


 


AD-58641.1
A-119322.1
UfsgsAfcAfaAfaUfAfAfcUfcAfcUfaUfaAfL96
563
A-119323.1
usUfsaUfaGfuGfaGfuuaUfuUfuGfuCfasasu
584
1513
HumRheMusRat
6


 


AD-58648.1
A-119322.2
UfsgsAfcAfaAfaUfAfAfcUfcAfcUfaUfaAfL96
564
A-119336.1
usUfsaUfsaGfsuGfsaGfsuuaUfsuUfsuGfsu
585
1513
HumRheMusRat
14







Cfsasasu






 


AD-58111.2
A-118316.1
GfaCfaAfaAfuAfAfCfuCfaCfuAfuAfaUfL96
565
A-118317.1
aUfuAfuAfgUfgAfguuAfuUfuUfgUfcsAfsa
586
1514
HumRheMusRat
2


 


AD-58642.1
A-119324.1
GfsasCfaAfaAfuAfAfCfuCfaCfuAfuAfaUfL96
566
A-119325.1
asUfsuAfuAfgUfgAfguuAfuUfuUfgUfcsasa
587
1514
HumRheMusRat
6


 


AD-58649.1
A-119324.2
GfsasCfaAfaAfuAfAfCfuCfaCfuAfuAfaUfL96
567
A-119337.1
asUfsuAfsuAfsgUfsgAfsguuAfsuUfsuUfsg
588
1514
HumRheMusRat
14







Ufscsasa






 


AD-58116.2
A-118396.1
GfuUfcCfgGfaUfAfUfuUfgAfaCfuUfuUfL96
568
A-118397.1
aAfaAfgUfuCfaAfauaUfcCfgGfaAfcsCfsg
589
4502
MusRat
2


 


AD-58647.1
A-119334.1
GfsusUfcCfgGfaUfAfUfuUfgAfaCfuUfuUfL96
569
A-119335.1
asAfsaAfgUfuCfaAfauaUfcCfgGfaAfcscsg
590
4502
MusRat
6


 


AD-58654.1
A-119334.2
GfsusUfcCfgGfaUfAfUfuUfgAfaCfuUfuUfL96
570
A-119342.1
asAfsaAfsgUfsuCfsaAfsauaUfscCfsgGfsa
591
4502
MusRat
14







Afscscsg






 


AD-58121.2
A-118382.1
UfgCfaGfaUfcAfAfAfcAfcAfaUfuUfcAfL96
571
A-118383.1
uGfaAfaUfuGfuGfuuuGfaUfcUfgCfasGfsa
592
4945
MusRat
2


 


AD-58645.1
A-119330.1
UfsgsCfaGfaUfcAfAfAfcAfcAfaUfuUfcAfL96
572
A-119331.1
usGfsaAfaUfuGfuGfuuuGfaUfcUfgCfasgsa
593
4945
MusRat
6


 


AD-58652.1
A-119330.2
UfsgsCfaGfaUfcAfAfAfcAfcAfaUfuUfcAfL96
573
A-119340.1
usGfsaAfsaUfsuGfsuGfsuuuGfsaUfscUfsg
594
4945
MusRat
14







Cfsasgsa






 


AD-58123.2
A-118320.1
AfaGfcAfaGfaUfAfUfuUfuUfaUfaAfuAfL96
574
A-118321.1
uAfuUfaUfaAfaAfauaUfcUfuGfcUfusUfsu
595
786
HumRheMus
2


 


AD-58643.1
A-119326.1
AfsasGfcAfaGfaUfAfUfuUfuUfaUfaAfuAfL96
575
A-119327.1
usAfsuUfaUfaAfaAfauaUfcUfuGfcUfususu
596
786
HumRheMus
6


 


AD-58650.1
A-119326.2
AfsasGfcAfaGfaUfAfUfuUfuUfaUfaAfuAfL96
576
A-119338.1
usAfsuUfsaUfsaAfsaAfsauaUfscUfsuGfsc
597
786
HumRheMus
14







Ufsususu






 


AD-58133.2
A-118386.1
CfaGfaUfcAfaAfCfAfcAfaUfuUfcAfgUfL96
577
A-118387.1
aCfuGfaAfaUfuGfuguUfuGfaUfcUfgsCfsa
598
4947
MusRat
2


 


AD-58646.1
A-119332.1
CfsasGfaUfcAfaAfCfAfcAfaUfuUfcAfgUfL96
578
A-119333.1
asCfsuGfaAfaUfuGfuguUfuGfaUfcUfgscsa
599
4947
MusRat
6


 


AD-58653.1
A-119332.2
CfsasGfaUfcAfaAfCfAfcAfaUfuUfcAfgUfL96
579
A-119341.1
asCfsuGfsaAfsaUfsuGfsuguUfsuGfsaUfsc
600
4947
MusRat
14







Ufsgscsa









Example 4
Design, Synthesis, and in Vitro Screening of Additional siRNAs
siRNA Design
C5 duplexes, 19 nucleotides long for both the sense and antisense strand, were designed using the human C5 mRNA sequence set forth in GenBank Accession No. NM—001735.2. Five-hundred and sixty-nine duplexes were initially identified that did not contain repeats longer than 7 nucleotides, spanning substantially the entire 5480 nucleotide transcript. All 569 duplexes are then scored for predicted efficacy according to a linear model that evaluates the nucleotide pair at each duplex position, and the dose and cell line to be used for screening. The duplexes are also matched against all transcripts in the human RefSeq collection using a custom brute force algorithm, and scored for lowest numbers of mismatches (per strand) to transcripts other than C5. Duplexes to be synthesized and screened are then selected from the 569, according to the following scheme: Beginning at the 5′ end of the transcript, a duplex is selected within a “window” of every 10±2 nucleotides that
1) had the highest predicted efficacy,
2) had at least one mismatch in both strands to all transcripts other than SERPINC1,
3) had not already been synthesized and screened as part of other duplex sets.
If no duplex is identified within a given window that satisfied all criteria, that window was skipped.
A detailed list of the 569 C5 sense and antisense strand sequences is shown in Table 20.
The in vitro efficacy of duplexes comprising the sense and antisense sequences listed in Table 20 is determined using the following methods.
Cell Culture and Transfections
HepG2 cells (ATCC, Manassas, Va.) are grown to near confluence at 37° C. in an atmosphere of 5% CO2 in Eagle's Minimum Essential Medium (ATCC) supplemented with 10% FBS, streptomycin, and glutamine (ATCC) before being released from the plate by trypsinization. Transfection is carried out by adding 14.8 μl of Opti-MEM plus 0.2 μl of Lipofectamine RNAiMax per well (Invitrogen, Carlsbad Calif. cat #13778-150) to 51 μl of each of the 164 siRNA duplexes to an individual well in a 96-well plate. The mixture is then incubated at room temperature for 15 minutes. 80 μl of complete growth media without antibiotic containing  ̃2.5×104 HepG2 cells is then added to the siRNA mixture. Cells are incubated for 24 hours prior to RNA purification. Experiments are performed at 20 nM and included naïve cells and cells transfected with AD-1955, a luciferase targeting siRNA as negative controls.
Total RNA Isolation Using DYNABEADS mRNA Isolation Kit (Invitrogen, Part #: 610-12)
Cells are harvested and lysed in 150 μl of Lysis/Binding Buffer then mixed for 5 minute at 700 rpm on a platform shaker (the mixing speed was the same throughout the process). Ten microliters of magnetic beads and 80 μl Lysis/Binding Buffer mixture are added to a round bottom plate and mixed for 1 minute. Magnetic beads are captured using magnetic stand and the supernatant is removed without disturbing the beads. After removing supernatant, the lysed cells are added to the remaining beads and mixed for 5 minutes. After removing supernatant, magnetic beads are washed 2 times with 150 μl Wash Buffer A and mixed for 1 minute. Beads are captured again and supernatant removed. Beads are then washed with 150 μl Wash Buffer B, captured and supernatant is removed. Beads are next washed with 150 μl Elution Buffer, captured and supernatant removed. Beads are allowed to dry for 2 minutes. After drying, 50 μl of Elution Buffer is added and mixed for 5 minutes at 70° C. Beads are captured on magnet for 5 minutes. Forty μl of supernatant, containing the isolated RNA is removed and added to another 96 well plate.
cDNA Synthesis Using ABI High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, Calif., Cat #4368813)
A master mix of 21 μl 10× Buffer, 0.8 μl 25×dNTPs, 2 μl Random primers, 1 μl Reverse Transcriptase, 1 μl RNase inhibitor and 3.2 μl of H2O per reaction is added into 10 μl total RNA. cDNA is generated using a Bio-Rad C-1000 or S-1000 thermal cycler (Hercules, Calif.) through the following steps: 25° C. 10 min, 37° C. 120 min, 85° C. 5 sec, 4° C. hold.
Real Time PCR
Two μl of cDNA is added to a master mix containing 0.5 μl human GAPDH TaqMan Probe (Applied Biosystems Cat #4326317E), 0.5 μl human SERPINC1 TaqMan probe (Applied Biosystems cat #Hs00892758_m1) and 5 μl Lightcycler 480 probe master mix (Roche Cat #04887301001) per well in a 384-well plate (Roche cat #04887301001). Real time PCR is performed in an LC480 Real Time PCR machine (Roche).
To calculate relative fold change, real time data is analyzed using the ΔΔCt method and normalized to assays performed with cells transfected with 20 nM AD-1955.







TABLE 20







Additional C5 unmodified sense and antisense strand sequences













Position in

SEQ ID

SEQ ID


Oligo Name
NM_001735.2
Sense Sequence
NO:
Antisense Sequence
NO:















NM_001735.2_3-21_s
 3-21
UAUCCGUGGUUUCCUGCUA
601
UAGCAGGAAACCACGGAUA
1170


 


NM_001735.2_10-28_s
10-28
GGUUUCCUGCUACCUCCAA
602
UUGGAGGUAGCAGGAAACC
1171


 


NM_001735.2_22-40_s
22-40
CCUCCAACCAUGGGCCUUU
603
AAAGGCCCAUGGUUGGAGG
1172


 


NM_001735.2_33-51_s
33-51
GGGCCUUUUGGGAAUACUU
604
AAGUAUUCCCAAAAGGCCC
1173


 


NM_001735.2_43-61_s
43-61
GGAAUACUUUGUUUUUUAA
605
UUAAAAAACAAAGUAUUCC
1174


 


NM_001735.2_49-67_s
49-67
CUUUGUUUUUUAAUCUUCC
606
GGAAGAUUAAAAAACAAAG
1175


 


NM_001735.2_63-81_s
63-81
CUUCCUGGGGAAAACCUGG
607
CCAGGUUUUCCCCAGGAAG
1176


 


NM_001735.2_71-89_s
71-89
GGAAAACCUGGGGACAGGA
608
UCCUGUCCCCAGGUUUUCC
1177


 


NM_001735.2_81-99_s
81-99
GGGACAGGAGCAAACAUAU
609
AUAUGUUUGCUCCUGUCCC
1178


 


NM_001735.2_91-109_s
 91-109
CAAACAUAUGUCAUUUCAG
610
CUGAAAUGACAUAUGUUUG
1179


 


NM_001735.2_102-120_s
102-120
CAUUUCAGCACCAAAAAUA
611
UAUUUUUGGUGCUGAAAUG
1180


 


NM_001735.2_109-127_s
109-127
GCACCAAAAAUAUUCCGUG
612
CACGGAAUAUUUUUGGUGC
1181


 


NM_001735.2_123-141_s
123-141
CCGUGUUGGAGCAUCUGAA
613
UUCAGAUGCUCCAACACGG
1182


 


NM_001735.2_130-148_s
130-148
GGAGCAUCUGAAAAUAUUG
614
CAAUAUUUUCAGAUGCUCC
1183


 


NM_001735.2_139-157_s
139157
GAAAAUAUUGUGAUUCAAG
615
CUUGAAUCACAAUAUUUUC
1184


 


NM_001735.2_150-168_s
150-168
GAUUCAAGUUUAUGGAUAC
616
GUAUCCAUAAACUUGAAUC
1185


 


NM_001735.2_163-181_s
163-181
GGAUACACUGAAGCAUUUG
617
CAAAUGCUUCAGUGUAUCC
1186


 


NM_001735.2_172-190_s
172-190
GAAGCAUUUGAUGCAACAA
618
UUGUUGCAUCAAAUGCUUC
1187


 


NM_001735.2_183-201_s
183-201
UGCAACAAUCUCUAUUAAA
619
UUUAAUAGAGAUUGUUGCA
1188


 


NM_001735.2_189-207_s
189-207
AAUCUCUAUUAAAAGUUAU
620
AUAACUUUUAAUAGAGAUU
1189


 


NM_001735.2_201-219_s
201-219
AAGUUAUCCUGAUAAAAAA
621
UUUUUUAUCAGGAUAACUU
1190


 


NM_001735.2_209-227_s
209-227
CUGAUAAAAAAUUUAGUUA
622
UAACUAAAUUUUUUAUCAG
1191


 


NM_001735.2_221-239_s
221-239
UUAGUUACUCCUCAGGCCA
623
UGGCCUGAGGAGUAACUAA
1192


 


NM_001735.2_230-248_s
230-248
CCUCAGGCCAUGUUCAUUU
624
AAAUGAACAUGGCCUGAGG
1193


 


NM_001735.2_242-260_s
242-260
UUCAUUUAUCCUCAGAGAA
625
UUCUCUGAGGAUAAAUGAA
1194


 


NM_001735.2_252-270_s
252-270
CUCAGAGAAUAAAUUCCAA
626
UUGGAAUUUAUUCUCUGAG
1195


 


NM_001735.2_259-277_s
259-277
AAUAAAUUCCAAAACUCUG
627
CAGAGUUUUGGAAUUUAUU
1196


 


NM_001735.2_273-291_s
273-291
CUCUGCAAUCUUAACAAUA
628
UAUUGUUAAGAUUGCAGAG
1197


 


NM_001735.2_282-300_s
282-300
CUUAACAAUACAACCAAAA
629
UUUUGGUUGUAUUGUUAAG
1198


 


NM_001735.2_292-310_s
292-310
CAACCAAAACAAUUGCCUG
630
CAGGCAAUUGUUUUGGUUG
1199


 


NM_001735.2_301-319_s
301-319
CAAUUGCCUGGAGGACAAA
631
UUUGUCCUCCAGGCAAUUG
1200


 


NM_001735.2_313-331_s
313-331
GGACAAAACCCAGUUUCUU
632
AAGAAACUGGGUUUUGUCC
1201


 


NM_001735.2_322-340_s
322-340
CCAGUUUCUUAUGUGUAUU
633
AAUACACAUAAGAAACUGG
1202


 


NM_001735.2_332-350_s
332-350
AUGUGUAUUUGGAAGUUGU
634
ACAACUUCCAAAUACACAU
1203


 


NM_001735.2_342-360_s
342-360
GGAAGUUGUAUCAAAGCAU
635
AUGCUUUGAUACAACUUCC
1204


 


NM_001735.2_349-367_s
349-367
GUAUCAAAGCAUUUUUCAA
636
UUGAAAAAUGCUUUGAUAC
1205


 


NM_001735.2_361-379_s
361-379
UUUUCAAAAUCAAAAAGAA
637
UUCUUUUUGAUUUUGAAAA
1206


 


NM_001735.2_371-389_s
371-389
CAAAAAGAAUGCCAAUAAC
638
GUUAUUGGCAUUCUUUUUG
1207


 


NM_001735.2_381-399_s
381-399
GCCAAUAACCUAUGACAAU
639
AUUGUCAUAGGUUAUUGGC
1208


 


NM_001735.2_389-407_s
389-407
CCUAUGACAAUGGAUUUCU
640
AGAAAUCCAUUGUCAUAGG
1209


 


NM_001735.2_399-417_s
399-417
UGGAUUUCUCUUCAUUCAU
641
AUGAAUGAAGAGAAAUCCA
1210


 


NM_001735.2_411-429_s
411-429
CAUUCAUACAGACAAACCU
642
AGGUUUGUCUGUAUGAAUG
1211


 


NM_001735.2_419-437_s
419-437
CAGACAAACCUGUUUAUAC
643
GUAUAAACAGGUUUGUCUG
1212


 


NM_001735.2_430-448_s
430-448
GUUUAUACUCCAGACCAGU
644
ACUGGUCUGGAGUAUAAAC
1213


 


NM_001735.2_441-459_s
441-459
AGACCAGUCAGUAAAAGUU
645
AACUUUUACUGACUGGUCU
1214


 


NM_001735.2_450-468_s
450-468
AGUAAAAGUUAGAGUUUAU
646
AUAAACUCUAACUUUUACU
1215


 


NM_001735.2_460-478_s
460-478
AGAGUUUAUUCGUUGAAUG
647
CAUUCAACGAAUAAACUCU
1216


 


NM_001735.2_470-488_s
470-488
CGUUGAAUGACGACUUGAA
648
UUCAAGUCGUCAUUCAACG
1217


 


NM_001735.2_483-501_s
483-501
CUUGAAGCCAGCCAAAAGA
649
UCUUUUGGCUGGCUUCAAG
1218


 


NM_001735.2_490-508_s
490-508
CCAGCCAAAAGAGAAACUG
650
CAGUUUCUCUUUUGGCUGG
1219


 


NM_001735.2_503-521_s
503-521
AAACUGUCUUAACUUUCAU
651
AUGAAAGUUAAGACAGUUU
1220


 


NM_001735.2_513-531_s
513-531
AACUUUCAUAGAUCCUGAA
652
UUCAGGAUCUAUGAAAGUU
1221


 


NM_001735.2_519-537_s
519-537
CAUAGAUCCUGAAGGAUCA
653
UGAUCCUUCAGGAUCUAUG
1222


 


NM_001735.2_529-547_s
529-547
GAAGGAUCAGAAGUUGACA
654
UGUCAACUUCUGAUCCUUC
1223


 


NM_001735.2_543-561_s
543-561
UGACAUGGUAGAAGAAAUU
655
AAUUUCUUCUACCAUGUCA
1224


 


NM_001735.2_553-571_s
553-571
GAAGAAAUUGAUCAUAUUG
656
CAAUAUGAUCAAUUUCUUC
1225


 


NM_001735.2_562-580_s
562-580
GAUCAUAUUGGAAUUAUCU
657
AGAUAAUUCCAAUAUGAUC
1226


 


NM_001735.2_571-589_s
571-589
GGAAUUAUCUCUUUUCCUG
658
CAGGAAAAGAGAUAAUUCC
1227


 


NM_001735.2_579-597_s
579-597
CUCUUUUCCUGACUUCAAG
659
CUUGAAGUCAGGAAAAGAG
1228


 


NM_001735.2_590-608_s
590-608
ACUUCAAGAUUCCGUCUAA
660
UUAGACGGAAUCUUGAAGU
1229


 


NM_001735.2_601-619_s
601-619
CCGUCUAAUCCUAGAUAUG
661
CAUAUCUAGGAUUAGACGG
1230


 


NM_001735.2_610-628_s
610-628
CCUAGAUAUGGUAUGUGGA
662
UCCACAUACCAUAUCUAGG
1231


 


NM_001735.2_623-641_s
623-641
UGUGGACGAUCAAGGCUAA
663
UUAGCCUUGAUCGUCCACA
1232


 


NM_001735.2_629-647_s
629-647
CGAUCAAGGCUAAAUAUAA
664
UUAUAUUUAGCCUUGAUCG
1233


 


NM_001735.2_642-660_s
642-660
AUAUAAAGAGGACUUUUCA
665
UGAAAAGUCCUCUUUAUAU
1234


 


NM_001735.2_649-667_s
649-667
GAGGACUUUUCAACAACUG
666
CAGUUGUUGAAAAGUCCUC
1235


 


NM_001735.2_662-680_s
662-680
CAACUGGAACCGCAUAUUU
667
AAAUAUGCGGUUCCAGUUG
1236


 


NM_001735.2_672-690_s
672-690
CGCAUAUUUUGAAGUUAAA
668
UUUAACUUCAAAAUAUGCG
1237


 


NM_001735.2_683-701_s
683-701
AAGUUAAAGAAUAUGUCUU
669
AAGACAUAUUCUUUAACUU
1238


 


NM_001735.2_691-709_s
691-709
GAAUAUGUCUUGCCACAUU
670
AAUGUGGCAAGACAUAUUC
1239


 


NM_001735.2_703-721_s
703-721
CCACAUUUUUCUGUCUCAA
671
UUGAGACAGAAAAAUGUGG
1240


 


NM_001735.2_713-731_s
713-731
CUGUCUCAAUCGAGCCAGA
672
UCUGGCUCGAUUGAGACAG
1241


 


NM_001735.2_719-737_s
719-737
CAAUCGAGCCAGAAUAUAA
673
UUAUAUUCUGGCUCGAUUG
1242


 


NM_001735.2_730-748_s
730-748
GAAUAUAAUUUCAUUGGUU
674
AACCAAUGAAAUUAUAUUC
1243


 


NM_001735.2_742-760_s
742-760
AUUGGUUACAAGAACUUUA
675
UAAAGUUCUUGUAACCAAU
1244


 


NM_001735.2_752-770_s
752-770
AGAACUUUAAGAAUUUUGA
676
UCAAAAUUCUUAAAGUUCU
1245


 


NM_001735.2_762-780_s
762-780
GAAUUUUGAAAUUACUAUA
677
UAUAGUAAUUUCAAAAUUC
1246


 


NM_001735.2_769-787_s
769-787
GAAAUUACUAUAAAAGCAA
678
UUGCUUUUAUAGUAAUUUC
1247


 


NM_001735.2_781-799_s
781-799
AAAGCAAGAUAUUUUUAUA
679
UAUAAAAAUAUCUUGCUUU
1248


 


NM_001735.2_789-807_s
789-807
AUAUUUUUAUAAUAAAGUA
680
UACUUUAUUAUAAAAAUAU
1249


 


NM_001735.2_803-821_s
803-821
AAGUAGUCACUGAGGCUGA
681
UCAGCCUCAGUGACUACUU
1250


 


NM_001735.2_810-828_s
810-828
CACUGAGGCUGACGUUUAU
682
AUAAACGUCAGCCUCAGUG
1251


 


NM_001735.2_822-840_s
822-840
CGUUUAUAUCACAUUUGGA
683
UCCAAAUGUGAUAUAAACG
1252


 


NM_001735.2_831-849_s
831-849
CACAUUUGGAAUAAGAGAA
684
UUCUCUUAUUCCAAAUGUG
1253


 


NM_001735.2_840-858_s
840-858
AAUAAGAGAAGACUUAAAA
685
UUUUAAGUCUUCUCUUAUU
1254


 


NM_001735.2_852-870_s
852-870
CUUAAAAGAUGAUCAAAAA
686
UUUUUGAUCAUCUUUUAAG
1255


 


NM_001735.2_859-877_s
859-877
GAUGAUCAAAAAGAAAUGA
687
UCAUUUCUUUUUGAUCAUC
1256


 


NM_001735.2_872-890_s
872-890
AAAUGAUGCAAACAGCAAU
688
AUUGCUGUUUGCAUCAUUU
1257


 


NM_001735.2_883-901_s
883-901
ACAGCAAUGCAAAACACAA
689
UUGUGUUUUGCAUUGCUGU
1258


 


NM_001735.2_893-911_s
893-911
AAAACACAAUGUUGAUAAA
690
UUUAUCAACAUUGUGUUUU
1259


 


NM_001735.2_899-917_s
899-917
CAAUGUUGAUAAAUGGAAU
691
AUUCCAUUUAUCAACAUUG
1260


 


NM_001735.2_913-931_s
913-931
GGAAUUGCUCAAGUCACAU
692
AUGUGACUUGAGCAAUUCC
1261


 


NM_001735.2_919-937_s
919-937
GCUCAAGUCACAUUUGAUU
693
AAUCAAAUGUGACUUGAGC
1262


 


NM_001735.2_930-948_s
930-948
AUUUGAUUCUGAAACAGCA
694
UGCUGUUUCAGAAUCAAAU
1263


 


NM_001735.2_939-957_s
939-957
UGAAACAGCAGUCAAAGAA
695
UUCUUUGACUGCUGUUUCA
1264


 


NM_001735.2_951-969_s
951-969
CAAAGAACUGUCAUACUAC
696
GUAGUAUGACAGUUCUUUG
1265


 


NM_001735.2_962-980_s
962-980
CAUACUACAGUUUAGAAGA
697
UCUUCUAAACUGUAGUAUG
1266


 


NM_001735.2_969-987_s
969-987
CAGUUUAGAAGAUUUAAAC
698
GUUUAAAUCUUCUAAACUG
1267


 


NM_001735.2_983-1001_s
 983-1001
UAAACAACAAGUACCUUUA
699
UAAAGGUACUUGUUGUUUA
1268


 


NM_001735.2_990-1008_s
 990-1008
CAAGUACCUUUAUAUUGCU
700
AGCAAUAUAAAGGUACUUG
1269


 


NM_001735.2_1002-1020_s
1002-1020
UAUUGCUGUAACAGUCAUA
701
UAUGACUGUUACAGCAAUA
1270


 


NM_001735.2_1011-1029_s
1011-1029
AACAGUCAUAGAGUCUACA
702
UGUAGACUCUAUGACUGUU
1271


 


NM_001735.2_1020-1038_s
1020-1038
AGAGUCUACAGGUGGAUUU
703
AAAUCCACCUGUAGACUCU
1272


 


NM_001735.2_1033-1051_s
1033-1051
GGAUUUUCUGAAGAGGCAG
704
CUGCCUCUUCAGAAAAUCC
1273


 


NM_001735.2_1042-1060_s
1042-1060
GAAGAGGCAGAAAUACCUG
705
CAGGUAUUUCUGCCUCUUC
1274


 


NM_001735.2_1050-1068_s
1050-1068
AGAAAUACCUGGCAUCAAA
706
UUUGAUGCCAGGUAUUUCU
1275


 


NM_001735.2_1061-1079_s
1061-1079
GCAUCAAAUAUGUCCUCUC
707
GAGAGGACAUAUUUGAUGC
1276


 


NM_001735.2_1071-1089_s
1071-1089
UGUCCUCUCUCCCUACAAA
708
UUUGUAGGGAGAGAGGACA
1277


 


NM_001735.2_1092-1110_s
1092-1110
GAAUUUGGUUGCUACUCCU
709
AGGAGUAGCAACCAAAUUC
1278


 


NM_001735.2_1102-1120_s
1102-1120
GCUACUCCUCUUUUCCUGA
710
UCAGGAAAAGAGGAGUAGC
1279


 


NM_001735.2_1109-1127_s
1109-1127
CUCUUUUCCUGAAGCCUGG
711
CCAGGCUUCAGGAAAAGAG
1280


 


NM_001735.2_1123-1141_s
1123-1141
CCUGGGAUUCCAUAUCCCA
712
UGGGAUAUGGAAUCCCAGG
1281


 


NM_001735.2_1133-1151_s
1133-1151
CAUAUCCCAUCAAGGUGCA
713
UGCACCUUGAUGGGAUAUG
1282


 


NM_001735.2_1139-1157_s
1139-1157
CCAUCAAGGUGCAGGUUAA
714
UUAACCUGCACCUUGAUGG
1283


 


NM_001735.2_1150-1168_s
1150-1168
CAGGUUAAAGAUUCGCUUG
715
CAAGCGAAUCUUUAACCUG
1284


 


NM_001735.2_1161-1179_s
1161-1179
UUCGCUUGACCAGUUGGUA
716
UACCAACUGGUCAAGCGAA
1285


 


NM_001735.2_1170-1188_s
1170-1188
CCAGUUGGUAGGAGGAGUC
717
GACUCCUCCUACCAACUGG
1286


 


NM_001735.2_1180-1198_s
1180-1198
GGAGGAGUCCCAGUAACAC
718
GUGUUACUGGGACUCCUCC
1287


 


NM_001735.2_1190-1208_s
1190-1208
CAGUAACACUGAAUGCACA
719
UGUGCAUUCAGUGUUACUG
1288


 


NM_001735.2_1200-1218_s
1200-1218
GAAUGCACAAACAAUUGAU
720
AUCAAUUGUUUGUGCAUUC
1289


 


NM_001735.2_1209-1227_s
1209-1227
AACAAUUGAUGUAAACCAA
721
UUGGUUUACAUCAAUUGUU
1290


 


NM_001735.2_1220-1238_s
1220-1238
UAAACCAAGAGACAUCUGA
722
UCAGAUGUCUCUUGGUUUA
1291


 


NM_001735.2_1232-1250_s
1232-1250
CAUCUGACUUGGAUCCAAG
723
CUUGGAUCCAAGUCAGAUG
1292


 


NM_001735.2_1243-1261_s
1243-1261
GAUCCAAGCAAAAGUGUAA
724
UUACACUUUUGCUUGGAUC
1293


 


NM_001735.2_1251-1269_s
1251-1269
CAAAAGUGUAACACGUGUU
725
AACACGUGUUACACUUUUG
1294


 


NM_001735.2_1260-1278_s
1260-1278
AACACGUGUUGAUGAUGGA
726
UCCAUCAUCAACACGUGUU
1295


 


NM_001735.2_1272-1290_s
1272-1290
UGAUGGAGUAGCUUCCUUU
727
AAAGGAAGCUACUCCAUCA
1296


 


NM_001735.2_1279-1297_s
1279-1297
GUAGCUUCCUUUGUGCUUA
728
UAAGCACAAAGGAAGCUAC
1297


 


NM_001735.2_1293-1311_s
1293-1311
GCUUAAUCUCCCAUCUGGA
729
UCCAGAUGGGAGAUUAAGC
1298


 


NM_001735.2_1303-1321_s
1303-1321
CCAUCUGGAGUGACGGUGC
730
GCACCGUCACUCCAGAUGG
1299


 


NM_001735.2_1313-1331_s
1313-1331
UGACGGUGCUGGAGUUUAA
731
UUAAACUCCAGCACCGUCA
1300


 


NM_001735.2_1320-1338_s
1320-1338
GCUGGAGUUUAAUGUCAAA
732
UUUGACAUUAAACUCCAGC
1301


 


NM_001735.2_1332-1350_s
1332-1350
UGUCAAAACUGAUGCUCCA
733
UGGAGCAUCAGUUUUGACA
1302


 


NM_001735.2_1342-1360_s
1342-1360
GAUGCUCCAGAUCUUCCAG
734
CUGGAAGAUCUGGAGCAUC
1303


 


NM_001735.2_1349-1367_s
1349-1367
CAGAUCUUCCAGAAGAAAA
735
UUUUCUUCUGGAAGAUCUG
1304


 


NM_001735.2_1362-1380_s
1362-1380
AGAAAAUCAGGCCAGGGAA
736
UUCCCUGGCCUGAUUUUCU
1305


 


NM_001735.2_1371-1389_s
1371-1389
GGCCAGGGAAGGUUACCGA
737
UCGGUAACCUUCCCUGGCC
1306


 


NM_001735.2_1382-1400_s
1382-1400
GUUACCGAGCAAUAGCAUA
738
UAUGCUAUUGCUCGGUAAC
1307


 


NM_001735.2_1393-1411_s
1393-1411
AUAGCAUACUCAUCUCUCA
739
UGAGAGAUGAGUAUGCUAU
1308


 


NM_001735.2_1399-1417_s
1399-1471
UACUCAUCUCUCAGCCAAA
740
UUUGGCUGAGAGAUGAGUA
1309


 


NM_001735.2_1412-1430_s
1412-1430
GCCAAAGUUACCUUUAUAU
741
AUAUAAAGGUAACUUUGGC
1310


 


NM_001735.2_1422-1440_s
1422-1440
CCUUUAUAUUGAUUGGACU
742
AGUCCAAUCAAUAUAAAGG
1311


 


NM_001735.2_1432-1450_s
1432-1450
GAUUGGACUGAUAACCAUA
743
UAUGGUUAUCAGUCCAAUC
1312


 


NM_001735.2_1439-1457_s
1439-1457
CUGAUAACCAUAAGGCUUU
744
AAAGCCUUAUGGUUAUCAG
1313


 


NM_001735.2_1451-1469_s
1451-1469
AGGCUUUGCUAGUGGGAGA
745
UCUCCCACUAGCAAAGCCU
1314


 


NM_001735.2_1462-1480_s
1462-1480
GUGGGAGAACAUCUGAAUA
746
UAUUCAGAUGUUCUCCCAC
1315


 


NM_001735.2_1471-1489_s
1471-1489
CAUCUGAAUAUUAUUGUUA
747
UAACAAUAAUAUUCAGAUG
1316


 


NM_001735.2_1479-1497_s
1479-1497
UAUUAUUGUUACCCCCAAA
748
UUUGGGGGUAACAAUAAUA
1317


 


NM_001735.2_1492-1510_s
1492-1510
CCCAAAAGCCCAUAUAUUG
749
CAAUAUAUGGGCUUUUGGG
1318


 


NM_001735.2_1493-1511_s
1493-1511
CCAAAAGCCCAUAUAUUGA
750
UCAAUAUAUGGGCUUUUGG
1319


 


NM_001735.2_1494-1512_s
1494-1512
CAAAAGCCCAUAUAUUGAC
751
GUCAAUAUAUGGGCUUUUG
1320


 


NM_001735.2_1495-1513_s
1495-1513
AAAAGCCCAUAUAUUGACA
752
UGUCAAUAUAUGGGCUUUU
1321


 


NM_001735.2_1496-1514_s
1496-1514
AAAGCCCAUAUAUUGACAA
753
UUGUCAAUAUAUGGGCUUU
1322


 


NM_001735.2_1497-1515_s
1497-1515
AAGCCCAUAUAUUGACAAA
754
UUUGUCAAUAUAUGGGCUU
1323


 


NM_001735.2_1498-1516_s
1498-1516
AGCCCAUAUAUUGACAAAA
755
UUUUGUCAAUAUAUGGGCU
1324


 


NM_001735.2_1499-1517_s
1499-1517
GCCCAUAUAUUGACAAAAU
756
AUUUUGUCAAUAUAUGGGC
1325


 


NM_001735.2_1500-1518_s
1500-1518
CCCAUAUAUUGACAAAAUA
757
UAUUUUGUCAAUAUAUGGG
1326


 


NM_001735.2_1501-1519_s
1501-1519
CCAUAUAUUGACAAAAUAA
758
UUAUUUUGUCAAUAUAUGG
1327


 


NM_001735.2_1502-1520_s
1502-1520
CAUAUAUUGACAAAAUAAC
759
GUUAUUUUGUCAAUAUAUG
1328


 


NM_001735.2_1503-1521_s
1503-1521
AUAUAUUGACAAAAUAACU
760
AGUUAUUUUGUCAAUAUAU
1329


 


NM_001735.2_1504-1522_s
1504-1522
UAUAUUGACAAAAUAACUC
761
GAGUUAUUUUGUCAAUAUA
1330


 


NM_001735.2_1505-1523_s
1505-1523
AUAUUGACAAAAUAACUCA
762
UGAGUUAUUUUGUCAAUAU
1331


 


NM_001735.2_1506-1524_s
1506-1524
UAUUGACAAAAUAACUCAC
763
GUGAGUUAUUUUGUCAAUA
1332


 


NM_001735.2_1507-1525_s
1507-1525
AUUGACAAAAUAACUCACU
764
AGUGAGUUAUUUUGUCAAU
1333


 


NM_001735.2_1508-1526_s
1508-1526
UUGACAAAAUAACUCACUA
765
UAGUGAGUUAUUUUGUCAA
1334


 


NM_001735.2_1509-1527_s
1509-1527
UGACAAAAUAACUCACUAU
766
AUAGUGAGUUAUUUUGUCA
1335


 


NM_001735.2_1510-1528_s
1510-1528
GACAAAAUAACUCACUAUA
767
UAUAGUGAGUUAUUUUGUC
1336


 


NM_001735.2_1513-1531_s
1513-1531
AAAAUAACUCACUAUAAUU
768
AAUUAUAGUGAGUUAUUUU
1337


 


NM_001735.2_1514-1532_s
1514-1532
AAAUAACUCACUAUAAUUA
769
UAAUUAUAGUGAGUUAUUU
1338


 


NM_001735.2_1515-1533_s
1515-1533
AAUAACUCACUAUAAUUAC
770
GUAAUUAUAGUGAGUUAUU
1339


 


NM_001735.2_1516-1534_s
1516-1534
AUAACUCACUAUAAUUACU
771
AGUAAUUAUAGUGAGUUAU
1340


 


NM_001735.2_1518-1536_s
1518-1536
AACUCACUAUAAUUACUUG
772
CAAGUAAUUAUAGUGAGUU
1341


 


NM_001735.2_1519-1537_s
1519-1537
ACUCACUAUAAUUACUUGA
773
UCAAGUAAUUAUAGUGAGU
1342


 


NM_001735.2_1520-1538_s
1520-1538
CUCACUAUAAUUACUUGAU
774
AUCAAGUAAUUAUAGUGAG
1343


 


NM_001735.2_1521-1539_s
1521-1539
UCACUAUAAUUACUUGAUU
775
AAUCAAGUAAUUAUAGUGA
1344


 


NM_001735.2_1523-1541_s
1523-1541
ACUAUAAUUACUUGAUUUU
776
AAAAUCAAGUAAUUAUAGU
1345


 


NM_001735.2_1524-1542_s
1524-1542
CUAUAAUUACUUGAUUUUA
777
UAAAAUCAAGUAAUUAUAG
1346


 


NM_001735.2_1525-1543_s
1525-1543
UAUAAUUACUUGAUUUUAU
778
AUAAAAUCAAGUAAUUAUA
1347


 


NM_001735.2_1526-1544_s
1526-1544
AUAAUUACUUGAUUUUAUC
779
GAUAAAAUCAAGUAAUUAU
1348


 


NM_001735.2_1527-1545_s
1527-1545
UAAUUACUUGAUUUUAUCC
780
GGAUAAAAUCAAGUAAUUA
1349


 


NM_001735.2_1528-1546_s
1528-1546
AAUUACUUGAUUUUAUCCA
781
UGGAUAAAAUCAAGUAAUU
1350


 


NM_001735.2_1529-1547_s
1529-1547
AUUACUUGAUUUUAUCCAA
782
UUGGAUAAAAUCAAGUAAU
1351


 


NM_001735.2_1540-1558_s
1540-1558
UUAUCCAAGGGCAAAAUUA
783
UAAUUUUGCCCUUGGAUAA
1352


 


NM_001735.2_1550-1568_s
1550-1568
GCAAAAUUAUCCACUUUGG
784
CCAAAGUGGAUAAUUUUGC
1353


 


NM_001735.2_1561-1579_s
1561-1579
CACUUUGGCACGAGGGAGA
785
UCUCCCUCGUGCCAAAGUG
1354


 


NM_001735.2_1571-1589_s
1571-1589
CGAGGGAGAAAUUUUCAGA
786
UCUGAAAAUUUCUCCCUCG
1355


 


NM_001735.2_1581-1599_s
1581-1599
AUUUUCAGAUGCAUCUUAU
787
AUAAGAUGCAUCUGAAAAU
1356


 


NM_001735.2_1591-1609_s
1591-1609
GCAUCUUAUCAAAGUAUAA
788
UUAUACUUUGAUAAGAUGC
1357


 


NM_001735.2_1600-1618_s
1600-1618
CAAAGUAUAAACAUUCCAG
789
CUGGAAUGUUUAUACUUUG
1358


 


NM_001735.2_1612-1630_s
1612-1630
AUUCCAGUAACACAGAACA
790
UGUUCUGUGUUACUGGAAU
1359


 


NM_001735.2_1622-1640_s
1622-1640
CACAGAACAUGGUUCCUUC
791
GAAGGAACCAUGUUCUGUG
1360


 


NM_001735.2_1632-1650_s
1632-1560
GGUUCCUUCAUCCCGACUU
792
AAGUCGGGAUGAAGGAACC
1361


 


NM_001735.2_1643-1661_s
1643-1661
CCCGACUUCUGGUCUAUUA
793
UAAUAGACCAGAAGUCGGG
1362


 


NM_001735.2_1653-1671_s
1653-1671
GGUCUAUUACAUCGUCACA
794
UGUGACGAUGUAAUAGACC
1363


 


NM_001735.2_1663-1681_s
1663-1681
AUCGUCACAGGAGAACAGA
795
UCUGUUCUCCUGUGACGAU
1364


 


NM_001735.2_1670-1688_s
1670-1688
CAGGAGAACAGACAGCAGA
796
UCUGCUGUCUGUUCUCCUG
1365


 


NM_001735.2_1682-1700_s
1682-1700
CAGCAGAAUUAGUGUCUGA
797
UCAGACACUAAUUCUGCUG
1366


 


NM_001735.2_1693-1711_s
1693-1711
GUGUCUGAUUCAGUCUGGU
798
ACCAGACUGAAUCAGACAC
1367


 


NM_001735.2_1703-1721_s
1703-1721
CAGUCUGGUUAAAUAUUGA
799
UCAAUAUUUAACCAGACUG
1368


 


NM_001735.2_1710-1728_s
1710-1728
GUUAAAUAUUGAAGAAAAA
800
UUUUUCUUCAAUAUUUAAC
1369


 


NM_001735.2_1722-1740_s
1722-1740
AGAAAAAUGUGGCAACCAG
801
CUGGUUGCCACAUUUUUCU
1370


 


NM_001735.2_1733-1751_s
1733-1751
GCAACCAGCUCCAGGUUCA
802
UGAACCUGGAGCUGGUUGC
1371


 


NM_001735.2_1740-1758_s
1740-1758
GCUCCAGGUUCAUCUGUCU
803
AGACAGAUGAACCUGGAGC
1372


 


NM_001735.2_1751-1769_s
1751-1769
AUCUGUCUCCUGAUGCAGA
804
UCUGCAUCAGGAGACAGAU
1373


 


NM_001735.2_1762-1780_s
1762-1780
GAUGCAGAUGCAUAUUCUC
805
GAGAAUAUGCAUCUGCAUC
1374


 


NM_001735.2_1771-1789_s
1771-1789
GCAUAUUCUCCAGGCCAAA
806
UUUGGCCUGGAGAAUAUGC
1375


 


NM_001735.2_1782-1800_s
1782-1800
AGGCCAAACUGUGUCUCUU
807
AAGAGACACAGUUUGGCCU
1376


 


NM_001735.2_1792-1810_s
1792-1810
GUGUCUCUUAAUAUGGCAA
808
UUGCCAUAUUAAGAGACAC
1377


 


NM_001735.2_1799-1817_s
1799-1817
UUAAUAUGGCAACUGGAAU
809
AUUCCAGUUGCCAUAUUAA
1378


 


NM_001735.2_1809-1827_s
1809-1827
AACUGGAAUGGAUUCCUGG
810
CCAGGAAUCCAUUCCAGUU
1379


 


NM_001735.2_1821-1839_s
1821-1839
UUCCUGGGUGGCAUUAGCA
811
UGCUAAUGCCACCCAGGAA
1380


 


NM_001735.2_1830-1848_s
1830-1848
GGCAUUAGCAGCAGUGGAC
812
GUCCACUGCUGCUAAUGCC
1381


 


NM_001735.2_1842-1860_s
1842-1860
AGUGGACAGUGCUGUGUAU
813
AUACACAGCACUGUCCACU
1382


 


NM_001735.2_1852-1870_s
1852-1870
GCUGUGUAUGGAGUCCAAA
814
UUUGGACUCCAUACACAGC
1383


 


NM_001735.2_1863-1881_s
1863-1881
AGUCCAAAGAGGAGCCAAA
815
UUUGGCUCCUCUUUGGACU
1384


 


NM_001735.2_1870-1888_s
1870-1888
AGAGGAGCCAAAAAGCCCU
816
AGGGCUUUUUGGCUCCUCU
1385


 


NM_001735.2_1883-1901_s
1883-1901
AGCCCUUGGAAAGAGUAUU
817
AAUACUCUUUCCAAGGGCU
1386


 


NM_001735.2_1893-1911_s
1893-1911
AAGAGUAUUUCAAUUCUUA
818
UAAGAAUUGAAAUACUCUU
1387


 


NM_001735.2_1900-1918_s
1900-1918
UUUCAAUUCUUAGAGAAGA
819
UCUUCUCUAAGAAUUGAAA
1388


 


NM_001735.2_1912-1930_s
1912-1930
GAGAAGAGUGAUCUGGGCU
820
AGCCCAGAUCACUCUUCUC
1389


 


NM_001735.2_1920-1938_s
1920-1938
UGAUCUGGGCUGUGGGGCA
821
UGCCCCACAGCCCAGAUCA
1390


 


NM_001735.2_1933-1951_s
1933-1951
GGGGCAGGUGGUGGCCUCA
822
UGAGGCCACCACCUGCCCC
1391


 


NM_001735.2_1943-1961_s
1943-1961
GUGGCCUCAACAAUGCCAA
823
UUGGCAUUGUUGAGGCCAC
1392


 


NM_001735.2_1950-1968_s
1950-1968
CAACAAUGCCAAUGUGUUC
824
GAACACAUUGGCAUUGUUG
1393


 


NM_001735.2_1959-1977_s
1959-1977
CAAUGUGUUCCACCUAGCU
825
AGCUAGGUGGAACACAUUG
1394


 


NM_001735.2_1969-1987_s
1969-1987
CACCUAGCUGGACUUACCU
826
AGGUAAGUCCAGCUAGGUG
1395


 


NM_001735.2_1979-1997_s
1979-1997
GACUUACCUUCCUCACUAA
827
UUAGUGAGGAAGGUAAGUC
1396


 


NM_001735.2_1991-2009_s
1991-2009
UCACUAAUGCAAAUGCAGA
828
UCUGCAUUUGCAUUAGUGA
1397


 


NM_001735.2_2001-2019_s
2001-2019
AAAUGCAGAUGACUCCCAA
829
UUGGGAGUCAUCUGCAUUU
1398


 


NM_001735.2_2013-2031_s
2013-2013
CUCCCAAGAAAAUGAUGAA
830
UUCAUCAUUUUCUUGGGAG
1399


 


NM_001735.2_2032-2050_s
2032-2050
CCUUGUAAAGAAAUUCUCA
831
UGAGAAUUUCUUUACAAGG
1400


 


NM_001735.2_2043-2061_s
2043-2061
AAUUCUCAGGCCAAGAAGA
832
UCUUCUUGGCCUGAGAAUU
1401


 


NM_001735.2_2053-2071_s
2053-2071
CCAAGAAGAACGCUGCAAA
833
UUUGCAGCGUUCUUCUUGG
1402


 


NM_001735.2_2063-2081_s
2063-2081
CGCUGCAAAAGAAGAUAGA
834
UCUAUCUUCUUUUGCAGCG
1403


 


NM_001735.2_2070-2088_s
2070-2088
AAAGAAGAUAGAAGAAAUA
835
UAUUUCUUCUAUCUUCUUU
1404


 


NM_001735.2_2082-2100_s
2082-2100
AGAAAUAGCUGCUAAAUAU
836
AUAUUUAGCAGCUAUUUCU
1405


 


NM_001735.2_2089-2107_s
2089-2107
GCUGCUAAAUAUAAACAUU
837
AAUGUUUAUAUUUAGCAGC
1406


 


NM_001735.2_2103-2121_s
2103-2121
ACAUUCAGUAGUGAAGAAA
838
UUUCUUCACUACUGAAUGU
1407


 


NM_001735.2_2110-2128_s
2110-2128
GUAGUGAAGAAAUGUUGUU
839
AACAACAUUUCUUCACUAC
1408


 


NM_001735.2_2119-2137_s
2119-2137
AAAUGUUGUUACGAUGGAG
840
CUCCAUCGUAACAACAUUU
1409


 


NM_001735.2_2130-2148_s
2130-2148
CGAUGGAGCCUGCGUUAAU
841
AUUAACGCAGGCUCCAUCG
1410


 


NM_001735.2_2142-2160_s
2142-2160
CGUUAAUAAUGAUGAAACC
842
GGUUUCAUCAUUAUUAACG
1411


 


NM_001735.2_2150-2168_s
2150-2168
AUGAUGAAACCUGUGAGCA
843
UGCUCACAGGUUUCAUCAU
1412


 


NM_001735.2_2160-2178_s
2160-2178
CUGUGAGCAGCGAGCUGCA
844
UGCAGCUCGCUGCUCACAG
1413


 


NM_001735.2_2170-2188_s
2170-2188
CGAGCUGCACGGAUUAGUU
845
AACUAAUCCGUGCAGCUCG
1414


 


NM_001735.2_2180-2198_s
2180-2198
GGAUUAGUUUAGGGCCAAG
846
CUUGGCCCUAAACUAAUCC
1415


 


NM_001735.2_2191-2209_s
2191-2209
GGGCCAAGAUGCAUCAAAG
847
CUUUGAUGCAUCUUGGCCC
1416


 


NM_001735.2_2202-2220_s
2202-2220
CAUCAAAGCUUUCACUGAA
848
UUCAGUGAAAGCUUUGAUG
1417


 


NM_001735.2_2209-2227_s
2209-2227
GCUUUCACUGAAUGUUGUG
849
CACAACAUUCAGUGAAAGC
1418


 


NM_001735.2_2219-2237_s
2219-2237
AAUGUUGUGUCGUCGCAAG
850
CUUGCGACGACACAACAUU
1419


 


NM_001735.2_2229-2247_s
2229-2247
CGUCGCAAGCCAGCUCCGU
851
ACGGAGCUGGCUUGCGACG
1420


 


NM_001735.2_2241-2259_s
2241-2259
GCUCCGUGCUAAUAUCUCU
852
AGAGAUAUUAGCACGGAGC
1421


 


NM_001735.2_2249-2267_s
2249-2267
CUAAUAUCUCUCAUAAAGA
853
UCUUUAUGAGAGAUAUUAG
1422


 


NM_001735.2_2263-2281_s
2263-2281
AAAGACAUGCAAUUGGGAA
854
UUCCCAAUUGCAUGUCUUU
1423


 


NM_001735.2_2272-2290_s
2272-2290
CAAUUGGGAAGGCUACACA
855
UGUGUAGCCUUCCCAAUUG
1424


 


NM_001735.2_2283-2301_s
2283-2301
GCUACACAUGAAGACCCUG
856
CAGGGUCUUCAUGUGUAGC
1425


 


NM_001735.2_2289-2307_s
2289-2307
CAUGAAGACCCUGUUACCA
857
UGGUAACAGGGUCUUCAUG
1426


 


NM_001735.2_2303-2321_s
2303-2321
UACCAGUAAGCAAGCCAGA
858
UCUGGCUUGCUUACUGGUA
1427


 


NM_001735.2_2311-2329_s
2311-2329
AGCAAGCCAGAAAUUCGGA
859
UCCGAAUUUCUGGCUUGCU
1428


 


NM_001735.2_2319-2337_s
2319-2337
AGAAAUUCGGAGUUAUUUU
860
AAAAUAACUCCGAAUUUCU
1429


 


NM_001735.2_2329-2347_s
2329-2347
AGUUAUUUUCCAGAAAGCU
861
AGCUUUCUGGAAAAUAACU
1430


 


NM_001735.2_2339-2357_s
2339-2357
CAGAAAGCUGGUUGUGGGA
862
UCCCACAACCAGCUUUCUG
1431


 


NM_001735.2_2352-2370_s
2352-2370
GUGGGAAGUUCAUCUUGUU
863
AACAAGAUGAACUUCCCAC
1432


 


NM_001735.2_2361-2379_s
2361-2379
UCAUCUUGUUCCCAGAAGA
864
UCUUCUGGGAACAAGAUGA
1433


 


NM_001735.2_2372-2390_s
2372-2390
CCAGAAGAAAACAGUUGCA
865
UGCAACUGUUUUCUUCUGG
1434


 


NM_001735.2_2383-2401_s
2383-2401
CAGUUGCAGUUUGCCCUAC
866
GUAGGGCAAACUGCAACUG
1435


 


NM_001735.2_2389-2407_s
2389-2407
CAGUUUGCCCUACCUGAUU
867
AAUCAGGUAGGGCAAACUG
1436


 


NM_001735.2_2401-2419_s
2401-2419
CCUGAUUCUCUAACCACCU
868
AGGUGGUUAGAGAAUCAGG
1437


 


NM_001735.2_2413-2431_s
2413-2431
ACCACCUGGGAAAUUCAAG
869
CUUGAAUUUCCCAGGUGGU
1438


 


NM_001735.2_2422-2440_s
2422-2440
GAAAUUCAAGGCGUUGGCA
870
UGCCAACGCCUUGAAUUUC
1439


 


NM_001735.2_2433-2451_s
2433-2451
CGUUGGCAUUUCAAACACU
871
AGUGUUUGAAAUGCCAACG
1440


 


NM_001735.2_2439-2457_s
2439-2457
CAUUUCAAACACUGGUAUA
872
UAUACCAGUGUUUGAAAUG
1441


 


NM_001735.2_2453-2471_s
2453-2471
GUAUAUGUGUUGCUGAUAC
873
GUAUCAGCAACACAUAUAC
1442


 


NM_001735.2_2463-2481_s
2463-2481
UGCUGAUACUGUCAAGGCA
874
UGCCUUGACAGUAUCAGCA
1443


 


NM_001735.2_2471-2489_s
2471-2489
CUGUCAAGGCAAAGGUGUU
875
AACACCUUUGCCUUGACAG
1444


 


NM_001735.2_2483-2501_s
2483-2501
AGGUGUUCAAAGAUGUCUU
876
AAGACAUCUUUGAACACCU
1445


 


NM_001735.2_2490-2508_s
2490-2508
CAAAGAUGUCUUCCUGGAA
877
UUCCAGGAAGACAUCUUUG
1446


 


NM_001735.2_2499-2517_s
2499-2517
CUUCCUGGAAAUGAAUAUA
878
UAUAUUCAUUUCCAGGAAG
1447


 


NM_001735.2_2511-2529_s
2511-2529
GAAUAUACCAUAUUCUGUU
879
AACAGAAUAUGGUAUAUUC
1448


 


NM_001735.2_2520-2538_s
2520-2538
AUAUUCUGUUGUACGAGGA
880
UCCUCGUACAACAGAAUAU
1449


 


NM_001735.2_2533-2551_s
2533-2551
CGAGGAGAACAGAUCCAAU
881
AUUGGAUCUGUUCUCCUCG
1450


 


NM_001735.2_2539-2557_s
2539-2557
GAACAGAUCCAAUUGAAAG
882
CUUUCAAUUGGAUCUGUUC
1451


 


NM_001735.2_2553-2571_s
2553-2571
GAAAGGAACUGUUUACAAC
883
GUUGUAAACAGUUCCUUUC
1452


 


NM_001735.2_2560-2578_s
2560-2578
ACUGUUUACAACUAUAGGA
884
UCCUAUAGUUGUAAACAGU
1453


 


NM_001735.2_2569-2587_s
2569-2587
AACUAUAGGACUUCUGGGA
885
UCCCAGAAGUCCUAUAGUU
1454


 


NM_001735.2_2583-2601_s
2583-2601
UGGGAUGCAGUUCUGUGUU
886
AACACAGAACUGCAUCCCA
1455


 


NM_001735.2_2592-2610_s
2592-2610
GUUCUGUGUUAAAAUGUCU
887
AGACAUUUUAACACAGAAC
1456


 


NM_001735.2_2600-2618_s
2600-2618
UUAAAAUGUCUGCUGUGGA
888
UCCACAGCAGACAUUUUAA
1457


 


NM_001735.2_2612-2630_s
2612-2630
CUGUGGAGGGAAUCUGCAC
889
GUGCAGAUUCCCUCCACAG
1458


 


NM_001735.2_2620-2638_s
2620-2638
GGAAUCUGCACUUCGGAAA
890
UUUCCGAAGUGCAGAUUCC
1459


 


NM_001735.2_2633-2651_s
2633-2651
CGGAAAGCCCAGUCAUUGA
891
UCAAUGACUGGGCUUUCCG
1460


 


NM_001735.2_2641-2659_s
2641-2659
CCAGUCAUUGAUCAUCAGG
892
CCUGAUGAUCAAUGACUGG
1461


 


NM_001735.2_2653-2671_s
2653-2671
CAUCAGGGCACAAAGUCCU
893
AGGACUUUGUGCCCUGAUG
1462


 


NM_001735.2_2659-2677_s
2659-2677
GGCACAAAGUCCUCCAAAU
894
AUUUGGAGGACUUUGUGCC
1463


 


NM_001735.2_2673-2691_s
2673-2691
CAAAUGUGUGCGCCAGAAA
895
UUUCUGGCGCACACAUUUG
1464


 


NM_001735.2_2682-2700_s
2682-2700
GCGCCAGAAAGUAGAGGGC
896
GCCCUCUACUUUCUGGCGC
1465


 


NM_001735.2_2691-2709_s
2691-2709
AGUAGAGGGCUCCUCCAGU
897
ACUGGAGGAGCCCUCUACU
1466


 


NM_001735.2_2702-2720_s
2702-2720
CCUCCAGUCACUUGGUGAC
898
GUCACCAAGUGACUGGAGG
1467


 


NM_001735.2_2709-2727_s
2709-2727
UCACUUGGUGACAUUCACU
899
AGUGAAUGUCACCAAGUGA
1468


 


NM_001735.2_2720-2738_s
2720-2738
CAUUCACUGUGCUUCCUCU
900
AGAGGAAGCACAGUGAAUG
1469


 


NM_001735.2_2739-2757_s
2739-2757
GGAAAUUGGCCUUCACAAC
901
GUUGUGAAGGCCAAUUUCC
1470


 


NM_001735.2_2749-2767_s
2749-2767
CUUCACAACAUCAAUUUUU
902
AAAAAUUGAUGUUGUGAAG
1471


 


NM_001735.2_2761-2779_s
2761-2779
AAUUUUUCACUGGAGACUU
903
AAGUCUCCAGUGAAAAAUU
1472


 


NM_001735.2_2770-2788_s
2770-2788
CUGGAGACUUGGUUUGGAA
904
UUCCAAACCAAGUCUCCAG
1473


 


NM_001735.2_2780-2798_s
2780-2798
GGUUUGGAAAAGAAAUCUU
905
AAGAUUUCUUUUCCAAACC
1474


 


NM_001735.2_2793-2811_s
2793-2811
AAUCUUAGUAAAAACAUUA
906
UAAUGUUUUUACUAAGAUU
1475


 


NM_001735.2_2802-2820_s
2802-2820
AAAAACAUUACGAGUGGUG
907
CACCACUCGUAAUGUUUUU
1476


 


NM_001735.2_2813-2831_s
2813-2831
GAGUGGUGCCAGAAGGUGU
908
ACACCUUCUGGCACCACUC
1477


 


NM_001735.2_2823-2841_s
2823-2841
AGAAGGUGUCAAAAGGGAA
909
UUCCCUUUUGACACCUUCU
1478


 


NM_001735.2_2829-2847_s
2829-2847
UGUCAAAAGGGAAAGCUAU
910
AUAGCUUUCCCUUUUGACA
1479


 


NM_001735.2_2843-2861_s
2843-2861
GCUAUUCUGGUGUUACUUU
911
AAAGUAACACCAGAAUAGC
1480


 


NM_001735.2_2852-2870_s
2852-2870
GUGUUACUUUGGAUCCUAG
912
CUAGGAUCCAAAGUAACAC
1481


 


NM_001735.2_2862-2880_s
2862-2880
GGAUCCUAGGGGUAUUUAU
913
AUAAAUACCCCUAGGAUCC
1482


 


NM_001735.2_2872-2890_s
2872-2890
GGUAUUUAUGGUACCAUUA
914
UAAUGGUACCAUAAAUACC
1483


 


NM_001735.2_2882-2900_s
2882-2900
GUACCAUUAGCAGACGAAA
915
UUUCGUCUGCUAAUGGUAC
1484


 


NM_001735.2_2892-2910_s
2892-2910
CAGACGAAAGGAGUUCCCA
916
UGGGAACUCCUUUCGUCUG
1485


 


NM_001735.2_2900-2918_s
2900-2918
AGGAGUUCCCAUACAGGAU
917
AUCCUGUAUGGGAACUCCU
1486


 


NM_001735.2_2909-2927_s
2909-2927
CAUACAGGAUACCCUUAGA
918
UCUAAGGGUAUCCUGUAUG
1487


 


NM_001735.2_2922-2940_s
2922-2940
CUUAGAUUUGGUCCCCAAA
919
UUUGGGGACCAAAUCUAAG
1488


 


NM_001735.2_2933-2951_s
2933-2951
UCCCCAAAACAGAAAUCAA
920
UUGAUUUCUGUUUUGGGGA
1489


 


NM_001735.2_2941-2959_s
2941-2959
ACAGAAAUCAAAAGGAUUU
921
AAAUCCUUUUGAUUUCUGU
1490


 


NM_001735.2_2951-2969_s
2951-2969
AAAGGAUUUUGAGUGUAAA
922
UUUACACUCAAAAUCCUUU
1491


 


NM_001735.2_2962-2980_s
2962-2980
AGUGUAAAAGGACUGCUUG
923
CAAGCAGUCCUUUUACACU
1492


 


NM_001735.2_2969-2987_s
2969-2987
AAGGACUGCUUGUAGGUGA
924
UCACCUACAAGCAGUCCUU
1493


 


NM_001735.2_2980-2998_s
2980-2998
GUAGGUGAGAUCUUGUCUG
925
CAGACAAGAUCUCACCUAC
1494


 


NM_001735.2_2989-3007_s
2989-3007
AUCUUGUCUGCAGUUCUAA
926
UUAGAACUGCAGACAAGAU
1495


 


NM_001735.2_3001-3019_s
3001-3019
GUUCUAAGUCAGGAAGGCA
927
UGCCUUCCUGACUUAGAAC
1496


 


NM_001735.2_3013-3031_s
3013-3031
GAAGGCAUCAAUAUCCUAA
928
UUAGGAUAUUGAUGCCUUC
1497


 


NM_001735.2_3020-3038_s
3020-3038
UCAAUAUCCUAACCCACCU
929
AGGUGGGUUAGGAUAUUGA
1498


 


NM_001735.2_3033-3051_s
3033-3051
CCACCUCCCCAAAGGGAGU
930
ACUCCCUUUGGGGAGGUGG
1499


 


NM_001735.2_3039-3057_s
3039-3057
CCCCAAAGGGAGUGCAGAG
931
CUCUGCACUCCCUUUGGGG
1500


 


NM_001735.2_3050-3068_s
3050-3068
GUGCAGAGGCGGAGCUGAU
932
AUCAGCUCCGCCUCUGCAC
1501


 


NM_001735.2_3060-3078_s
3060-3078
GGAGCUGAUGAGCGUUGUC
933
GACAACGCUCAUCAGCUCC
1502


 


NM_001735.2_3072-3090_s
3072-3090
CGUUGUCCCAGUAUUCUAU
934
AUAGAAUACUGGGACAACG
1503


 


NM_001735.2_3079-3097_s
3079-3097
CCAGUAUUCUAUGUUUUUC
935
GAAAAACAUAGAAUACUGG
1504


 


NM_001735.2_3091-3109_s
3091-3109
GUUUUUCACUACCUGGAAA
936
UUUCCAGGUAGUGAAAAAC
1505


 


NM_001735.2_3102-3120_s
3102-3120
CCUGGAAACAGGAAAUCAU
937
AUGAUUUCCUGUUUCCAGG
1506


 


NM_001735.2_3122-3140_s
3122-3140
GGAACAUUUUUCAUUCUGA
938
UCAGAAUGAAAAAUGUUCC
1507


 


NM_001735.2_3133-3151_s
3133-3151
CAUUCUGACCCAUUAAUUG
939
CAAUUAAUGGGUCAGAAUG
1508


 


NM_001735.2_3142-3160_s
3142-3160
CCAUUAAUUGAAAAGCAGA
940
UCUGCUUUUCAAUUAAUGG
1509


 


NM_001735.2_3153-3171_s
3153-3171
AAAGCAGAAACUGAAGAAA
941
UUUCUUCAGUUUCUGCUUU
1510


 


NM_001735.2_3161-3179_s
3161-3179
AACUGAAGAAAAAAUUAAA
942
UUUAAUUUUUUCUUCAGUU
1511


 


NM_001735.2_3169-3187_s
3169-3187
AAAAAAUUAAAAGAAGGGA
943
UCCCUUCUUUUAAUUUUUU
1512


 


NM_001735.2_3183-3201_s
3183-3201
AGGGAUGUUGAGCAUUAUG
944
CAUAAUGCUCAACAUCCCU
1513


 


NM_001735.2_3192-3210_s
3192-3210
GAGCAUUAUGUCCUACAGA
945
UCUGUAGGACAUAAUGCUC
1514


 


NM_001735.2_3200-3218_s
3200-3218
UGUCCUACAGAAAUGCUGA
946
UCAGCAUUUCUGUAGGACA
1515


 


NM_001735.2_3211-3229_s
3211-3229
AAUGCUGACUACUCUUACA
947
UGUAAGAGUAGUCAGCAUU
1516


 


NM_001735.2_3220-3238_s
3220-3238
UACUCUUACAGUGUGUGGA
948
UCCACACACUGUAAGAGUA
1517


 


NM_001735.2_3229-3247_s
3229-3247
AGUGUGUGGAAGGGUGGAA
949
UUCCACCCUUCCACACACU
1518


 


NM_001735.2_3240-3258_s
3240-3258
GGGUGGAAGUGCUAGCACU
950
AGUGCUAGCACUUCCACCC
1519


 


NM_001735.2_3250-3268_s
3250-3268
GCUAGCACUUGGUUAACAG
951
CUGUUAACCAAGUGCUAGC
1520


 


NM_001735.2_3260-3278_s
3260-3278
GGUUAACAGCUUUUGCUUU
952
AAAGCAAAAGCUGUUAACC
1521


 


NM_001735.2_3273-3291_s
3273-3291
UGCUUUAAGAGUACUUGGA
953
UCCAAGUACUCUUAAAGCA
1522


 


NM_001735.2_3283-3301_s
3283-3301
GUACUUGGACAAGUAAAUA
954
UAUUUACUUGUCCAAGUAC
1523


 


NM_001735.2_3292-3310_s
3292-3317
CAAGUAAAUAAAUACGUAG
955
CUACGUAUUUAUUUACUUG
1524


 


NM_001735.2_3299-3317_s
3299-3317
AUAAAUACGUAGAGCAGAA
956
UUCUGCUCUACGUAUUUAU
1525


 


NM_001735.2_3310-3328_s
3310-3328
GAGCAGAACCAAAAUUCAA
957
UUGAAUUUUGGUUCUGCUC
1526


 


NM_001735.2_3322-3340_s
3322-3340
AAUUCAAUUUGUAAUUCUU
958
AAGAAUUACAAAUUGAAUU
1527


 


NM_001735.2_3332-3350_s
3332-3350
GUAAUUCUUUAUUGUGGCU
959
AGCCACAAUAAAGAAUUAC
1528


 


NM_001735.2_3342-3360_s
3342-3360
AUUGUGGCUAGUUGAGAAU
960
AUUCUCAACUAGCCACAAU
1529


 


NM_001735.2_3349-3367_s
3349-3367
CUAGUUGAGAAUUAUCAAU
961
AUUGAUAAUUCUCAACUAG
1530


 


NM_001735.2_3360-3378_s
3360-3378
UUAUCAAUUAGAUAAUGGA
962
UCCAUUAUCUAAUUGAUAA
1531


 


NM_001735.2_3373-3391_s
3373-3391
AAUGGAUCUUUCAAGGAAA
963
UUUCCUUGAAAGAUCCAUU
1532


 


NM_001735.2_3380-3398_s
3380-3398
CUUUCAAGGAAAAUUCACA
964
UGUGAAUUUUCCUUGAAAG
1533


 


NM_001735.2_3391-3409_s
3391-3409
AAUUCACAGUAUCAACCAA
965
UUGGUUGAUACUGUGAAUU
1534


 


NM_001735.2_3399-3417_s
3399-3417
GUAUCAACCAAUAAAAUUA
966
UAAUUUUAUUGGUUGAUAC
1535


 


NM_001735.2_3411-3429_s
3411-3429
AAAAUUACAGGGUACCUUG
967
CAAGGUACCCUGUAAUUUU
1536


 


NM_001735.2_3419-3437_s
3419-3437
AGGGUACCUUGCCUGUUGA
968
UCAACAGGCAAGGUACCCU
1537


 


NM_001735.2_3433-3451_s
3433-3451
GUUGAAGCCCGAGAGAACA
969
UGUUCUCUCGGGCUUCAAC
1538


 


NM_001735.2_3441-3459_s
3441-3559
CCGAGAGAACAGCUUAUAU
970
AUAUAAGCUGUUCUCUCGG
1539


 


NM_001735.2_3452-3470_s
3452-3470
GCUUAUAUCUUACAGCCUU
971
AAGGCUGUAAGAUAUAAGC
1540


 


NM_001735.2_3460-3478_s
3460-3478
CUUACAGCCUUUACUGUGA
972
UCACAGUAAAGGCUGUAAG
1541


 


NM_001735.2_3482-3500_s
3482-3500
GAAUUAGAAAGGCUUUCGA
973
UCGAAAGCCUUUCUAAUUC
1542


 


NM_001735.2_3492-3510_s
3492-3510
GGCUUUCGAUAUAUGCCCC
974
GGGGCAUAUAUCGAAAGCC
1543


 


NM_001735.2_3499-3517_s
3499-3517
GAUAUAUGCCCCCUGGUGA
975
UCACCAGGGGGCAUAUAUC
1544


 


NM_001735.2_3513-3531_s
3513-3531
GGUGAAAAUCGACACAGCU
976
AGCUGUGUCGAUUUUCACC
1545


 


NM_001735.2_3522-3540_s
3522-3540
CGACACAGCUCUAAUUAAA
977
UUUAAUUAGAGCUGUGUCG
1546


 


NM_001735.2_3529-3547_s
3529-3547
GCUCUAAUUAAAGCUGACA
978
UGUCAGCUUUAAUUAGAGC
1547


 


NM_001735.2_3542-3560_s
3542-3560
CUGACAACUUUCUGCUUGA
979
UCAAGCAGAAAGUUGUCAG
1548


 


NM_001735.2_3549-3567_s
3549-3567
CUUUCUGCUUGAAAAUACA
980
UGUAUUUUCAAGCAGAAAG
1549


 


NM_001735.2_3560-3578_s
3560-3578
AAAAUACACUGCCAGCCCA
981
UGGGCUGGCAGUGUAUUUU
1550


 


NM_001735.2_3573-3591_s
3573-3591
AGCCCAGAGCACCUUUACA
982
UGUAAAGGUGCUCUGGGCU
1551


 


NM_001735.2_3581-3599_s
3581-3599
GCACCUUUACAUUGGCCAU
983
AUGGCCAAUGUAAAGGUGC
1552


 


NM_001735.2_3589-3607_s
3589-3607
ACAUUGGCCAUUUCUGCGU
984
ACGCAGAAAUGGCCAAUGU
1553


 


NM_001735.2_3602-3620_s
3602-3620
CUGCGUAUGCUCUUUCCCU
985
AGGGAAAGAGCAUACGCAG
1554


 


NM_001735.2_3613-3631_s
3613-3631
CUUUCCCUGGGAGAUAAAA
986
UUUUAUCUCCCAGGGAAAG
1555


 


NM_001735.2_3623-3641_s
3623-3641
GAGAUAAAACUCACCCACA
987
UGUGGGUGAGUUUUAUCUC
1556


 


NM_001735.2_3631-3649_s
3631-3649
ACUCACCCACAGUUUCGUU
988
AACGAAACUGUGGGUGAGU
1557


 


NM_001735.2_3640-3658_s
3640-3658
CAGUUUCGUUCAAUUGUUU
989
AAACAAUUGAACGAAACUG
1558


 


NM_001735.2_3650-3668_s
3650-3668
CAAUUGUUUCAGCUUUGAA
990
UUCAAAGCUGAAACAAUUG
1559


 


NM_001735.2_3662-3680_s
3662-3680
CUUUGAAGAGAGAAGCUUU
991
AAAGCUUCUCUCUUCAAAG
1560


 


NM_001735.2_3669-3687_s
3669-3687
GAGAGAAGCUUUGGUUAAA
992
UUUAACCAAAGCUUCUCUC
1561


 


NM_001735.2_3682-3700_s
3682-3700
GUUAAAGGUAAUCCACCCA
993
UGGGUGGAUUACCUUUAAC
1562


 


NM_001735.2_3691-3709_s
3691-3709
AAUCCACCCAUUUAUCGUU
994
AACGAUAAAUGGGUGGAUU
1563


 


NM_001735.2_3699-3717_s
3699-3717
CAUUUAUCGUUUUUGGAAA
995
UUUCCAAAAACGAUAAAUG
1564


 


NM_001735.2_3710-3728_s
3710-3728
UUUGGAAAGACAAUCUUCA
996
UGAAGAUUGUCUUUCCAAA
1565


 


NM_001735.2_3721-3739_s
3721-3739
AAUCUUCAGCAUAAAGACA
997
UGUCUUUAUGCUGAAGAUU
1566


 


NM_001735.2_3730-3748_s
3730-3748
CAUAAAGACAGCUCUGUAC
998
GUACAGAGCUGUCUUUAUG
1567


 


NM_001735.2_3741-3759_s
3741-3759
CUCUGUACCUAACACUGGU
999
ACCAGUGUUAGGUACAGAG
1568


 


NM_001735.2_3752-3770_s
3752-3770
ACACUGGUACGGCACGUAU
1000
AUACGUGCCGUACCAGUGU
1569


 


NM_001735.2_3762-3780_s
3762-3780
GGCACGUAUGGUAGAAACA
1001
UGUUUCUACCAUACGUGCC
1570


 


NM_001735.2_3771-3789_s
3771-3789
GGUAGAAACAACUGCCUAU
1002
AUAGGCAGUUGUUUCUACC
1571


 


NM_001735.2_3779-3797_s
3779-3797
CAACUGCCUAUGCUUUACU
1003
AGUAAAGCAUAGGCAGUUG
1572


 


NM_001735.2_3791-3809_s
3791-3809
CUUUACUCACCAGUCUGAA
1004
UUCAGACUGGUGAGUAAAG
1573


 


NM_001735.2_3803-3821_s
3803-3821
GUCUGAACUUGAAAGAUAU
1005
AUAUCUUUCAAGUUCAGAC
1574


 


NM_001735.2_3809-3827_s
3809-3827
ACUUGAAAGAUAUAAAUUA
1006
UAAUUUAUAUCUUUCAAGU
1575


 


NM_001735.2_3819-3837_s
3819-3837
UAUAAAUUAUGUUAACCCA
1007
UGGGUUAACAUAAUUUAUA
1576


 


NM_001735.2_3829-3847_s
3829-3847
GUUAACCCAGUCAUCAAAU
1008
AUUUGAUGACUGGGUUAAC
1577


 


NM_001735.2_3839-3857_s
3839-3857
UCAUCAAAUGGCUAUCAGA
1009
UCUGAUAGCCAUUUGAUGA
1578


 


NM_001735.2_3851-3869_s
3851-3869
UAUCAGAAGAGCAGAGGUA
1010
UACCUCUGCUCUUCUGAUA
1579


 


NM_001735.2_3863-3881_s
3863-3881
AGAGGUAUGGAGGUGGCUU
1011
AAGCCACCUCCAUACCUCU
1580


 


NM_001735.2_3872-3890_s
3872-3890
GAGGUGGCUUUUAUUCAAC
1012
GUUGAAUAAAAGCCACCUC
1581


 


NM_001735.2_3883-3901_s
3883-3901
UAUUCAACCCAGGACACAA
1013
UUGUGUCCUGGGUUGAAUA
1582


 


NM_001735.2_3893-3911_s
3893-3911
AGGACACAAUCAAUGCCAU
1014
AUGGCAUUGAUUGUGUCCU
1583


 


NM_001735.2_3899-3917_s
3899-3917
CAAUCAAUGCCAUUGAGGG
1015
CCCUCAAUGGCAUUGAUUG
1584


 


NM_001735.2_3909-3927_s
3909-3927
CAUUGAGGGCCUGACGGAA
1016
UUCCGUCAGGCCCUCAAUG
1585


 


NM_001735.2_3922-3940_s
3922-3940
ACGGAAUAUUCACUCCUGG
1017
CCAGGAGUGAAUAUUCCGU
1586


 


NM_001735.2_3930-3948_s
3930-3948
UUCACUCCUGGUUAAACAA
1018
UUGUUUAACCAGGAGUGAA
1587


 


NM_001735.2_3939-3957_s
3939-3957
GGUUAAACAACUCCGCUUG
1019
CAAGCGGAGUUGUUUAACC
1588


 


NM_001735.2_3951-3969_s
3951-3969
CCGCUUGAGUAUGGACAUC
1020
GAUGUCCAUACUCAAGCGG
1589


 


NM_001735.2_3963-3981_s
3963-3981
GGACAUCGAUGUUUCUUAC
1021
GUAAGAAACAUCGAUGUCC
1590


 


NM_001735.2_3969-3987_s
3969-3987
CGAUGUUUCUUACAAGCAU
1022
AUGCUUGUAAGAAACAUCG
1591


 


NM_001735.2_3981-3999_s
3981-3999
CAAGCAUAAAGGUGCCUUA
1023
UAAGGCACCUUUAUGCUUG
1592


 


NM_001735.2_3992-4010_s
3992-4010
GUGCCUUACAUAAUUAUAA
1024
UUAUAAUUAUGUAAGGCAC
1593


 


NM_001735.2_3999-4017_s
3999-4017
ACAUAAUUAUAAAAUGACA
1025
UGUCAUUUUAUAAUUAUGU
1594


 


NM_001735.2_4009-4027_s
4009-4027
AAAAUGACAGACAAGAAUU
1026
AAUUCUUGUCUGUCAUUUU
1595


 


NM_001735.2_4020-4038_s
4020-4038
CAAGAAUUUCCUUGGGAGG
1027
CCUCCCAAGGAAAUUCUUG
1596


 


NM_001735.2_4029-4047_s
4029-4047
CCUUGGGAGGCCAGUAGAG
1028
CUCUACUGGCCUCCCAAGG
1597


 


NM_001735.2_4041-4059_s
4041-4059
AGUAGAGGUGCUUCUCAAU
1029
AUUGAGAAGCACCUCUACU
1598


 


NM_001735.2_4051-4069_s
4051-4069
CUUCUCAAUGAUGACCUCA
1030
UGAGGUCAUCAUUGAGAAG
1599


 


NM_001735.2_4062-4080_s
4062-4080
UGACCUCAUUGUCAGUACA
1031
UGUACUGACAAUGAGGUCA
1600


 


NM_001735.2_4072-4090_s
4072-4090
GUCAGUACAGGAUUUGGCA
1032
UGCCAAAUCCUGUACUGAC
1601


 


NM_001735.2_4080-4098_s
4080-4098
AGGAUUUGGCAGUGGCUUG
1033
CAAGCCACUGCCAAAUCCU
1602


 


NM_001735.2_4092-4110_s
4092-4110
UGGCUUGGCUACAGUACAU
1034
AUGUACUGUAGCCAAGCCA
1603


 


NM_001735.2_4099-4117_s
4099-4117
GCUACAGUACAUGUAACAA
1035
UUGUUACAUGUACUGUAGC
1604


 


NM_001735.2_4113-4131_s
4113-4131
AACAACUGUAGUUCACAAA
1036
UUUGUGAACUACAGUUGUU
1605


 


NM_001735.2_4120-4138_s
4120-4138
GUAGUUCACAAAACCAGUA
1037
UACUGGUUUUGUGAACUAC
1606


 


NM_001735.2_4130-4148_s
4130-4148
AAACCAGUACCUCUGAGGA
1038
UCCUCAGAGGUACUGGUUU
1607


 


NM_001735.2_4143-4161_s
4143-4161
UGAGGAAGUUUGCAGCUUU
1039
AAAGCUGCAAACUUCCUCA
1608


 


NM_001735.2_4153-4171_s
4153-4171
UGCAGCUUUUAUUUGAAAA
1040
UUUUCAAAUAAAAGCUGCA
1609


 


NM_001735.2_4163-4181_s
4163-4181
AUUUGAAAAUCGAUACUCA
1041
UGAGUAUCGAUUUUCAAAU
1610


 


NM_001735.2_4173-4191_s
4173-4191
CGAUACUCAGGAUAUUGAA
1042
UUCAAUAUCCUGAGUAUCG
1611


 


NM_001735.2_4182-4200_s
4182-4200
GGAUAUUGAAGCAUCCCAC
1043
GUGGGAUGCUUCAAUAUCC
1612


 


NM_001735.2_4189-4207_s
4189-4207
GAAGCAUCCCACUACAGAG
1044
CUCUGUAGUGGGAUGCUUC
1613


 


NM_001735.2_4199-4217_s
4199-4217
ACUACAGAGGCUACGGAAA
1045
UUUCCGUAGCCUCUGUAGU
1614


 


NM_001735.2_4212-4230_s
4212-4230
CGGAAACUCUGAUUACAAA
1046
UUUGUAAUCAGAGUUUCCG
1615


 


NM_001735.2_4221-4239_s
4221-4239
UGAUUACAAACGCAUAGUA
1047
UACUAUGCGUUUGUAAUCA
1616


 


NM_001735.2_4232-4250_s
4232-4250
GCAUAGUAGCAUGUGCCAG
1048
CUGGCACAUGCUACUAUGC
1617


 


NM_001735.2_4240-4258_s
4240-4258
GCAUGUGCCAGCUACAAGC
1049
GCUUGUAGCUGGCACAUGC
1618


 


NM_001735.2_4251-4269_s
4251-4269
CUACAAGCCCAGCAGGGAA
1050
UUCCCUGCUGGGCUUGUAG
1619


 


NM_001735.2_4260-4278_s
4260-4278
CAGCAGGGAAGAAUCAUCA
1051
UGAUGAUUCUUCCCUGCUG
1620


 


NM_001735.2_4270-4288_s
4270-4288
GAAUCAUCAUCUGGAUCCU
1052
AGGAUCCAGAUGAUGAUUC
1621


 


NM_001735.2_4283-4301_s
4283-4301
GAUCCUCUCAUGCGGUGAU
1053
AUCACCGCAUGAGAGGAUC
1622


 


NM_001735.2_4289-4307_s
4289-4307
CUCAUGCGGUGAUGGACAU
1054
AUGUCCAUCACCGCAUGAG
1623


 


NM_001735.2_4299-4317_s
4299-4317
GAUGGACAUCUCCUUGCCU
1055
AGGCAAGGAGAUGUCCAUC
1624


 


NM_001735.2_4311-4329_s
4311-4329
CUUGCCUACUGGAAUCAGU
1056
ACUGAUUCCAGUAGGCAAG
1625


 


NM_001735.2_4322-4340_s
4322-4340
GAAUCAGUGCAAAUGAAGA
1057
UCUUCAUUUGCACUGAUUC
1626


 


NM_001735.2_4332-4350_s
4332-4350
AAAUGAAGAAGACUUAAAA
1058
UUUUAAGUCUUCUUCAUUU
1627


 


NM_001735.2_4339-4357_s
4339-4357
GAAGACUUAAAAGCCCUUG
1059
CAAGGGCUUUUAAGUCUUC
1628


 


NM_001735.2_4353-4371_s
4353-4371
CCUUGUGGAAGGGGUGGAU
1060
AUCCACCCCUUCCACAAGG
1629


 


NM_001735.2_4360-4378_s
4360-4378
GAAGGGGUGGAUCAACUAU
1061
AUAGUUGAUCCACCCCUUC
1630


 


NM_001735.2_4370-4388_s
4370-4388
AUCAACUAUUCACUGAUUA
1062
UAAUCAGUGAAUAGUUGAU
1631


 


NM_001735.2_4380-4398_s
4380-4398
CACUGAUUACCAAAUCAAA
1063
UUUGAUUUGGUAAUCAGUG
1632


 


NM_001735.2_4393-4411_s
4393-4411
AUCAAAGAUGGACAUGUUA
1064
UAACAUGUCCAUCUUUGAU
1633


 


NM_001735.2_4402-4420_s
4402-4420
GGACAUGUUAUUCUGCAAC
1065
GUUGCAGAAUAACAUGUCC
1634


 


NM_001735.2_4413-4431_s
4413-4431
UCUGCAACUGAAUUCGAUU
1066
AAUCGAAUUCAGUUGCAGA
1635


 


NM_001735.2_4422-4440_s
4422-4440
GAAUUCGAUUCCCUCCAGU
1067
ACUGGAGGGAAUCGAAUUC
1636


 


NM_001735.2_4432-4450_s
4432-4450
CCCUCCAGUGAUUUCCUUU
1068
AAAGGAAAUCACUGGAGGG
1637


 


NM_001735.2_4441-4459_s
4441-4459
GAUUUCCUUUGUGUACGAU
1069
AUCGUACACAAAGGAAAUC
1638


 


NM_001735.2_4453-4471_s
4453-4471
GUACGAUUCCGGAUAUUUG
1070
CAAAUAUCCGGAAUCGUAC
1639


 


NM_001735.2_4462-4480_s
4462-4480
CGGAUAUUUGAACUCUUUG
1071
CAAAGAGUUCAAAUAUCCG
1640


 


NM_001735.2_4473-4491_s
4473-4491
ACUCUUUGAAGUUGGGUUU
1072
AAACCCAACUUCAAAGAGU
1641


 


NM_001735.2_4482-4500_s
4482-4500
AGUUGGGUUUCUCAGUCCU
1073
AGGACUGAGAAACCCAACU
1642


 


NM_001735.2_4490-4508_s
4490-4508
UUCUCAGUCCUGCCACUUU
1074
AAAGUGGCAGGACUGAGAA
1643


 


NM_001735.2_4503-4521_s
4503-4521
CACUUUCACAGUGUACGAA
1075
UUCGUACACUGUGAAAGUG
1644


 


NM_001735.2_4509-4527_s
4509-4527
CACAGUGUACGAAUACCAC
1076
GUGGUAUUCGUACACUGUG
1645


 


NM_001735.2_4523-4541_s
4523-4541
ACCACAGACCAGAUAAACA
1077
UGUUUAUCUGGUCUGUGGU
1646


 


NM_001735.2_4531-4549_s
4531-4549
CCAGAUAAACAGUGUACCA
1078
UGGUACACUGUUUAUCUGG
1647


 


NM_001735.2_4540-4558_s
4540-4558
CAGUGUACCAUGUUUUAUA
1079
UAUAAAACAUGGUACACUG
1648


 


NM_001735.2_4551-4569_s
4551-4569
GUUUUAUAGCACUUCCAAU
1080
AUUGGAAGUGCUAUAAAAC
1649


 


NM_001735.2_4562-4580_s
4562-4580
CUUCCAAUAUCAAAAUUCA
1081
UGAAUUUUGAUAUUGGAAG
1650


 


NM_001735.2_4570-4588_s
4570-4588
AUCAAAAUUCAGAAAGUCU
1082
AGACUUUCUGAAUUUUGAU
1651


 


NM_001735.2_4581-4599_s
4581-4599
GAAAGUCUGUGAAGGAGCC
1083
GGCUCCUUCACAGACUUUC
1652


 


NM_001735.2_4591-4609_s
4591-4609
GAAGGAGCCGCGUGCAAGU
1084
ACUUGCACGCGGCUCCUUC
1653


 


NM_001735.2_4601-4619_s
4601-4619
CGUGCAAGUGUGUAGAAGC
1085
GCUUCUACACACUUGCACG
1654


 


NM_001735.2_4612-4630_s
4612-4630
GUAGAAGCUGAUUGUGGGC
1086
GCCCACAAUCAGCUUCUAC
1655


 


NM_001735.2_4619-4637_s
4619-4637
CUGAUUGUGGGCAAAUGCA
1087
UGCAUUUGCCCACAAUCAG
1656


 


NM_001735.2_4629-4647_s
4629-4647
GCAAAUGCAGGAAGAAUUG
1088
CAAUUCUUCCUGCAUUUGC
1657


 


NM_001735.2_4639-4657_s
4639-4657
GAAGAAUUGGAUCUGACAA
1089
UUGUCAGAUCCAAUUCUUC
1658


 


NM_001735.2_4651-4669_s
4651-4669
CUGACAAUCUCUGCAGAGA
1090
UCUCUGCAGAGAUUGUCAG
1659


 


NM_001735.2_4663-4681_s
4663-4681
GCAGAGACAAGAAAACAAA
1091
UUUGUUUUCUUGUCUCUGC
1660


 


NM_001735.2_4670-4688_s
4670-4688
CAAGAAAACAAACAGCAUG
1092
CAUGCUGUUUGUUUUCUUG
1661


 


NM_001735.2_4681-4699_s
4681-4699
ACAGCAUGUAAACCAGAGA
1093
UCUCUGGUUUACAUGCUGU
1662


 


NM_001735.2_4693-4711_s
4693-4711
CCAGAGAUUGCAUAUGCUU
1094
AAGCAUAUGCAAUCUCUGG
1663


 


NM_001735.2_4702-4720_s
4702-4720
GCAUAUGCUUAUAAAGUUA
1095
UAACUUUAUAAGCAUAUGC
1664


 


NM_001735.2_4710-4728_s
4710-4728
UUAUAAAGUUAGCAUCACA
1096
UGUGAUGCUAACUUUAUAA
1665


 


NM_001735.2_4722-4740_s
4722-4740
CAUCACAUCCAUCACUGUA
1097
UACAGUGAUGGAUGUGAUG
1666


 


NM_001735.2_4733-4751_s
4733-4751
UCACUGUAGAAAAUGUUUU
1098
AAAACAUUUUCUACAGUGA
1667


 


NM_001735.2_4740-4758_s
4740-4758
AGAAAAUGUUUUUGUCAAG
1099
CUUGACAAAAACAUUUUCU
1668


 


NM_001735.2_4750-4768_s
4750-4768
UUUGUCAAGUACAAGGCAA
1100
UUGCCUUGUACUUGACAAA
1669


 


NM_001735.2_4763-4781_s
4763-4781
AGGCAACCCUUCUGGAUAU
1101
AUAUCCAGAAGGGUUGCCU
1670


 


NM_001735.2_4770-4788_s
4770-4788
CCUUCUGGAUAUCUACAAA
1102
UUUGUAGAUAUCCAGAAGG
1671


 


NM_001735.2_4779-4797_s
4779-4797
UAUCUACAAAACUGGGGAA
1103
UUCCCCAGUUUUGUAGAUA
1672


 


NM_001735.2_4790-4808_s
4790-4808
CUGGGGAAGCUGUUGCUGA
1104
UCAGCAACAGCUUCCCCAG
1673


 


NM_001735.2_4799-4817_s
4799-4817
CUGUUGCUGAGAAAGACUC
1105
GAGUCUUUCUCAGCAACAG
1674


 


NM_001735.2_4813-4831_s
4813-4831
GACUCUGAGAUUACCUUCA
1106
UGAAGGUAAUCUCAGAGUC
1675


 


NM_001735.2_4819-4837_s
4819-4837
GAGAUUACCUUCAUUAAAA
1107
UUUUAAUGAAGGUAAUCUC
1676


 


NM_001735.2_4831-4849_s
4831-4849
AUUAAAAAGGUAACCUGUA
1108
UACAGGUUACCUUUUUAAU
1677


 


NM_001735.2_4841-4859_s
4841-4859
UAACCUGUACUAACGCUGA
1109
UCAGCGUUAGUACAGGUUA
1678


 


NM_001735.2_4850-4868_s
4850-4868
CUAACGCUGAGCUGGUAAA
1110
UUUACCAGCUCAGCGUUAG
1679


 


NM_001735.2_4863-4881_s
4863-4881
GGUAAAAGGAAGACAGUAC
1111
GUACUGUCUUCCUUUUACC
1680


 


NM_001735.2_4871-4889_s
4871-4889
GAAGACAGUACUUAAUUAU
1112
AUAAUUAAGUACUGUCUUC
1681


 


NM_001735.2_4881-4899_s
4881-4899
CUUAAUUAUGGGUAAAGAA
1113
UUCUUUACCCAUAAUUAAG
1682


 


NM_001735.2_4893-4911_s
4893-4911
UAAAGAAGCCCUCCAGAUA
1114
UAUCUGGAGGGCUUCUUUA
1683


 


NM_001735.2_4902-4920_s
4902-4920
CCUCCAGAUAAAAUACAAU
1115
AUUGUAUUUUAUCUGGAGG
1684


 


NM_001735.2_4912-4930_s
4912-4930
AAAUACAAUUUCAGUUUCA
1116
UGAAACUGAAAUUGUAUUU
1685


 


NM_001735.2_4923-4941_s
4923-4941
CAGUUUCAGGUACAUCUAC
1117
GUAGAUGUACCUGAAACUG
1686


 


NM_001735.2_4931-4949_s
4931-4949
GGUACAUCUACCCUUUAGA
1118
UCUAAAGGGUAGAUGUACC
1687


 


NM_001735.2_4942-4960_s
4942-4960
CCUUUAGAUUCCUUGACCU
1119
AGGUCAAGGAAUCUAAAGG
1688


 


NM_001735.2_4952-4970_s
4952-4970
CCUUGACCUGGAUUGAAUA
1120
UAUUCAAUCCAGGUCAAGG
1689


 


NM_001735.2_4961-4979_s
4961-4979
GGAUUGAAUACUGGCCUAG
1121
CUAGGCCAGUAUUCAAUCC
1690


 


NM_001735.2_4971-4989_s
4971-4989
CUGGCCUAGAGACACAACA
1122
UGUUGUGUCUCUAGGCCAG
1691


 


NM_001735.2_4979-4997_s
4979-4997
GAGACACAACAUGUUCAUC
1123
GAUGAACAUGUUGUGUCUC
1692


 


NM_001735.2_4991-5009_s
4991-5009
GUUCAUCGUGUCAAGCAUU
1124
AAUGCUUGACACGAUGAAC
1693


 


NM_001735.2_5000-5018_s
5000-5018
GUCAAGCAUUUUUAGCUAA
1125
UUAGCUAAAAAUGCUUGAC
1694


 


NM_001735.2_5013-5031_s
5013-5031
AGCUAAUUUAGAUGAAUUU
1126
AAAUUCAUCUAAAUUAGCU
1695


 


NM_001735.2_5022-5040_s
5022-5040
AGAUGAAUUUGCCGAAGAU
1127
AUCUUCGGCAAAUUCAUCU
1696


 


NM_001735.2_5033-5051_s
5033-5051
CCGAAGAUAUCUUUUUAAA
1128
UUUAAAAAGAUAUCUUCGG
1697


 


NM_001735.2_5043-5061_s
5043-5061
CUUUUUAAAUGGAUGCUAA
1129
UUAGCAUCCAUUUAAAAAG
1698


 


NM_001735.2_5053-5071_s
5053-5071
GGAUGCUAAAAUUCCUGAA
1130
UUCAGGAAUUUUAGCAUCC
1699


 


NM_001735.2_5059-5077_s
5059-5077
UAAAAUUCCUGAAGUUCAG
1131
CUGAACUUCAGGAAUUUUA
1700


 


NM_001735.2_5071-5089_s
5071-5089
AGUUCAGCUGCAUACAGUU
1132
AACUGUAUGCAGCUGAACU
1701


 


NM_001735.2_5080-5098_s
5080-5098
GCAUACAGUUUGCACUUAU
1133
AUAAGUGCAAACUGUAUGC
1702


 


NM_001735.2_5093-5111_s
5093-5111
ACUUAUGGACUCCUGUUGU
1134
ACAACAGGAGUCCAUAAGU
1703


 


NM_001735.2_5099-5117_s
5099-5117
GGACUCCUGUUGUUGAAGU
1135
ACUUCAACAACAGGAGUCC
1704


 


NM_001735.2_5109-5127_s
5109-5127
UGUUGAAGUUCGUUUUUUU
1136
AAAAAAACGAACUUCAACA
1705


 


NM_001735.2_5122-5140_s
5122-5140
UUUUUUGUUUUCUUCUUUU
1137
AAAAGAAGAAAACAAAAAA
1706


 


NM_001735.2_5132-5150_s
5132-5150
UCUUCUUUUUUUAAACAUU
1138
AAUGUUUAAAAAAAGAAGA
1707


 


NM_001735.2_5139-5157_s
5139-5157
UUUUUAAACAUUCAUAGCU
1139
AGCUAUGAAUGUUUAAAAA
1708


 


NM_001735.2_5152-5170_s
5152-5170
AUAGCUGGUCUUAUUUGUA
1140
UACAAAUAAGACCAGCUAU
1709


 


NM_001735.2_5159-5177_s
5159-5177
GUCUUAUUUGUAAAGCUCA
1141
UGAGCUUUACAAAUAAGAC
1710


 


NM_001735.2_5170-5188_s
5170-5188
AAAGCUCACUUUACUUAGA
1142
UCUAAGUAAAGUGAGCUUU
1711


 


NM_001735.2_5182-5200_s
5182-5200
ACUUAGAAUUAGUGGCACU
1143
AGUGCCACUAAUUCUAAGU
1712


 


NM_001735.2_5192-5210_s
5192-5210
AGUGGCACUUGCUUUUAUU
1144
AAUAAAAGCAAGUGCCACU
1713


 


NM_001735.2_5202-5220_s
5202-5220
GCUUUUAUUAGAGAAUGAU
1145
AUCAUUCUCUAAUAAAAGC
1714


 


NM_001735.2_5212-5230_s
5212-5230
GAGAAUGAUUUCAAAUGCU
1146
AGCAUUUGAAAUCAUUCUC
1715


 


NM_001735.2_5220-5238_s
5220-5238
UUUCAAAUGCUGUAACUUU
1147
AAAGUUACAGCAUUUGAAA
1716


 


NM_001735.2_5231-5249_s
5231-5249
GUAACUUUCUGAAAUAACA
1148
UGUUAUUUCAGAAAGUUAC
1717


 


NM_001735.2_5241-5259_s
5241-5259
GAAAUAACAUGGCCUUGGA
1149
UCCAAGGCCAUGUUAUUUC
1718


 


NM_001735.2_5253-5271_s
5253-5271
CCUUGGAGGGCAUGAAGAC
1150
GUCUUCAUGCCCUCCAAGG
1719


 


NM_001735.2_5259-5277_s
5259-5277
AGGGCAUGAAGACAGAUAC
1151
GUAUCUGUCUUCAUGCCCU
1720


 


NM_001735.2_5273-5291_s
5273-5291
GAUACUCCUCCAAGGUUAU
1152
AUAACCUUGGAGGAGUAUC
1721


 


NM_001735.2_5279-5297_s
5279-5297
CCUCCAAGGUUAUUGGACA
1153
UGUCCAAUAACCUUGGAGG
1722


 


NM_001735.2_5293-5311_s
5293-5311
GGACACCGGAAACAAUAAA
1154
UUUAUUGUUUCCGGUGUCC
1723


 


NM_001735.2_5301-5319_s
5301-5319
GAAACAAUAAAUUGGAACA
1155
UGUUCCAAUUUAUUGUUUC
1724


 


NM_001735.2_5311-5329_s
5311-5329
AUUGGAACACCUCCUCAAA
1156
UUUGAGGAGGUGUUCCAAU
1725


 


NM_001735.2_5322-5340_s
5322-5340
UCCUCAAACCUACCACUCA
1157
UGAGUGGUAGGUUUGAGGA
1726


 


NM_001735.2_5331-5349_s
5331-5349
CUACCACUCAGGAAUGUUU
1158
AAACAUUCCUGAGUGGUAG
1727


 


NM_001735.2_5343-5361_s
5343-5361
AAUGUUUGCUGGGGCCGAA
1159
UUCGGCCCCAGCAAACAUU
1728


 


NM_001735.2_5349-5367_s
5349-5367
UGCUGGGGCCGAAAGAACA
1160
UGUUCUUUCGGCCCCAGCA
1729


 


NM_001735.2_5360-5378_s
5360-5378
AAAGAACAGUCCAUUGAAA
1161
UUUCAAUGGACUGUUCUUU
1730


 


NM_001735.2_5371-5389_s
5371-5389
CAUUGAAAGGGAGUAUUAC
1162
GUAAUACUCCCUUUCAAUG
1731


 


NM_001735.2_5380-5398_s
5380-5398
GGAGUAUUACAAAAACAUG
1163
CAUGUUUUUGUAAUACUCC
1732


 


NM_001735.2_5391-5409_s
5391-5409
AAAACAUGGCCUUUGCUUG
1164
CAAGCAAAGGCCAUGUUUU
1733


 


NM_001735.2_5399-5417_s
5399-5417
GCCUUUGCUUGAAAGAAAA
1165
UUUUCUUUCAAGCAAAGGC
1734


 


NM_001735.2_5409-5427_s
5409-5427
GAAAGAAAAUACCAAGGAA
1166
UUCCUUGGUAUUUUCUUUC
1735


 


NM_001735.2_5420-5438_s
5420-5438
CCAAGGAACAGGAAACUGA
1167
UCAGUUUCCUGUUCCUUGG
1736


 


NM_001735.2_5433-5451_s
5433-5451
AACUGAUCAUUAAAGCCUG
1168
CAGGCUUUAAUGAUCAGUU
1737


 


NM_001735.2_5441-5459_s
5441-5459
AUUAAAGCCUGAGUUUGCU
1169
AGCAAACUCAGGCUUUAAU
1738









Example 5
In Vivo C5 Silencing
Groups of three female cynomolgus macaques were treated with C5-siRNA AD-58641 subcutaneously in the scapular and mid-dorsal areas of the back at 2.5 mg/kg or 5 mg/kg doses or a vehicle control. Two rounds of dosing were administered with eight doses in each round given every third day. Serum C5 was collected and evaluated using an ELISA assay specific for C5 detection (Abcam) at the indicated time points (FIG. 13). C5 levels were normalized to the average of three pre-dose samples. Samples collected prior to dosing, and on day 23 (24 hours after the last dose administered in the first round of treatment) were analyzed by complete serum chemistry, hematology and coagulation panels.
Analysis of serum C5 protein levels relative to pre-treatment serum C5 protein levels demonstrated that the 5 mg/kg AD-58641 dosing regimen reduced serum C5 protein levels up to 98% (FIG. 12). The average serum C5 levels were reduced by 97% at the nadir, indicating that the majority of circulating C5 is hepatic in origin. There was potent, dose-dependent and durable knock-down of serum C5 protein levels with subcutaneous administration of AD-58641. No changes in hematology, serum chemistry or coagulation parameters were identified 24 hours after the first round of dosing.
Serum hemolytic activity was also analyzed using a sensitized sheep erythrocyte assay to measure classical pathway activity. The percent hemolysis was calculated relative to maximal hemolysis and to background hemolysis in control samples. Mean hemolysis values+/−the SEM for three animals were calculated and analyzed (FIG. 13). Hemolysis was reduced up to 94% in the 5 mg/kg dosing regimen with an average inhibition of 92% at the nadir. The reduction in hemolysis was maintained for greater than two weeks following the last dose.
Example 6
In Vitro Screening of Additional siRNAs
The C5 sense and antisense strand sequences shown in Table 20 were modified at the 3′-terminus with a short sequence of deoxy-thymine nucleotides (dT) (Table 21). The in vitro efficacy of duplexes comprising the sense and antisense sequences listed in Table 21 was determined using the following methods.
Cell Culture and Transfections
Hep3B cells (ATCC, Manassas, Va.) were grown to near confluence at 37° C. in an atmosphere of 5% CO2 in EMEM (ATCC) supplemented with 10% FBS, before being released from the plate by trypsinization. Transfection was carried out by adding 5 μl of Opti-MEM plus 0.1 μl of Lipofectamine RNAiMax per well (Invitrogen, Carlsbad Calif. cat #13778-150) to 5 μl of siRNA duplexes per well into a 384-well plate and incubated at room temperature for 15 minutes. 40 μl of complete growth media containing  ̃5×103 Hep3B cells were then added to the siRNA mixture. Cells were incubated for 24 hours prior to RNA purification. Experiments were performed at 10 nM final duplex concentration.
Total RNA Isolation Using DYNABEADS mRNA Isolation Kit (Invitrogen, Part #: 610-12)
RNA isolation was performed using a semi-automated process of a Biotek EL 405 washer. Briefly, cells were lysed in 75 μl of Lysis/Binding Buffer containing 2 ul of Dynabeads, then mixed for 10 minutes on setting 7 of an electromagnetic shaker (Union Scientific). Magnetic beads were captured using magnetic stand and the supernatant was removed. After removing supernatant, magnetic beads were washed with 90 μl Wash Buffer A, followed by 90 μl of Wash buffer B. Beads were then washed twice with 100 ul of Elution buffer which was then aspirated and cDNA generated directly on bead bound RNA in the 384 well plate.
cDNA Synthesis Using ABI High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, Calif., Cat #4368813)
A master mix of 2 μl 10× Buffer, 0.8 μl 25×dNTPs, 2 μl Random primers, 1 μl Reverse Transcriptase, 1 μl RNase inhibitor and 3.2 μl of H2O per reaction were added directly to the bead bound RNA in the 384 well plates used for RNA isolation. Plates were then shaken on an electromagnetic shaker for 10 minutes and then placed in a 37° C. incubator for 2 hours. Following this incubation, plates were place on a shake in an 80° C. incubator for 7 minutes to inactivate the enzyme and elute the RNA/cDNA from the beads.
Real Time PCR
2 μl of cDNA were added to a master mix containing 0.5 μl GAPDH TaqMan Probe (Applied Biosystems Cat #4326317E), 0.5 μl C5 TaqMan probe (Applied Biosystems cat #Hs00156197_M1) and 5 μl Lightcycler 480 probe master mix (Roche Cat #04887301001) per well in a 384 well plates (Roche cat #04887301001). Real time PCR was done in a Roche LC480 Real Time PCR system (Roche). Each duplex was tested in at least two independent transfections and each transfection was assayed in duplicate.
To calculate relative fold change, real time data were analyzed using the ΔΔCt method and normalized to assays performed with cells transfected with 10 nM AD-1955, or mock transfected cells.
Table 22 shows the results of a single dose screen in Hep3B cells transfected with the indicated dT modified iRNAs. Data are expressed as percent of message remaining relative to untreated cells.







TABLE 21







dT Modified C5 iRNAs














SEQ ID
Position in

SEQ ID


Duplex ID
Sense Sequence
NO:
NM_001735.2
Antisense Sequence
NO:





AD-61779.2
UAUCCGUGGUUUCCUGCUAdTdT
1739
 3-21
UAGCAGGAAACCACGGAUAdTdT
2306


 


AD-61785.2
GGUUUCCUGCUACCUCCAAdTdT
1740
10-28
UUGGAGGUAGCAGGAAACCdTdT
2307


 


AD-61791.2
CCUCCAACCAUGGGCCUUUdTdT
1741
22-40
AAAGGCCCAUGGUUGGAGGdTdT
2308


 


AD-61797.2
GGGCCUUUUGGGAAUACUUdTdT
1742
33-51
AAGUAUUCCCAAAAGGCCCdTdT
2309


 


AD-61803.2
GGAAUACUUUGUUUUUUAAdTdT
1743
43-61
UUAAAAAACAAAGUAUUCCdTdT
2310


 


AD-61809.2
CUUUGUUUUUUAAUCUUCCdTdT
1744
49-67
GGAAGAUUAAAAAACAAAGdTdT
2311


 


AD-61815.2
CUUCCUGGGGAAAACCUGGdTdT
1745
63-81
CCAGGUUUUCCCCAGGAAGdTdT
2312


 


AD-61821.2
GGAAAACCUGGGGACAGGAdTdT
1746
71-89
UCCUGUCCCCAGGUUUUCCdTdT
2313


 


AD-61780.2
GGGACAGGAGCAAACAUAUdTdT
1747
81-99
AUAUGUUUGCUCCUGUCCCdTdT
2314


 


AD-61786.2
CAAACAUAUGUCAUUUCAGdTdT
1748
 91-109
CUGAAAUGACAUAUGUUUGdTdT
2315


 


AD-61792.2
CAUUUCAGCACCAAAAAUAdTdT
1749
102-120
UAUUUUUGGUGCUGAAAUGdTdT
2316


 


AD-61798.2
GCACCAAAAAUAUUCCGUGdTdT
1750
109-127
CACGGAAUAUUUUUGGUGCdTdT
2317


 


AD-61804.2
CCGUGUUGGAGCAUCUGAAdTdT
1751
123-141
UUCAGAUGCUCCAACACGGdTdT
2318


 


AD-61810.2
GGAGCAUCUGAAAAUAUUGdTdT
1752
130-148
CAAUAUUUUCAGAUGCUCCdTdT
2319


 


AD-61816.2
GAAAAUAUUGUGAUUCAAGdTdT
1753
139-157
CUUGAAUCACAAUAUUUUCdTdT
2320


 


AD-61822.2
GAUUCAAGUUUAUGGAUACdTdT
1754
150-168
GUAUCCAUAAACUUGAAUCdTdT
2321


 


AD-61781.2
GGAUACACUGAAGCAUUUGdTdT
1755
163-181
CAAAUGCUUCAGUGUAUCCdTdT
2322


 


AD-61787.2
GAAGCAUUUGAUGCAACAAdTdT
1756
172-190
UUGUUGCAUCAAAUGCUUCdTdT
2323


 


AD-61793.2
UGCAACAAUCUCUAUUAAAdTdT
1757
183-201
UUUAAUAGAGAUUGUUGCAdTdT
2324


 


AD-61799.2
AAUCUCUAUUAAAAGUUAUdTdT
1758
189-207
AUAACUUUUAAUAGAGAUUdTdT
2325


 


AD-61805.2
AAGUUAUCCUGAUAAAAAAdTdT
1759
201-219
UUUUUUAUCAGGAUAACUUdTdT
2326


 


AD-61811.2
CUGAUAAAAAAUUUAGUUAdTdT
1760
209-227
UAACUAAAUUUUUUAUCAGdTdT
2327


 


AD-61817.2
UUAGUUACUCCUCAGGCCAdTdT
1761
221-239
UGGCCUGAGGAGUAACUAAdTdT
2328


 


AD-61823.2
CCUCAGGCCAUGUUCAUUUdTdT
1762
230-248
AAAUGAACAUGGCCUGAGGdTdT
2329


 


AD-61782.2
UUCAUUUAUCCUCAGAGAAdTdT
1763
242-260
UUCUCUGAGGAUAAAUGAAdTdT
2330


 


AD-61788.2
CUCAGAGAAUAAAUUCCAAdTdT
1764
252-270
UUGGAAUUUAUUCUCUGAGdTdT
2331


 


AD-61794.2
AAUAAAUUCCAAAACUCUGdTdT
1765
259-277
CAGAGUUUUGGAAUUUAUUdTdT
2332


 


AD-61800.2
CUCUGCAAUCUUAACAAUAdTdT
1766
273-291
UAUUGUUAAGAUUGCAGAGdTdT
2333


 


AD-61806.2
CUUAACAAUACAACCAAAAdTdT
1767
282-300
UUUUGGUUGUAUUGUUAAGdTdT
2334


 


AD-61812.2
CAACCAAAACAAUUGCCUGdTdT
1768
292-310
CAGGCAAUUGUUUUGGUUGdTdT
2335


 


AD-61818.2
CAAUUGCCUGGAGGACAAAdTdT
1769
301-319
UUUGUCCUCCAGGCAAUUGdTdT
2336


 


AD-61824.2
GGACAAAACCCAGUUUCUUdTdT
1770
313-331
AAGAAACUGGGUUUUGUCCdTdT
2337


 


AD-61783.2
CCAGUUUCUUAUGUGUAUUdTdT
1771
322-340
AAUACACAUAAGAAACUGGdTdT
2338


 


AD-61789.2
AUGUGUAUUUGGAAGUUGUdTdT
1772
332-350
ACAACUUCCAAAUACACAUdTdT
2339


 


AD-61795.2
GGAAGUUGUAUCAAAGCAUdTdT
1773
342-360
AUGCUUUGAUACAACUUCCdTdT
2340


 


AD-61801.2
GUAUCAAAGCAUUUUUCAAdTdT
1774
349-367
UUGAAAAAUGCUUUGAUACdTdT
2341


 


AD-61807.2
UUUUCAAAAUCAAAAAGAAdTdT
1775
361-379
UUCUUUUUGAUUUUGAAAAdTdT
2342


 


AD-61813.2
CAAAAAGAAUGCCAAUAACdTdT
1776
371-389
GUUAUUGGCAUUCUUUUUGdTdT
2343


 


AD-61819.2
GCCAAUAACCUAUGACAAUdTdT
1777
381-399
AUUGUCAUAGGUUAUUGGCdTdT
2344


 


AD-61825.2
CCUAUGACAAUGGAUUUCUdTdT
1778
389-407
AGAAAUCCAUUGUCAUAGGdTdT
2345


 


AD-61784.2
UGGAUUUCUCUUCAUUCAUdTdT
1779
399-417
AUGAAUGAAGAGAAAUCCAdTdT
2346


 


AD-61790.2
CAUUCAUACAGACAAACCUdTdT
1780
411-429
AGGUUUGUCUGUAUGAAUGdTdT
2347


 


AD-61796.2
CAGACAAACCUGUUUAUACdTdT
1781
419-437
GUAUAAACAGGUUUGUCUGdTdT
2348


 


AD-61802.2
GUUUAUACUCCAGACCAGUdTdT
1782
430-448
ACUGGUCUGGAGUAUAAACdTdT
2349


 


AD-61808.2
AGACCAGUCAGUAAAAGUUdTdT
1783
441-459
AACUUUUACUGACUGGUCUdTdT
2350


 


AD-61814.2
AGUAAAAGUUAGAGUUUAUdTdT
1784
450-468
AUAAACUCUAACUUUUACUdTdT
2351


 


AD-61820.2
AGAGUUUAUUCGUUGAAUGdTdT
1785
460-478
CAUUCAACGAAUAAACUCUdTdT
2352


 


AD-61826.2
CGUUGAAUGACGACUUGAAdTdT
1786
470-488
UUCAAGUCGUCAUUCAACGdTdT
2353


 


AD-61832.2
CUUGAAGCCAGCCAAAAGAdTdT
1787
483-501
UCUUUUGGCUGGCUUCAAGdTdT
2354


 


AD-61838.2
CCAGCCAAAAGAGAAACUGdTdT
1788
490-508
CAGUUUCUCUUUUGGCUGGdTdT
2355


 


AD-61844.2
AAACUGUCUUAACUUUCAUdTdT
1789
503-521
AUGAAAGUUAAGACAGUUUdTdT
2356


 


AD-61850.2
AACUUUCAUAGAUCCUGAAdTdT
1790
513-531
UUCAGGAUCUAUGAAAGUUdTdT
2357


 


AD-61856.2
CAUAGAUCCUGAAGGAUCAdTdT
1791
519-537
UGAUCCUUCAGGAUCUAUGdTdT
2358


 


AD-61862.2
GAAGGAUCAGAAGUUGACAdTdT
1792
529-547
UGUCAACUUCUGAUCCUUCdTdT
2359


 


AD-61868.2
UGACAUGGUAGAAGAAAUUdTdT
1793
543-561
AAUUUCUUCUACCAUGUCAdTdT
2360


 


AD-61827.2
GAAGAAAUUGAUCAUAUUGdTdT
1794
553-571
CAAUAUGAUCAAUUUCUUCdTdT
2361


 


AD-61833.2
GAUCAUAUUGGAAUUAUCUdTdT
1795
562-580
AGAUAAUUCCAAUAUGAUCdTdT
2362


 


AD-61839.2
GGAAUUAUCUCUUUUCCUGdTdT
1796
571-589
CAGGAAAAGAGAUAAUUCCdTdT
2363


 


AD-61845.2
CUCUUUUCCUGACUUCAAGdTdT
1797
579-597
CUUGAAGUCAGGAAAAGAGdTdT
2364


 


AD-61851.2
ACUUCAAGAUUCCGUCUAAdTdT
1798
590-608
UUAGACGGAAUCUUGAAGUdTdT
2365


 


AD-61857.2
CCGUCUAAUCCUAGAUAUGdTdT
1799
601-619
CAUAUCUAGGAUUAGACGGdTdT
2366


 


AD-61863.2
CCUAGAUAUGGUAUGUGGAdTdT
1800
610-628
UCCACAUACCAUAUCUAGGdTdT
2367


 


AD-61869.2
UGUGGACGAUCAAGGCUAAdTdT
1801
623-641
UUAGCCUUGAUCGUCCACAdTdT
2368


 


AD-61828.2
CGAUCAAGGCUAAAUAUAAdTdT
1802
629-647
UUAUAUUUAGCCUUGAUCGdTdT
2369


 


AD-61834.2
AUAUAAAGAGGACUUUUCAdTdT
1803
642-660
UGAAAAGUCCUCUUUAUAUdTdT
2370


 


AD-61840.2
GAGGACUUUUCAACAACUGdTdT
1804
649-667
CAGUUGUUGAAAAGUCCUCdTdT
2371


 


AD-61846.2
CAACUGGAACCGCAUAUUUdTdT
1805
662-680
AAAUAUGCGGUUCCAGUUGdTdT
2372


 


AD-61852.2
CGCAUAUUUUGAAGUUAAAdTdT
1806
672-690
UUUAACUUCAAAAUAUGCGdTdT
2373


 


AD-61858.2
AAGUUAAAGAAUAUGUCUUdTdT
1807
683-701
AAGACAUAUUCUUUAACUUdTdT
2374


 


AD-61864.2
GAAUAUGUCUUGCCACAUUdTdT
1808
691-709
AAUGUGGCAAGACAUAUUCdTdT
2375


 


AD-61870.2
CCACAUUUUUCUGUCUCAAdTdT
1809
703-721
UUGAGACAGAAAAAUGUGGdTdT
2376


 


AD-61829.2
CUGUCUCAAUCGAGCCAGAdTdT
1810
713-731
UCUGGCUCGAUUGAGACAGdTdT
2377


 


AD-61835.2
CAAUCGAGCCAGAAUAUAAdTdT
1811
719-737
UUAUAUUCUGGCUCGAUUGdTdT
2378


 


AD-61841.2
GAAUAUAAUUUCAUUGGUUdTdT
1812
730-748
AACCAAUGAAAUUAUAUUCdTdT
2379


 


AD-61847.2
AUUGGUUACAAGAACUUUAdTdT
1813
742-760
UAAAGUUCUUGUAACCAAUdTdT
2380


 


AD-61853.2
AGAACUUUAAGAAUUUUGAdTdT
1814
752-770
UCAAAAUUCUUAAAGUUCUdTdT
2381


 


AD-61859.2
GAAUUUUGAAAUUACUAUAdTdT
1815
762-780
UAUAGUAAUUUCAAAAUUCdTdT
2382


 


AD-61865.2
GAAAUUACUAUAAAAGCAAdTdT
1816
769-787
UUGCUUUUAUAGUAAUUUCdTdT
2383


 


AD-61871.2
AAAGCAAGAUAUUUUUAUAdTdT
1817
781-799
UAUAAAAAUAUCUUGCUUUdTdT
2384


 


AD-61830.2
AUAUUUUUAUAAUAAAGUAdTdT
1818
789-807
UACUUUAUUAUAAAAAUAUdTdT
2385


 


AD-61836.2
AAGUAGUCACUGAGGCUGAdTdT
1819
803-821
UCAGCCUCAGUGACUACUUdTdT
2386


 


AD-61842.2
CACUGAGGCUGACGUUUAUdTdT
1820
810-828
AUAAACGUCAGCCUCAGUGdTdT
2387


 


AD-61848.2
CGUUUAUAUCACAUUUGGAdTdT
1821
822-840
UCCAAAUGUGAUAUAAACGdTdT
2388


 


AD-61854.2
CACAUUUGGAAUAAGAGAAdTdT
1822
831-849
UUCUCUUAUUCCAAAUGUGdTdT
2389


 


AD-61860.2
AAUAAGAGAAGACUUAAAAdTdT
1823
840-858
UUUUAAGUCUUCUCUUAUUdTdT
2390


 


AD-61866.2
CUUAAAAGAUGAUCAAAAAdTdT
1824
852-870
UUUUUGAUCAUCUUUUAAGdTdT
2391


 


AD-61872.2
GAUGAUCAAAAAGAAAUGAdTdT
1825
859-877
UCAUUUCUUUUUGAUCAUCdTdT
2392


 


AD-61831.2
AAAUGAUGCAAACAGCAAUdTdT
1826
872-890
AUUGCUGUUUGCAUCAUUUdTdT
2393


 


AD-61837.2
ACAGCAAUGCAAAACACAAdTdT
1827
883-901
UUGUGUUUUGCAUUGCUGUdTdT
2394


 


AD-61843.2
AAAACACAAUGUUGAUAAAdTdT
1828
893-911
UUUAUCAACAUUGUGUUUUdTdT
2395


 


AD-61849.2
CAAUGUUGAUAAAUGGAAUdTdT
1829
899-917
AUUCCAUUUAUCAACAUUGdTdT
2396


 


AD-61855.2
GGAAUUGCUCAAGUCACAUdTdT
1830
913-931
AUGUGACUUGAGCAAUUCCdTdT
2397


 


AD-61861.2
GCUCAAGUCACAUUUGAUUdTdT
1831
919-937
AAUCAAAUGUGACUUGAGCdTdT
2398


 


AD-61867.2
AUUUGAUUCUGAAACAGCAdTdT
1832
930-948
UGCUGUUUCAGAAUCAAAUdTdT
2399


 


AD-62062.1
UGAAACAGCAGUCAAAGAAdTdT
1833
939-957
UUCUUUGACUGCUGUUUCAdTdT
2400


 


AD-62068.1
CAAAGAACUGUCAUACUACdTdT
1834
951-969
GUAGUAUGACAGUUCUUUGdTdT
2401


 


AD-62074.1
CAUACUACAGUUUAGAAGAdTdT
1835
962-980
UCUUCUAAACUGUAGUAUGdTdT
2402


 


AD-62080.1
CAGUUUAGAAGAUUUAAACdTdT
1836
969-987
GUUUAAAUCUUCUAAACUGdTdT
2403


 


AD-62086.1
UAAACAACAAGUACCUUUAdTdT
1837
 983-1001
UAAAGGUACUUGUUGUUUAdTdT
2404


 


AD-62092.1
CAAGUACCUUUAUAUUGCUdTdT
1838
 990-1008
AGCAAUAUAAAGGUACUUGdTdT
2405


 


AD-62098.1
UAUUGCUGUAACAGUCAUAdTdT
1839
1002-1020
UAUGACUGUUACAGCAAUAdTdT
2406


 


AD-62104.1
AACAGUCAUAGAGUCUACAdTdT
1840
1011-1029
UGUAGACUCUAUGACUGUUdTdT
2407


 


AD-62063.1
AGAGUCUACAGGUGGAUUUdTdT
1841
1020-1038
AAAUCCACCUGUAGACUCUdTdT
2408


 


AD-62069.1
GGAUUUUCUGAAGAGGCAGdTdT
1842
1033-1051
CUGCCUCUUCAGAAAAUCCdTdT
2409


 


AD-62075.1
GAAGAGGCAGAAAUACCUGdTdT
1843
1042-1060
CAGGUAUUUCUGCCUCUUCdTdT
2410


 


AD-62081.1
AGAAAUACCUGGCAUCAAAdTdT
1844
1050-1068
UUUGAUGCCAGGUAUUUCUdTdT
2411


 


AD-62087.1
GCAUCAAAUAUGUCCUCUCdTdT
1845
1061-1079
GAGAGGACAUAUUUGAUGCdTdT
2412


 


AD-62093.1
UGUCCUCUCUCCCUACAAAdTdT
1846
1071-1089
UUUGUAGGGAGAGAGGACAdTdT
2413


 


AD-62099.1
GAAUUUGGUUGCUACUCCUdTdT
1847
1092-1110
AGGAGUAGCAACCAAAUUCdTdT
2414


 


AD-62105.1
GCUACUCCUCUUUUCCUGAdTdT
1848
1102-1120
UCAGGAAAAGAGGAGUAGCdTdT
2415


 


AD-62064.1
CUCUUUUCCUGAAGCCUGGdTdT
1849
1109-1127
CCAGGCUUCAGGAAAAGAGdTdT
2416


 


AD-62070.1
CCUGGGAUUCCAUAUCCCAdTdT
1850
1123-1141
UGGGAUAUGGAAUCCCAGGdTdT
2417


 


AD-62076.1
CAUAUCCCAUCAAGGUGCAdTdT
1851
1133-1151
UGCACCUUGAUGGGAUAUGdTdT
2418


 


AD-62082.1
CCAUCAAGGUGCAGGUUAAdTdT
1852
1139-1157
UUAACCUGCACCUUGAUGGdTdT
2419


 


AD-62088.1
CAGGUUAAAGAUUCGCUUGdTdT
1853
1150-1168
CAAGCGAAUCUUUAACCUGdTdT
2420


 


AD-62094.1
UUCGCUUGACCAGUUGGUAdTdT
1854
1161-1179
UACCAACUGGUCAAGCGAAdTdT
2421


 


AD-62100.1
CCAGUUGGUAGGAGGAGUCdTdT
1855
1170-1188
GACUCCUCCUACCAACUGGdTdT
2422


 


AD-62106.1
GGAGGAGUCCCAGUAACACdTdT
1856
1180-1198
GUGUUACUGGGACUCCUCCdTdT
2423


 


AD-62065.1
CAGUAACACUGAAUGCACAdTdT
1857
1190-1208
UGUGCAUUCAGUGUUACUGdTdT
2424


 


AD-62071.1
GAAUGCACAAACAAUUGAUdTdT
1858
1200-1218
AUCAAUUGUUUGUGCAUUCdTdT
2425


 


AD-62077.1
AACAAUUGAUGUAAACCAAdTdT
1859
1209-1227
UUGGUUUACAUCAAUUGUUdTdT
2426


 


AD-62083.1
UAAACCAAGAGACAUCUGAdTdT
1860
1220-1238
UCAGAUGUCUCUUGGUUUAdTdT
2427


 


AD-62089.1
CAUCUGACUUGGAUCCAAGdTdT
1861
1232-1250
CUUGGAUCCAAGUCAGAUGdTdT
2428


 


AD-62095.1
GAUCCAAGCAAAAGUGUAAdTdT
1862
1243-1261
UUACACUUUUGCUUGGAUCdTdT
2429


 


AD-62101.1
CAAAAGUGUAACACGUGUUdTdT
1863
1251-1269
AACACGUGUUACACUUUUGdTdT
2430


 


AD-62107.1
AACACGUGUUGAUGAUGGAdTdT
1864
1260-1278
UCCAUCAUCAACACGUGUUdTdT
2431


 


AD-62066.1
UGAUGGAGUAGCUUCCUUUdTdT
1865
1272-1290
AAAGGAAGCUACUCCAUCAdTdT
2432


 


AD-62072.1
GUAGCUUCCUUUGUGCUUAdTdT
1866
1279-1297
UAAGCACAAAGGAAGCUACdTdT
2433


 


AD-62078.1
GCUUAAUCUCCCAUCUGGAdTdT
1867
1293-1311
UCCAGAUGGGAGAUUAAGCdTdT
2434


 


AD-62084.1
CCAUCUGGAGUGACGGUGCdTdT
1868
1303-1321
GCACCGUCACUCCAGAUGGdTdT
2435


 


AD-62090.1
UGACGGUGCUGGAGUUUAAdTdT
1869
1313-1331
UUAAACUCCAGCACCGUCAdTdT
2436


 


AD-62096.1
GCUGGAGUUUAAUGUCAAAdTdT
1870
1320-1338
UUUGACAUUAAACUCCAGCdTdT
2437


 


AD-62102.1
UGUCAAAACUGAUGCUCCAdTdT
1871
1332-1350
UGGAGCAUCAGUUUUGACAdTdT
2438


 


AD-62108.1
GAUGCUCCAGAUCUUCCAGdTdT
1872
1342-1360
CUGGAAGAUCUGGAGCAUCdTdT
2439


 


AD-62067.1
CAGAUCUUCCAGAAGAAAAdTdT
1873
1349-1367
UUUUCUUCUGGAAGAUCUGdTdT
2440


 


AD-62073.1
AGAAAAUCAGGCCAGGGAAdTdT
1874
1362-1380
UUCCCUGGCCUGAUUUUCUdTdT
2441


 


AD-62079.1
GGCCAGGGAAGGUUACCGAdTdT
1875
1371-1389
UCGGUAACCUUCCCUGGCCdTdT
2442


 


AD-62085.1
GUUACCGAGCAAUAGCAUAdTdT
1876
1382-1400
UAUGCUAUUGCUCGGUAACdTdT
2443


 


AD-62091.1
AUAGCAUACUCAUCUCUCAdTdT
1877
1393-1411
UGAGAGAUGAGUAUGCUAUdTdT
2444


 


AD-62097.1
UACUCAUCUCUCAGCCAAAdTdT
1878
1399-1417
UUUGGCUGAGAGAUGAGUAdTdT
2445


 


AD-62103.1
GCCAAAGUUACCUUUAUAUdTdT
1879
1412-1430
AUAUAAAGGUAACUUUGGCdTdT
2446


 


AD-62109.1
CCUUUAUAUUGAUUGGACUdTdT
1880
1422-1440
AGUCCAAUCAAUAUAAAGGdTdT
2447


 


AD-62115.1
GAUUGGACUGAUAACCAUAdTdT
1881
1432-1450
UAUGGUUAUCAGUCCAAUCdTdT
2448


 


AD-62121.1
CUGAUAACCAUAAGGCUUUdTdT
1882
1439-1457
AAAGCCUUAUGGUUAUCAGdTdT
2449


 


AD-62127.1
AGGCUUUGCUAGUGGGAGAdTdT
1883
1451-1469
UCUCCCACUAGCAAAGCCUdTdT
2450


 


AD-62133.1
GUGGGAGAACAUCUGAAUAdTdT
1884
1462-1480
UAUUCAGAUGUUCUCCCACdTdT
2451


 


AD-62139.1
CAUCUGAAUAUUAUUGUUAdTdT
1885
1471-1489
UAACAAUAAUAUUCAGAUGdTdT
2452


 


AD-62145.1
UAUUAUUGUUACCCCCAAAdTdT
1886
1479-1497
UUUGGGGGUAACAAUAAUAdTdT
2453


 


AD-62151.1
CCCAAAAGCCCAUAUAUUGdTdT
1887
1492-1510
CAAUAUAUGGGCUUUUGGGdTdT
2454


 


AD-62110.1
CCAAAAGCCCAUAUAUUGAdTdT
1888
1493-1511
UCAAUAUAUGGGCUUUUGGdTdT
2455


 


AD-62116.1
CAAAAGCCCAUAUAUUGACdTdT
1889
1494-1512
GUCAAUAUAUGGGCUUUUGdTdT
2456


 


AD-62122.1
AAAAGCCCAUAUAUUGACAdTdT
1890
1495-1513
UGUCAAUAUAUGGGCUUUUdTdT
2457


 


AD-62128.1
AAAGCCCAUAUAUUGACAAdTdT
1891
1496-1514
UUGUCAAUAUAUGGGCUUUdTdT
2458


 


AD-62134.1
AAGCCCAUAUAUUGACAAAdTdT
1892
1497-1515
UUUGUCAAUAUAUGGGCUUdTdT
2459


 


AD-62140.1
AGCCCAUAUAUUGACAAAAdTdT
1893
1498-1516
UUUUGUCAAUAUAUGGGCUdTdT
2460


 


AD-62146.1
GCCCAUAUAUUGACAAAAUdTdT
1894
1499-1517
AUUUUGUCAAUAUAUGGGCdTdT
2461


 


AD-62152.1
CCCAUAUAUUGACAAAAUAdTdT
1895
1500-1518
UAUUUUGUCAAUAUAUGGGdTdT
2462


 


AD-62111.1
CCAUAUAUUGACAAAAUAAdTdT
1896
1501-1519
UUAUUUUGUCAAUAUAUGGdTdT
2463


 


AD-62117.1
CAUAUAUUGACAAAAUAACdTdT
1897
1502-1520
GUUAUUUUGUCAAUAUAUGdTdT
2464


 


AD-62123.1
AUAUAUUGACAAAAUAACUdTdT
1898
1503-1521
AGUUAUUUUGUCAAUAUAUdTdT
2465


 


AD-62129.1
UAUAUUGACAAAAUAACUCdTdT
1899
1504-1522
GAGUUAUUUUGUCAAUAUAdTdT
2466


 


AD-62135.1
AUAUUGACAAAAUAACUCAdTdT
1900
1505-1523
UGAGUUAUUUUGUCAAUAUdTdT
2467


 


AD-62141.1
UAUUGACAAAAUAACUCACdTdT
1901
1506-1524
GUGAGUUAUUUUGUCAAUAdTdT
2468


 


AD-62147.1
AUUGACAAAAUAACUCACUdTdT
1902
1507-1525
AGUGAGUUAUUUUGUCAAUdTdT
2469


 


AD-62153.1
UUGACAAAAUAACUCACUAdTdT
1903
1508-1526
UAGUGAGUUAUUUUGUCAAdTdT
2470


 


AD-62112.1
UGACAAAAUAACUCACUAUdTdT
1904
1509-1527
AUAGUGAGUUAUUUUGUCAdTdT
2471


 


AD-62118.1
GACAAAAUAACUCACUAUAdTdT
1905
1510-1528
UAUAGUGAGUUAUUUUGUCdTdT
2472


 


AD-62124.1
AAAAUAACUCACUAUAAUUdTdT
1906
1513-1531
AAUUAUAGUGAGUUAUUUUdTdT
2473


 


AD-62130.1
AAAUAACUCACUAUAAUUAdTdT
1907
1514-1532
UAAUUAUAGUGAGUUAUUUdTdT
2474


 


AD-62136.1
AAUAACUCACUAUAAUUACdTdT
1908
1515-1533
GUAAUUAUAGUGAGUUAUUdTdT
2475


 


AD-62142.1
AUAACUCACUAUAAUUACUdTdT
1909
1516-1534
AGUAAUUAUAGUGAGUUAUdTdT
2476


 


AD-62148.1
AACUCACUAUAAUUACUUGdTdT
1910
1518-1536
CAAGUAAUUAUAGUGAGUUdTdT
2477


 


AD-62154.1
ACUCACUAUAAUUACUUGAdTdT
1911
1519-1537
UCAAGUAAUUAUAGUGAGUdTdT
2478


 


AD-62113.1
CUCACUAUAAUUACUUGAUdTdT
1912
1520-1538
AUCAAGUAAUUAUAGUGAGdTdT
2479


 


AD-62119.1
UCACUAUAAUUACUUGAUUdTdT
1913
1521-1539
AAUCAAGUAAUUAUAGUGAdTdT
2480


 


AD-62125.1
ACUAUAAUUACUUGAUUUUdTdT
1914
1523-1541
AAAAUCAAGUAAUUAUAGUdTdT
2481


 


AD-62131.1
CUAUAAUUACUUGAUUUUAdTdT
1915
1524-1542
UAAAAUCAAGUAAUUAUAGdTdT
2482


 


AD-62137.1
UAUAAUUACUUGAUUUUAUdTdT
1916
1525-1543
AUAAAAUCAAGUAAUUAUAdTdT
2483


 


AD-62143.1
AUAAUUACUUGAUUUUAUCdTdT
1917
1526-1544
GAUAAAAUCAAGUAAUUAUdTdT
2484


 


AD-62149.1
UAAUUACUUGAUUUUAUCCdTdT
1918
1527-1545
GGAUAAAAUCAAGUAAUUAdTdT
2485


 


AD-62155.1
AAUUACUUGAUUUUAUCCAdTdT
1919
1528-1546
UGGAUAAAAUCAAGUAAUUdTdT
2486


 


AD-62114.1
AUUACUUGAUUUUAUCCAAdTdT
1920
1529-1547
UUGGAUAAAAUCAAGUAAUdTdT
2487


 


AD-62120.1
UUAUCCAAGGGCAAAAUUAdTdT
1921
1540-1558
UAAUUUUGCCCUUGGAUAAdTdT
2488


 


AD-62126.1
GCAAAAUUAUCCACUUUGGdTdT
1922
1550-1568
CCAAAGUGGAUAAUUUUGCdTdT
2489


 


AD-62132.1
CACUUUGGCACGAGGGAGAdTdT
1923
1561-1579
UCUCCCUCGUGCCAAAGUGdTdT
2490


 


AD-62138.1
CGAGGGAGAAAUUUUCAGAdTdT
1924
1571-1589
UCUGAAAAUUUCUCCCUCGdTdT
2491


 


AD-62144.1
AUUUUCAGAUGCAUCUUAUdTdT
1925
1581-1599
AUAAGAUGCAUCUGAAAAUdTdT
2492


 


AD-62150.1
GCAUCUUAUCAAAGUAUAAdTdT
1926
1591-1609
UUAUACUUUGAUAAGAUGCdTdT
2493


 


AD-62156.1
CAAAGUAUAAACAUUCCAGdTdT
1927
1600-1618
CUGGAAUGUUUAUACUUUGdTdT
2494


 


AD-62162.1
AUUCCAGUAACACAGAACAdTdT
1928
1612-1630
UGUUCUGUGUUACUGGAAUdTdT
2495


 


AD-62168.1
CACAGAACAUGGUUCCUUCdTdT
1929
1622-1640
GAAGGAACCAUGUUCUGUGdTdT
2496


 


AD-62174.1
GGUUCCUUCAUCCCGACUUdTdT
1930
1632-1650
AAGUCGGGAUGAAGGAACCdTdT
2497


 


AD-62180.1
CCCGACUUCUGGUCUAUUAdTdT
1931
1643-1661
UAAUAGACCAGAAGUCGGGdTdT
2498


 


AD-62186.1
GGUCUAUUACAUCGUCACAdTdT
1932
1653-1671
UGUGACGAUGUAAUAGACCdTdT
2499


 


AD-62192.1
AUCGUCACAGGAGAACAGAdTdT
1933
1663-1681
UCUGUUCUCCUGUGACGAUdTdT
2500


 


AD-62198.1
CAGGAGAACAGACAGCAGAdTdT
1934
1670-1688
UCUGCUGUCUGUUCUCCUGdTdT
2501


 


AD-62157.1
CAGCAGAAUUAGUGUCUGAdTdT
1935
1682-1700
UCAGACACUAAUUCUGCUGdTdT
2502


 


AD-62163.1
GUGUCUGAUUCAGUCUGGUdTdT
1936
1693-1711
ACCAGACUGAAUCAGACACdTdT
2503


 


AD-62169.1
CAGUCUGGUUAAAUAUUGAdTdT
1937
1703-1721
UCAAUAUUUAACCAGACUGdTdT
2504


 


AD-62175.1
GUUAAAUAUUGAAGAAAAAdTdT
1938
1710-1728
UUUUUCUUCAAUAUUUAACdTdT
2505


 


AD-62181.1
AGAAAAAUGUGGCAACCAGdTdT
1939
1722-1740
CUGGUUGCCACAUUUUUCUdTdT
2506


 


AD-62187.1
GCAACCAGCUCCAGGUUCAdTdT
1940
1733-1751
UGAACCUGGAGCUGGUUGCdTdT
2507


 


AD-62193.1
GCUCCAGGUUCAUCUGUCUdTdT
1941
1740-1758
AGACAGAUGAACCUGGAGCdTdT
2508


 


AD-62199.1
AUCUGUCUCCUGAUGCAGAdTdT
1942
1751-1769
UCUGCAUCAGGAGACAGAUdTdT
2509


 


AD-62158.1
GAUGCAGAUGCAUAUUCUCdTdT
1943
1762-1780
GAGAAUAUGCAUCUGCAUCdTdT
2510


 


AD-62164.1
GCAUAUUCUCCAGGCCAAAdTdT
1944
1771-1789
UUUGGCCUGGAGAAUAUGCdTdT
2511


 


AD-62170.1
AGGCCAAACUGUGUCUCUUdTdT
1945
1782-1800
AAGAGACACAGUUUGGCCUdTdT
2512


 


AD-62176.1
GUGUCUCUUAAUAUGGCAAdTdT
1946
1792-1810
UUGCCAUAUUAAGAGACACdTdT
2513


 


AD-62182.1
UUAAUAUGGCAACUGGAAUdTdT
1947
1799-1817
AUUCCAGUUGCCAUAUUAAdTdT
2514


 


AD-62188.1
AACUGGAAUGGAUUCCUGGdTdT
1948
1809-1827
CCAGGAAUCCAUUCCAGUUdTdT
2515


 


AD-62194.1
UUCCUGGGUGGCAUUAGCAdTdT
1949
1821-1839
UGCUAAUGCCACCCAGGAAdTdT
2516


 


AD-62200.1
GGCAUUAGCAGCAGUGGACdTdT
1950
1830-1848
GUCCACUGCUGCUAAUGCCdTdT
2517


 


AD-62159.1
AGUGGACAGUGCUGUGUAUdTdT
1951
1842-1860
AUACACAGCACUGUCCACUdTdT
2518


 


AD-62165.1
GCUGUGUAUGGAGUCCAAAdTdT
1952
1852-1870
UUUGGACUCCAUACACAGCdTdT
2519


 


AD-62171.1
AGUCCAAAGAGGAGCCAAAdTdT
1953
1863-1881
UUUGGCUCCUCUUUGGACUdTdT
2520


 


AD-62177.1
AGAGGAGCCAAAAAGCCCUdTdT
1954
1870-1888
AGGGCUUUUUGGCUCCUCUdTdT
2521


 


AD-62183.1
AGCCCUUGGAAAGAGUAUUdTdT
1955
1883-1901
AAUACUCUUUCCAAGGGCUdTdT
2522


 


AD-62189.1
AAGAGUAUUUCAAUUCUUAdTdT
1956
1893-1911
UAAGAAUUGAAAUACUCUUdTdT
2523


 


AD-62195.1
UUUCAAUUCUUAGAGAAGAdTdT
1957
1900-1918
UCUUCUCUAAGAAUUGAAAdTdT
2524


 


AD-62201.1
GAGAAGAGUGAUCUGGGCUdTdT
1958
1912-1930
AGCCCAGAUCACUCUUCUCdTdT
2525


 


AD-62160.1
UGAUCUGGGCUGUGGGGCAdTdT
1959
1920-1938
UGCCCCACAGCCCAGAUCAdTdT
2526


 


AD-62166.1
GGGGCAGGUGGUGGCCUCAdTdT
1960
1933-1951
UGAGGCCACCACCUGCCCCdTdT
2527


 


AD-62172.1
GUGGCCUCAACAAUGCCAAdTdT
1961
1943-1961
UUGGCAUUGUUGAGGCCACdTdT
2528


 


AD-62178.1
CAACAAUGCCAAUGUGUUCdTdT
1962
1950-1968
GAACACAUUGGCAUUGUUGdTdT
2529


 


AD-62184.1
CAAUGUGUUCCACCUAGCUdTdT
1963
1959-1977
AGCUAGGUGGAACACAUUGdTdT
2530


 


AD-62190.1
CACCUAGCUGGACUUACCUdTdT
1964
1969-1987
AGGUAAGUCCAGCUAGGUGdTdT
2531


 


AD-62196.1
GACUUACCUUCCUCACUAAdTdT
1965
1979-1997
UUAGUGAGGAAGGUAAGUCdTdT
2532


 


AD-62202.1
UCACUAAUGCAAAUGCAGAdTdT
1966
1991-2009
UCUGCAUUUGCAUUAGUGAdTdT
2533


 


AD-62161.1
AAAUGCAGAUGACUCCCAAdTdT
1967
2001-2019
UUGGGAGUCAUCUGCAUUUdTdT
2534


 


AD-62167.1
CUCCCAAGAAAAUGAUGAAdTdT
1968
2013-2031
UUCAUCAUUUUCUUGGGAGdTdT
2535


 


AD-62173.1
CCUUGUAAAGAAAUUCUCAdTdT
1969
2032-2050
UGAGAAUUUCUUUACAAGGdTdT
2536


 


AD-62179.1
AAUUCUCAGGCCAAGAAGAdTdT
1970
2043-2061
UCUUCUUGGCCUGAGAAUUdTdT
2537


 


AD-62185.1
CCAAGAAGAACGCUGCAAAdTdT
1971
2053-2071
UUUGCAGCGUUCUUCUUGGdTdT
2538


 


AD-62191.1
CGCUGCAAAAGAAGAUAGAdTdT
1972
2063-2081
UCUAUCUUCUUUUGCAGCGdTdT
2539


 


AD-62197.1
AAAGAAGAUAGAAGAAAUAdTdT
1973
2070-2088
UAUUUCUUCUAUCUUCUUUdTdT
2540


 


AD-62203.1
AGAAAUAGCUGCUAAAUAUdTdT
1974
2082-2100
AUAUUUAGCAGCUAUUUCUdTdT
2541


 


AD-62209.1
GCUGCUAAAUAUAAACAUUdTdT
1975
2089-2107
AAUGUUUAUAUUUAGCAGCdTdT
2542


 


AD-62215.1
ACAUUCAGUAGUGAAGAAAdTdT
1976
2103-2121
UUUCUUCACUACUGAAUGUdTdT
2543


 


AD-62221.1
GUAGUGAAGAAAUGUUGUUdTdT
1977
2110-2128
AACAACAUUUCUUCACUACdTdT
2544


 


AD-62227.1
AAAUGUUGUUACGAUGGAGdTdT
1978
2119-2137
CUCCAUCGUAACAACAUUUdTdT
2545


 


AD-62233.1
CGAUGGAGCCUGCGUUAAUdTdT
1979
2130-2148
AUUAACGCAGGCUCCAUCGdTdT
2546


 


AD-62239.1
CGUUAAUAAUGAUGAAACCdTdT
1980
2142-2160
GGUUUCAUCAUUAUUAACGdTdT
2547


 


AD-62245.1
AUGAUGAAACCUGUGAGCAdTdT
1981
2150-2168
UGCUCACAGGUUUCAUCAUdTdT
2548


 


AD-62204.1
CUGUGAGCAGCGAGCUGCAdTdT
1982
2160-2178
UGCAGCUCGCUGCUCACAGdTdT
2549


 


AD-62210.1
CGAGCUGCACGGAUUAGUUdTdT
1983
2170-2188
AACUAAUCCGUGCAGCUCGdTdT
2550


 


AD-62216.1
GGAUUAGUUUAGGGCCAAGdTdT
1984
2180-2198
CUUGGCCCUAAACUAAUCCdTdT
2551


 


AD-62222.1
GGGCCAAGAUGCAUCAAAGdTdT
1985
2191-2209
CUUUGAUGCAUCUUGGCCCdTdT
2552


 


AD-62228.1
CAUCAAAGCUUUCACUGAAdTdT
1986
2202-2220
UUCAGUGAAAGCUUUGAUGdTdT
2553


 


AD-62234.1
GCUUUCACUGAAUGUUGUGdTdT
1987
2209-2227
CACAACAUUCAGUGAAAGCdTdT
2554


 


AD-62240.1
AAUGUUGUGUCGUCGCAAGdTdT
1988
2219-2237
CUUGCGACGACACAACAUUdTdT
2555


 


AD-62246.1
CGUCGCAAGCCAGCUCCGUdTdT
1989
2229-2247
ACGGAGCUGGCUUGCGACGdTdT
2556


 


AD-62205.1
GCUCCGUGCUAAUAUCUCUdTdT
1990
2241-2259
AGAGAUAUUAGCACGGAGCdTdT
2557


 


AD-62211.1
CUAAUAUCUCUCAUAAAGAdTdT
1991
2249-2267
UCUUUAUGAGAGAUAUUAGdTdT
2558


 


AD-62217.1
AAAGACAUGCAAUUGGGAAdTdT
1992
2263-2281
UUCCCAAUUGCAUGUCUUUdTdT
2559


 


AD-62223.1
CAAUUGGGAAGGCUACACAdTdT
1993
2272-2290
UGUGUAGCCUUCCCAAUUGdTdT
2560


 


AD-62229.1
GCUACACAUGAAGACCCUGdTdT
1994
2283-2301
CAGGGUCUUCAUGUGUAGCdTdT
2561


 


AD-62235.1
CAUGAAGACCCUGUUACCAdTdT
1995
2289-2307
UGGUAACAGGGUCUUCAUGdTdT
2562


 


AD-62241.1
UACCAGUAAGCAAGCCAGAdTdT
1996
2303-2321
UCUGGCUUGCUUACUGGUAdTdT
2563


 


AD-62247.1
AGCAAGCCAGAAAUUCGGAdTdT
1997
2311-2329
UCCGAAUUUCUGGCUUGCUdTdT
2564


 


AD-62206.1
AGAAAUUCGGAGUUAUUUUdTdT
1998
2319-2337
AAAAUAACUCCGAAUUUCUdTdT
2565


 


AD-62212.1
AGUUAUUUUCCAGAAAGCUdTdT
1999
2329-2347
AGCUUUCUGGAAAAUAACUdTdT
2566


 


AD-62218.1
CAGAAAGCUGGUUGUGGGAdTdT
2000
2339-2357
UCCCACAACCAGCUUUCUGdTdT
2567


 


AD-62224.1
GUGGGAAGUUCAUCUUGUUdTdT
2001
2352-2370
AACAAGAUGAACUUCCCACdTdT
2568


 


AD-62230.1
UCAUCUUGUUCCCAGAAGAdTdT
2002
2361-2379
UCUUCUGGGAACAAGAUGAdTdT
2569


 


AD-62236.1
CCAGAAGAAAACAGUUGCAdTdT
2003
2372-2390
UGCAACUGUUUUCUUCUGGdTdT
2570


 


AD-62242.1
CAGUUGCAGUUUGCCCUACdTdT
2004
2383-2401
GUAGGGCAAACUGCAACUGdTdT
2571


 


AD-62248.1
CAGUUUGCCCUACCUGAUUdTdT
2005
2389-2407
AAUCAGGUAGGGCAAACUGdTdT
2572


 


AD-62207.1
CCUGAUUCUCUAACCACCUdTdT
2006
2401-2419
AGGUGGUUAGAGAAUCAGGdTdT
2573


 


AD-62213.1
ACCACCUGGGAAAUUCAAGdTdT
2007
2413-2431
CUUGAAUUUCCCAGGUGGUdTdT
2574


 


AD-62219.1
GAAAUUCAAGGCGUUGGCAdTdT
2008
2422-2440
UGCCAACGCCUUGAAUUUCdTdT
2575


 


AD-62225.1
CGUUGGCAUUUCAAACACUdTdT
2009
2433-2451
AGUGUUUGAAAUGCCAACGdTdT
2576


 


AD-62231.1
CAUUUCAAACACUGGUAUAdTdT
2010
2439-2457
UAUACCAGUGUUUGAAAUGdTdT
2577


 


AD-62237.1
GUAUAUGUGUUGCUGAUACdTdT
2011
2453-2471
GUAUCAGCAACACAUAUACdTdT
2578


 


AD-62243.1
UGCUGAUACUGUCAAGGCAdTdT
2012
2463-2481
UGCCUUGACAGUAUCAGCAdTdT
2579


 


AD-62249.1
CUGUCAAGGCAAAGGUGUUdTdT
2013
2471-2489
AACACCUUUGCCUUGACAGdTdT
2580


 


AD-62208.1
AGGUGUUCAAAGAUGUCUUdTdT
2014
2483-2501
AAGACAUCUUUGAACACCUdTdT
2581


 


AD-62214.1
CAAAGAUGUCUUCCUGGAAdTdT
2015
2490-2508
UUCCAGGAAGACAUCUUUGdTdT
2582


 


AD-62220.1
CUUCCUGGAAAUGAAUAUAdTdT
2016
2499-2517
UAUAUUCAUUUCCAGGAAGdTdT
2583


 


AD-62226.1
GAAUAUACCAUAUUCUGUUdTdT
2017
2511-2529
AACAGAAUAUGGUAUAUUCdTdT
2584


 


AD-62232.1
AUAUUCUGUUGUACGAGGAdTdT
2018
2520-2538
UCCUCGUACAACAGAAUAUdTdT
2585


 


AD-62238.1
CGAGGAGAACAGAUCCAAUdTdT
2019
2533-2551
AUUGGAUCUGUUCUCCUCGdTdT
2586


 


AD-62244.1
GAACAGAUCCAAUUGAAAGdTdT
2020
2539-2557
CUUUCAAUUGGAUCUGUUCdTdT
2587


 


AD-61874.1
GAAAGGAACUGUUUACAACdTdT
2021
2553-2571
GUUGUAAACAGUUCCUUUCdTdT
2588


 


AD-61880.1
ACUGUUUACAACUAUAGGAdTdT
2022
2560-2578
UCCUAUAGUUGUAAACAGUdTdT
2589


 


AD-61886.1
AACUAUAGGACUUCUGGGAdTdT
2023
2569-2587
UCCCAGAAGUCCUAUAGUUdTdT
2590


 


AD-61892.1
UGGGAUGCAGUUCUGUGUUdTdT
2024
2583-2601
AACACAGAACUGCAUCCCAdTdT
2591


 


AD-61898.1
GUUCUGUGUUAAAAUGUCUdTdT
2025
2592-2610
AGACAUUUUAACACAGAACdTdT
2592


 


AD-61904.1
UUAAAAUGUCUGCUGUGGAdTdT
2026
2600-2618
UCCACAGCAGACAUUUUAAdTdT
2593


 


AD-61910.1
CUGUGGAGGGAAUCUGCACdTdT
2027
2612-2630
GUGCAGAUUCCCUCCACAGdTdT
2594


 


AD-61916.1
GGAAUCUGCACUUCGGAAAdTdT
2028
2620-2638
UUUCCGAAGUGCAGAUUCCdTdT
2595


 


AD-61875.1
CGGAAAGCCCAGUCAUUGAdTdT
2029
2633-2651
UCAAUGACUGGGCUUUCCGdTdT
2596


 


AD-61881.1
CCAGUCAUUGAUCAUCAGGdTdT
2030
2641-2659
CCUGAUGAUCAAUGACUGGdTdT
2597


 


AD-61887.1
CAUCAGGGCACAAAGUCCUdTdT
2031
2653-2671
AGGACUUUGUGCCCUGAUGdTdT
2598


 


AD-61893.1
GGCACAAAGUCCUCCAAAUdTdT
2032
2659-2677
AUUUGGAGGACUUUGUGCCdTdT
2599


 


AD-61899.1
CAAAUGUGUGCGCCAGAAAdTdT
2033
2673-2691
UUUCUGGCGCACACAUUUGdTdT
2600


 


AD-61905.1
GCGCCAGAAAGUAGAGGGCdTdT
2034
2682-2700
GCCCUCUACUUUCUGGCGCdTdT
2601


 


AD-61911.1
AGUAGAGGGCUCCUCCAGUdTdT
2035
2691-2709
ACUGGAGGAGCCCUCUACUdTdT
2602


 


AD-61917.1
CCUCCAGUCACUUGGUGACdTdT
2036
2702-2720
GUCACCAAGUGACUGGAGGdTdT
2603


 


AD-61876.1
UCACUUGGUGACAUUCACUdTdT
2037
2709-2727
AGUGAAUGUCACCAAGUGAdTdT
2604


 


AD-61882.1
CAUUCACUGUGCUUCCUCUdTdT
2038
2720-2738
AGAGGAAGCACAGUGAAUGdTdT
2605


 


AD-61888.1
GGAAAUUGGCCUUCACAACdTdT
2039
2739-2757
GUUGUGAAGGCCAAUUUCCdTdT
2606


 


AD-61894.1
CUUCACAACAUCAAUUUUUdTdT
2040
2749-2767
AAAAAUUGAUGUUGUGAAGdTdT
2607


 


AD-61900.1
AAUUUUUCACUGGAGACUUdTdT
2041
2761-2779
AAGUCUCCAGUGAAAAAUUdTdT
2608


 


AD-61906.1
CUGGAGACUUGGUUUGGAAdTdT
2042
2770-2788
UUCCAAACCAAGUCUCCAGdTdT
2609


 


AD-61912.1
GGUUUGGAAAAGAAAUCUUdTdT
2043
2780-2798
AAGAUUUCUUUUCCAAACCdTdT
2610


 


AD-61918.1
AAUCUUAGUAAAAACAUUAdTdT
2044
2793-2811
UAAUGUUUUUACUAAGAUUdTdT
2611


 


AD-61877.1
AAAAACAUUACGAGUGGUGdTdT
2045
2802-2820
CACCACUCGUAAUGUUUUUdTdT
2612


 


AD-61883.1
GAGUGGUGCCAGAAGGUGUdTdT
2046
2813-2831
ACACCUUCUGGCACCACUCdTdT
2613


 


AD-61889.1
AGAAGGUGUCAAAAGGGAAdTdT
2047
2823-2841
UUCCCUUUUGACACCUUCUdTdT
2614


 


AD-61895.1
UGUCAAAAGGGAAAGCUAUdTdT
2048
2829-2847
AUAGCUUUCCCUUUUGACAdTdT
2615


 


AD-61901.1
GCUAUUCUGGUGUUACUUUdTdT
2049
2843-2861
AAAGUAACACCAGAAUAGCdTdT
2616


 


AD-61907.1
GUGUUACUUUGGAUCCUAGdTdT
2050
2852-2870
CUAGGAUCCAAAGUAACACdTdT
2617


 


AD-61913.1
GGAUCCUAGGGGUAUUUAUdTdT
2051
2862-2880
AUAAAUACCCCUAGGAUCCdTdT
2618


 


AD-61919.1
GGUAUUUAUGGUACCAUUAdTdT
2052
2872-2890
UAAUGGUACCAUAAAUACCdTdT
2619


 


AD-61878.1
GUACCAUUAGCAGACGAAAdTdT
2053
2882-2900
UUUCGUCUGCUAAUGGUACdTdT
2620


 


AD-61884.1
CAGACGAAAGGAGUUCCCAdTdT
2054
2892-2910
UGGGAACUCCUUUCGUCUGdTdT
2621


 


AD-61890.1
AGGAGUUCCCAUACAGGAUdTdT
2055
2900-2918
AUCCUGUAUGGGAACUCCUdTdT
2622


 


AD-61896.1
CAUACAGGAUACCCUUAGAdTdT
2056
2909-2927
UCUAAGGGUAUCCUGUAUGdTdT
2623


 


AD-61902.1
CUUAGAUUUGGUCCCCAAAdTdT
2057
2922-2940
UUUGGGGACCAAAUCUAAGdTdT
2624


 


AD-61908.1
UCCCCAAAACAGAAAUCAAdTdT
2058
2933-2951
UUGAUUUCUGUUUUGGGGAdTdT
2625


 


AD-61914.1
ACAGAAAUCAAAAGGAUUUdTdT
2059
2941-2959
AAAUCCUUUUGAUUUCUGUdTdT
2626


 


AD-61920.1
AAAGGAUUUUGAGUGUAAAdTdT
2060
2951-2969
UUUACACUCAAAAUCCUUUdTdT
2627


 


AD-61879.1
AGUGUAAAAGGACUGCUUGdTdT
2061
2962-2980
CAAGCAGUCCUUUUACACUdTdT
2628


 


AD-61885.1
AAGGACUGCUUGUAGGUGAdTdT
2062
2969-2987
UCACCUACAAGCAGUCCUUdTdT
2629


 


AD-61891.1
GUAGGUGAGAUCUUGUCUGdTdT
2063
2980-2998
CAGACAAGAUCUCACCUACdTdT
2630


 


AD-61897.1
AUCUUGUCUGCAGUUCUAAdTdT
2064
2989-3007
UUAGAACUGCAGACAAGAUdTdT
2631


 


AD-61903.1
GUUCUAAGUCAGGAAGGCAdTdT
2065
3001-3019
UGCCUUCCUGACUUAGAACdTdT
2632


 


AD-61909.1
GAAGGCAUCAAUAUCCUAAdTdT
2066
3013-3031
UUAGGAUAUUGAUGCCUUCdTdT
2633


 


AD-61915.1
UCAAUAUCCUAACCCACCUdTdT
2067
3020-3038
AGGUGGGUUAGGAUAUUGAdTdT
2634


 


AD-61921.1
CCACCUCCCCAAAGGGAGUdTdT
2068
3033-3051
ACUCCCUUUGGGGAGGUGGdTdT
2635


 


AD-61927.1
CCCCAAAGGGAGUGCAGAGdTdT
2069
3039-3057
CUCUGCACUCCCUUUGGGGdTdT
2636


 


AD-61933.1
GUGCAGAGGCGGAGCUGAUdTdT
2070
3050-3068
AUCAGCUCCGCCUCUGCACdTdT
2637


 


AD-61939.1
GGAGCUGAUGAGCGUUGUCdTdT
2071
3060-3078
GACAACGCUCAUCAGCUCCdTdT
2638


 


AD-61945.1
CGUUGUCCCAGUAUUCUAUdTdT
2072
3072-3090
AUAGAAUACUGGGACAACGdTdT
2639


 


AD-61951.1
CCAGUAUUCUAUGUUUUUCdTdT
2073
3079-3097
GAAAAACAUAGAAUACUGGdTdT
2640


 


AD-61957.1
GUUUUUCACUACCUGGAAAdTdT
2074
3091-3109
UUUCCAGGUAGUGAAAAACdTdT
2641


 


AD-61963.1
CCUGGAAACAGGAAAUCAUdTdT
2075
3102-3120
AUGAUUUCCUGUUUCCAGGdTdT
2642


 


AD-61922.1
GGAACAUUUUUCAUUCUGAdTdT
2076
3122-3140
UCAGAAUGAAAAAUGUUCCdTdT
2643


 


AD-61928.1
CAUUCUGACCCAUUAAUUGdTdT
2077
3133-3151
CAAUUAAUGGGUCAGAAUGdTdT
2644


 


AD-61934.1
CCAUUAAUUGAAAAGCAGAdTdT
2078
3142-3160
UCUGCUUUUCAAUUAAUGGdTdT
2645


 


AD-61940.1
AAAGCAGAAACUGAAGAAAdTdT
2079
3153-3171
UUUCUUCAGUUUCUGCUUUdTdT
2646


 


AD-61946.1
AACUGAAGAAAAAAUUAAAdTdT
2080
3161-3179
UUUAAUUUUUUCUUCAGUUdTdT
2647


 


AD-61952.1
AAAAAAUUAAAAGAAGGGAdTdT
2081
3169-3187
UCCCUUCUUUUAAUUUUUUdTdT
2648


 


AD-61958.1
AGGGAUGUUGAGCAUUAUGdTdT
2082
3183-3201
CAUAAUGCUCAACAUCCCUdTdT
2649


 


AD-61964.1
GAGCAUUAUGUCCUACAGAdTdT
2083
3192-3210
UCUGUAGGACAUAAUGCUCdTdT
2650


 


AD-61923.1
UGUCCUACAGAAAUGCUGAdTdT
2084
3200-3218
UCAGCAUUUCUGUAGGACAdTdT
2651


 


AD-61929.1
AAUGCUGACUACUCUUACAdTdT
2085
3211-3229
UGUAAGAGUAGUCAGCAUUdTdT
2652


 


AD-61935.1
UACUCUUACAGUGUGUGGAdTdT
2086
3220-3238
UCCACACACUGUAAGAGUAdTdT
2653


 


AD-61941.1
AGUGUGUGGAAGGGUGGAAdTdT
2087
3229-3247
UUCCACCCUUCCACACACUdTdT
2654


 


AD-61947.1
GGGUGGAAGUGCUAGCACUdTdT
2088
3240-3258
AGUGCUAGCACUUCCACCCdTdT
2655


 


AD-61953.1
GCUAGCACUUGGUUAACAGdTdT
2089
3250-3268
CUGUUAACCAAGUGCUAGCdTdT
2656


 


AD-61959.1
GGUUAACAGCUUUUGCUUUdTdT
2090
3260-3278
AAAGCAAAAGCUGUUAACCdTdT
2657


 


AD-61965.1
UGCUUUAAGAGUACUUGGAdTdT
2091
3273-3291
UCCAAGUACUCUUAAAGCAdTdT
2658


 


AD-61924.1
GUACUUGGACAAGUAAAUAdTdT
2092
3283-3301
UAUUUACUUGUCCAAGUACdTdT
2659


 


AD-61930.1
CAAGUAAAUAAAUACGUAGdTdT
2093
3292-3310
CUACGUAUUUAUUUACUUGdTdT
2660


 


AD-61936.1
AUAAAUACGUAGAGCAGAAdTdT
2094
3299-3317
UUCUGCUCUACGUAUUUAUdTdT
2661


 


AD-61942.1
GAGCAGAACCAAAAUUCAAdTdT
2095
3310-3328
UUGAAUUUUGGUUCUGCUCdTdT
2662


 


AD-61948.1
AAUUCAAUUUGUAAUUCUUdTdT
2096
3322-3340
AAGAAUUACAAAUUGAAUUdTdT
2663


 


AD-61954.1
GUAAUUCUUUAUUGUGGCUdTdT
2097
3332-3350
AGCCACAAUAAAGAAUUACdTdT
2664


 


AD-61960.1
AUUGUGGCUAGUUGAGAAUdTdT
2098
3342-3360
AUUCUCAACUAGCCACAAUdTdT
2665


 


AD-61966.1
CUAGUUGAGAAUUAUCAAUdTdT
2099
3349-3367
AUUGAUAAUUCUCAACUAGdTdT
2666


 


AD-61925.1
UUAUCAAUUAGAUAAUGGAdTdT
2100
3360-3378
UCCAUUAUCUAAUUGAUAAdTdT
2667


 


AD-61931.1
AAUGGAUCUUUCAAGGAAAdTdT
2101
3373-3391
UUUCCUUGAAAGAUCCAUUdTdT
2668


 


AD-61937.1
CUUUCAAGGAAAAUUCACAdTdT
2102
3380-3398
UGUGAAUUUUCCUUGAAAGdTdT
2669


 


AD-61943.1
AAUUCACAGUAUCAACCAAdTdT
2103
3391-3409
UUGGUUGAUACUGUGAAUUdTdT
2670


 


AD-61949.1
GUAUCAACCAAUAAAAUUAdTdT
2104
3399-3417
UAAUUUUAUUGGUUGAUACdTdT
2671


 


AD-61955.1
AAAAUUACAGGGUACCUUGdTdT
2105
3411-3429
CAAGGUACCCUGUAAUUUUdTdT
2672


 


AD-61961.1
AGGGUACCUUGCCUGUUGAdTdT
2106
3419-3437
UCAACAGGCAAGGUACCCUdTdT
2673


 


AD-61967.1
GUUGAAGCCCGAGAGAACAdTdT
2107
3433-3451
UGUUCUCUCGGGCUUCAACdTdT
2674


 


AD-61926.1
CCGAGAGAACAGCUUAUAUdTdT
2108
3441-3459
AUAUAAGCUGUUCUCUCGGdTdT
2675


 


AD-61932.1
GCUUAUAUCUUACAGCCUUdTdT
2109
3452-3470
AAGGCUGUAAGAUAUAAGCdTdT
2676


 


AD-61938.1
CUUACAGCCUUUACUGUGAdTdT
2110
3460-3478
UCACAGUAAAGGCUGUAAGdTdT
2677


 


AD-61944.1
GAAUUAGAAAGGCUUUCGAdTdT
2111
3482-3500
UCGAAAGCCUUUCUAAUUCdTdT
2678


 


AD-61950.1
GGCUUUCGAUAUAUGCCCCdTdT
2112
3492-3510
GGGGCAUAUAUCGAAAGCCdTdT
2679


 


AD-61956.1
GAUAUAUGCCCCCUGGUGAdTdT
2113
3499-3517
UCACCAGGGGGCAUAUAUCdTdT
2680


 


AD-61962.1
GGUGAAAAUCGACACAGCUdTdT
2114
3513-3531
AGCUGUGUCGAUUUUCACCdTdT
2681


 


AD-61968.1
CGACACAGCUCUAAUUAAAdTdT
2115
3522-3540
UUUAAUUAGAGCUGUGUCGdTdT
2682


 


AD-61974.1
GCUCUAAUUAAAGCUGACAdTdT
2116
3529-3547
UGUCAGCUUUAAUUAGAGCdTdT
2683


 


AD-61980.1
CUGACAACUUUCUGCUUGAdTdT
2117
3542-3560
UCAAGCAGAAAGUUGUCAGdTdT
2684


 


AD-61986.1
CUUUCUGCUUGAAAAUACAdTdT
2118
3549-3567
UGUAUUUUCAAGCAGAAAGdTdT
2685


 


AD-61992.1
AAAAUACACUGCCAGCCCAdTdT
2119
3560-3578
UGGGCUGGCAGUGUAUUUUdTdT
2686


 


AD-61998.1
AGCCCAGAGCACCUUUACAdTdT
2120
3573-3591
UGUAAAGGUGCUCUGGGCUdTdT
2687


 


AD-62004.1
GCACCUUUACAUUGGCCAUdTdT
2121
3581-3599
AUGGCCAAUGUAAAGGUGCdTdT
2688


 


AD-62010.1
ACAUUGGCCAUUUCUGCGUdTdT
2122
3589-3607
ACGCAGAAAUGGCCAAUGUdTdT
2689


 


AD-61969.1
CUGCGUAUGCUCUUUCCCUdTdT
2123
3602-3620
AGGGAAAGAGCAUACGCAGdTdT
2690


 


AD-61975.1
CUUUCCCUGGGAGAUAAAAdTdT
2124
3613-3631
UUUUAUCUCCCAGGGAAAGdTdT
2691


 


AD-61981.1
GAGAUAAAACUCACCCACAdTdT
2125
3623-3641
UGUGGGUGAGUUUUAUCUCdTdT
2692


 


AD-61987.1
ACUCACCCACAGUUUCGUUdTdT
2126
3631-3649
AACGAAACUGUGGGUGAGUdTdT
2693


 


AD-61993.1
CAGUUUCGUUCAAUUGUUUdTdT
2127
3640-3658
AAACAAUUGAACGAAACUGdTdT
2694


 


AD-61999.1
CAAUUGUUUCAGCUUUGAAdTdT
2128
3650-3668
UUCAAAGCUGAAACAAUUGdTdT
2695


 


AD-62005.1
CUUUGAAGAGAGAAGCUUUdTdT
2129
3662-3680
AAAGCUUCUCUCUUCAAAGdTdT
2696


 


AD-62011.1
GAGAGAAGCUUUGGUUAAAdTdT
2130
3669-3687
UUUAACCAAAGCUUCUCUCdTdT
2697


 


AD-61970.1
GUUAAAGGUAAUCCACCCAdTdT
2131
3682-3700
UGGGUGGAUUACCUUUAACdTdT
2698


 


AD-61976.1
AAUCCACCCAUUUAUCGUUdTdT
2132
3691-3709
AACGAUAAAUGGGUGGAUUdTdT
2699


 


AD-61982.1
CAUUUAUCGUUUUUGGAAAdTdT
2133
3699-3717
UUUCCAAAAACGAUAAAUGdTdT
2700


 


AD-61988.1
UUUGGAAAGACAAUCUUCAdTdT
2134
3710-3728
UGAAGAUUGUCUUUCCAAAdTdT
2701


 


AD-61994.1
AAUCUUCAGCAUAAAGACAdTdT
2135
3721-3739
UGUCUUUAUGCUGAAGAUUdTdT
2702


 


AD-62006.1
CUCUGUACCUAACACUGGUdTdT
2136
3741-3759
ACCAGUGUUAGGUACAGAGdTdT
2703


 


AD-62012.1
ACACUGGUACGGCACGUAUdTdT
2137
3752-3770
AUACGUGCCGUACCAGUGUdTdT
2704


 


AD-61971.1
GGCACGUAUGGUAGAAACAdTdT
2138
3762-3780
UGUUUCUACCAUACGUGCCdTdT
2705


 


AD-61977.1
GGUAGAAACAACUGCCUAUdTdT
2139
3771-3789
AUAGGCAGUUGUUUCUACCdTdT
2706


 


AD-61983.1
CAACUGCCUAUGCUUUACUdTdT
2140
3779-3797
AGUAAAGCAUAGGCAGUUGdTdT
2707


 


AD-61989.1
CUUUACUCACCAGUCUGAAdTdT
2141
3791-3809
UUCAGACUGGUGAGUAAAGdTdT
2708


 


AD-61995.1
GUCUGAACUUGAAAGAUAUdTdT
2142
3803-3821
AUAUCUUUCAAGUUCAGACdTdT
2709


 


AD-62001.1
ACUUGAAAGAUAUAAAUUAdTdT
2143
3809-3827
UAAUUUAUAUCUUUCAAGUdTdT
2710


 


AD-62007.1
UAUAAAUUAUGUUAACCCAdTdT
2144
3819-3837
UGGGUUAACAUAAUUUAUAdTdT
2711


 


AD-62013.1
GUUAACCCAGUCAUCAAAUdTdT
2145
3829-3847
AUUUGAUGACUGGGUUAACdTdT
2712


 


AD-61972.1
UCAUCAAAUGGCUAUCAGAdTdT
2146
3839-3857
UCUGAUAGCCAUUUGAUGAdTdT
2713


 


AD-61978.1
UAUCAGAAGAGCAGAGGUAdTdT
2147
3851-3869
UACCUCUGCUCUUCUGAUAdTdT
2714


 


AD-61984.1
AGAGGUAUGGAGGUGGCUUdTdT
2148
3863-3881
AAGCCACCUCCAUACCUCUdTdT
2715


 


AD-61990.1
GAGGUGGCUUUUAUUCAACdTdT
2149
3872-3890
GUUGAAUAAAAGCCACCUCdTdT
2716


 


AD-61996.1
UAUUCAACCCAGGACACAAdTdT
2150
3883-3901
UUGUGUCCUGGGUUGAAUAdTdT
2717


 


AD-62002.1
AGGACACAAUCAAUGCCAUdTdT
2151
3893-3911
AUGGCAUUGAUUGUGUCCUdTdT
2718


 


AD-62008.1
CAAUCAAUGCCAUUGAGGGdTdT
2152
3899-3917
CCCUCAAUGGCAUUGAUUGdTdT
2719


 


AD-62014.1
CAUUGAGGGCCUGACGGAAdTdT
2153
3909-3927
UUCCGUCAGGCCCUCAAUGdTdT
2720


 


AD-61973.1
ACGGAAUAUUCACUCCUGGdTdT
2154
3922-3940
CCAGGAGUGAAUAUUCCGUdTdT
2721


 


AD-61979.1
UUCACUCCUGGUUAAACAAdTdT
2155
3930-3948
UUGUUUAACCAGGAGUGAAdTdT
2722


 


AD-61985.1
GGUUAAACAACUCCGCUUGdTdT
2156
3939-3957
CAAGCGGAGUUGUUUAACCdTdT
2723


 


AD-61991.1
CCGCUUGAGUAUGGACAUCdTdT
2157
3951-3969
GAUGUCCAUACUCAAGCGGdTdT
2724


 


AD-61997.1
GGACAUCGAUGUUUCUUACdTdT
2158
3963-3981
GUAAGAAACAUCGAUGUCCdTdT
2725


 


AD-62003.1
CGAUGUUUCUUACAAGCAUdTdT
2159
3969-3987
AUGCUUGUAAGAAACAUCGdTdT
2726


 


AD-62009.1
CAAGCAUAAAGGUGCCUUAdTdT
2160
3981-3999
UAAGGCACCUUUAUGCUUGdTdT
2727


 


AD-62056.1
GUGCCUUACAUAAUUAUAAdTdT
2161
3992-4010
UUAUAAUUAUGUAAGGCACdTdT
2728


 


AD-62015.1
ACAUAAUUAUAAAAUGACAdTdT
2162
3999-4017
UGUCAUUUUAUAAUUAUGUdTdT
2729


 


AD-62021.1
AAAAUGACAGACAAGAAUUdTdT
2163
4009-4027
AAUUCUUGUCUGUCAUUUUdTdT
2730


 


AD-62027.1
CAAGAAUUUCCUUGGGAGGdTdT
2164
4020-4038
CCUCCCAAGGAAAUUCUUGdTdT
2731


 


AD-62033.1
CCUUGGGAGGCCAGUAGAGdTdT
2165
4029-4047
CUCUACUGGCCUCCCAAGGdTdT
2732


 


AD-62039.1
AGUAGAGGUGCUUCUCAAUdTdT
2166
4041-4059
AUUGAGAAGCACCUCUACUdTdT
2733


 


AD-62045.1
CUUCUCAAUGAUGACCUCAdTdT
2167
4051-4069
UGAGGUCAUCAUUGAGAAGdTdT
2734


 


AD-62051.1
UGACCUCAUUGUCAGUACAdTdT
2168
4062-4080
UGUACUGACAAUGAGGUCAdTdT
2735


 


AD-62057.1
GUCAGUACAGGAUUUGGCAdTdT
2169
4072-4090
UGCCAAAUCCUGUACUGACdTdT
2736


 


AD-62016.1
AGGAUUUGGCAGUGGCUUGdTdT
2170
4080-4098
CAAGCCACUGCCAAAUCCUdTdT
2737


 


AD-62022.1
UGGCUUGGCUACAGUACAUdTdT
2171
4092-4110
AUGUACUGUAGCCAAGCCAdTdT
2738


 


AD-62028.1
GCUACAGUACAUGUAACAAdTdT
2172
4099-4117
UUGUUACAUGUACUGUAGCdTdT
2739


 


AD-62034.1
AACAACUGUAGUUCACAAAdTdT
2173
4113-4131
UUUGUGAACUACAGUUGUUdTdT
2740


 


AD-62040.1
GUAGUUCACAAAACCAGUAdTdT
2174
4120-4138
UACUGGUUUUGUGAACUACdTdT
2741


 


AD-62046.1
AAACCAGUACCUCUGAGGAdTdT
2175
4130-4148
UCCUCAGAGGUACUGGUUUdTdT
2742


 


AD-62052.1
UGAGGAAGUUUGCAGCUUUdTdT
2176
4143-4161
AAAGCUGCAAACUUCCUCAdTdT
2743


 


AD-62058.1
UGCAGCUUUUAUUUGAAAAdTdT
2177
4153-4171
UUUUCAAAUAAAAGCUGCAdTdT
2744


 


AD-62017.1
AUUUGAAAAUCGAUACUCAdTdT
2178
4163-4181
UGAGUAUCGAUUUUCAAAUdTdT
2745


 


AD-62023.1
CGAUACUCAGGAUAUUGAAdTdT
2179
4173-4191
UUCAAUAUCCUGAGUAUCGdTdT
2746


 


AD-62029.1
GGAUAUUGAAGCAUCCCACdTdT
2180
4182-4200
GUGGGAUGCUUCAAUAUCCdTdT
2747


 


AD-62035.1
GAAGCAUCCCACUACAGAGdTdT
2181
4189-4207
CUCUGUAGUGGGAUGCUUCdTdT
2748


 


AD-62041.1
ACUACAGAGGCUACGGAAAdTdT
2182
4199-4217
UUUCCGUAGCCUCUGUAGUdTdT
2749


 


AD-62047.1
CGGAAACUCUGAUUACAAAdTdT
2183
4212-4230
UUUGUAAUCAGAGUUUCCGdTdT
2750


 


AD-62053.1
UGAUUACAAACGCAUAGUAdTdT
2184
4221-4239
UACUAUGCGUUUGUAAUCAdTdT
2751


 


AD-62059.1
GCAUAGUAGCAUGUGCCAGdTdT
2185
4232-4250
CUGGCACAUGCUACUAUGCdTdT
2752


 


AD-62018.1
GCAUGUGCCAGCUACAAGCdTdT
2186
4240-4258
GCUUGUAGCUGGCACAUGCdTdT
2753


 


AD-62024.1
CUACAAGCCCAGCAGGGAAdTdT
2187
4251-4269
UUCCCUGCUGGGCUUGUAGdTdT
2754


 


AD-62030.1
CAGCAGGGAAGAAUCAUCAdTdT
2188
4260-4278
UGAUGAUUCUUCCCUGCUGdTdT
2755


 


AD-62036.1
GAAUCAUCAUCUGGAUCCUdTdT
2189
4270-4288
AGGAUCCAGAUGAUGAUUCdTdT
2756


 


AD-62042.1
GAUCCUCUCAUGCGGUGAUdTdT
2190
4283-4301
AUCACCGCAUGAGAGGAUCdTdT
2757


 


AD-62048.1
CUCAUGCGGUGAUGGACAUdTdT
2191
4289-4307
AUGUCCAUCACCGCAUGAGdTdT
2758


 


AD-62054.1
GAUGGACAUCUCCUUGCCUdTdT
2192
4299-4317
AGGCAAGGAGAUGUCCAUCdTdT
2759


 


AD-62060.1
CUUGCCUACUGGAAUCAGUdTdT
2193
4311-4329
ACUGAUUCCAGUAGGCAAGdTdT
2760


 


AD-62019.1
GAAUCAGUGCAAAUGAAGAdTdT
2194
4322-4340
UCUUCAUUUGCACUGAUUCdTdT
2761


 


AD-62025.1
AAAUGAAGAAGACUUAAAAdTdT
2195
4332-4350
UUUUAAGUCUUCUUCAUUUdTdT
2762


 


AD-62031.1
GAAGACUUAAAAGCCCUUGdTdT
2196
4339-4357
CAAGGGCUUUUAAGUCUUCdTdT
2763


 


AD-62037.1
CCUUGUGGAAGGGGUGGAUdTdT
2197
4353-4371
AUCCACCCCUUCCACAAGGdTdT
2764


 


AD-62043.1
GAAGGGGUGGAUCAACUAUdTdT
2198
4360-4378
AUAGUUGAUCCACCCCUUCdTdT
2765


 


AD-62049.1
AUCAACUAUUCACUGAUUAdTdT
2199
4370-4388
UAAUCAGUGAAUAGUUGAUdTdT
2766


 


AD-62055.1
CACUGAUUACCAAAUCAAAdTdT
2200
4380-4398
UUUGAUUUGGUAAUCAGUGdTdT
2767


 


AD-62061.1
AUCAAAGAUGGACAUGUUAdTdT
2201
4393-4411
UAACAUGUCCAUCUUUGAUdTdT
2768


 


AD-62020.1
GGACAUGUUAUUCUGCAACdTdT
2202
4402-4420
GUUGCAGAAUAACAUGUCCdTdT
2769


 


AD-62026.1
UCUGCAACUGAAUUCGAUUdTdT
2203
4413-4431
AAUCGAAUUCAGUUGCAGAdTdT
2770


 


AD-62032.1
GAAUUCGAUUCCCUCCAGUdTdT
2204
4422-4440
ACUGGAGGGAAUCGAAUUCdTdT
2771


 


AD-62038.1
CCCUCCAGUGAUUUCCUUUdTdT
2205
4432-4450
AAAGGAAAUCACUGGAGGGdTdT
2772


 


AD-62044.1
GAUUUCCUUUGUGUACGAUdTdT
2206
4441-4459
AUCGUACACAAAGGAAAUCdTdT
2773


 


AD-62050.1
GUACGAUUCCGGAUAUUUGdTdT
2207
4453-4471
CAAAUAUCCGGAAUCGUACdTdT
2774


 


AD-62320.1
CGGAUAUUUGAACUCUUUGdTdT
2208
4462-4480
CAAAGAGUUCAAAUAUCCGdTdT
2775


 


AD-62326.1
ACUCUUUGAAGUUGGGUUUdTdT
2209
4473-4491
AAACCCAACUUCAAAGAGUdTdT
2776


 


AD-62332.1
AGUUGGGUUUCUCAGUCCUdTdT
2210
4482-4500
AGGACUGAGAAACCCAACUdTdT
2777


 


AD-62338.1
UUCUCAGUCCUGCCACUUUdTdT
2211
4490-4508
AAAGUGGCAGGACUGAGAAdTdT
2778


 


AD-62344.1
CACUUUCACAGUGUACGAAdTdT
2212
4503-4521
UUCGUACACUGUGAAAGUGdTdT
2779


 


AD-62350.1
CACAGUGUACGAAUACCACdTdT
2213
4509-4527
GUGGUAUUCGUACACUGUGdTdT
2780


 


AD-62356.1
ACCACAGACCAGAUAAACAdTdT
2214
4523-4541
UGUUUAUCUGGUCUGUGGUdTdT
2781


 


AD-62362.1
CCAGAUAAACAGUGUACCAdTdT
2215
4531-4549
UGGUACACUGUUUAUCUGGdTdT
2782


 


AD-62321.1
CAGUGUACCAUGUUUUAUAdTdT
2216
4540-4558
UAUAAAACAUGGUACACUGdTdT
2783


 


AD-62327.1
GUUUUAUAGCACUUCCAAUdTdT
2217
4551-4569
AUUGGAAGUGCUAUAAAACdTdT
2784


 


AD-62333.1
CUUCCAAUAUCAAAAUUCAdTdT
2218
4562-4580
UGAAUUUUGAUAUUGGAAGdTdT
2785


 


AD-62339.1
AUCAAAAUUCAGAAAGUCUdTdT
2219
4570-4588
AGACUUUCUGAAUUUUGAUdTdT
2786


 


AD-62345.1
GAAAGUCUGUGAAGGAGCCdTdT
2220
4581-4599
GGCUCCUUCACAGACUUUCdTdT
2787


 


AD-62351.1
GAAGGAGCCGCGUGCAAGUdTdT
2221
4591-4609
ACUUGCACGCGGCUCCUUCdTdT
2788


 


AD-62357.1
CGUGCAAGUGUGUAGAAGCdTdT
2222
4601-4619
GCUUCUACACACUUGCACGdTdT
2789


 


AD-62363.1
GUAGAAGCUGAUUGUGGGCdTdT
2223
4612-4630
GCCCACAAUCAGCUUCUACdTdT
2790


 


AD-62322.1
CUGAUUGUGGGCAAAUGCAdTdT
2224
4619-4637
UGCAUUUGCCCACAAUCAGdTdT
2791


 


AD-62328.1
GCAAAUGCAGGAAGAAUUGdTdT
2225
4629-4647
CAAUUCUUCCUGCAUUUGCdTdT
2792


 


AD-62334.1
GAAGAAUUGGAUCUGACAAdTdT
2226
4639-4657
UUGUCAGAUCCAAUUCUUCdTdT
2793


 


AD-62340.1
CUGACAAUCUCUGCAGAGAdTdT
2227
4651-4669
UCUCUGCAGAGAUUGUCAGdTdT
2794


 


AD-62346.1
GCAGAGACAAGAAAACAAAdTdT
2228
4663-4681
UUUGUUUUCUUGUCUCUGCdTdT
2795


 


AD-62352.1
CAAGAAAACAAACAGCAUGdTdT
2229
4670-4688
CAUGCUGUUUGUUUUCUUGdTdT
2796


 


AD-62358.1
ACAGCAUGUAAACCAGAGAdTdT
2230
4681-4699
UCUCUGGUUUACAUGCUGUdTdT
2797


 


AD-62364.1
CCAGAGAUUGCAUAUGCUUdTdT
2231
4693-4711
AAGCAUAUGCAAUCUCUGGdTdT
2798


 


AD-62323.1
GCAUAUGCUUAUAAAGUUAdTdT
2232
4702-4720
UAACUUUAUAAGCAUAUGCdTdT
2799


 


AD-62329.1
UUAUAAAGUUAGCAUCACAdTdT
2233
4710-4728
UGUGAUGCUAACUUUAUAAdTdT
2800


 


AD-62335.1
CAUCACAUCCAUCACUGUAdTdT
2234
4722-4740
UACAGUGAUGGAUGUGAUGdTdT
2801


 


AD-62341.1
UCACUGUAGAAAAUGUUUUdTdT
2235
4733-4751
AAAACAUUUUCUACAGUGAdTdT
2802


 


AD-62347.1
AGAAAAUGUUUUUGUCAAGdTdT
2236
4740-4758
CUUGACAAAAACAUUUUCUdTdT
2803


 


AD-62353.1
UUUGUCAAGUACAAGGCAAdTdT
2237
4750-4768
UUGCCUUGUACUUGACAAAdTdT
2804


 


AD-62359.1
AGGCAACCCUUCUGGAUAUdTdT
2238
4763-4781
AUAUCCAGAAGGGUUGCCUdTdT
2805


 


AD-62365.1
CCUUCUGGAUAUCUACAAAdTdT
2239
4770-4788
UUUGUAGAUAUCCAGAAGGdTdT
2806


 


AD-62324.1
UAUCUACAAAACUGGGGAAdTdT
2240
4779-4797
UUCCCCAGUUUUGUAGAUAdTdT
2807


 


AD-62330.1
CUGGGGAAGCUGUUGCUGAdTdT
2241
4790-4808
UCAGCAACAGCUUCCCCAGdTdT
2808


 


AD-62336.1
CUGUUGCUGAGAAAGACUCdTdT
2242
4799-4817
GAGUCUUUCUCAGCAACAGdTdT
2809


 


AD-62342.1
GACUCUGAGAUUACCUUCAdTdT
2243
4813-4831
UGAAGGUAAUCUCAGAGUCdTdT
2810


 


AD-62348.1
GAGAUUACCUUCAUUAAAAdTdT
2244
4819-4837
UUUUAAUGAAGGUAAUCUCdTdT
2811


 


AD-62354.1
AUUAAAAAGGUAACCUGUAdTdT
2245
4831-4849
UACAGGUUACCUUUUUAAUdTdT
2812


 


AD-62360.1
UAACCUGUACUAACGCUGAdTdT
2246
4841-4859
UCAGCGUUAGUACAGGUUAdTdT
2813


 


AD-62366.1
CUAACGCUGAGCUGGUAAAdTdT
2247
4850-4868
UUUACCAGCUCAGCGUUAGdTdT
2814


 


AD-62325.1
GGUAAAAGGAAGACAGUACdTdT
2248
4863-4881
GUACUGUCUUCCUUUUACCdTdT
2815


 


AD-62331.1
GAAGACAGUACUUAAUUAUdTdT
2249
4871-4889
AUAAUUAAGUACUGUCUUCdTdT
2816


 


AD-62337.1
CUUAAUUAUGGGUAAAGAAdTdT
2250
4881-4899
UUCUUUACCCAUAAUUAAGdTdT
2817


 


AD-62343.1
UAAAGAAGCCCUCCAGAUAdTdT
2251
4893-4911
UAUCUGGAGGGCUUCUUUAdTdT
2818


 


AD-62349.1
CCUCCAGAUAAAAUACAAUdTdT
2252
4902-4920
AUUGUAUUUUAUCUGGAGGdTdT
2819


 


AD-62355.1
AAAUACAAUUUCAGUUUCAdTdT
2253
4912-4930
UGAAACUGAAAUUGUAUUUdTdT
2820


 


AD-62361.1
CAGUUUCAGGUACAUCUACdTdT
2254
4923-4941
GUAGAUGUACCUGAAACUGdTdT
2821


 


AD-62367.1
GGUACAUCUACCCUUUAGAdTdT
2255
4931-4949
UCUAAAGGGUAGAUGUACCdTdT
2822


 


AD-62373.1
CCUUUAGAUUCCUUGACCUdTdT
2256
4942-4960
AGGUCAAGGAAUCUAAAGGdTdT
2823


 


AD-62379.1
CCUUGACCUGGAUUGAAUAdTdT
2257
4952-4970
UAUUCAAUCCAGGUCAAGGdTdT
2824


 


AD-62385.1
GGAUUGAAUACUGGCCUAGdTdT
2258
4961-4979
CUAGGCCAGUAUUCAAUCCdTdT
2825


 


AD-62391.1
CUGGCCUAGAGACACAACAdTdT
2259
4971-4989
UGUUGUGUCUCUAGGCCAGdTdT
2826


 


AD-62397.1
GAGACACAACAUGUUCAUCdTdT
2260
4979-4997
GAUGAACAUGUUGUGUCUCdTdT
2827


 


AD-62403.1
GUUCAUCGUGUCAAGCAUUdTdT
2261
4991-5009
AAUGCUUGACACGAUGAACdTdT
2828


 


AD-62409.1
GUCAAGCAUUUUUAGCUAAdTdT
2262
5000-5018
UUAGCUAAAAAUGCUUGACdTdT
2829


 


AD-62368.1
AGCUAAUUUAGAUGAAUUUdTdT
2263
5013-5031
AAAUUCAUCUAAAUUAGCUdTdT
2830


 


AD-62374.1
AGAUGAAUUUGCCGAAGAUdTdT
2264
5022-5040
AUCUUCGGCAAAUUCAUCUdTdT
2831


 


AD-62380.1
CCGAAGAUAUCUUUUUAAAdTdT
2265
5033-5051
UUUAAAAAGAUAUCUUCGGdTdT
2832


 


AD-62386.1
CUUUUUAAAUGGAUGCUAAdTdT
2266
5043-5061
UUAGCAUCCAUUUAAAAAGdTdT
2833


 


AD-62392.1
GGAUGCUAAAAUUCCUGAAdTdT
2267
5053-5071
UUCAGGAAUUUUAGCAUCCdTdT
2834


 


AD-62398.1
UAAAAUUCCUGAAGUUCAGdTdT
2268
5059-5077
CUGAACUUCAGGAAUUUUAdTdT
2835


 


AD-62404.1
AGUUCAGCUGCAUACAGUUdTdT
2269
5071-5089
AACUGUAUGCAGCUGAACUdTdT
2836


 


AD-62410.1
GCAUACAGUUUGCACUUAUdTdT
2270
5080-5098
AUAAGUGCAAACUGUAUGCdTdT
2837


 


AD-62369.1
ACUUAUGGACUCCUGUUGUdTdT
2271
5093-5111
ACAACAGGAGUCCAUAAGUdTdT
2838


 


AD-62375.1
GGACUCCUGUUGUUGAAGUdTdT
2272
5099-5117
ACUUCAACAACAGGAGUCCdTdT
2839


 


AD-62381.1
UGUUGAAGUUCGUUUUUUUdTdT
2273
5109-5127
AAAAAAACGAACUUCAACAdTdT
2840


 


AD-62387.1
UUUUUUGUUUUCUUCUUUUdTdT
2274
5122-5140
AAAAGAAGAAAACAAAAAAdTdT
2841


 


AD-62393.1
UCUUCUUUUUUUAAACAUUdTdT
2275
5132-5150
AAUGUUUAAAAAAAGAAGAdTdT
2842


 


AD-62399.1
UUUUUAAACAUUCAUAGCUdTdT
2276
5139-5157
AGCUAUGAAUGUUUAAAAAdTdT
2843


 


AD-62405.1
AUAGCUGGUCUUAUUUGUAdTdT
2277
5152-5170
UACAAAUAAGACCAGCUAUdTdT
2844


 


AD-62411.1
GUCUUAUUUGUAAAGCUCAdTdT
2278
5159-5177
UGAGCUUUACAAAUAAGACdTdT
2845


 


AD-62370.1
AAAGCUCACUUUACUUAGAdTdT
2279
5170-5188
UCUAAGUAAAGUGAGCUUUdTdT
2846


 


AD-62376.1
ACUUAGAAUUAGUGGCACUdTdT
2280
5182-5200
AGUGCCACUAAUUCUAAGUdTdT
2847


 


AD-62382.1
AGUGGCACUUGCUUUUAUUdTdT
2281
5192-5210
AAUAAAAGCAAGUGCCACUdTdT
2848


 


AD-62388.1
GCUUUUAUUAGAGAAUGAUdTdT
2282
5202-5220
AUCAUUCUCUAAUAAAAGCdTdT
2849


 


AD-62394.1
GAGAAUGAUUUCAAAUGCUdTdT
2283
5212-5230
AGCAUUUGAAAUCAUUCUCdTdT
2850


 


AD-62400.1
UUUCAAAUGCUGUAACUUUdTdT
2284
5220-5238
AAAGUUACAGCAUUUGAAAdTdT
2851


 


AD-62406.1
GUAACUUUCUGAAAUAACAdTdT
2285
5231-5249
UGUUAUUUCAGAAAGUUACdTdT
2852


 


AD-62412.1
GAAAUAACAUGGCCUUGGAdTdT
2286
5241-5259
UCCAAGGCCAUGUUAUUUCdTdT
2853


 


AD-62371.1
CCUUGGAGGGCAUGAAGACdTdT
2287
5253-5271
GUCUUCAUGCCCUCCAAGGdTdT
2854


 


AD-62377.1
AGGGCAUGAAGACAGAUACdTdT
2288
5259-5277
GUAUCUGUCUUCAUGCCCUdTdT
2855


 


AD-62383.1
GAUACUCCUCCAAGGUUAUdTdT
2289
5273-5291
AUAACCUUGGAGGAGUAUCdTdT
2856


 


AD-62389.1
CCUCCAAGGUUAUUGGACAdTdT
2290
5279-5297
UGUCCAAUAACCUUGGAGGdTdT
2857


 


AD-62395.1
GGACACCGGAAACAAUAAAdTdT
2291
5293-5311
UUUAUUGUUUCCGGUGUCCdTdT
2858


 


AD-62401.1
GAAACAAUAAAUUGGAACAdTdT
2292
5301-5319
UGUUCCAAUUUAUUGUUUCdTdT
2859


 


AD-62407.1
AUUGGAACACCUCCUCAAAdTdT
2293
5311-5329
UUUGAGGAGGUGUUCCAAUdTdT
2860


 


AD-62413.1
UCCUCAAACCUACCACUCAdTdT
2294
5322-5340
UGAGUGGUAGGUUUGAGGAdTdT
2861


 


AD-62372.1
CUACCACUCAGGAAUGUUUdTdT
2295
5331-5349
AAACAUUCCUGAGUGGUAGdTdT
2862


 


AD-62378.1
AAUGUUUGCUGGGGCCGAAdTdT
2296
5343-5361
UUCGGCCCCAGCAAACAUUdTdT
2863


 


AD-62384.1
UGCUGGGGCCGAAAGAACAdTdT
2297
5349-5367
UGUUCUUUCGGCCCCAGCAdTdT
2864


 


AD-62390.1
AAAGAACAGUCCAUUGAAAdTdT
2298
5360-5378
UUUCAAUGGACUGUUCUUUdTdT
2865


 


AD-62396.1
CAUUGAAAGGGAGUAUUACdTdT
2299
5371-5389
GUAAUACUCCCUUUCAAUGdTdT
2866


 


AD-62402.1
GGAGUAUUACAAAAACAUGdTdT
2300
5380-5398
CAUGUUUUUGUAAUACUCCdTdT
2867


 


AD-62408.1
AAAACAUGGCCUUUGCUUGdTdT
2301
5391-5409
CAAGCAAAGGCCAUGUUUUdTdT
2868


 


AD-62414.1
GCCUUUGCUUGAAAGAAAAdTdT
2302
5399-5417
UUUUCUUUCAAGCAAAGGCdTdT
2869


 


AD-62415.1
GAAAGAAAAUACCAAGGAAdTdT
2303
5409-5427
UUCCUUGGUAUUUUCUUUCdTdT
2870


 


AD-62416.1
CCAAGGAACAGGAAACUGAdTdT
2304
5420-5438
UCAGUUUCCUGUUCCUUGGdTdT
2871


 


AD-62417.1
AACUGAUCAUUAAAGCCUGdTdT
2305
5433-5451
CAGGCUUUAAUGAUCAGUUdTdT
2872
















TABLE 22







C5 single dose screen (10 mM) in Hep3B cells with dT modified iRNAs










Duplex ID
Avg. % message remaining














AD-61779.2
43.2



AD-61785.2
22.5



AD-61791.2
27.3



AD-61797.2
30.5



AD-61803.2
30.9



AD-61809.2
75.1



AD-61815.2
90.7



AD-61821.2
33.7



AD-61780.2
53.5



AD-61786.2
34.4



AD-61792.2
27.5



AD-61798.2
23.3



AD-61804.2
23.6



AD-61810.2
33.4



AD-61816.2
39.7



AD-61822.2
24.9



AD-61781.2
31.2



AD-61787.2
22.8



AD-61793.2
28.4



AD-61799.2
91



AD-61805.2
22.1



AD-61811.2
90.9



AD-61817.2
26.1



AD-61823.2
41.3



AD-61782.2
42.5



AD-61788.2
28.9



AD-61794.2
133.5



AD-61800.2
27.9



AD-61806.2
42.8



AD-61812.2
26.9



AD-61818.2
30.6



AD-61824.2
29.3



AD-61783.2
61.3



AD-61789.2
25.5



AD-61795.2
34.2



AD-61801.2
24.2



AD-61807.2
42.8



AD-61813.2
31



AD-61819.2
42.2



AD-61825.2
31



AD-61784.2
34.1



AD-61790.2
26.8



AD-61796.2
34.6



AD-61802.2
30



AD-61808.2
23.5



AD-61814.2
45.3



AD-61820.2
56



AD-61826.2
31.6



AD-61832.2
36.2



AD-61838.2
39.7



AD-61844.2
37



AD-61850.2
66.3



AD-61856.2
172.6



AD-61862.2
41.3



AD-61868.2
32.2



AD-61827.2
52.7



AD-61833.2
29.6



AD-61839.2
41.5



AD-61845.2
29.7



AD-61851.2
37



AD-61857.2
34.9



AD-61863.2
33.3



AD-61869.2
38.2



AD-61828.2
30.3



AD-61834.2
27.1



AD-61840.2
64.3



AD-61846.2
42



AD-61852.2
25.2



AD-61858.2
96.7



AD-61864.2
29.6



AD-61870.2
30.5



AD-61829.2
92.7



AD-61835.2
24.8



AD-61841.2
59.2



AD-61847.2
30.9



AD-61853.2
35.2



AD-61859.2
40.1



AD-61865.2
42.3



AD-61871.2
55.8



AD-61830.2
162.9



AD-61836.2
28.8



AD-61842.2
18.2



AD-61848.2
25



AD-61854.2
42.3



AD-61860.2
41.7



AD-61866.2
28.9



AD-61872.2
64.7



AD-61831.2
16.9



AD-61837.2
24.9



AD-61843.2
27.5



AD-61849.2
25.8



AD-61855.2
20



AD-61861.2
28.6



AD-61867.2
18



AD-62062.1
22



AD-62068.1
29.9



AD-62074.1
40.2



AD-62080.1
30.4



AD-62086.1
21



AD-62092.1
20



AD-62098.1
38.4



AD-62104.1
42.7



AD-62063.1
26.6



AD-62069.1
55.6



AD-62075.1
114.4



AD-62081.1
21.2



AD-62087.1
33.8



AD-62093.1
26.3



AD-62099.1
23.9



AD-62105.1
30.1



AD-62064.1
32



AD-62070.1
135.7



AD-62076.1
84.3



AD-62082.1
42.3



AD-62088.1
36.5



AD-62094.1
66



AD-62100.1
66.4



AD-62106.1
33.9



AD-62065.1
33



AD-62071.1
38.4



AD-62077.1
27.8



AD-62083.1
44.7



AD-62089.1
42.7



AD-62095.1
46.6



AD-62101.1
35.3



AD-62107.1
29.9



AD-62066.1
33.5



AD-62072.1
27.5



AD-62078.1
49.9



AD-62084.1
117.6



AD-62090.1
44



AD-62096.1
33.5



AD-62102.1
39.2



AD-62108.1
69.5



AD-62067.1
32.3



AD-62073.1
81.1



AD-62079.1
46.8



AD-62085.1
31.6



AD-62091.1
32



AD-62097.1
35.3



AD-62103.1
35.6



AD-62109.1
24.7



AD-62115.1
25.7



AD-62121.1
23.1



AD-62127.1
36.3



AD-62133.1
50.9



AD-62139.1
84.1



AD-62145.1
90.8



AD-62151.1
56.9



AD-62110.1
26



AD-62116.1
145.5



AD-62122.1
198.7



AD-62128.1
178.4



AD-62134.1
52.4



AD-62140.1
55.6



AD-62146.1
47.2



AD-62152.1
16.4



AD-62111.1
49.3



AD-62117.1
46.2



AD-62123.1
95.1



AD-62129.1
156.2



AD-62135.1
62



AD-62141.1
128.1



AD-62147.1
146.2



AD-62153.1
35.5



AD-62112.1
43



AD-62118.1
32



AD-62124.1
48.4



AD-62130.1
49.4



AD-62136.1
141.9



AD-62142.1
38.7



AD-62148.1
165.2



AD-62154.1
94.7



AD-62113.1
52.5



AD-62119.1
44



AD-62125.1
129.9



AD-62131.1
68.9



AD-62137.1
106



AD-62143.1
176.1



AD-62149.1
201.3



AD-62155.1
143.3



AD-62114.1
22.8



AD-62120.1
34.6



AD-62126.1
44.6



AD-62132.1
39.5



AD-62138.1
34.5



AD-62144.1
28



AD-62150.1
22.1



AD-62156.1
44.1



AD-62162.1
19.8



AD-62168.1
17.3



AD-62174.1
27



AD-62180.1
15.8



AD-62186.1
20.5



AD-62192.1
33.9



AD-62198.1
14



AD-62157.1
19.3



AD-62163.1
15.4



AD-62169.1
23.6



AD-62175.1
29.6



AD-62181.1
26.4



AD-62187.1
28.8



AD-62193.1
22.9



AD-62199.1
16.4



AD-62158.1
18.5



AD-62164.1
19.1



AD-62170.1
15



AD-62176.1
62.7



AD-62182.1
70.8



AD-62188.1
81.1



AD-62194.1
63.6



AD-62200.1
21.6



AD-62159.1
42.8



AD-62165.1
27.7



AD-62171.1
31.9



AD-62177.1
29.6



AD-62183.1
25.2



AD-62189.1
32.7



AD-62195.1
73.1



AD-62201.1
35.6



AD-62160.1
56.5



AD-62166.1
115.1



AD-62172.1
107.4



AD-62178.1
71.3



AD-62184.1
27.2



AD-62190.1
37.2



AD-62196.1
19.5



AD-62202.1
19.4



AD-62161.1
23.7



AD-62167.1
24.4



AD-62173.1
36



AD-62179.1
50.5



AD-62185.1
40.5



AD-62191.1
39.3



AD-62197.1
39.4



AD-62203.1
34.1



AD-62209.1
34.6



AD-62215.1
31



AD-62221.1
16.3



AD-62227.1
68.5



AD-62233.1
34.3



AD-62239.1
37.2



AD-62245.1
31.2



AD-62204.1
33



AD-62210.1
29



AD-62216.1
38.7



AD-62222.1
34.5



AD-62228.1
30.3



AD-62234.1
15.2



AD-62240.1
26.2



AD-62246.1
40.4



AD-62205.1
17.1



AD-62211.1
20.9



AD-62217.1
49.8



AD-62223.1
40



AD-62229.1
26.7



AD-62235.1
21.5



AD-62241.1
46.2



AD-62247.1
40.4



AD-62206.1
42.2



AD-62212.1
51.7



AD-62218.1
26



AD-62224.1
40.3



AD-62230.1
32.8



AD-62236.1
52.4



AD-62242.1
33.1



AD-62248.1
18



AD-62207.1
19.7



AD-62213.1
43.4



AD-62219.1
39.8



AD-62225.1
34.3



AD-62231.1
37.2



AD-62237.1
25.9



AD-62243.1
19.8



AD-62249.1
13.8



AD-62208.1
13.7



AD-62214.1
16.6



AD-62220.1
25.2



AD-62226.1
27



AD-62232.1
36.5



AD-62238.1
51.5



AD-62244.1
31.5



AD-61874.1
27.1



AD-61880.1
30.8



AD-61886.1
30.4



AD-61892.1
48.9



AD-61898.1
24.7



AD-61904.1
125.9



AD-61910.1
45.7



AD-61916.1
25.7



AD-61875.1
33.4



AD-61881.1
64



AD-61887.1
36.7



AD-61893.1
22.9



AD-61899.1
84.5



AD-61905.1
32.1



AD-61911.1
23.7



AD-61917.1
22.1



AD-61876.1
47.3



AD-61882.1
26.5



AD-61888.1
27.7



AD-61894.1
64.8



AD-61900.1
89.8



AD-61906.1
22.4



AD-61912.1
19.8



AD-61918.1
37.1



AD-61877.1
145



AD-61883.1
31.5



AD-61889.1
33.9



AD-61895.1
37.5



AD-61901.1
26.1



AD-61907.1
33



AD-61913.1
33.1



AD-61919.1
36.6



AD-61878.1
26.9



AD-61884.1
33.9



AD-61890.1
37.2



AD-61896.1
41.7



AD-61902.1
58.6



AD-61908.1
28



AD-61914.1
31.4



AD-61920.1
27.1



AD-61879.1
33.1



AD-61885.1
33.7



AD-61891.1
41.3



AD-61897.1
39.4



AD-61903.1
51.5



AD-61909.1
48.6



AD-61915.1
122.4



AD-61921.1
66.4



AD-61927.1
40.5



AD-61933.1
27.7



AD-61939.1
28.1



AD-61945.1
30



AD-61951.1
33.7



AD-61957.1
32.6



AD-61963.1
17



AD-61922.1
32.9



AD-61928.1
28.3



AD-61934.1
24



AD-61940.1
28.2



AD-61946.1
33.2



AD-61952.1
167.9



AD-61958.1
37



AD-61964.1
30.6



AD-61923.1
51.2



AD-61929.1
29.4



AD-61935.1
61



AD-61941.1
29.5



AD-61947.1
28.9



AD-61953.1
23.7



AD-61959.1
18.9



AD-61965.1
17



AD-61924.1
24.1



AD-61930.1
31.9



AD-61936.1
36.9



AD-61942.1
13.8



AD-61948.1
40.2



AD-61954.1
41.8



AD-61960.1
24.1



AD-61966.1
18.9



AD-61925.1
52.4



AD-61931.1
25.8



AD-61937.1
19.1



AD-61943.1
27.8



AD-61949.1
26.5



AD-61955.1
83.8



AD-61961.1
26



AD-61967.1
16.3



AD-61926.1
17.8



AD-61932.1
18.6



AD-61938.1
31.9



AD-61944.1
29.5



AD-61950.1
57.8



AD-61956.1
42.1



AD-61962.1
30



AD-61968.1
29.1



AD-61974.1
50.8



AD-61980.1
19.7



AD-61986.1
36.4



AD-61992.1
36.3



AD-61998.1
18.3



AD-62004.1
14



AD-62010.1
56.8



AD-61969.1
30



AD-61975.1
51.1



AD-61981.1
37.6



AD-61987.1
32.5



AD-61993.1
23.4



AD-61999.1
43.8



AD-62005.1
23.8



AD-62011.1
32.7



AD-61970.1
39.6



AD-61976.1
27.5



AD-61982.1
64.9



AD-61988.1
29.5



AD-61994.1
40.5



AD-62006.1
42.1



AD-62012.1
21



AD-61971.1
27.1



AD-61977.1
23.4



AD-61983.1
57.5



AD-61989.1
25.8



AD-61995.1
18.2



AD-62001.1
29.7



AD-62007.1
106.4



AD-62013.1
36.1



AD-61972.1
40.5



AD-61978.1
49.1



AD-61984.1
24.3



AD-61990.1
38.8



AD-61996.1
40.5



AD-62002.1
32.5



AD-62008.1
35.3



AD-62014.1
23.6



AD-61973.1
39.3



AD-61979.1
27.4



AD-61985.1
31.3



AD-61991.1
34.9



AD-61997.1
29.2



AD-62003.1
25.9



AD-62009.1
21.1



AD-62056.1
16.3



AD-62015.1
139.3



AD-62021.1
36.4



AD-62027.1
42.4



AD-62033.1
62



AD-62039.1
35.2



AD-62045.1
30.8



AD-62051.1
22.9



AD-62057.1
31.8



AD-62016.1
29.2



AD-62022.1
36.9



AD-62028.1
52.6



AD-62034.1
31



AD-62040.1
30.7



AD-62046.1
28.2



AD-62052.1
23.7



AD-62058.1
77.9



AD-62017.1
41



AD-62023.1
27



AD-62029.1
31.8



AD-62035.1
46.4



AD-62041.1
25.3



AD-62047.1
20



AD-62053.1
37.1



AD-62059.1
31



AD-62018.1
37.8



AD-62024.1
34.7



AD-62030.1
50.4



AD-62036.1
25.5



AD-62042.1
32.5



AD-62048.1
28.3



AD-62054.1
55.6



AD-62060.1
26.9



AD-62019.1
29



AD-62025.1
78.5



AD-62031.1
152.8



AD-62037.1
27.3



AD-62043.1
33.8



AD-62049.1
46



AD-62055.1
24.5



AD-62061.1
30.5



AD-62020.1
25.1



AD-62026.1
24.9



AD-62032.1
23



AD-62038.1
21.2



AD-62044.1
34.1



AD-62050.1
22.4



AD-62320.1
16.6



AD-62326.1
16.6



AD-62332.1
15.4



AD-62338.1
41.9



AD-62344.1
19.6



AD-62350.1
32.3



AD-62356.1
20.4



AD-62362.1
27.8



AD-62321.1
18.7



AD-62327.1
14.8



AD-62333.1
22.2



AD-62339.1
134.5



AD-62345.1
32.1



AD-62351.1
35.6



AD-62357.1
31



AD-62363.1
28.2



AD-62322.1
45.1



AD-62328.1
30.1



AD-62334.1
39.1



AD-62340.1
24.3



AD-62346.1
35.4



AD-62352.1
33.8



AD-62358.1
45.7



AD-62364.1
19.7



AD-62323.1
40.5



AD-62329.1
57.5



AD-62335.1
27.6



AD-62341.1
69.2



AD-62347.1
125.9



AD-62353.1
53.1



AD-62359.1
38.1



AD-62365.1
23.6



AD-62324.1
27.1



AD-62330.1
25.1



AD-62336.1
25.3



AD-62342.1
45.4



AD-62348.1
91.6



AD-62354.1
132.1



AD-62360.1
31.6



AD-62366.1
14.2



AD-62325.1
27.9



AD-62331.1
31.5



AD-62337.1
33.9



AD-62343.1
36.1



AD-62349.1
37.6



AD-62355.1
38.8



AD-62361.1
46.1



AD-62367.1
23.6



AD-62373.1
32.1



AD-62379.1
29.6



AD-62385.1
35.7



AD-62391.1
33.7



AD-62397.1
54.1



AD-62403.1
34.8



AD-62409.1
28.2



AD-62368.1
29.7



AD-62374.1
29.6



AD-62380.1
30.6



AD-62386.1
23.4



AD-62392.1
30.5



AD-62398.1
48.7



AD-62404.1
24.8



AD-62410.1
21.9



AD-62369.1
27.4



AD-62375.1
31.9



AD-62381.1
27.3



AD-62387.1
77



AD-62393.1
93.3



AD-62399.1
150.2



AD-62405.1
28.5



AD-62411.1
19.4



AD-62370.1
16.3



AD-62376.1
48.2



AD-62382.1
28.5



AD-62388.1
49.9



AD-62394.1
29.9



AD-62400.1
45.2



AD-62406.1
23



AD-62412.1
45.5



AD-62371.1
66.5



AD-62377.1
49.5



AD-62383.1
73.8



AD-62389.1
82.4



AD-62395.1
31.8



AD-62401.1
31.2



AD-62407.1
30.2



AD-62413.1
28.1



AD-62372.1
43



AD-62378.1
17.9



AD-62384.1
29.6



AD-62390.1
37.7



AD-62396.1
26



AD-62402.1
31.6



AD-62408.1
46.6



AD-62414.1
27.2



AD-62415.1
17.6



AD-62416.1
25.3



AD-62417.1
36.3



AD-61779.2
43.2



AD-61785.2
22.5



AD-61791.2
27.3



AD-61797.2
30.5



AD-61803.2
30.9



AD-61809.2
75.1



AD-61815.2
90.7



AD-61821.2
33.7



AD-61780.2
53.5



AD-61786.2
34.4



AD-61792.2
27.5



AD-61798.2
23.3



AD-61804.2
23.6










Example 7
In Vivo Screening of Additional siRNAs
Based on the sequence of AD-58643, an additional four sense and three antisense sequences were synthesized and used to prepare twelve, 21/25 mer compounds (Table 23). In general, the antisense strands of these compounds were extended with a dTdT and the duplexes had fewer fluoro-modified nucleotides.
C57BL/6 mice (N=3 per group) were injected subcutaneously with 1 mg/kg of these GalNAc conjugated duplexes, serum was collected on day 0 pre-bleed, and day 5, and the levels of C5 proteins were quantified by ELISA. C5 protein levels were normalized to the day 0 pre-bleed level.
FIG. 14 shows the results of an in vivo single dose screen with the indicated iRNAs. Data are expressed as percent of C5 protein remaining relative to pre-bleed levels. Those iRNAs having improved efficacy as compared to the parent compound included AD-62510, AD-62643, AD-62645, AD-62646, AD-62650, and AD-62651. These iRNAs also demonstrated similar potencies (IC50 of about 23-59 pM).
The efficacy of these iRNAs was also tested in C57Bl/6 mice using a single-dosing administration protocol. Mice were subcutaneously administered AD-62510, AD-62643, AD-62645, AD-62646, AD-62650, and AD-62651 at a 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 2.5 mg/kg dose. Serum was collected at days 0 and 5 and analyzed for C5 protein levels by ELISA. C5 levels were normalized to the day 0 pre-bleed level.
FIG. 15 shows that there is a dose response with all of the tested iRNAs and that single-dosing of all of these iRNAs achieved silencing of C5 protein similar to or better than AD-58641.
The duration of silencing of AD-62510, AD-62643, AD-62645, AD-62646, AD-62650, and AD-62651 in vivo was determined by administering a single 1.0 mg/kg dose to C57Bl/6 mice and determining the amount of C5 protein present on days 6, 13, 20, 27, and 34 by ELISA. C5 levels were normalized to the day 0 pre-bleed level.
As demonstrated in FIG. 16, each of the iRNAs tested has the same recovery kinetics as AD-62643 trending toward the best silencing, but within the error of the assay.
AD-62510, AD-62643, AD-62645, AD-62646, AD-62650, and AD-62651 were further tested for efficacy and to evaluate the cumulative effect of the iRNAs in rats using a repeat administration protocol. Wild-type Sprague Dawley rats were subcutaneously injected with each of the iRNAs at a 5.0 mg/kg/dose on days 0, 4, and 7. Serum was collected on days 0, 4, 7, 11, 14, 18, 25, 28, and 32. Serum hemolytic activity was quantified as described above.
The results depicted in FIG. 17 demonstrate that all of the tested iRNAs have a potent and durable decrease in hemolytic activity and a similar recovery of hemolysis to that observed with AD-58641 treatment.







TABLE 23







Modified Sense and Antisense Strand Sequences of GalNAc-Conjugated C5 dsRNAs.



















SEQ


Duplex


SEQ ID


ID


ID
sense ID
Sense (5′ to 3′)
NO:
AS ID
Antisense (5′ to 3′)
NO:





AD-58643
A-119326.1
AfsasGfcAfaGfaUfAfU
2873
A-119327.1
usAfsuUfaUfaAfaAfauaUfcUfuGfcUfususu
2886




fuUfuUfaUfaAfuAfL96


 


AD-62642
A-125167.7
asasGfcAfaGfaUfAfU
2874
A-125139.1
usAfsuuaUfaAfaAfauaUfcUfuGfcuususudTdT
2887




fuUfuuAfuAfauaL96


 


AD-62510
A-125167.7
asasGfcAfaGfaUfAfU
2875
A-125173.2
usAfsUfuAfuAfAfaAfauaUfcUfuGfcuususudTdT
2888




fuUfuuAfuAfauaL96


 


AD-62643
A-125167.7
asasGfcAfaGfaUfAfU
2876
A-125647.1
usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT
2889




fuUfuuAfuAfauaL96


 


AD-62644
A-125157.17
asasGfcAfaGfaUfA
2877
A-125139.1
usAfsuuaUfaAfaAfauaUfcUfuGfcuususudTdT
2890




fUfuUfuuAfuaAfuaL96


 


AD-62645
A-125157.17
asasGfcAfaGfaUfA
2878
A-125173.2
usAfsUfuAfuAfAfaAfauaUfcUfuGfcuususudTdT
2891




fUfuUfuuAfuaAfuaL96


 


AD-62646
A-125157.17
asasGfcAfaGfaUfA
2879
A-125647.1
usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT
2892




fUfuUfuuAfuaAfuaL96


 


AD-62647
A-125134.1
asasgcaagauaUfuuuua
2880
A-125139.1
usAfsuuaUfaAfaAfauaUfcUfuGfcuususudTdT
2893




(Tgn)aauaL96


 


AD-62648
A-125134.1
asasgcaagauaUfuuuua
2881
A-125173.2
usAfsUfuAfuAfAfaAfauaUfcUfuGfcuususudTdT
2894




(Tgn)aauaL96


 


AD-62649
A-125134.1
asasgcaagauaUfuuuua
2882
A-125647.1
usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT
2895




(Tgn)aauaL96


 


AD-62428
A-125127.2
asasgcaagaUfaU
2883
A-125139.1
usAfsuuaUfaAfaAfauaUfcUfuGfcuususudTdT
2896




fuuuuauaauaL96


 


AD-62650
A-125127.2
asasgcaagaUfaU
2884
A-125173.2
usAfsUfuAfuAfAfaAfauaUfcUfuGfcuususudTdT
2897




fuuuuauaauaL96


 


AD-62651
A-125127.2
asasgcaagaUfaU
2885
A-125647.1
usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT
2898




fuuuuauaauaL96

## Claims

1. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5, wherein said dsRNA agent comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity which comprises at least 17 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of 5′-UAUUAUAAAAAUAUCUUGCUUUU-3′ (SEQ ID NO:113), and wherein said dsRNA agent comprises at least one modified nucleotide.

2. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5, wherein said dsRNA agent comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity which comprises at least 17 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of 5′-UAUUAUAAAAAUAUCUUGCUUUU-3′ (SEQ ID NO:113),
wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, and
wherein said sense strand is conjugated to a ligand attached at the 3′-terminus.

3. The dsRNA agent of claim 2, wherein all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand are modified nucleotides.

4. The dsRNA agent of claim 2, wherein the modified nucleotide is selected from the group consisting of a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or a dodecanoic acid bisdecylamide group.

5. The dsRNA agent of claim 4, wherein the modified nucleotide is a 2′-O-methyl nucleotide or a 2′-fluoro nucleotide.

6. The dsRNA agent of claim 1, wherein the region of complementarity is between 19 and 23 nucleotides in length.

7. The dsRNA agent of claim 1, wherein each strand is no more than 30 nucleotides in length.

8. The dsRNA agent of claim 1, wherein at least one strand comprises a 3′ overhang of at least 2 nucleotides.

9. The dsRNA agent of claim 1, wherein said agent further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.

10. The dsRNA agent of claim 1, further comprising a ligand.

11. The dsRNA agent of claim 10, wherein the ligand is conjugated to the 3′ end of the sense strand of the agent.

12. The dsRNA agent of claim 11, wherein the ligand is an N-acetylgalactosamine (GalNAc) derivative.

13. The dsRNA agent of claim 12, wherein the ligand is

14. The dsRNA agent of claim 13, wherein the agent is conjugated to the ligand as shown in the following schematic



and, wherein X is O or S.

15. The dsRNA agent of claim 14, wherein the X is O.

16. The dsRNA agent of claim 1, wherein the region of complementarity consists of the nucleotide sequence of 5′-UAUUAUAAAAAUAUCUUGCUUUU-3′ (SEQ ID NO:113).

17. The dsRNA agent of claim 1, wherein the agent comprises a sense strand comprising the nucleotide sequence of 5′-AAGCAAGAUAUUUUUAUAAUA-3′ (SEQ ID NO:62), and an antisense strand comprising the nucleotide sequence of 5′-UAUUAUAAAAAUAUCUUGCUUUU-3′ (SEQ ID NO:113).

18. The dsRNA agent of claim 17, wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U, respectively; Af, Gf, Cf and Uf are 2′-fluoro A, G, C and U, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage.

19. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5, wherein said dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyl (2′-OMe) A, G, C, and U, respectively; Af, Gf, Cf and Uf are 2′-fluoro A, G, C and U, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage; and
wherein said sense strand is conjugated at the 3′-terminus to the ligand

20. A cell comprising the dsRNA agent of claim 19.

21. A pharmaceutical composition for inhibiting expression of a complement component C5 gene comprising the dsRNA agent of claim 19.

22. A method of inhibiting complement component C5 expression in a cell, the method comprising:
(a) contacting the cell with the dsRNA agent of claim 19; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a complement component C5 gene, thereby inhibiting expression of the complement component C5 gene in the cell.

23. The method of claim 22, wherein said cell is within a subject.

24. The method of claim 22, wherein the subject is a human.

25. A method of treating a subject having a disease or disorder that would benefit from a reduction in complement component C5 expression, the method comprising administering to the subject a therapeutically effective amount of the dsRNA agent of claim 19, thereby treating said subject.

26. The method of claim 25, wherein the disorder is a complement component C5-associated disease.

27. A method of preventing at least one symptom in a subject having or prone to having a disease or disorder that would benefit from a reduction in complement component C5 expression, the method comprising administering to the subject a prophylactically effective amount of the dsRNA agent of claim 19, thereby preventing at least one symptom in the subject having or prone to having a disorder that would benefit from a reduction in C5 expression.

28. The method of claim 22, further comprising contacting the cell with an anti-complement component C5 antibody, or antigen-binding fragment thereof.

29. The method of claim 25, further comprising administering to the subject an anti-complement component C5 antibody, or antigen-binding fragment thereof.

30. The method of claim 27, further comprising administering to the subject an anti-complement component C5 antibody, or antigen-binding fragment thereof.